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SUM M ARY
R ad ioactive  iodine (^ 34 )  is w ide ly  used in the tre a tm e n t o f 
thy ro tox icos is : an estim ated 500,000 patien ts have been given th is  fo rm  of 
therapy since its  widespread a v a ila b ility  in the la te  1940s. Despite th is 
experience there  is s t i l l  unce rta in ty  about the response o f patients to  ^34 ,  
p a rtic u la r ly  in  the f ir s t  year a fte r tre a tm e n t; the lag between ^34  
adm in is tra tio n  and biochem ical response can cause problems in pa tien t 
management. There are also surp ris ing ly  few  data on the e ffe c ts  o f ^ 34  on 
th y ro id  physiological processes: much o f what is known was published before 
the a v a ila b ility  o f accurate measurement o f thy ro id  hormone levels and 
th y ro id  s tim u la ting  hormone. This thesis a ttem pts to  address these points. 
The e ffe c ts  o f an tithy ro id  drug tre a tm e n t on response to  ^ 34  are also 
exam ined, and the possible reasons fo r  in te rac tions between a n tith y ro id  drugs 
and 134 tre a tm e n t explored.
In the f ir s t  part o f the experim enta l section o f the thesis the early  
e ffe c ts  o f radioiodine (^34 )  tre a tm e n t in patients w ith  thyro tox icos is  were 
exam ined. In 50% o f patients serum concentrations o f thyrox ine  (T4) and 
tri- io d o th y ro n in e  (T3) rose 48 hours a fte r ^34  adm in is tra tion , although in 
none was th is  associated w ith  c lin ic a l de te rio ra tion . A s im ila r find ing  was 
noted in patients who had been given carb im azole tre a tm e n t fo r  a m in im um  
o f th ree  months before ^ 34  adm in is tra tion . There were no m a jo r changes in 
serum thyrog lobu lin  or TRAb levels fo llow ing  -*-34  tre a tm e n t, and no 
re la tionsh ip  between changes in these variables and thy ro id  hormone 
concentrations was observed.
The e ffe c t o f ^34  therapy on early  (20 m inute) uptake o f ^ 3I 
fo llo w in g  intravenous in jec tion  o f radioisotope was examined se ria lly  in 55 
patien ts w ith  thyrotoxicosis: 24 o f these had been trea ted  before ^34  w ith  
carb im azole. In a ll subjects 20 m inute  uptake o f ^ 3I, which was taken to 
represent iodide trapping by the thy ro id , fe l l by fou r weeks a fte r ^34  
adm in is tra tion . In those patients who subsequently developed perm anent 
hypothyro id ism  w ith in  the next few  months uptake values rem ained low . In 
contrast, a small rise in uptake measurements fo llow ing  the in it ia l fa l l 
occurred in those patients who were b iochem ica lly  euthyro id  one year a fte r 
^ 34  adm in is tra tion . Patients who were s t i l l  th y ro to x ic  one year a fte r ^34  
adm in is tra tion  had a higher 20 m inute uptake o f 1^3j before ^34
adm in is tra tion  (p < 0 .0 5 ), and showed only a sm all fa ll in uptake a fte r 134  
tre a tm e n t. Thus, by four weeks a fte r tre a tm e n t 20 m inute uptake in those 
patien ts who were euthyro id  one year a fte r tre a tm e n t was higher than in 
those who became hypothyroid, and low er than in those who rem ained 
th y ro to x ic  (both p < 0 .0 5 ). A ll patients whose uptake o f ^23I was 4% or less 
fou r weeks a fte r  ^ 34  adm in is tra tion  subsequently became e ithe r eu thyro id  or 
hypothyro id , w h ile  a ll whose uptake was greate r than 8% at th is  tim e  fa ile d  
to  ente r rem ission. The maximum change in uptake o f ^23I occurred w ith in  
fou r weeks o f ^ 34  therapy, and i t  is suggested tha t early  iodide uptake 
measurements may be used to  p red ic t outcome a fte r ^34  adm in is tra tion .
Six patien ts had an episode o f trans ien t hypothyroidism  fo llo w in g  134
therapy. In tw o  of these patien ts, in whom measurements were made, th is 
was shown to  be associated w ith  revers ib le  defects o f iodide o rg an ifica tion  
(measured by perchlorate  discharge). In three others ^23I uptake 
measurements 20 and 60 m inutes a fte r intravenous adm in is tra tion  o f
rad ioisotope were consistent w ith  a defect o f iodide o rgan ifica tion . I t
appears, the re fo re , tha t permanent hypothyro id ism  is a consequence o f m ajor 
im pa irm en t o f iodide trapping; in con trast, i f  trapp ing is not irre ve rs ib ly  
damaged, and there  is a defect o f iodide o rg an ifica tion  present, the tendency 
fo r  such defects to  recover means th a t the associated hypothyroid ism  may be 
trans ien t. I f  early  iodide uptake a fte r 134  tre a tm e n t is ^2%  in a pa tien t 
w ith  hypothyro id ism , an iodide o rg an ifica tion  defect may be p a r tia lly  
responsible fo r  the hypothyroidism .
Iodide o rgan ifica tion  was fo rm a lly  studied in 24 patients given ^ 34  
tre a tm e n t using an intravenous perch lora te  discharge tes t. Nine had evidence 
of an o rg an ifica tion  defect w ith in  th ree  months a fte r tre a tm e n t. In a ll 
patients there  was a tendency fo r these defects to  improve w ith  tim e , and 
there  was no evidence tha t iodide o rgan ifica tion  im pairm ent had a m ajor 
in fluence on thy ro id  biochem ical func tion .
A m ajor theme o f the thesis is the in te rac tio n  between carb im azole  
and 134  tre a tm e n t. O f 79 patients studied, 36 were made euthyro id  w ith  
carb im azole before 134  adm in is tra tion . Carbim azole p re trea tm en t (drug 
stopped at least 72 hours before ^34 )  caused a reduction  in the incidence o f 
hypothyroid ism  during the f ir s t  tw e lve  months a fte r ^ 34  trea tm en t (19% v 
42%, p <0 .05 ). As carbim azole trea tm en t can cause in tra th y ro id a l iodide 
depletion, the poss ib ility  tha t th is apparent "rad io -p ro tec tive " e ffe c t o f
carb im azole  was a consequence o f a reduced thyro ida l e ffe c tiv e  ha lf l i fe  o f 
131i was studied. Carb im azole  p re trea tm en t (fo r a m in im um  o f three 
months) was, however, shown not to  a ffe c t the b io log ica l h a lf l i fe ,  the 
e ffe c tiv e  ha lf l i fe  o f ^ 34 ,  or the estim ated rad ia tion  dose to  the thy ro id . 
In a study o f the e ffe c t o f m eth im azole  tre a tm e n t on thy ro id  h is to logy and 
autoradiographic d is tribu tion  of ^ 23I in ra t thyro id , stopping the drug 48 
hours before sa c rifice  was shown to  resu lt in near norm alisa tion  o f thy ro id  
h is to log ica l appearance and iodide d is trib u tio n . Thus, the e ffe c ts  o f 
carb im azole on early  outcom e a fte r  1 3 4  tre a tm e n t are un like ly  to  be due to  
a lte ra tio n  o f thyro id  d is tribu tion  or re ten tion  o f 13 4 .  I t  is suggested tha t 
scavenging o f rad ia tion-produced fre e  radicals by e ithe r drug or m e tabo lite  
may account fo r the rad iop ro te c tive  e ffe c t fo llow ing  ^ 34  tre a tm e n t.
In the f in a l part o f the thesis the phenomenon o f a n tith y ro id  drug 
accum ulation by thyro id  tissue was examined, w ith  p a rticu la r re ference  to 
p o ten tia l in te rac tions between a n tith y ro id  drugs and iodide. In mouse 
thy ro id , a n tith y ro id  drug (m eth im azole  and p ropy lth iou rac il labelled w ith  33S) 
accum ulation was p a rtly  inh ib ited  by acute blockade o f the anion tra p  by 
perch lora te . These drugs were also shown to  be concentrated w ith in  mouse 
sa liva ry  gland (submandibular): tissue loca lisa tion  was s im ila r to  th a t o f ^24 -  
iod ide, being in the in tra lobu la r duct and convoluted granular tubule . Using 
h istochem ica l techniques, peroxidase a c tiv ity , and glucose-6-phosphate 
dehydrogenase, which is necessary fo r hydrogen peroxide generation, were 
localised to  the same areas. P erch lo ra te  again caused a s ligh t fa l l  in the
amount o f drug taken up by tissue. F in a lly , 33S -p ropy lth iourac il was also
shown to  be concentrated by phagocytosing human polym orphonuclear cells, 
which contain myeloperoxidase. D rug uptake was not a ffe c ted  by perch lora te  
or ouabain, both o f which in h ib it spec ific  membrane bound anion trapping, 
but was inh ib ited  by iodide, and unlabelled m ethim azole and p ropy lth iou rac il 
a t concentrations which also inh ib ited  myeloperoxidase a c tiv ity  (measured by 
chem ilum inescence). These studies suggest tha t a n tith y ro id  drug accum ulation 
by tissue is not dependent on a spec ific  anion trapping mechanism, but on 
the presence of tissue peroxidase. In te ra c tio n  between peroxidase and drug
results in inh ib ition  o f iodide o rg an ifica tion  and leads to  drug ox ida tion : i t  is
suggested tha t drug oxidation is key to  its  in tra ce llu la r accum ulation, w ith  
trans fe r o f drug across the ce ll membrane being a passive process regula ted 
by the concentra tion  o f free , non-m etabolised drug w ith in  the ce ll.
Decreased thy ro id  iodide content lim its  drug ox ida tion , and i t  is possible tha t 
th is secondarily  reduces accum ula tion  w ith in  tissue, accounting fo r the 
e ffe c ts  o f perch lo ra te  in mouse th y ro id  and sa liva ry  tissue described.
The ac tion  of a n tith y ro id  drugs to  in h ib it iodide o rgan ifica tion , the 
accum ula tion  o f a n tith y ro id  drugs w ith in  ta rge t tissue, and the 
ra d io p ro te c tive  e ffe c t o f these agents fo llo w in g  ^34  may a ll be consequences 
o f the chem ica l ox ida tive  p o ten tia l o f the drugs which allows in te rac tio n  
w ith  hydrogen peroxide/peroxidase systems and tissue free  radicals.
CHAPTER ONE -  REVIEW
Section One
1.1. Norm al Thyroid Function
1.1.1. H is to r ic a l background
A lthough the description o f endemic c re tin ism  is a ttr ib u te d  to 
Paracelsus in 1603, i t  was not u n til the m id 19th C entury tha t the
re la tionsh ip  between thyro id  dysfunction and i l l  health was fu l ly  appreciated 
(Iason 1946). The f ir s t  c lin ica l descriptions o f thyro tox icos is  were made by 
P arry in 1825 and Graves some 10 years la te r (Graves 1835; Parry 1825): 
ne ither, however, realised tha t thyro id  enlargem ent was o f pathogenic 
s ign ificance . The p rim ary  ro le  o f the thyro id  gland in the genesis o f the 
syndrome now recognised as thyro tox icos is  was not established u n til the
1880s, when the earlies t subtota l thyro idectom ies fo r  the condition were 
perform ed (Werner 1978a). Since th a t tim e  there have been m ajor advances 
in the understanding o f norm al thy ro id  physiology, and in the pathophysiology 
o f thy ro id  dysfunction . A lthough o f only passing in te res t to th is thesis, the 
dem onstration o f the high iodine content o f thyrog lobu lin  by Oswald (1899), 
the description o f the chem ical s truc tu re  o f thyroxine  by H arring ton  (1926) 
and the d iscovery o f tr i- iodo thy ron ine  by Gross and P itt-R iv e rs  (1954) have 
been m ilestones in the development o f the cu rren t s ta te  o f knowledge. 
S im ila rly , the d e fin itio n  o f the th y ro id -p itu ita ry  feedback loop in 1949
(Hoskins 1949) and the iso lation o f im m unoglobulin-derived, long-acting  
thy ro id  s tim u la to r in patients w ith  thyro tox icos is  by Adams and Purves (1956) 
have been m ajor conceptual steps in the understanding o f normal and 
abnormal thy ro id  func tion . However, despite the accum ulation o f  th is large 
body of knowledge, there remain areas o f unce rta in ty  and em piric ism  s t i l l  
p reva lent in the management o f thyrotox icosis.
1.1.2. N orm al thy ro id  anatomy and physiology
The norm al thyro id  gland is a bilobed s truc tu re  ly ing  an te rio r to the 
trachea in fe r io r to  the thyro id  ca rtilage . The tw o lobes are jo ined by a 
cen tra l isthmus which is an te rio r to the second and th ird  cartilag inous rings. 
M icroscop ica lly  the gland is seen to be composed o f fo llic le s  which are
approxim ate ly spherical structures w ith  an outer shell o f a single layer o f
Fig 1
HISTOLOGICAL SECTION (HAEMATOXYLIN AND EOSIN, x300) OF NORMAL 
HUMAN THYROID._______________________________________
HOMOGENOUS COLLOID ENCLOSED BY FOLLICULAR CELIS COMPRISE 
THE BASIC UNIT, THE FOLLICLE. NOTE VARIATION IN FOLLICULAR 
SIZE. IODIDE IS TRAPPED FROM THE BASAL (OUTER) BORDER OF 
THE FOLLICULAR CELL, AND TRANSPORTED TO THE INNER BORDER 
(CELL/COLLOID INTERFACE) WHICH IS THE SITE OF THYROID HORMONE 
SYNTHESIS.
e p ith e lia l ce lls enclosing a homogeneous co llo id  composed o f thyrog lobu lin , an 
iod inated g lycopro te in . The fo llic le  is enclosed by a basement membrane; 
thy ro id  gland strom a - connective tissue w ith  a rich  cap illa ry  and lym pha tic  
netw ork - lies between fo llic le s . A much sm aller number o f secre to ry  cells 
are enclosed by the basement membrane, but do not com m unicate w ith  the 
lumen o f the fo llic le  and are known as p a ra fo llicu la r (C) cells (W olfe, Voelkel 
and Tashjian, 1974). These secrete ca lc ito n in . A representative  h is to log ica l 
section o f norm al human thyro id  is shown in F igure 1.
On e lectron  m icroscopy the fo llic u la r  cells are noted to  be polarised, 
w ith  the ce ll nucleus at the basal part o f the ce ll; the apex o f the ce ll is 
o rien ta ted  towards the lumen o f the fo llic le .  P ro jecting  from  the apical 
portion  o f the ce ll in to  the lumen o f the fo llic le  are m ic ro v illi,  and the 
surface area o f the ce ll in contact w ith  co llo id  m ateria l is the re fo re  g rea tly  
increased. The thyro id  fo llic u la r ce ll is responsible fo r the m anufacture o f 
the co llo id  g lycopro te in , thyrog lobu lin , on which is produced thy ro id  hormones 
(thyrox ine  and tri- iodo thyron ine ). B r ie fly , iodide o f d ie ta ry  o rig in , c ircu la tin g  
in the blood stream , is concentrated w ith in  the fo llic u la r ce ll by means o f a 
h ighly e ff ic ie n t iodide trap . The 30-fo ld  concentration which resu lts is 
necessary in view o f the sca rc ity  o f iodine in the environm ent (Stanley and 
Astwood, 1949). Iodide trapping, which occurs a t the basal membrane o f the 
fo llic u la r  ce ll, is not spec ific  fo r  iodide: re la ted  molecules o f the halide 
group such as brom ide, complex anions such as perchlorate and pertechnetate 
and pseudo-halides such as th iocyanate are also concentrated w ith in  fo llic u la r  
cells by th is  mechanism (W olff, 1963). Iodide transport across the fo llic u la r  
ce ll membrane is an ac tive , energy dependent process linked to membrane 
bound sodium/potassium ATPase (W o lff and H a lm i, 1963).
Fo llow ing transport w ith in  the ce ll, iodide is incorporated in to  organic
form  in a series of chem ical reactions. I t  is like ly  tha t the in it ia l step
involves the oxidation o f iodide to  iodine (2 x Tv—^  I^ + 2e): th is is catalysed
by the haem protein enzyme, thy ro id  peroxidase (Taurog, 1970), which is 
localised on the apical margin o f the ce ll at the ce ll m em brane/co llo id  
in te rfa ce  (Tice and Wollman, 1974). There remains some controversy about 
the exact nature o f the physical s ta te  o f the oxidised species o f iodine. 
M olecular iodine (I2 ), enzyme-bound iodin ium  (I+) or enzyme-bound iodine free  
radical (I*) are a ll the o re tica lly  capable o f reacting  w ith  the amino acid
tyrosine to fo rm  mono- and diiodotyrosines (Taurog, 1978). Tyrosine residues
Iodide + peroxidase + ^ 2  —► activated [enzyme - I] complex
(either I ‘ or I + or I 2)
Fig 2
(a) + (b) SCHEMATIC REPRESENTATION OF IODOTHYRONINE FORMATION
TYROSINE RESIDUES ON THE THYROGLOBULIN MOLECULE ARE IODINATED 
AT EITHER 3 , OR 3* AND 5 POSITIONS TO GIVE MONO OR DI- 
IODOTYROSYL RESIDUES. THIS IS CATALYSED BY THYROID PEROXIDASE 
/H202 (2a, ABOVE).(THE PRECISE IODINATING SPECIES IS UNCERTAIN). 
COUPLING OF IODOTYROSYL RESIDUES ON THE THYROGLOBULIN MOLECULE 
GIVES THYROID HORMONES (2b BELOW).
Activated [enzyme-I] + Iodinated 
tyrosyl residue 
(at 3 = mono, or 
3+5 = Dl-iodotyrosyl)
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are part o f the polypeptide s tru c tu re  o f thyrog lobu lin , and the iod ina tion  of 
tyrosine  also occurs at the ce ll/lum en  in te rface  o f the fo llic le  (Ekholm and 
W ollman, 1975). Steps leading to  the production o f iodotyrosines are shown 
schem atica lly  in F igure 2.
Subsequent coupling o f iodotyrosine residues in a thyro id-peroxidase 
catalysed reaction  leads to  production o f thy ro id  hormone bound to 
thyrog lobu lin : the native  s tru c tu re  o f thyrog lobu lin  is necessary fo r this 
reaction  to  proceed most e ff ic ie n t ly  (Lamas, Taurog, Salvatore, e t a l., 1975). 
Coupling o f one m olecule o f m onoiodotyrosine w ith  one o f d iiodotyrosine 
produces tri- iod o thy ro n in e ; or tw o molecules o f d iiodotyrosine w il l give 
te tra iodo thyron ine  (thyrox ine) (F igure 2) (H arington and Barger, 1927). 
Thyro id  hormones rem ain stored w ith in  the co llo id  as pep tide-linked  iod inated 
amino acids on the thyrog lobu lin  molecule. Release o f fre e -th y ro id  hormone 
in to  the c ircu la tio n  the re fo re  requires in it ia l proteolysis o f thyrog lobu lin . 
Small droplets o f co llo id  are engulfed by the apical portion  o f the fo llic u la r  
ce ll in a process o f endocytosis; these droplets then fuse w ith  lysosomes 
which contain proteases (Selje lid , R e ith  and Nakken, 1970). The libe ra ted  
thy ro id  hormones are released in to  the c ircu la tio n  via the basal portion o f 
the fo llic u la r  ce ll: iod inated amino acids libe ra ted  from  thyrog lobu lin  at the 
same tim e  are dehalogenated, and the iodide derived from  th is process is 
rec ircu la ted  w ith in  the pathway summarised above (Stanbury, 1974).
1.1.3. C ontro l o f thyro id  gland secretion
The observation th a t the p itu ita ry  glands o f some cre tins were 
enlarged (R eich lin , 1978) led eventua lly to the cyberne tic  theory o f 
th y ro id /p itu ita ry  feedback con tro l expressed by Hoskins (1949). The 
im portance o f p itu ita ry  regu la tion  in maintenance o f normal thy ro id  function  
is demonstrated by the development of thyro id  gland atrophy and c lin ica l 
hypothyroidism  in hypophysectomised subjects (Burger and Pate l, 1977). 
Thyro id s tim u la ting  hormone (TSH) produced by the thy ro troph  cells o f the 
an te rio r p itu ita ry  is a 30,000 dalton glycoprote in consisting o f 2 sub-units: an 
alpha sub-unit which is common to other p itu ita ry  hormones, such as 
lu te in iz ing  hormone and FSH, and a beta sub-unit which is responsible fo r 
b io log ica l expression o f TSH a c tiv ity  (Pierce, 1971). TSH binds to a spec ific  
recepto r on the basal portion  o f the fo llic u la r ce ll, and exerts a number o f 
e ffe c ts  on fo llic u la r ce ll func tion . Many of these e ffec ts  are secondary to
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Fig 3
HYPOTHALAMIC/PITUITARY/THYROID AXIS
THYROTROFHIN-RELEASING HORMONE, PRODUCED IN THE HYPOTHALAMUS IS 
TRANSPORTED VIA THE PORTAL CIRCULATION TO THE ANTERIOR PITUITARY, 
TO TONICALLY REGULATE THYROTROFHIN (TSH) RELEASE. TSH 
STIMULATES IODIDE UPTAKE, ORGANIFICATION AND THYROID HORMONE 
RELEASE BY THE THYROID GLAND. THYROID HORMONE INHIBITS SYNTHESIS 
AND RELEASE OF TSH BY THE PITUITARY, AND MAY ALSO INFLUENCE 
HYPOTHALAMIC TRH SECRETION. OTHER HYPOTHALAMIC FACTORS SUCH AS 
DOPAMINE AND SOMATOSTATIN MAY ALSO MODULATE TSH SECRETION.
s tim u la tion  o f adenylate cyclase and a ffe c t production o f cyc lic  AMP 
(Dum ont, 1971); more recen tly  the im portance o f phospholipid tu rnover, 
generation o f ca lc ium  as a second messenger and o f the calcium  dependent 
enzyme, ca lm odu lin  in in tra ce llu la r transduction  o f the TSH signal has been 
dem onstrated (Brown, W alker and Tom linson, 1985; O llis , M acN eil, W alker, e t 
a l., 1983).
The ea rlie s t e ffe c t o f TSH is to  increase co llo id  drople t fo rm a tion  at 
the apical brush border, leading to  release o f p reform ed thyro id  hormone in to  
the c ircu la tio n  (Tonoue, Tong and S toic, 1970). TSH leads to an in it ia l rise 
in the e ff lu x  o f iodide from  the fo llic u la r  ce ll, fo llow ed , a fte r a lag period 
o f a few  hours, by a sustained increase in iodide trapping (H alm i, 1961). As 
th is is the ra te - lim it in g  step in thy ro id  hormonogenesis, the resu lt is 
accelerated thy ro id  hormone production (Ingbar, 1978). However, the 
increased ra te  o f hormone production appears also to  arise from  increased 
o rg an ifica tion  and coupling o f iodotyrosines, which is seen even when iodide 
trapp ing is blocked by perch lora te , ind ica ting  a TSH-m ediated increase in 
thy ro id  peroxidase a c tiv ity  (Tong, 1966). F in a lly , TSH has marked e ffe c ts  on 
fo llic u la r  ce ll carbohydrate, lip id , p ro te in  and nucle ic acid m etabolism , which 
resu lt in thy ro id  ce ll division and thyro id  gland grow th (Begg and Munro, 
1965).
1.1.4. H yp o th a la m ic /p itu ita ry /th y ro id  axis
The thy ro id  and p itu ita ry  p a rtic ipa te  in a classical negative feedback 
loop, so th a t the secretory products o f the thy ro id  gland (thyroxine  and t r i ­
iodothyronine) in h ib it p itu ita ry  TSH synthesis and release (C otton, Gorman 
and M aybury, 1971) (Figure 3). Conversely, when T4 and T3 fa ll,  TSH 
secretion is enhanced. In tu rn , m aintenance o f norm al TSH secretion depends 
on thy ro troph in  releasing hormone (TRH) synthesis and its  release from  
hypotha lam ic pep tiderg ic  neurones in to  the hypophyseal porta l c ircu la tio n  
(Burgus, Dunn, Desiderio, et a l., 1970). Thus, i f  the p itu ita ry  s ta lk  is 
sectioned, p itu ita ry  TSH secretion fa lls  and secondary hypothyroidism  ensues. 
O ther hypotha lam ic substances which may p o te n tia lly  influence TSH synthesis 
and release are (inh ib ito ry) som atostatin  and dopamine, and (s tim u la to ry ) 
alpha adrenoreceptor agonists (Scanlon, Rees-Smith and H a ll, 1978). I t  is 
lik e ly  tha t there  is thyro id  hormone feedback in fluencing hypothalam ic 
a c tiv ity  in man, although the im portance o f th is is controversia l (Feek,
Sawers, Brown, e t al. 1980).
1.1.5. C ircu la tin g  thy ro id  hormones
The princ ipa l secre to ry  product o f the thyro id  gland is thyrox ine  (T4). 
The mean da ily  T4 secretion ra te  is about 90 ug, which represents about 10% 
o f the ex tra thy ro ida l T4 pool (Chopra, 1978). T4 c ircu la tes  in plasma la rge ly  
(> 99%) bound to  ca rrie r p ro te ins: the high a ff in ity ,  low capacity  thyrox ine  
binding globulin, and the low a f f in ity  high capacity  thyrox ine  binding 
prealbum in (N ico lo ff, 1978). These ca rrie r proteins act as bu ffe rs , damping 
the e ffe c t o f sudden a lte ra tio n  in thy ro id  gland secretion on free  thy ro id  
hormone concentrations: i t  has also been suggested th a t ca rrie r prote ins may 
serve to  regula te  the ra te  o f uptake o f free  thyro id  hormone by organs such 
as the placenta (Ekins, Sinha, Woods, e t a l., 1983; Pharoah, Connolly, Ekins, 
e t a l., 1984). C a rrie r p ro te in  bound thyroxine  is in equ ilib rium  w ith  free  
thy ro id  hormone in plasma.
U n til the 1950s i t  was thought th a t a ll the e ffe c ts  o f thy ro id  hormone 
were m ediated through T4. W ith  the discovery o f tr i- iod o thy ro n in e  (T3) by 
Gross and P itt-R iv e rs  (1954) i t  became apparent tha t the action  o f thy ro id  
hormone could not be soley a ttr ib u te d  to  T4. I t  now seems lik e ly  th a t a ll 
the actions o f thyro id  hormone a t a ce llu la r level are mediated through T3 
(Brown, Chopra and C orne ll, 1974). A lthough some c ircu la tin g  T3 is derived 
fro m  thyro ida l secretion, the p rinc ip le  source o f T3 is from  periphera l 
deiod ination o f T4: th is occurs m ain ly in liv e r and kidney (Braverm an, Ingbar 
and S terling, 1970). In a ll ce lls, some recepto r bound T3 is derived from  
in tra c e llu la r conversion o f T4 to  T3: the proportion o f T3 derived in th is  way 
varies from  tissue to tissue. A n te rio r p itu ita ry  gland tissue has a high 
ob liga to ry  in tra ce llu la r conversion ra te  o f T4 to  T3 (Siwa, D ick and Larsen, 
1978). A fa ll in c ircu la tin g  T4 concentrations w il l,  the re fo re , lead to a 
shortage o f in tra ce llu la r T3 in p itu ita ry  tissue, w hile  other tissues which do 
not depend upon in tra ce llu la r T4 deiod ination to  the same exten t w il l not be 
a ffe c ted . I t  is in this way th a t the p itu ita ry  ce ll may sense the need fo r 
increased thyro id  hormone production and so increase TSH secretion at _a_ 
tim e  when other tissues have an adequate supply o f thyro id  hormone at 
nuclear recepto r leve l.
Coupling o f T3 w ith  its  spec ific  nuclear receptors has a genomic 
e ffe c t leading to an increase in m RNA synthesis, which contro ls synthesis o f
new p ro te in  (Oppenheimer, Koerner and Schw artz, 1972). I t  is possible, but 
by no means ce rta in , tha t a ll the ce llu la r actions o f T3 are m ediated in th is 
way. These actions include the s tim u la tion  o f energy-dependent transport o f 
amino acids and e lec tro ly tes  across plasma membranes, enzyme synthesis and 
increased ce ll m ito t ic  a c t iv ity  (Ism a il-Be ig i and Edelman, 1971; S oko lo ff and 
Kaufm ann, 1961.
Section Two
1.2. C lin ica l Aspects of Thyrotoxicosis
1.2.1. In troduction
Thyrotoxicosis is the c lin ic a l sta te  produced by increased thyro ida l 
release o f hormone, leading to  sustained e levation o f plasma thy ro id  hormone 
levels (occasionally ingestion o f thy ro id  hormone can m im ic  features of 
thyro tox icos is : thyro tox icos is  fa c ita ta ). Common symptoms o f thyro tox icos is  
include fa tigue , anx ie ty , pa lp ita tions , w eight loss, heat in to le rance  and excess 
sweating (Werner, 1978b). Crooks and Wayne evaluated symptoms and signs 
o f the disease in a group o f pa tien ts  w ith  thyro tox icos is  in an a tte m p t to 
im prove diagnostic d isc rim ina tion  from  patients w ith  non-thyro id  illness 
(Crooks, Wayne and Robb, 1960). In th is study, heat in to le rance  and w eight 
loss were shown to be good d iscrim ina to rs , w hile  c lin ica l exam ination findings 
o f value included hyperkinesis, tachycard ia , trem or and warm  e x trem itie s .
Some degree o f thyro id  gland enlargem ent is usual: in young patients 
the gland tends to  be d iffu se ly  enlarged and vascular, o ften  w ith  an overly ing  
b ru it. In older subjects, or in subjects w ith  a long h is to ry  o f go itre , the 
gland may be f irm  and even nodular. In up to  16% o f patien ts the gland 
may be impalpable especia lly, in o lder patients (Greenwood, D aly and 
H im sw orth , 1985).
Thyrotoxicosis is o ften  associated w ith  abnorm a lity  in the appearance 
o f the eyes. Ocular changes can very w ide ly: in a ll subjects w ith  thy ro id  
hormone excess upper eyelid re tra c tio n  may occur, im pa rting  a "s ta ring " 
appearance to  the eyes. In im m uno log ica lly-m edia ted  thy ro id  disease the 
spec ific  ophthalm opathy, f ir s t  described by Graves, may develop. This may 
include pe rio rb ita l swelling, proptosis (un ila te ra l or b ila te ra l), and con junctiva l 
oedema. In f iltra t io n  and la te r fib ros is  o f the in tra -o rb ita l muscles can lead 
to  dip lopia. In some instances there  may be a rise in in tra -o cu la r pressure 
and in severe cases sight may be threatened (Werner, 1977).
1.2.2. Epidemiology o f thyro tox icos is
The true  incidence and prevalence o f thyro tox icos is  is d if f ic u l t  to 
assess. In a com m unity survey in the N orth  o f England, Tunbridge and 
colleagues reported a prevalence o f thyrotox icosis o f 1.1 - 1.6%, w ith  a male
to  fem ale  ra tio  o f 1/10 Tunbridge, Evered and H a ll, et a l., 1977). This 
would lead to  an expected annual incidence o f 2-3 cases per 1000 fem ales 
per year. These figures accord w ith  an e a rlie r survey o f G.P. p ractices 
reported  by Logan and Cushion (1958). I t  is lik e ly  tha t the prevalence o f 
thy ro tox icos is  is in fluenced by preva iling  d ie ta ry  iodine in take: in some
countries where programmes to increase d ie ta ry  iodine in take have been 
conducted, an increased incidence o f thyro tox icos is  has been documented 
(C onnolly, V idor and S tew art, 1970; Ek, Johansson and Von Porat, 1963). The 
high proportion  o f such cases in a study in Tasmania were shown to  have 
measurable long acting  thyro id  s tim u la to r (LATS) concentrations, suggesting 
th a t the previous iodine defic iency was responsible fo r  m aintenance o f
euthyro id ism  in the presence o f abnormal thyro id  s tim u la tion  (V idor e t al, 
1973). An e ffe c t o f iodine its e lf  on production thy ro id  im m unological 
s tim u la to rs  is, however, d if f ic u l t  to  exclude.
Thyro toxicosis is found in a ll races: true  d iffe rences in prevalence
among ra c ia l or geographical groups are d if f ic u l t  to define in view o f the 
e ffe c t o f iodine a v a ila b ility  discussed above. The incidence o f the disorder 
in Japan, where iodine in take is high, has been estim ated as 8 cases per 
1000 fem ales per year (H offenberg, 1973).
The disease is uncommon in ch ild ren and adolescents. A lthough
thyro tox icos is  has tra d itio n a lly  been seen as a disease o f m iddle l ife ,  a study 
in Denm ark has suggested tha t the disorder may be commoner than 
previously thought in the e lderly  (Ronnov-Jessen and K irkegaard, 1973). One 
fea tu re  o f th is  study, which showed a hospita l bias o f e lderly  (> 65 years) to 
younger patients o f 6:1 was the a typ ica l presentation in older patients.
The m a jo rity  o f patients w ith  thyro tox icos is  have im m uno log ica lly  
m ediated thyro id  disease (Graves’ disease): the im m unological abnorm alities 
w ill be discussed la te r. A sm all number o f patients have a so lita ry
hyperfunction ing  nodule responsible fo r excess hormone secretion. Las tly , in 
some patients w ith  thyrotoxicosis a m u ltinodu la r go itre  appears responsible 
fo r the disorder. I t  has been suggested th a t in such patients a long standing 
non-tox ic  go itre  escapes from  the usual feedback contro l mechanism, and 
th a t hormone secretion becomes autonomous (Studer, 1982). In th is s itua tion  
iodine a v a ila b ility  may assume greate r im portance in se tting  the leve l o f 
thy ro id  hormone secretion, and in te rm itte n t or chronic thyrotoxicosis may 
supervene. However, the recent d iscovery o f antibodies which prom ote
th y ro id  grow th has suggested tha t im m unological fac to rs  may be of 
ae tio log ica l s ign ificance in the developm ent o f non-tox ic  go itre  (Valente, 
V it t i ,  R o te lla , e t a l., 1983), and i t  is possible tha t the pathogenesis o f tox ic  
m u ltinodu la r go itre  more closely resembles th a t o f Graves' disease than has 
been previously thought.
In the U n ited  States i t  has been suggested th a t as many as 30% of 
_pationts wLtin thyrotoxicosis have a subacute1 1 "silent11 thyroiditis, characterised, 
by s e lf- lim it in g  thy ro id  hormone excess associated w ith  low thyro id  iodide 
uptake measurements (K le in  and Levey, 1982). However, in te rp re ta tio n  of 
the s ign ificance  o f low iodine uptake measurements is d if f ic u l t  w ith o u t 
knowledge o f preva iling  d ie ta ry  iodine in take, and estim ate o f absolute 
thy ro id  iodine uptake. H is to log ica l exam ination o f thy ro id  tissue from  such 
patien ts shows lym phocytic  in f ilt ra t io n , and the re la tionsh ip  o f th is disorder 
w ith  classical Graves' disease is unclear. The incidence o f this disorder in 
the U nited  K ingdom  is not known.
1.2.3. G enetic fac to rs  in thyro tox icos is
I t  has been recognised fo r some tim e  th a t autoimm une thyro id  disease 
occurs more frequen tly  in f ir s t  and second degree re la tives  o f a ffe c ted  
subjects than in the general population (R o itt and Doniach, 1958; Doniach, 
1975). The exact mode o f inheritance remains unclear: i t  has been suggested 
th a t an autosomal recessive mode w ith  reduced penetrance m ight be present, 
although a lte rna tives  have been suggested (Fraser, 1963; M a rtin , 1945). More 
re ce n tly , i t  has become clear tha t Graves' disease is inherited  in genetic 
linkage w ith  ce rta in  ce ll-su rface  h is to co m p a tib ility  antigens: in Caucasian
subjects H LA  B-8 and DRw3 are increased in frequency (Svejgaard, P la tz  and 
Ryder, 1984), w h ile  in a Japanese population Bw35 has been shown to  be 
increased in frequency (Kawa, Nakamura and Nakazawa, et a l., 1977). These 
m arkers may be o f value in p red ic ting  the like lihood o f development o f a 
rem ission o f thyrotoxicosis during a n tith y ro id  drug trea tm en t (M cGregor, 
Rees-Smith, H a ll, et al., 1980).
1.2.4. Patho log ica l features
In classical Graves' disease the thy ro id  gland is d iffuse ly  enlarged and 
more vascular than usual. M icroscop ica lly  there  is hyperplasia o f the 
fo llic le s  w ith  re la tive  loss o f co llo id ; the fo llic u la r  cells become elongated
and there  is o ften  evidence o f increased lym phoid tissue w ith in  the gland. 
On e lectron  m icroscopy there is evidence of increased m etabo lic  and 
syn the tic  a c t iv ity  w ith  hypertrophy o f golgi apparatus and an increased 
number o f m itochondriae (Meissner, 1978).
In to x ic  nodular go itre  the m icroscopic appearance is essentia lly  tha t 
o f non -tox ic  m u ltinodu la r go itre . H e terogene ity  o f fo llic le  size, w ith  some 
large fo llic le s  distended w ith  co llo id  but others showing marked invo lu tion , is 
ev ident. Areas o f fib rosis  is seen between groups o f fo llic le s , g iving rise to 
the nodular appearance and te x tu re  o f the gland. The spectrum  o f fo llic u la r  
size re fle c ts  the non-homogeneous nature o f m etabo lic  and syn the tic  a c t iv ity  
w ith in  the gland (Studer, P ete r and G erber, 1985).
1.2.5. Im m unolog ica l abnorm alities in Graves' disease
In d ire c t evidence tha t abnormal func tion  o f the immune system is 
invo lved in the pathogenesis o f Graves' disease includes the h is to log ica l 
appearance o f lym phocytic  in f i lt ra t io n  o f the gland, the enlargem ent o f the 
thym us which is known to  be present in some patients w ith  Graves' disease, 
and the association between Graves' disease and other o rgan-spec ific  
autoim m une disorders such as Addisonian pernicious anaemia and autoim m une 
adrena litis  (Irv ine , 1967). More d ire c t evidence th a t the pathogenic 
abno rm a lity  in the condition was an antibody d irected  against, and 
s tim u la to ry  to  the TSH recepto r came in the la te  1950s w ith  the descrip tion  
o f lo n g -acting thyro id  s tim u la to r (LATS) isolated from  the im m unoglobulin 
fra c tio n  o f serum of patients w ith  thyro tox icos is  (long-acting  is in comparison 
w ith  the duration o f the action o f TSH) (Adams and Purves, 1956). LATS 
could be shown to be present in some, but not a ll, patients w ith  Graves' 
disease (H ard isty, Hanford, Humphries, e t a l., 1981; O llis , Tomlinson and 
Munro, 1985). Arnaud and colleagues showed tha t LATS was capable o f 
s tim u la ting  normal thyro id  tissue (Arnaud, Kneubuhler, Seiling, et a l., 1965); 
fu r th e r, a co rre la tion  could be dem onstrated between LATS a c tiv ity  and 
rad io iod ine turnover in the thyro ids o f thy ro to x ic  subjects, and these data 
s trong ly  supported the suggestion th a t LATS was a d irec t cause o f thy ro id  
hormone excess (Carneiro, D orring ton  and Munro, 1966).
Adams and Kennedy (1967) subsequently described another gamma 
g lobu lin -derived substance which could block LATS binding to  the TSH 
recep to r but which was devoid o f s tim u la to ry  a c tiv ity  in the mouse thyro id
(LATS p ro te c to r, LATS-P). In untrea ted th y ro to x ic  patients LATS-P levels 
are genera lly higher than those o f LATS; e ithe r LATS or LATS-P have been 
shown to  be present in sera o f up to  86% o f th y ro to x ic  subjects (H ard isty  et 
a l., 1981).
Since the in it ia l discovery o f such thy ro id  s tim u la ting  antibodies, a 
number o f o ther techniques fo r de tection  and quan tifica tion  o f antibody 
d irec ted  against the TSH recep to r have been developed. Evidence o f thy ro id  
s tim u la tion  can be obtained using in v itro  measurement o f c yc lic  AMP or T3 
generation from  standardised thyro id  tissue (A tkinson and K enda ll-T ay lo r, 
1981; B idey, M arshall and Ekins, 1981), de tection  o f the a b ility  o f antibodies 
to  bind to  the TSH recepto r can be perform ed by measuring in h ib ition  o f 
binding o f labelled TSH to pu rified  thy ro id  membranes (Rees-Smith, Pyle, 
Peterson, e t a l., 1977). I t  is not always clear, however, w hether these
varied assay systems are detecting  the same antibodies: i t  is probable th a t 
there  is a spectrum  o f thy ro id  d irected  antibodies in Graves' disease. 
R ecently  the presence of antibodies which bind to  the TSH recep to r, but 
which do not s tim u la te  cyc lic  AMP generation have been described, and these 
c lea rly  d if fe r  from  those which s tim u la te  thy ro id  function  (Endo, Kasagi and 
Konish i, 1978). I t  is possible tha t these TSH recep to r binding, non­
s tim u la ting  antibodies are involved in the pathogenesis o f some 
im m uno log ica lly  m ediated hypothyro id ism : i t  has recen tly  been suggested th a t 
these may account fo r some cases of neonatal hypothyroid ism  in m others 
w ith  Graves' disease (Matsuura, Yamada, Nohara, et a l., 1980). A fu r th e r 
recent discovery has been the description  o f antibodies which s tim u la te  
thy ro id  grow th but not hormonogenesis (Valente et a l., 1983). This may 
account fo r  the long recognised discrepancy between thyro id  size and c lin ica l 
and b iochem ical severity  o f thyro tox icos is : i t  is possible tha t go itre
developm ent in thyrotoxicosis is at least p a rtly  dependent on thyro id  growth 
s tim u la ting  im m unoglobulin. I t  remains to be explained how antibody 
d irected  against the same recepto r can s tim u la te  separately functions 
subserved by the one troph ic  hormone (TSH).
As was in it ia lly  dem onstrated to  be the case w ith  LATS, not a ll 
patien ts w ith  Graves' disease can be shown to  be positive fo r  one single type 
o f antibody a c tiv ity . Thus, only about 75% o f patients w ith  the disorder can 
be shown to  have antibody which blocks the binding o f TSH (TRAb) to  its  
recep to r (Rees-Smith et a l., 1977). However, in a study where a b a tte ry  o f
d iffe re n t antibody detection  assays were perform ed in a group o f patients 
w ith  Graves' disease, 100% o f patients were shown to  have one or o ther type 
o f antibody present, although no co rre la tion  was seen between the various 
assays (H ard is ty , K enda ll-T ay lo r, A tkinson, et a l., 1983).
O ther autoantibodies d irected  against thy ro id  fo llic u la r  ce ll 
components, such as antim icrosom al or an tith y rog lobu lin  antibodies are 
present in varying  t i t r e  in subjects w ith  Graves' disease (M ori and Kriss,
1971). These are un like ly  to be o f d ire c t patho log ica l s ign ificance.
The cause o f production o f antibodies d irected  against the TSH 
recep to r in Graves' disease remains unclear. A n tibody production by the B- 
lym phocyte is p a rtly  con tro lled  by T-lym phocytes which may e ithe r prom ote 
(helper ce ll) or in h ib it (suppressor ce ll) antibody production. I t  has been 
suggested th a t production o f autoantibody is due to  development o f a 
norm a lly  suppressed "fo rb idden" clone o f B -lym phocytes, as a consequence o f 
a de fect in suppressor T -c e ll func tion  (Strakosch, Wenzel, Row, et a l., 1982; 
Thielmans, Van H aelst, DeWaele, e t a l., 1981). A bnorm a lities o f 
suppressor/helper T -c e ll ra tio  have been dem onstrated in thyro id -de rived  
lym phocytes in Graves' disease (Ludgate, M cG regor, Weetman, et a l., 1984). 
Thus, w h ile  the exact mechanism is unclear, i t  seems lik e ly  tha t excess 
thy ro id  hormone production is due to abnormal s tim u la tion  o f the TSH 
recep to r by autoantibodies which may be produced as a consequence of 
abnormal T -lym phocyte  m odulation o f B -lym phocyte  func tion .
The ro le  o f non-humoral immune e ffe c to r mechanisms in the 
pathogenesis o f Graves' disease is uncerta in . Plasma cells, com plem ent and 
immune complexes have been dem onstrated by imm unofluoresence studies in 
thy ro id  glands from  patients w ith  thyro tox icos is  (Feldman, Becker and 
Montsopoulos, 1976) as was the presence o f ce ll dependent cy to to x ic  antibody 
(Werner, Wegelius, F ie re r, et a l., 1972; Tomasi, 1978). Such abnorm alities 
would be more in keeping w ith  an in fla m m a to ry  response (e.g. chronic 
th y ro id itis ). However, i f  Graves' disease and Hashimoto's th y ro id itis  are, as 
seems lik e ly  fro m  c lin ica l and epidem iological studies, opposite ends o f the 
spectrum  of autoimm une thyro id  disease, i t  would be expected th a t, in 
im m unopathological studies, a continuum o f humoral and ce llu la r 
im m unological abnorm alities a ffe c tin g  thy ro id  tissue would be present. Thus, 
in an ind iv idua l w ith  c lin ica l thyro toxicosis, im m unopathological features o f 
chronic th y ro id it is  may also be present, just as evidence o f abnormal humoral
im m unological a c t iv ity  may be seen in some patien ts w ith  p rim ary 
hypothyro id ism .
1.2.6. N a tu ra l h is to ry  o f Graves' disease
Since the advent o f e ffe c tiv e  tre a tm e n t fo r thyro tox icos is , i t  has been 
d if f ic u l t  to  study the natu ra l course o f untreated disease. In the era before 
thy ro id  surgery i t  was estim ated th a t m o rta lity  o f the cond ition  was between 
8 and 12% (S a ttle r, 1952). In the rem ainder, the course o f Graves' disease 
varied from  a single sh o rt- live d  s e lf- lim it in g  episode, through repeated
episodes o f spontaneouosly re m itt in g  relapses to  chronic u n rem itting  disease. 
The percentage of patients expected to  enter spontaneously long te rm  
rem ission was around 25% (S a ttle r, 1952).
In more recent tim es, in fo rm a tion  about the natu ra l h is to ry  o f the
cond ition  may be obtained fro m  studies o f patients tre a te d  w ith  beta
adrenoreceptor b locking drugs. Propranolol has been shown not to  e ffe c t 
t it re s  o f TSH recep to r d irected  antibodies, and so is un like ly  to  have any 
a ffe c t on the underlying course o f the disease (M cGregor, Peterson,
M cLachlan, e t a l., 1980); rem ission rates in patien ts tre a te d  only w ith
propranolol are, the re fo re , lik e ly  to  re f le c t spontaneous rem ission ra tes. As, 
however, e lderly  subjects and subjects w ith  more severe disease tend not to 
be included in such studies, such in fo rm a tion  may over-es tim ate  the true
rem ission ra te . In 28 subjects given propranolol, M cL a rty  reported a
rem ission ra te  over a 16 month period of ju s t under 18% (M cLa rty , B row nlie , 
A lexander, e t a l., 1973), in an e a rlie r study exam ining the fa l l in uptake o f 
tra ce r rad io iod ine, response was seen in 22% o f patients (P imstone, Jo ffe , 
P im stone, e t a l., 1969). This is in general agreement w ith  o ther studies, and 
suggests th a t the true  spontaneous remission ra te  over a 1-2 year period is 
less than 25%. This is lik e ly  to  be a ffec ted  by, amongst o ther things,
a v a ila b ility  o f d ie ta ry  iodide.
SECTION THREE
1.3. R A D IO A C TIVE IO D IN E  IN  THE TR EATM ENT OF 
THYRO TO XICO SIS
1.3.1. In troduc tion
E xterna l irrad ia tio n  o f the thy ro id  was used as a tre a tm e n t fo r
thyro tox icos is  w ith  some success (around 50% response ra te ) in the 1920s. 
In te rna l irra d ia tio n  o f the thy ro id  was, however, only made possible by the 
production o f rad ioactive  isotopes o f iodine. The f ir s t  man made 
rad ioisotope o f iodine ( - ^ 1) was produced by neutron bom bardm ent by Ferm i 
(1934); i t  was dem onstrated th a t th is  isotope (^^®I) was accum ulated and 
d is tribu ted  in the same manner as stable ( - ^ I )  iodide in thy ro id  tissue. 
These fundam enta l observations paved the way fo r the use o f rad ioac tive  
iodine in the tre a tm e n t o f thyrotoxicosis, f i r s t  reported  by H e rtz  and Roberts 
(1942) using the short-lived  isotope ^ ^ 1  (decay h a lf- l ife  o f 12 hours). 
In tensive investiga tion  in to  th is  novel therapeutic  approach fo llow ed , and 
Chapman and Evans (1946) described the results o f the use o f 1 ^ 1  in 22 
th y ro to x ic  patients. In th a t same year, ^ -^ I was released by the A to m ic  
Energy Commission in the U n ited  States fo r national d is trib u tio n , and the
f ir s t  large scale tr ia ls  o f the use o f th a t isotope began.
In the U nited Kingdom, the use of - ^ 1  in the tre a tm e n t o f 
thyro tox icos is  was f ir s t  reported  by B lom fie ld  and co-workers in S he ffie ld  in 
1951: 20 patients had been trea ted  since 1949, and in th is  in it ia l re p o rt a ll
cases responded to  therapy, although some required more than one tre a tm e n t.
No pa tien t was reported to have become hypothyroid (B lom fie ld , Jones, 
M cGregor, et a l., 1951).
Since these early days a large number (probably in excess o f 500 000) 
patients have been given -^^ I fo r  thyro toxicosis. Sane of the relevant 
experience reported w ill be discussed below.
1.3.2. R adiobio logical aspects
L ike  stable iodide, a ll radioisotopes o f iodine are w e ll absorbed from  
the gut (Hainan, 1964). The e ffic ie n cy  o f the thy ro id  iodide trap , 
p a rticu la rly  in thyrotoxicosis, ensures tha t a large proportion  o f iodide 
adm inistered o ra lly  is accum ulated w ith in  the gland and incorpora ted in 
thy ro id  hormone, linked to molecules o f thyrog lobulin . As thy ro id  hormone in
th is  fo rm  is stored and located p rin c ip a lly  w ith in  the co llo id  o f the gland, i t  
fo llow s th a t rad ioactive  iodine is also localised there. The the rapeu tic  
e ffic a c y  o f rad ioactive  iodine therapy depends on th is  high concentra tion  o f 
isotope w ith in  the gland so tha t rad ia tion  damage to  the thy ro id  follicle ce il 
can occur w ith o u t a s ig n ifican t e ffe c t on neighbouring or d ista l s tructures.
l ^ l i  has been the radioisotope used p rin c ip a lly  in radioiodine therapy. 
The rad ioisotope decays w ith  a physical h a lf- l ife  o f 8.05 days. The p rinc ipa l 
decay products are beta partic les (e lectrons) released when nuclear neutrons 
convert in to  protons, and gamma rays, which are given o ff  as trans itions 
occur between the excited  and ground s ta te  o f the nuclei. In th is process o f 
decay, l ^ l j  \s converted to  stable -^ x e n o n  (Barnes, Rhodes and Wagner, 
1978). The beta partic les e m itted  by the radioisotope during decay are 
responsible fo r  about 95% o f the tissue rad ia tion  absorbed by the gland and 
hence fo r  the the rapeu tic  e ffe c t. These beta partic les , o f mean energy 0.19 
Mev, are absorbed w ith in  a re la tiv e ly  short distance (maximum range in 
tissue = 2100 pM). This, however, is considerably greater than the length o f 
the fo llic u la r  ce ll (10 pM) and, indeed, o f fo llic u la r  d iam eter (150-200 pM) 
(G reig, M cDougall and Hainan, 1972). Thus, ^-^1 deposited in the co llo id  o f 
one fo ll ic le  can irrad ia te  not only the ce lls o f tha t fo llic le  but also ce lls o f 
surrounding fo llic le s . A lthough, the re fo re , the d is tribu tion  o f ^ -^ I  in 
hyperp lastic  thy ro id  tissue may be patchy (K reu tze r, M ille r, Soley, e t al. 
1958), the emission characte ris tics  o f ^ ^ 1  probably ensure tha t a s ig n ifican t 
dose o f rad ia tion  is delivered to  a ll fo llic le s .
The exact mechanisms o f rad ia tion  induced ce ll damage responsible fo r  
the the rapeu tic  action o f ^-^1 are not fu l ly  understood. I t  is possible th a t 
the energy absorbed by the tissue from  the beta emission results in the 
generation o f free-oxygen (superoxide) rad icals: these free  radicals may cause 
chem ical damage to the ce ll, leading to  im pa irm ent o f b io log ica l func tion  
(Phil and Edjarn, 1958). This damage is not confined to  the aspects o f ce ll 
func tion  involved in thyro id  hormonogenesis: a fte r trea tm en t w ith  1 ^ 1  ce ll 
lifespan is reduced (in high dose rad ia tion  induced-cell death w ill,  o f course, 
resu lt) (Freeburg, Kurland and B lum gart, 1953). There is o ften  im pa irm ent o f 
rep roductive  a b ility , so tha t during m itosis the ce ll dies (A l-H indaw i and 
Wilson, 1965). Thus, fo llow ing  a sublethal dose o f - ^ 1 ,  although ce ll 
func tion  may persist fo r some tim e , the e ffe c ts  o f therapy on the capacity  
o f cells to  rep lica te  ensure eventual ce ll death (W alinder, Jonsson and Sjoden,
34.
1972).
I t  has been established from  experim enta l studies invo lv ing irra d ia tio n  
o f ra t thy ro id  tissue, and fo llow -up  of patien ts tre a te d  w ith  ^ -^ I,  th a t the 
ce ll mechanisms involved in rep lica tion  are more sensitive to  rad ia tion  
damage when compared w ith  the re la tive  rad ioresistance o f ce ll m etabo lic  
func tion  (Philp, 1966). Fo llow ing  133-1 therapy, the re fo re , the gland may be 
capable o f continued thyro id  hormone synthesis. When ce ll d ivis ion is 
s tim u la ted , however, the ce ll is unable to  undergo norm al m itosis and dies. 
In the norm al thy ro id  gland most cells are in interphase (i.e. not d iv id ing), 
although in a gland s tim u la ted  by e ithe r TSH or im m unological s tim u la to rs
the ra te  o f m itos is is increased (Greig et a l., 1969). Thus, gradual loss o f
thy ro id  ce il number may occur la te  a fte r 131j therapy is given, leading to
eventual thy ro id  fa ilu re . In a s im ila r manner, the go itrogenic properties o f
a n tith y ro id  drugs a fte r 131j therapy in experim enta l animals are lim ite d  
because o f m ito t ic  ce ll death (Doniach, 1953). Thus the im m ediate e ffe c t o f 
1-^1 tre a tm e n t on gland function  w ill depend upon a number o f ce llu la r 
physiological processes. Assuming th a t im m edia te  ce ll death does not occur, 
th y ro id  hormone secre tion  fo llow ing  131j adm in is tra tion  w il l be a func tion  o f 
the e ffe c ts  o f tre a tm e n t on thyro id  trapping, iodide oxidation and 
incorpora tion  in to  thyrog lobu lin , and on thy ro id  hormone release. In the long 
te rm , the a b ility  to  m ain ta in  hormone secretion w il l  also depend upon the
a b ility  to  m a in ta in  thy ro id  ce ll number through ce ll d iv is ion. The im p lica tio n  
of these concepts in c lin ica l aspects o f thy ro id  func tion  w ill be discussed
la te r.
Gamma emission from  decay of - ^ 1  contribu tes l i t t le  to  tissue
damage. However, th is emission allows ex te rna l gamma counting over the 
thy ro id  to  be perform ed, g iving accurate measurement o f radioisotope uptake 
by the gland.
1.3.3. H is to log ica l changes
The e ffe c ts  o f 131j therapy on thy ro id  gland histology have been 
reported  in a number o f studies. W ith in  tw o months o f adm in is tra tion  o f the 
isotope, ce ll necrosis, breakdown o f fo llic u la r s tru c tu re , in te rs tit ia l oedema 
and in te rs t it ia l fib ros is  are seen (Andrews, Kniseley, B igelow, et a l., 1954; 
Dobyns, V icke ry, M aloof, et a l., 1953). In anim al studies evidence of
chromosomal damage has been noted (Moore and C o lv in , 1966). There is
evidence tha t some o f the above e ffe c ts  are dose re la ted . A lthough in the 
ra t s ig n ifican t damage is caused by sm all doses o f 3-31i (2 4 0  RAD) (Speight, 
Baba and Wilson, 1968), a conventional therapy dose o f 131j jn man w }ji 
de liver around 5000 RADS.
Despite these abnormal h is to log ica l findings, thy ro id  tissue in such 
studies has been shown to  re ta in  the a b ility  to  tra p  iodide (Andrews et a l., 
1954): th is  is fu r th e r evidence of the re la tive  resistance o f the m etabo lic  
functions o f the fo llic u la r  ce ll to  the e ffe c ts  o f rad ia tion .
1.3.4.Choice o f isotope in rad io iod ine therapy
Ease o f p roduction, su itab le  spectra o f beta and gamma emission, and 
early  c lin ica l experience led to  the widespread use o f 131j jn the tre a tm e n t 
o f thyro tox icos is  in the 1950s and 1960s. I t  became apparent, however, tha t 
there  was a high incidence o f iatrogenic hypothyroid ism  in such patien ts, and 
th is  appeared to  be an inev itab le  consequence o f the emission characte ris tics  
o f th is radioisotope, leading to  rad ia tion  damage o f the thy ro id  fo llic u la r  ce ll 
nucleus w ith  consequent ce ll s te r iliz a tio n . In v itro  studies o f fib rob lasts  in 
cu ltu re  showed th a t cytop lasm ic irrad ia tio n  had no e ffe c t on ce ll d ivision, 
w h ile  irrad ia tio n  o f the nucleus resulted in ce ll s te r iliz a tio n  (Munro, 1970). 
The mean distance of tra v e l o f e lectrons e m itted  by decay o f 131j js many 
tim es longer than the length o f the thy ro id  fo llic u la r  ce ll, and nuclear 
irra d ia tio n  is the re fo re  inev itab le . These concepts led to  a ttem pts to 
evaluate an a lte rna tive  isotope of iodine ( ^ -T )  in the tre a tm e n t o f 
thyro tox icos is . - ^ 1  decays by emission o f low energy X -rays (27-35 Kev) 
and low energy e lectrons (3-34.5 Kev) (Anon, 1985a); the la rger proportion of 
rad ia tion  dose to  the thy ro id  is derived from  the la t te r .  These low energy 
electrons have a maximum range in tissue of 25 pM and since the fo llic u la r 
ce ll nucleus is 10 pM from  the apex ce ll/c o llo id  in te rfa ce , i t  was argued 
th a t i t  would la rge ly  escape rad ia tion  damage from  ^-^^1. Thus the e ffec ts  
o f rad ia tion  on ce ll d iv is ion would be reduced, w ith  consequent reduction in 
la te r hypothyroid ism  (E rtl,  Feinendegen and H e in iger, 1970; G reig, McDougal 
and Hainan, 1972). In theory, the only part o f the fo llic u la r  ce ll to  be 
substantia lly  irrad ia ted  would be the area adjacent to  the ce ll/co llo id  
in te rface , which is a s ite  o f iodide o rgan ifica tion .
In it ia l anim al studies supported th is hypothesis. In the ra t, reports 
suggested tha t 125j did not  s ig n ifica n tly  a ffe c t nuclear DNA synthesis or the
basally s ited iodide transport mechanism (Berdjis, Byers and B ice, 1972; 
V icke ry  and W illiam s, 1971).
M cDougall and co-workers were the f ir s t  to  report resu lts o f 125j 
therapy in patients w ith  thyro tox icos is , in a study dem onstrating th a t the 
isotope was e ffe c tiv e  in tre a tin g  the condition (M cDougall, G reig and 
G illesp ie , 1971). In a subsequent re p o rt o f the e ffe c ts  o f ^-25j tre a tm e n t in 
297 subjects, fo llow ed  fo r a m in im um  o f 6 months, the same group found 
th a t op tim a l results were obtained w ith  an estim ated dose o f 300 p C i/g  o f 
thy ro id  tissue (Bremner, M cDougall and G reig, 1973): com paring three doses 
o f 125iy these authors found th a t subjects given the lowest dose had a 
reduced incidence o f hypothyroid ism  in comparison w ith  the o ther tw o groups: 
64% o f the subjects in the low dose group were euthyro id . O ther in it ia l 
studies were encouraging: in a re p o rt from  New Y ork, three o f six patien ts 
had an episode o f reversib le hypothyro id ism  in the early  months a fte r therapy 
(W erner and Johnson, 1971). However, in longer te rm  fo llow -up  o f patients 
given i t  became apparent th a t the incidence o f hypothyro id ism
increased stead ily  w ith  tim e , as had already been dem onstrated w ith  131j 
(W eidger, Johnson and W erner, 1974). The incidence o f hypothyro id ism  
appeared to  be dose re la ted , and a high percentage of patients required more 
than one tre a tm e n t o f ^ ^ I .  i n a fo llow -up  study, 33% of patien ts given 
- ^ 1  became hypothyroid (M cDougall and Greig, 1976). I t  the re fo re  appeared 
th a t 125i tre a tm e n t o ffe red  no m ajor advantage when compared w ith  ^ 4 ,  
despite the prom ising early  anim al and human studies (Chapman, 1971; 
M cDougall and Greig, 1976). As ^31i had been in use fo r  than 20 year 
w ith o u t evidence o f other harm fu l e ffe c t,  i t  remained the isotope o f choice.
1.3.5. E arly  response to rad ioiodine therapy
As m ight be expected, the response of the thy ro to x ic  pa tien t to  ^-^1 
tre a tm e n t is not absolute: ra the r, there  is a spectrum o f outcome a fte r 
tre a tm e n t both in term s of tim e  and magnitude of response. This leads to 
an e lem ent o f uncerta in ty  w ith  regard to  early response to  3.31J. 
Considerable e ffo r t  has been expended in analysis o f facto rs which in fluence 
the outcome a fte r trea tm en t: i t  is intended to  consider these below. In th is 
section the response examined is th a t occurring early (w ith in  the f ir s t  12 
months) a fte r therapy. The problem o f la te  response (i.e. tha t o f cum ula tive  
permanent hypothyroidism ) w ill be discussed la te r.
The early  changes in thy ro id  physiology a fte r 3.31j adm in is tra tion  are 
not w e ll documented: th is  is la rge ly  a re fle c tio n  o f the dependence in vivo 
on tra ce r isotope studies which are techn ica lly  d i f f ic u l t  to  perfo rm  in 
subjects given the rapeu tic  doses of l ^ l j .  Evidence o f a m ild  rad ia tion  
th y ro id it is  is seen in a number o f patients who com plain o f d iscom fo rt in the 
neck several days a fte r tre a tm e n t (Einhorn, E inhorn, Fagraeus, e t a l., 1967). 
Associated w ith  th is  may be a rise in c ircu la tin g  thy ro id  hormone
concentrations, probably due to  leakage o f preform ed thy ro id  hormone across 
damaged ce ll membrane (Lam berg, Hernberg, Wahlberg, et a l., 1958). In 
some patients th is has been reported  to be associated w ith  d e te rio ra tion  in 
c lin ica l condition (Lam berg, 1959). Thus, in 1959, Lam berg reported  tha t 
thy ro id  cris is was seen in 5 o f 144 patients shortly  a fte r ^31i Was given: in 
view  of the date o f the re p o rt there  was no co rrobora ting  b iochem ica l data 
to  con firm  the probable rise in thyro id  hormone concentra tions in these 
patien ts. The same group reviewed th e ir experience o f a fu r th e r 387
patients trea ted  w ith  1311 and reported  tha t "im pending thy ro id  cris is" 
occurred in fou r (V iherkoski, Lam berg, Hernberg, e t a l., 1970). In su ffic ie n t 
data are availab le, however, to  ascerta in whether these fou r subjects
m an ifest d iffe re n t b iochem ica l changes from  the 383 in whom no c lin ica l 
de te rio ra tion  was seen. Shafer and N u tta l (1975) exam ined T3 and T4 
concentrations a fte r ^ -^ I  adm in is tra tion . They dem onstrated th a t in most 
subjects a sm all rise in T3 and T4 occurred, but tha t th is  was not re la ted  to 
dose. The rise in T3 appeared to  be greater, possibly re fle c tin g  the sm aller 
e x trace llu la r pool o f T3. In th is  study the authors suggested tha t c lin ica l 
de te rio ra tion  associated w ith  the rise in c ircu la tin g  thy ro id  hormone levels 
occurred around 5 days a fte r tre a tm e n t. In con trast, C reu tz ig  and 
colleagues, in a study o f 46 patients given - ^ I  tre a tm e n t, reported  only a 
sm all and inconsistent rise in T3 w ith in  the f ir s t  week a fte r trea tm en t
(C reutz ig , K a llfe lz , H a indl, et a l., 1976). More re ce n tly , Tamagnia reported 
tha t in a group of 14 patients given Propranolol along w ith  ^-^1, no m ajor 
change in T4 or T3 was seen (Tamagna, Levine and Hershmann, 1979). In 
three subjects a para lle l rise in both hormones did occur 10-12 days a fte r 
trea tm en t, but was not associated w ith  any c lin ica l de te rio ra tion . No 
re la tionsh ip  was seen between hormone change a fte r  tre a tm e n t and 
p re trea tm ent hormone levels or gland size.
Despite this ra the r co n flic tin g  evidence, the occurrence o f thyro id
storm  or c lin ica l d e te rio ra tion  a fte r 3.31j tre a tm e n t is w ide ly  acknowledged. 
Some o f the reports  o f its  occurrence are, however, ra the r anecdotal (Anon, 
1972): in a number o f cases in te rcu rre n t c lin ica l problems seem equally lik e ly  
to  be responsible fo r  the de te rio ra tion  as ^31i tre a tm e n t. However, Parker 
and Lawson (1973) in a re trospective  study reported  the occurrence o f 33 
deaths in patien ts w ith  thyro tox icos is , 20% o f whom had had 131j tre a tm e n t 
in the preceding th ree  weeks. A lthough there was in su ffic ie n t c lin ica l or
b iochem ica l data in ind iv idua l cases to  come to  any conclusions, i t  is possible 
th a t, in some o f these subjects, de te rio ra tion  in c lin ica l s ta te  resu lted from  
hormone release a fte r  131i adm in is tra tion . Patien ts w ith  m ajor in te rcu rre n t
illness may be especia lly at risk .
Support fo r  the concept o f d isruption o f thy ro id  ce ll in te g r ity  leading 
to  release o f hormone comes from  evidence o f a rise in c ircu la tin g  
thyrog lobu lin  concentrations shortly  a fte r 131j tre a tm e n t (Gardner, Rothm an 
and U tig e r, 1979): i t  is possible th a t th is  paralle ls a rise in T3 and T4 levels, 
although there  are no data on th is point.
A p a rt from  th is ra the r non-specific  " in ju ry "  pa tte rn  which may occur 
a fte r ^31j therapy, subsequent thy ro id  hormone production w il l be determ ined 
by the e ffe c ts  o f - ^ 1  on the ind iv idua l components o f hormonogenesis: iodide 
trapp ing and iodide o rgan ifica tion . I f  ce ll death occurs, both trapping and 
o rg an ifica tion  fa i l,  and hypothyroidism  ensues rapd ily .
Studies o f the e ffe c t o f 131j 0n iodide transport and o rgan ifica tion  in
vivo re ly  on tra ce r radioisotope studies, e ithe r radioiodide or rad ioactive
m ateria ls  which are trapped by the thy ro id  in a s im ila r manner, such as
-P e rtechneta te . In two early studies M yant (1953 a + b) examined 2-
hour uptake o f - ^ 1  in a sm all group o f patients given therapeutic  ^ -^ I.  He 
found th a t three weeks a fte r trea tm en t uptake values were, in the m a jo rity  
o f subjects, low er than subsequent values suggesting a temporary inh ib ition  
o f iodide uptake. However, there are considerable techn ica l d i f f i c u l t i e s  in 
measuring 131j uptake in a gland w ith  a high background count o f the same 
radioisotope, and the accuracy of these data may be open to  question. I t  is 
o f in te res t tha t M yant noted the persistance of high uptake values in some 
patients c lin ic a lly  euthyro id  a fte r 31j. He concluded tha t "ce lls  have the 
a b ility  to  trap  iodide, but tha t hormone secretion is abnorm al". This would 
be consistent w ith  a defect o f iodide o rgan ifica tion  and preservation o f 
trapp ing func tion  by the gland.
In a m ajor study o f tra ce r radioisotope behaviour in re la tion  to  the 
tre a tm e n t o f thyro tox icos is  Larsson (1955) in c lu d e d  3- and 24-hour uptake 
studies o f ^.31j ancj a|s0 examined urinary 131i e x c re tio n . He showed tha t 
in patients who a tta ined  c lin ica l euthyro id ism  the "a b il ity  o f the gland to  
accum ulate 131j was 0fte n  depressed to  a subnormal leve l during the f ir s t  
few  months a fte r  tre a tm e n t, fo llow ed by a recovery during the fo llow ing  
months". He also reported  a lag between change in rad ioisotope uptake and 
c lin ica l and b iochem ica l responses, and suggested th a t radioisotope studies 
m ight have some p red ic tive  value. L ike  M yant (1953a), he also showed tha t 
uptake measurements were elevated in some patients who were c lin ic a lly  
euthyro id  a fte r tre a tm e n t. As the uptake measurements in th is  study were 
a ll " la te "  (i.e . g reater than 3 hours a fte r adm in is tra tion  o f isotope), no 
d e fin ite  conclusions can be drawn about the e ffe c t o f 131j tre a tm e n t on the 
d iscrete  functions o f iodide trapp ing and o rgan ifica tion .
Einhorn and Hastad (1961) examined early  (11 m inute) uptakes o f 132j 
in 41 patien ts, three and eight weeks a fte r ^ -^ I therapy. They showed tha t 
in the m a jo rity  o f patien ts early  iodide uptake had fa lle n  by three weeks 
a fte r tre a tm e n t: in subjects who entered remission th is  fa l l  was greater than 
in subjects who fa ile d  to  respond. This study, in which a very early  uptake 
was measured, suggests tha t the in it ia l fa l l  in uptake seen a fte r ^31i 
tre a tm e n t is a consequence of rad ia tion  inh ib ition  o f iodide trapp ing. As th is 
step is ra te - lim it in g  in thyro id  hormonogenesis (Ingbar, 1978), th is w ill have a 
m ajor in fluence on subsequent b iochem ical function .
In 1973, Sagel and co-workers reported, in a re trospective  study, th a t 
a 6-hour uptake which fa ile d  to fa l l a fte r ^-^1 tre a tm e n t was a p red ic to r o f 
relapse of thyro tox icos is  (Sagel, Epstein and Jackson, 1973). Sequential 
uptake data were not included in th is study.
The find ing  th a t changes in thyro id  iodide handling precede a ltered 
hormone secretion has been confirm ed by o ther workers: Franco showed tha t 
w h ile  uptake values had fa llen  w ith in  two weeks o f ^ -^ I tre a tm e n t, changes 
in T3 and T4 occurred several weeks la te r (Franco, Coppler and Kovaleski, 
1970). Using ^ mTc, Gray (1975) showed tha t a 15 m in uptake fe ll in most, 
but not a ll, patients given 131i ancj w^ 0 subsequently became hypothyroid or 
euthyro id  w ith in  tw o months of trea tm en t. In some patients who fa iled  to 
enter remission a sm all fa l l in uptake was also seen, but th is was not a 
consistent find ing . As th is isotope is not organ ified  in human thyro id , such
changes in uptake should re f le c t ^.31j re la ted e ffe c ts  on iodide trapping. I t  
is o f in te res t tha t in patien ts given 3-23i therapy, 99m-j-c uptake fe ll w ith in  
two days a fte r tre a tm e n t.
Gray (1975) also studied the e ffe c t o f 131j ancj 125j tre a tm e n t on 
iodide o rgan ifica tion  using an intravenous perchlorate  discharge tes t. He 
dem onstrated tha t in the f ir s t  3 months 33% o f patients had a defect o f 
iodide o rgan ifica tion  a fte r 3-31j tre a tm e n t, but, a t la te r periods a fte r therapy, 
such defects were uncommon. In contrast, o rgan ifica tion  defects were seen 
in 64% of patients given 3.23i  therapy, and this high incidence persisted over 
the next few  months. This would tend to  support the hypothesis, discussed 
above, tha t ^ ^ I  irrad ia tes  p rin c ip a lly  the portion o f the ce ll responsible fo r 
iodide o rgan ifica tion , in con tras t to  131j w hich delivers a more un ifo rm  ce ll 
rad ia tion  dose.
There have been no o ther spec ific  studies o f the e ffe c t o f 131j 
tre a tm e n t on iodide o rg an ifica tion . However, a number o f authors have 
reported  tha t patients who became euthyro id were abnorm ally sensitive to 
iodide induced myxoedema, and th a t the doses o f iodide necessary to  cause 
th is were unusually sm all. This may be in d irec t evidence o f a pa rtia l 
o rgan ifica tion  block in such subjects, although no d ire c t measurements o f 
iodide o rgan ifica tion  were reported  (Braverman, Woebert and Ingbar, 1969; 
Braverm an, Ingbar, Vagenakis, e t a l., 1971).
In summary, the re fo re , there are surpris ing ly few  data on the early 
e ffe c ts  of l - ^ I  on thyro id  physiological processes: many of the available 
findings were published before the widespread a va ila b lity  o f accurate 
measurement o f T3, T4 and TSH. Most studies o f thy ro id  iodide handling in 
th is  s itua tion  have not been designed to  separate iodide trapp ing from  iodide 
o rgan ifica tion . There is general agreement tha t uptake o f tra ce r radioisotope 
fa lls  to  a variable exten t a fte r the adm in istra tion  of ^ -^ I.  In a proportion 
of patients uptake values may subsequently re tu rn  towards p re trea tm ent 
levels. The studies o f Gray (1975) and the early uptake studies o f Einhorn 
and Hasted (1961) suggest tha t most o f the changes seen in uptake are a 
consequence o f an e ffe c t on iodide trapping, and tha t iodide o rgan ifica tion  is 
re la tiv e ly  unimpaired. These concepts are examined fu r th e r in the 
experim enta l section o f th is thesis.
Data on other physiological variables, such as in te rm ed ia ry  m etabolism  
or contro l of thyro id  hormone release are not available. From  the foregoing
discussion i t  is c lear tha t c lin ic a l and b iochem ical responses to l - ^ I
tre a tm e n t are dependent upon the e ffe c t o f therapy on thy ro id  iodide
handling.
1.3.6. O utcom e and c lin ica l response fo llow ing  1 ^ 1  therapy
The spectrum  o f b iochem ical and c lin ic a l response to - ^ I  re fle c ts  the 
v a r ia b ility  o f the e ffe c t o f therapy on thy ro id  physiological processes:
d ivision o f patien ts in to  d iscrete  categories o f thyro id  status (e.g. 
hypothyro id , eu thyro id , th y ro to x ic ) is based on biochem ical assessment using 
ra the r a rb itra ry  ranges o f c ircu la tin g  thy ro id  hormone concentrations. The 
c la ss ifica tion  is, however, c lin ic a lly  convenient and allows comparison o f 
resu lts o f therapy to be made from  one series to  another. Before the
developm ent o f accurate radioimmunoassay techniques fo r measurement o f 
thy ro id  hormone concentrations, b iochem ica l d e fin itio n  o f thyro id  status was 
less re lia b le . This is especially so o f patien ts w ith  m ild  hypothyro id ism , and 
i t  is lik e ly  th a t in early  series the incidence o f th is was underestim ated.
In general term s, th y ro to x ic  patien ts given tre a tm e n t may rem ain
th y ro to x ic  or become euthyro id  w ith in  a variable  period o f tim e . 
Subsequently, euthyro id  patients may have a relapse o f thyro tox icos is , rem ain 
euthyro id  or become hypothyro id. In a few  instances subjects who have 
become hypothyro id  recover normal thy ro id  hormone secretion (trans ien t 
hypothyro id ism ). As discussed previously, the development o f hypothyro id ism  
a fte r  a long period of stable euthyro id ism  (la te  hypothyroid ism ) is thought to  
be a consequence o f gradual thyro id  fa ilu re  resu lting  from  rad ia tion  induced 
ce ll s te r iliz a tio n  and death. This w ill be discussed la te r.
During the f ir s t  two weeks a fte r ^ -^ I  tre a tm e n t there is m ild  
rad ia tion  th y ro id it is  which may be accompanied by a rise in c ircu la tin g  
thy ro id  hormone concentrations (1.3.3.). In some patients th is may be 
accompanied by a variable degree o f loca l tenderness and pain on swallow ing. 
Early  estim ates suggest tha t these symptoms are lim ite d  to less than 10% o f 
patien ts trea ted  although spec ific  enquiry may reveal a higher incidence 
(Becker and H urley, 1971).
Fo llow ing  the adm in is tra tion  o f 1 ^ 1  there is a lag period before 
b iochem ica l response becomes evident (Larsson, 1955), accounted fo r by the 
stores o f preform ed thyro id  hormone contained w ith in  the co llo id  o f the 
gland which have a b io log ica l h a lf l i fe  o f 14 days. The e lim ina tion  h a lf- l ife
o f thyroxine  in plasma is approx im ate ly  seven days and even i f  l ^ l j  therapy 
causes a cessation o f a ll new thyro id  hormone synthesis, there w il l be an 
inev itab le  delay o f several weeks before the b iochem ica l and c lin ica l 
m an ifesta tions o f hypothyro id ism  are evident (N ic o lo ff, Low , Dussault, e t a l.,
1972).
The exten t o f the b iochem ica l response to  1 ^ 1  w il l depend upon the 
residual capacity  o f the gland to  secrete thyro id  hormone. The aim o f 
tre a tm e n t has usually been to  render the pa tien t eu thyro id , and
hypothyroidism  has been seen as a disadvantage. Because o f th is , studies
were conducted to see i f  low doses o f could reduce the incidence of
hypothyroid ism  (Glennon, Gordon and Sawin, 1972; Hagen, O u lle tte  and 
Chapman, 1967; H ard is ty , Sm ith, B ethe ll, et a l., 1981). In most the
incidence o f early  hypothyro id ism  was reported to  be dose re la ted : i t
appears, however, th a t th is  occurred at the expense o f fa ilu re  o f a greater 
p roportion  o f patien ts than norm al to  respond adequately to  tre a tm e n t so 
th a t m u ltip le  doses o f 1 ^ 1  become necessary. In some series in which lower 
than usual doses o f ^ -^ I  have been given, response rates are d if f ic u l t  to
evaluate, as ^ -^ I  has been given in com bination w ith  long-te rm  potassium 
iodide or an tith y ro id  tre a tm e n t (Cevallos, Hagen and M aloof, 1974; Rapoport, 
Caplan and De G root, 1973; Sridama, M cC orm ick, Kaplan, e t a l., 1984). 
Summarised data from  a representative  selection o f series, illu s tra tin g  the 
e ffe c t o f dose on response ra te  and incidence o f early  hypothyro id ism , are 
shown in Table 1.
O f the patients who fa i l to  respond w ith in  a few  months to  the in it ia l 
dose o f ^-'^1, the m a jo rity  become euthyro id  fo llow ing  a second dose: a small 
number o f patients require  three doses or more. Most patien ts respond to 
1 ^ 1  trea tm en t w ith in  six months, and, in most series, there is the re fo re  
l i t t le  d iffe rence  in response ra te  at six months compared to tha t at 12
months (Dworkin, 1974). S im ila rly , the m a jo rity  o f cases o f early 
hypothyroidism  are detected w ith in  the f ir s t  six months of tre a tm e n t (N ofa l, 
Beierwaltes and Patno, 1966).
In summary, the response to  l - ^ I  occurs early a fte r tre a tm e n t: the
dose o f l - ^ I  p a rtly  determ ines th is response. Hypothyro id ism  as a resu lt o f
therapy can a ffe c t between 8 and 90% o f patien ts, in the f ir s t  year,
131depending on the dose o f I  given. There is some evidence tha t the 
incidence o f early  hypothyroid ism  is increasing as a resu lt o f a tendency
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towards adm in is tra tion  o f h igher doses o f l ^ l j  (A le v iza k i, A le v izak i and 
Ikkos, 1985). In the experience o f the Mayo C lin ic  over the last 30 years, 
the incidence o f early  hypothyro id ism  in the most recent years is greater 
than 90% (Cunnien, Hay, Gorman, e t a l., 1982).
1.3.7. T ransient hypothyro id ism
Occurrence o f hypothyro id ism , which is reversib le  w ith in  the f ir s t  few  
months a fte r tre a tm e n t, has been reported in several studies o f patients 
given 1 ^ 1  (Chapman, M aloof, M aisterrena, e t a l., 1954). The incidence of 
th is varies from  series to  series. Segal e t al. reported data on more than 
1600 patien ts, and found th a t 7% had an episode o f trans ien t hypothyroidism 
a fte r tre a tm e n t (Segal, S ilver, Yokalem , e t a l., 1961). M cG irr found th a t 
11% o f patients in a sm a lle r series developed th is com p lica tion  (M cG irr, 
Thomson and M urray, 1964); more recen tly , Sawers and colleagues detected 
the phenomenon in 5% o f subjects given l ^ l j  (Sawers e t a l., 1982). I t  is o f 
in te res t, the re fo re , th a t some authors make no m ention o f the phenomenon. 
The mechanism of recovery o f thyro id  function  has not been adequately 
explained, nor have methods o f d iffe re n tia tin g  p o te n tia lly  trans ien t 
hypothyroid ism  from  permanent loss o f thyro id  func tion  been described. 
Dorfm ann has suggested th a t i f  hypothyroid ism  occurs in a subject shortly  
a fte r  therapy, in whom l i t t le  change in go itre  size has occurred, there
is a possib ility  tha t recovery o f thyro id  function  may occur (Dorfm ann, 
Young and C are tta , 1977). The fa ilu re  o f some authors to  de tec t transien t 
hypothyroid ism  suggests th a t in some series the incidence o f early , permanent 
hypothyroidism may be increased owing to the inclusion o f subjects w ith  
p o te n tia lly  reversib le  thy ro id  fa ilu re . The phenomenon o f trans ien t 
hypothyroid ism  and the experience in the present work are examined more 
fu lly  la te r.
1.3.8. Factors which in fluence the early  response to  1 ^ 1  therapy
(a) G oitre  size In most series o f patients given 1-^1, ca lcu la tion  o f 
the adm inistered dose has included a correction  fa c to r fo r  go itre  size, 
resu lting  in patients w ith  large goitres receiving greater doses o f ^ -^ I  than 
those w ith  sm aller glands. In a review  of 850 patients trea ted  over 16 
years, N ofa l concluded tha t hypothyroidism  occurred w ith  increasing 
frequency in patients w ith  sm all goitres (Nofal et al. 1966). This may e ithe r
re f le c t a rea l tendency fo r patien ts w ith  sm all glands to  be more susceptible 
to 1-^1 tre a tm e n t, or may ind icate  tha t the accuracy o f most estim ates o f 
go itre  size is poor, w ith  a tendency fo r c lin ic ians to  under-estim ate  the mass 
o f large go itres. However, the find ing  o f a higher incidence of 
hypothyro id ism  in patien ts w ith  sm all go itres was also noted by Segal in a 
rev iew  o f 1600 trea ted  patients (Segal e t a l. 1961). In patients w ith  an
estim ated gland mass o f less than 30 g, 12% developed hypothyroid ism  w h ils t 
only 4.4% o f those w ith  an estim ated gland mass o f g reater than 60 g did 
so.
(b) N od u la rity  o f go itre  Most patients w ith  thyro tox icos is  have Graves' 
disease, and thus have re la tiv e ly  d iffuse goitres. Thyro id  nodu la rity  results 
in re la tiv e  resistance to  the e ffe c ts  o f 1 ^ 1  tre a tm e n t, so tha t the incidence 
o f early  post tre a tm e n t hypothyroid ism  is reduced (M ille r, 1971), and a higher 
percentage o f pa tien ts  require  more than one dose o f l - ^ I .  This resistance 
to  the e ffe c ts  o f 1-^1 may be a consequence o f the non-homogeneous 
d is trib u tio n  o f 1-^1 which can be dem onstrated using autoradiography 
(K reu tze r e t a l. 1950), so tha t the func tiona l mass o f thyro id  tissue 
irrad ia ted  is less. The incidence o f la te  onset hypothyro id ism  in patients
w ith  nodular goitres given may not, however, be reduced (Fontana,
C u rti,  B igg i, e t a l., 1980).
(c) O ther tre a tm e n t o f thyro tox icos is  In his m ajor re trospective  
review  o f 1600 patients given ^ ^ 1 ,  Segal reported th a t p re trea tm en t o f 
patien ts w ith  a n tith y ro id  drugs was associated w ith  a low er incidence o f 
hypothyroid ism  (4.3% versus 9.4%) (Segal e t al. 1961). The e ffe c t o f 
p re trea tm en t w ith  the a n tith y ro id  drug m e thy lth io u ra c il on response to  1-^1 
tre a tm e n t was prospective ly studied by Crooks e t a l., who compared a group 
o f patien ts given the drug u n til f ive  days before ^ -^ I  w ith  a s im ila r group
given no p re trea tm en t, and showed tha t the single dose cure ra te  was
reduced in the fo rm e r group (Crooks, Buchanan, Wayne, e t a l., 1960). In a 
fo llow -up  study, Buchanan showed tha t th is e ffe c t was not seen in patients 
p re trea ted  w ith  potassium perchlorate  (Buchanan, Keutras, Crooks, e t a l., 
1965). In a study o f the e ffe c t o f p re trea tm en t w ith  carbim azole on 
response to  1 ^ 1  therapy, Goolden and Fraser (1969) were unable to 
dem onstrate any e ffe c t on outcome over one year. However, trea tm en t w ith  
carb im azole both before and a fte r l ^ l j  therapy was reported to  lessen the 
incidence o f early  hypothyroidism  in comparison w ith  1-^1 alone (A ro,
H uttunen, Lam berg, e t a l., 1981; B lidda l, Hansen, Rogowski, et a l., 1982; 
Reynolds and Kotchen, 1979). In these studies a n tith y ro id  drugs were stopped 
48 hours before was given and res ta rted  48 hours a fte r  tre a tm e n t. In a
much sm aller study Steinbach and co-workers reported  tha t concurrent
tre a tm e n t w ith  p ro py lth io u rac il or m ethim azole reduced the incidence of 
early  hypothyroid ism  compared w ith  ^--^I alone, although the numbers 
involved in th is study (11 patien ts in each group) make the sign ificance of 
th is report uncerta in  (Steinbach, Donoghue and Goldman, 1979).
These data suggest th a t the e ffe c t o f l ^ l j  j s re duced in patients given 
th ioury lene a n tith y ro id  drugs both before and a fte r 1 ^ 1  tre a tm e n t, w hile  the 
find ing  o f Crooks and colleagues (1960) suggests th a t th is  also occurs in 
patien ts given a n tith y ro id  drugs only before 1-^1. The mechanism o f this
e ffe c t is unclear. A ll o f the drugs shown to  have an e ffe c t are members o f 
the th iourylene group, whereas perch lora te , which had no demonstrable e ffe c t 
in the study o f Buchanan e t al. (1965) is chem ica lly  and pharm acologically 
d iss im ilar. Thiourylene drugs are accum ulated and undergo m etabo lic
degradation w ith in  the thy ro id  gland. I t  is possible, the re fo re , tha t the 
e ffe c t o f these drugs on response to  ^ -^ I  is a consequence o f a 
pharm acological in te rac tio n  between drug and thyro id  gland. Drugs o f th is 
class act by inh ib iting  iodide o rgan ifica tion  (M aloof, Sm ith and Soodak, 1969), 
and i t  may be tha t the reduction  o f response to  1-^1 tre a tm e n t is a 
consequence o f im pa irm ent o f re ten tion  o f radioisotope w ith in  the thyro id  
gland. The only study which has examined th is  po in t is tha t o f Crooks et al. 
(1960) who reported th a t the b io log ica l h a lf- life  o f therapeutic  ^ -^ I  was not 
a ffe c ted  by p re trea tm ent w ith  m e thy lth iou rac il. The mechanism of the
rad io -p ro te c tive  e ffe c t o f an tith y ro id  drug tre a tm e n t is examined fu rth e r in 
th is  thesis.
Previous thyro id  surgery or previous 1-^1 tre a tm e n t increase the 
incidence o f post tre a tm e n t hypothyroidism  (Segal e t al. 1961), presumably by 
decreasing the functiona l mass o f thyro id  tissue to be irrad ia ted .
(d) Ind iv idua l se n s itiv ity  From the discussion above i t  w il l be evident 
tha t the early response to  1 ^ 1  therapy is d if f ic u lt  to p red ic t and is 
influenced by a number o f fac to rs . The con tribu tion  o f ind iv idua l sens itiv ity  
to  irrad ia tio n  in determ in ing  the response is d if f ic u lt  to  determ ine; th is is 
p a rtly  because o f problems inherent in accurate measurement o f the dose o f 
irrad ia tio n  deposited per un it o f thyro id  tissue fo llow ing  l ^ l j  adm in is tra tion .
I t  seems like ly , however, tha t there  are in te rind iv idua l fac to rs  which also 
in fluence the ex ten t o f tissue damage caused by 1-^1.
1.3.9. La te  hypothyroid ism
The concept th a t hypothyro id ism , occurring " la te " a fte r l ^ l j  therapy is 
a consequence o f ce ll s te r iliz a tio n , has been w ide ly accepted (Philp, 1966). 
There is in v itro  evidence th a t thy ro id  ce lls are unable to  re p lica te  a fte r 
re la tiv e ly  small doses o f 1-^1, when ce llu la r m etabo lic  func tion  is unim paired 
(A l-H indaaw i and Wilson, 1963; Munro, 1970), and th is e ffe c t is irreve rs ib le . 
I t  is there fo re  reasonable to  suggest tha t a s im ila r mechanism in vivo 
accounts fo r gradually developing, la te-onset thyro id  fa ilu re .
I t  has been suggested th a t im m unological fac to rs  m ight play a pa rt in 
the development o f hypothyro id ism . Green and Wilson (1964) dem onstrated 
th a t the incidence o f hypothyroid ism  a fte r  subtota l thyro idectom y was re la ted  
to  h is to log ica l evidence o f th y ro id it is  in excised tissue, and suggested th a t, in 
a s im ila r manner, the occurrence o f hypothyroid ism  a fte r 1 ^ 1  therapy m igh t 
be re la ted  to  im m unological d isturbance. Burke and S ilverste in  (1969) 
reported  tha t thyro id  autoantibodies were found, in higher t i t re ,  in patien ts 
becoming hypothyroid in the f ir s t  year a fte r l ^ l j  therapy, but did not extend 
the study to examine hypothyroidism  occurring  la te r. In a re trospec tive  
study o f patients fo llow ed fo r  up to  12 years, Lundell and Holm  (1980) 
dem onstrated tha t hypothyroid ism  was s ig n ifica n tly  more common in patients 
who had high t itre s  o f antibody to  thyrog lobulin  and cytop lasm ic antigen 
before trea tm en t. In patients who developed such antibodies a fte r tre a tm e n t 
hypothyroid ism  also occurred more commonly. However, closer exam ination 
o f these data suggests tha t the increase in hypothyroidism  was a phenomenon 
occurring  in the f ir s t  12 months a fte r tre a tm e n t, and the annual incidence 
o f hypothyroidism  the re a fte r was s im ila r in patients who were antibody 
positive  or negative. From the above studies, the re fo re , there is no 
convincing evidence tha t la te  hypothyroid ism  is d ire c tly  re la ted  to 
im m unological fac to rs .
In a ll series o f patients fo llow ed  fo r a number o f years a fte r  l - ^ I  
tre a tm e n t, the percentage of patien ts who become hypothyro id  has been 
noted to increase w ith  tim e . Greig (1973) found tha t 15 years a fte r 
tre a tm e n t, nearly 80% o f patients were hypothyroid, w hile  N o fa l et al. (1966) 
in the United States reported a 70% incidence at 10 years a fte r tre a tm e n t.
In comparison, a surg ica lly  tre a te d  group had a 10 year incidence o f 
hypothyro id ism  o f 43%. This la te  incidence of hypothyro id ism  is ra the r 
higher than reported in early  series, and th is is lik e ly  to  be a consequence o f 
the longer period of fo llow -up  in la te r studies. The annual ra te  o f 
development o f hypothyroid ism  a fte r  the f ir s t  year is reported  in most series 
to  be between 2 and 4% per year (D w orkin, 1971; Greig 1966; T o ft,  Irv ine , 
Seth, e t a l., 1975). This appears to  be unrelated to  the dose o f l ^ l j  
adm inistered: Glennon et al. (1972), in a review  o f patients given between 3 
and 4 m Ci o f l - ^ I  reported  an annual incidence o f hypothyroidism  o f 3-4%, 
s im ila r to the figu re  quoted in the study by Sm ith and Wilson (1967) in the 
U n ited  Kingdom in which a range o f doses o f l ^ I  were adm inistered. Thus, 
a lthough dose of ^ -^ I  influences the early  development o f hypothyro id ism , 
la te  onset thy ro id  fa ilu re  appears to  be an inexorable, dose independent 
phenomenon.
Patients w ith  m u ltinodu la r go itre , or autonomously func tion ing  single 
nodules have been thought to  be re la tiv e ly  res istant to  the e ffe c ts  o f 1-^1 
M ille r , 1971). However, in a c a re fu lly  analysed series using l i fe  table 
method o f analysis, the cum ula tive  incidence o f hypothyroid ism  20 years 
a fte r tre a tm e n t was found to  be 44% (Fontana et al. 1980). In o ther studies 
o f patients w ith  e ithe r m u ltip le  or single nodules given - ^ 1 ,  the occurrence 
o f hypothyroid ism  was s im ila r to  th a t seen in patients w ith  d iffuse  goitres 
(Hamburger, Kadian and Rossin, 1967), and may re f le c t the low  dose of 
rad ia tion  necessary to  cause ce ll s te r iliz a tio n  (W alinder et al. 1972).
As m ight be expected, the development o f hypothyroid ism  la te  a fte r 
tre a tm e n t is a gradual process w ith  insidious c lin ica l onset. T o ft has 
characterised the biochem ical fea tures o f la te  onset hypothyroid ism  in a 
series o f papers (T o ft, Irv ine , H unte r, et a l., 1974; T o ft e t a l., 1975; T o ft, 
Irv in e , Seth, e t a l., 1978). He dem onstrated tha t only those patients who 
were euthyro id (normal T4 and T3) but w ith  an elevated concentra tion  o f 
TSH develop hypothyroid ism  over a re la tiv e ly  short period o f fo llow -up . In 
any 12 months period, a fte r the f ir s t  year, between 2 and 6% o f such 
patients w ill become hypothyro id, which is in general agreement w ith  other 
annual rates discussed above. Patients w ith  normal basal TSH concentrations 
did not become hypothyroid over th is  tim e , although a few  developed high 
basal TSH levels. This p re d ic ta b ility  o f development o f thy ro id  fa ilu re  has 
im p lica tions fo r the organisation o f long-te rm  fo llow -up  o f patien ts given
1-^1 therapy ( discussed below).
1.3.10. Subclin ica l hypothyro id ism
This te rm  is used to  describe the b iochem ica l syndrome o f a high 
basal concentra tion  o f TSH associated w ith  c ircu la tin g  T3 and T4 levels 
w ith in  the norm al re ference range. While there  is no dispute tha t patients 
w ith  b iochem ical hypothyro id ism  require  thy ro id  hormone rep lacem ent 
therapy, the true  thy ro id  status o f patien ts who are subc lin ica lly  hypothyro id  
is a m a tte r o f some debate (Evered, Orm ston, Sm ith, et a l., 1973; Evered, 
Young, Tunbridge, et a l., 1975; T o ft, K e lle t, Sawers, et a l., 1982). The 
problem only became recognised w ith  the development o f accurate and w ide ly 
availab le assays fo r TSH. I t  is c lear from  the studies o f T o ft, however, tha t 
a proportion  o f patients w il l develop subclin ica l hypothyroid ism  fo llow ing  1 ^ 1  
therapy, and th a t around 2-6% o f such patients w ill become fra n k ly  
hypothyroid  over 12 months o f fo llow -up .
I t  is lik e ly  th a t the e levated basal TSH re fle c ts  a sm all fa l l in free  
thy ro id  hormone concentrations. This s tim u la tes the thy ro id  to  secrete more 
hormone in an a tte m p t to  m ain ta in  euthyro id ism . In the TSH stim u la ted  
gland the ra tio  o f m onoiodotyrosine to d i-iodotyrosine  is increased and, 
fo llow ing  coupling, T3 is the re fo re  secreted in g reate r than usual amounts, 
w h ile  T4 concentrations may not change (Taurog, 1978). The unique 
requirem ent o f p itu ita ry  tissue fo r a high proportion  o f in tra ce llu la r T3 to  be 
derived from  loca l m onodeiodination o f T4 means th a t the TSH induced rise 
in c ircu la tin g  T3 does not suppress the increased TSH secretion (Siwa e t al. 
1978). Thus, increased thyro id  hormone secretion may be m aintained w ith o u t 
desensitising the th y ro id /p itu ita ry  feedback loop. As other body tissues are 
able to  u tilise  c ircu la tin g  T3 fo r thyro id  hormone needs, i t  is lik e ly  tha t 
tissue euthyro id ism  is m aintained. Studies o f cardiac c o n tra c tility  in patients 
w ith  subclin ica l hypothyroid ism , have shown tha t T4 tre a tm e n t produces no 
demonstrable change in cardiac function  (Ridgway, Cooper, W alker, et a l.,
1980). I f  th is im plies tha t there is no hypothyroidism  at tissue level (o ther 
than the p itu ita ry ) there may be no ju s tif ic a tio n  fo r rou tine  use o f thy ro id  
hormone replacem ent in such patients, especially i f  more than 90% o f th is 
group are lik e ly  to  have unchanging biochem ical thyro id  function  during 
short-te rm  fo llow -up . However, i t  has been suggested tha t subclin ica l 
hypothyroidism  is a risk fa c to r fo r ischaemic heart disease. Tunbridge and
50
colleagues review ed 105 patients trea ted  previously w ith  therapy, and
showed tha t those w ith  raised basal TSH concentrations but norm al T3 and 
T4 levels had e levation  of serum cholestero l (Tunbridge, Harsoulis and 
Goolden, 1974). Fo llow -up one year la te r showed tha t no m ajor change in 
b iochem ical func tion  had occurred. This e levation  o f cholestero l m ight be an 
arguement in favour o f tre a tin g  such patients w ith  thyrox ine . I t  is the re fo re  
o f some in te res t th a t re trospective  studies o f patien ts w ith  ischaemic heart 
disease have suggested tha t the incidence o f m ild  abnorm alities o f thy ro id  
func tion  (positive  thy ro id  autoantibodies or borderline e levation o f TSH) is 
greater than normal (Tieche, Lipi, Gutzwiller, et al., 1981). This is 
an important question which remains unresolved at present. ____
1.3.11. Adverse e ffe c ts  o f - ^ 1  tre a tm e n t
A pa rt the inexorable development o f hypothyro id ism , 1-^1 tre a tm e n t is 
rem arkably free  o f side e ffe c ts . In a sm all number o f patients m ild  
rad ia tion  th y ro id it is  results in loca l tenderness over the gland, and the 
possible exacerbation o f thyrotoxicosis due to  a trans ien t rise in T3 and T4 
concentrations fo llo w in g  adm in is tra tion  has been discussed previously.
(a) Salivary gland function  The sa liva ry  glands in man are able to 
trap  iodide in a s im ila r manner to  the thy ro id , although no s ig n ifican t 
o rgan ifica tion  o f  the anion subsequently occurs, and iodide is secreted in 
saliva (B row n-G rant and Taylor, 1963; F le tche r, Honour and Rowlands, 1956; 
Lazarus, 1972). 1 ^ 1  is the re fo re  accum ulated by sa livary glands and, 
although re ten tio n  o f the isotope w il l be re la tiv e ly  short-lived , some rad ia tion  
e ffe c ts  m ight be expected. In patients given ^ -^ I  in large doses fo r thy ro id  
cancer some im pa irm en t o f sa livary gland func tion  has been reported 
(Doniach, 1978), resu lting  in dryness o f the mouth. There are, however, no 
reports o f th is  occurring as a permanent consequence of conventional 
therapeutic  doses of ^ -^ I  given fo r thyro tox icos is .
(b) P arathyro id  function  The p ro x im ity  o f the parathyro id glands to 
the thyro id  suggests tha t rad ia tion  induced im pa irm ent o f parathyro id  
function  m ight occur a fte r ^ -^ I adm in is tra tion . Adams and Chalmers (1965) 
suggested tha t 10% patients given 1-^lj have im paired parathyro id  reserve, 
based on abnorm alities in the m ob iliza tion  o f ca lcium  from  bone a fte r 
adm in is tra tion  o f the calcium  chelator EDTA. Harden and colleagues 
dem onstrated increased urinary phosphate excre tion  in patients fo llow ing  l - ^ I
tre a tm e n t, and also suggested tha t parathyro id  func tion  m igh t be dim inished 
(Harden, H arrison and A lexander, 1963). There are, however, very few  
documented cases o f gross biochem ical hypoparathyro id ism  w ith  
hypocalcaem ia fo llo w in g  1-^1 tre a tm e n t ( Orme and C onnolly, 1971; J ia la l, 
P illa y  and Asm al, 1980).
The other im p o rta n t hormone involved in ca lc ium  homeostasis is 
ca lc iton in , secreted by the pa ra fo llicu la r (C) cells o f the thy ro id . Again, i t  
would be reasonable to  suspect tha t ca lc iton in  de fic iency m ight be a 
consequence o f 1-^1 therapy. The e ffec ts  o f ca lc ito n in  de fic iency on serum 
ca lc ium  and bone tu rnover rates are not c lear (Sm ith, Fraser and Wilson,
1973). However, i t  has been suggested th a t the reduction  in to ta l bone mass 
seen in thyro idectom ised  subjects is a consequence o f ca lc ito n in  defic iency 
(M cD erm ott, K idd , B lue, e t a l., 1983). In a study o f bone density in patients 
w ith  trea ted  and untrea ted thyro tox icos is , Fraser and colleagues showed tha t 
patients trea ted  w ith  - ^ 1  had a low er bone density than those given 
a n tith y ro id  drugs or surgery (Fraser, Anderson, Sm ith, e t a l., 1971). This 
may re f le c t ca lc ito n in  defic iency, although the availab le data on ca lc iton in  
levels before and a fte r  1-^1 trea tm en t in th y ro to x ic  subjects suggest th a t 
secretion o f the hormone is m aintained (Fraser and Wilson, 1971).
1.3.12. E ffe c t on dysthyro id  eye disease
Exacerbation o f existing  ophthalm opathy in patien ts w ith  Graves' 
disease has been reported  a fte r 1-^1 tre a tm e n t (H am ilton , Schultz and De 
Gowin, 1960). The true  risk o f this p o te n tia lly  serious adverse reaction  is 
d if f ic u l t  to  assess, as the course of ophthalm opathy associated w ith  Graves' 
disease does not always para lle l tha t o f the thy ro id  disorder. Jones and 
colleagues in 1969 reported  the results o f seria l measurements o f 
exophthalmos fo llow ing  ^ -^ I  trea tm en t, and dem onstrated th a t the degree o f 
proptosis increased in the f ir s t  year a fte r therapy, w ith  the maximum ra te  o f 
increase occurring  in the early months (Jones, Munro and Wilson, 1969). 
However, o ther authors have reported tha t exacerbation o f eye signs occurs 
w ith  a ll form s o f tre a tm e n t fo r Graves' disease and is not confined to  
patients given 1-^1 (Barte ls and Irie , 1961): in an early  study, Soley (1942) 
suggested tha t 50% o f patients trea ted  surg ica lly  showed some evidence of 
de te rio ra tion  o f ophthalm opathy.
P o ten tia l causes o f worsening of eye disease a fte r  l ^ l j  trea tm en t are
not fu l ly  understood. Immune fac to rs  have been thought to  be im p o rta n t: 
H e tze l reported  tha t only pa tien ts who had detectab le  concentra tions o f 
LATS which rose a fte r 1 ^ 1  tre a tm e n t showed progression o f eye signs 
(H etze l, Mason and Wang, 1968), consistent w ith  findings from  an e a r lie r 
study in the U nited States in which i t  was suggested tha t eye disease could 
develop fo r the f ir s t  tim e  in pa tien ts given ^ -^ I  in whom LATS measurem ent 
became positive  (Kriss, Pleshakov, Rosenblum, e t a l., 1967). In untrea ted  
tL y ro trm c c s is  there is, however, no close re la tionsh ip  between degree o f 
ophthalm opathy and leve l o f thy ro id  d irected  antibody (Feldt-Rasmussen, 
Kem p, Bech, e t a l., 1981). I t  may be th a t LATS is not responsible fo r  the 
progression o f the eye signs, but acts as a m arker o f some o ther 
im m unological event. M acDougall and K riss (1974) suggested th a t a fte r  ^ ^ I  
tre a tm e n t there was release o f thy ro id  antigen ic m a te ria l. In the presence 
o f antibodies (i.e. an tithyrog lobu lin  or an tim icrosom al) immune complexes may 
fo rm , which could be deposited in re tro -o rb ita l tissue. This could then be 
associated w ith  lym phocy tic  in f i lt ra t io n  and increased in fla m m a to ry  response, 
and consequent exacerbation o f the cond ition . I t  may be o f re levence th a t 
the lym pha tic  drainage of the o rb it and thy ro id  are connected (K riss, Konish i 
and Herman, 1975). A lthough th is  theory  is plausible, there is l i t t le  d ire c t 
evidence in its  support. However, during the 1960s a ttem pts were made to  
tre a t thyro id  ophthalm opathy by e x tirp a tio n  o f the thy ro id  e ithe r by surgery 
or radioiodine ablation to abolish the source o f thy ro id  antigenic m a te ria l. 
This p o te n tia lly  hazardous tre a tm e n t showed no m ajor bene fit in im provem ent 
o f eye disease (Boyle, G reig, Thomson, e t a l., 1969), and the p rac tice  fe l l
in to  decline. More recen tly  the existence o f a separate antibody d irec ted
against ex tra -ocu la r muscle tissue has been id e n tifie d  in patients w ith  Graves' 
disease, and i t  may be tha t d isturbance in the fo rm a tion  of th is antibody
accounts fo r some exacerbation o f eye disease fo llow ing  tre a tm e n t o f 
thyro tox icos is  (Atkinson, Holcombe, Tay lo r, et a l., 1984; Faryna, Nauman and 
Gardas, 1985).
I t  is thought possible tha t dysthyro id  eye disease is worsened by
ia trogen ic  hypothyroid ism , possibly associated w ith  TSH excess (Bolonkin, 
Tate, Luber, et a l., 1975). The reason fo r th is is unknown. In te re s tin g ly , 
Jones et al. (1969) suggested tha t the most marked de te rio ra tion  in eye signs 
fo llow ing  l ^ l j  tre a tm e n t occurred in those subjects w ith  rapid w e ight gain. 
These subjects may have had hypothyro id ism  although biochem ical data are
not availab le.
Thus, although worsening o f dysthyro id  eye disease may occur a fte r 
tre a tm e n t, the problem  may also be associated w ith  o the r form s o f 
therapy. The cause o f the d e te rio ra tio n  is not known, a lthough may be 
associated w ith  changes in th y ro id  or thy ro id  associated im m uno log ica l 
fa c to rs  as a consequence o f 1 ^ 1  therapy.
1.3.13. Carcinogenesis
In the early  days o f l - ^ I  tre a tm e n t, there  was concern th a t a la te  
consequence m ight be thy ro id  carcinogenesis. In ch ild ren  given low  dose 
ex te rna l rad ia tion  to  head and neck and fo llow ed-up  many years la te r  thy ro id  
nodule fo rm a tion  and thy ro id  carcinom a have been reported  in a num ber o f 
studies (Hemelmann, H a ll, P h illip s , e t a l., 1975; Rooney and P ow e ll, 1959). 
S im ila r ly , in the populations o f H irosh im a and Nagasaki exposed to  ra d ia tion  
fro m  nuclear explosions there  is a c le a rly  increased incidence o f thy ro id  
cancer (Wood, Tanagaki, Neuski, e t a l., 1969), and in anim al studies thy ro id  
tum ours can be induced by irra d ia tio n  (Doniach, 1958). One fe a tu re  o f a ll 
these studies, however, has been the  re la tiv e ly  low  leve l o f ra d ia tio n  to  the 
thy ro id , estim ated by Doniach (1953) to  be in the region o f 200 Rad, and i t  
has even been suggested th a t ra d ia tion  doses o f as low  as 9 Rad to  the 
thy ro id  m ight increase the incidence o f thy ro id  cancer (Anon, 1985). In 
con tras t, conventional doses o f ^ ^ 1  w ill de liver around 5000 Rad to  the 
th y ro id  (Hainan, 1964). This high dose causes ce ll s te r iliz a t io n , and ce ll 
death during m itosis precludes carcinogenesis. I t  is reasonable to  expect tha t 
sublethal doses o f rad ia tion  could, however, cause chromosomal damage which 
would lead to  the development o f carcinom a. I t  appears, the re fo re , th a t the 
apparently inescapable cum ula tive  la te  hypothyroidism  as a consequence of 
131l is an outcome which p ro tec ts  patients from  the risk o f ia trogen ic  
carcinogenesis.
Despite these the o re tica l arguements the development o f thy ro id  
cancer in patients given 1 ^ 1  therapy has occasionally been described: 7 cases 
have been reported in lite ra tu re  (Hamburger and M eier, 1971; Sheline, 
Lindsay, M cCorm ack, et a l., 1962). This, however, is probably less than the 
expected incidence o f thy ro id  cancer in a population the size o f th a t given 
1-^1 (Hainan, 1985; H offm an, 1984). In one series i t  was reported  tha t 
thy ro id  nodules developed in 3 out o f 18 patients aged less than 20 years
given 1 ^ 1  therapy, and in one pa tien t a low grade carcinom a was 
dem onstrated (Sheline e t al. 1962). These patients were given low doses o f 
l ^ l j  (less than 2 m C i). In view  o f the evidence th a t low leve l rad ia tion  to 
the head and neck in ch ildren can predispose to subsequent development o f 
thy ro id  cancer, there  appears to  be l i t t le  ju s tif ic a tio n  fo r g iving sm alle r than 
conventional doses o f ^ -^ I  in the tre a tm e n t o f thyro tox icos is .
1.3.14. Leukaemoqenesis
There have been sporadic reports o f leukaemia developing in subjects 
given 1-^1 fo r thyro tox icos is  (Dobyns, Sheline, Workman, e t a l., 1974; Pochin, 
1960). However, both in the U .K . and in the U n ited  States, the fo llow -up  of 
large numbers o f patients has not dem onstrated an increased incidence of 
e ithe r acute or chronic leukaem ia a ttr ibu ta b le  to  1 ^ 1 . The the o re tica l 
rad ia tion  dose to  the bone m arrow  would be around 2 Rad, which is ha lf the 
dose expected to  double the spontaneous m utation  ra te . In a recent review  
Hainan (1985) concluded th a t there  was no risk o f leukaemogenesis from  the 
doses o f 1 ^ 1  g}Ven fo r thyro tox icos is .
1.3.15. G enetic damage
Blood borne - ^ 1 ,  and ^ ^ 1  excreted in the urine, w il l cause gonadal 
irrad ia tio n , and there has been concern tha t th is m ight cause damage to
germ cells in ovary and testes. In male subjects given large doses o f 1-^1 
fo r thyro id  carcinom a, azoospermia and dose-dependent e levation o f serum 
FSH have been documented (Handelsman and T u rtle , 1983). However, such 
e ffec ts  are only apparent w ith  doses o f ^ ^ 1  in excess of 50 m C i. Robertson 
and Gorman (1976) ca lcu la ted tha t fo llow ing  a 10 mCi dose o f - ^ 1 ,  the 
rad ia tion  dose delivered to  the gonads is around 3 Rads, which is s im ila r to 
tha t from  abdominal X -rays such as intravenous pyelography. In a large 
series o f patien ts given ^ ^ I  tre a tm e n t, ch ildren conceived subsequently 
showed no evidence o f genetic damage (Chapman, 1971b). In view o f th is, 
cu rren t recomendations are th a t ^ -^ I  may be given to  patients o f
childbearing age, w ithou t fea r o f long term  damage to  germ ce ll tissue
(Hainan, 1985).
1.3.16. Irra d ia tion  o f the foetus
Iodide crosses the placenta: i f  pregnant women are given ^ -^ I,  the
foetus w il l be exposed to  rad ia tion , and from  about 12 weeks gestation, the 
foe ta l thyro id  is capable o f trapp ing iodide. has not been given to
pregnant women as a m a tte r o f po licy but despite th is  a surpris ing ly high
number o f patien ts, especially in the U n ited  States, have been given 1 ^1
during pregnancy, norm a lly  in the f ir s t  tr im e s te r. In a survey of a large 
number o f centres in the U nited  States, S to ffe r and Hamburger (1976) 
discovered 237 cases given l - ^ I  during the f ir s t  tr im e s te r. There was no
increase in the spontaneous abortion ra te  or in perina ta l m o rta lity , and the
congenita l m a lfo rm a tion  ra te  was not d iffe re n t from  th a t expected in a 
s im ila r group o f pregnant women not given 1 ^ 1  therapy. Six in fants were, 
however hypothyro id, probably as a consequence of accum ulation o f l ^ l j  in 
developing thy ro id  tissue. In a separate case report one in fa n t o f a m other 
given 103 m Ci o f 1-^1 w ith  thyro id  cancer during the f ir s t  tr im e s te r had 
hypothyroidism  and hypoparathyroid ism  (Richards, B rewer, Conley, e t al.,
1981). Thus, although there appears to  be no m ajor hazard to  the foetus 
when the m other is acc iden ta lly  given a conventional dose o f - ^ 1  in the
early stage o f pregnancy, i t  is prudent to avoid th is fo rm  o f trea tm en t in 
pregnant patients.
1.3.17. E ffe c t o f rad io iod ine therapy on c ircu la tin g  thy ro id  autoantibodies
The re la tionsh ip  o f thyro id  autoantibodies to  the development o f 
hypothyroidism  a fte r ^ -^ I  trea tm en t has been discussed previously
(1.3.9.). There is now considerable evidence th a t ^ -^ I  tre a tm e n t may its e lf
m od ify  autoantibody synthesis. In a number o f studies i t  has been shown 
tha t the t i t re  o f antibodies d irected against the TSH recep to r rises w ith in  
the f ir s t  few  months a fte r - ^ 1  adm in istra tion , and th a t levels subsequently 
decline (Atkinson, M cGregor, K endall-Taylor, et a l., 1982; Bech and Madsen, 
1980). Patients who are antibody negative before 1-^1 trea tm en t may 
become positive. This phenomenon has also been dem onstrated w ith  
antibodies d irected against thyro id  ce ll cytop lasm ic components and 
thyrog lobulin  (Einhorn, Fagraeus and Jonsson, 1965; O 'Gormon, S ta ffu rth  and 
Ballentyne, 1964). I t  seems un like ly  tha t th is rise in antibodies is o f major 
pathogenic s ign ificance in the events fo llow ing  ^ -^ I  adm in is tra tion  (Bech, 
Blundal, Nielson, 1982; Lundell and Holm , 1980). The cause o f the rise is 
not e n tire ly  c lear. I t  is possible tha t the recognised e ffe c ts  o f irrad ia tion  on 
T-lym phocyte subset populations, leading to  a fa l l in the ra tio  o f suppressor
to  helper ce lls, results in enhanced antibody production (M cGregor, 
M cLachlan, Rees-Smith, et a l., 1979). Release o f thyro id  antigenic m a te ria l 
fo llow ing  rad ia tion  d isruption o f ce ll in te g r ity  may also be o f re levance. 
W hether such immune events can be involved in po ten tia l exacerbation o f 
dysthyro id  eye disease a fte r 1 ^ 1  is a m a tte r o f speculation (A tkinson e t al. 
1984; M cDougall and Kriss, 1974).
1.3.18. C lin ica l use of radioiodine
E arly  fears about genetic hazards from  tre a tm e n t led to  a
tendency in the U nited Kingdom to  l im it  th is  fo rm  o f therapy to patients 
over ch ildbearing age. In p rac tice , th is meant tha t tre a tm e n t was not given 
to  patients below 40 years o f age (Hainan, 1985). I t  is now accepted tha t 
there  is no discernible genetic or ca rc inogenetic  hazard from  l ^ l j  therapy, 
and most recent recommendations suggest tha t patients younger than 40 
years can be trea ted  w ith  sa fe ty  (Hainan, 1985). In the U n ited  States o f 
A m erica  th is  has been p ractice  fo r  a number o f years. There is s t i l l  a
natu ra l re luctance to  give th is  fo rm  o f tre a tm e n t to  children in view o f the
evidence o f the development o f thy ro id  tumours years a fte r low dose 
ex te rna l irrad ia tio n  o f the neck (Hempelman et al. 1975). However, there  is 
no ob jec tive  contra ind ica tion  to giving ^^^1 tre a tm e n t to ch ildren, and in the 
U n ited  States th is has been proposed as the tre a tm e n t o f choice (Hamburger, 
1985).
There are few  spec ific  contra ind ications to 1-^1 therapy in 
thyro tox icos is . C lea rly , thyro id  surgery is the trea tm en t o f choice where a 
large go itre  causes pressure symptoms. Large glands may be less lik e ly  to 
shrink in the short term  a fte r * ^ 1  therapy, p a rticu la rly  where there is an 
elem ent o f nodu la rity , and there may be cosm etic arguements in favour o f 
surgery in patients w ith  this fo rm  o f disease. Such patients may require tw o
or more doses of 1-^1 to  e ffe c t cure (M ille r, 1971), and in th is s itua tion
surg ical tre a tm e n t may o ffe r a more rapid and e ffe c tiv e  a lte rna tive .
In view of the uncerta in ty  about the e ffe c t o f 1 ^1  trea tm en t on the 
course o f dysthyro id eye disease, some authorities  advocate avoiding th is 
fo rm  of therapy in patients w ith  m oderate to  severe eye signs (Bartels and 
Ir ie , 1961). As discussed in a ea rlie r section, evidence on this point is 
ra the r inconclusive.
The e ffe c t o f p re trea tm ent w ith  an tith y ro id  drugs on response to  l ^ l j
has been discussed previously. The m ajor bene fit to  pa tien ts is tha t 
p o ten tia l fo r  im m ediate  worsening o f the condition a fte r adm in is tra tion
may be avoided: the main disadvantage is tha t the possible ra d io -p ro te c tive  
e ffe c t o f a n tith y ro id  drugs may lead to  delay before fin a l cure is achieved. 
This may be overcome by increasing the dose o f 1-^1 given to  such patients 
(Crooks et al. 1960). Where a n tith y ro id  drugs are given im m ed ia te ly  a fte r 
1-^1 adm in is tra tion , the b iochem ical response to  rad ia tion  w il l be obscured, 
and on d iscontinuation of drug tre a tm e n t the pa tien t may be at risk  o f 
relapse of thyro toxicosis. In comparison, beta b locker therapy given as 
concurrent tre a tm e n t w ith  1 ^ 1  may be e ffe c tiv e  in con tro lling  symptoms o f 
thyro tox icos is  u n til tre a tm e n t takes e ffe c t (Hadden, M ontgom ery, Shanks, et 
a l., 1968; S terling  and H offenberg , 1971). W ith these drugs re liab le  
assessment o f the e ffe c t o f l ^ l j  on thy ro id  hormone levels can be made. 
Beta blockers w ill not, o f course, have any e ffe c t on the release of 
pre form ed hormone from  the gland im m ed ia te ly  a fte r l ^ l j  -ls g iveru
Evidence tha t the early response o f the thyro id  to  therapy is
dose-related has been presented ea rlie r. As the annual cum ula tive  incidence 
of la te  hypothyroidism  appears to  be independent o f dose, i t  has been 
suggested tha t a ll patients should receive a large enough dose to  ensure 
euthyro id ism , even i f  th is im plies tre a tin g  the m a jo rity  o f patien ts from  an 
early  stage w ith  thyro id  hormone replacem ent (Wise, Aahmad and Burnet, 
1975). In studies where a ttem pts have been made to con tro l the rad ia tion  
dose delivered to  the thyro id , form ulae fo r  ca lcu la ting  the ora l dose o f l ^ l j  
to  be adm inisterd have been derived. Most o f these include a measurement 
o f iodide uptake by the gland using tra ce r radioisotopes o f iodide and an 
estim ate  of gland size (Beierwaltes, 1978). The k ine tics  o f tra ce r doses of 
^•^1 w ith in  the thyro id  are probably s im ila r to  those of therapy doses, and 
the assumptions made about the uptake and re ten tion  o f therapy doses of 
1-^1 based on tra ce r studies appear to  be generally co rrec t (O'Conner, Cullen 
and Malone, 1979). The m ajor inaccuracy in dosim etry arises from  estim ate 
o f thyro id  mass, which is usually perform ed c lin ica lly . More accurate 
estim ate  of mass can be had by sc in tig raph ic  estim ation o f thyro id  surface 
area (Brown and Spencer, 1978) or from  the use o f thy ro id  ultrasound 
(Rasmussen and H jo rth , 1974). Even w ith  these more ob jective  techniques, 
however, there has been l i t t le  a ttem p t to  va lidate the mass estim ates w ith  
actua l gland size measured a fte r surg ical rem oval o f the thyro id .
There have been few  a ttem pts to con firm  the accuracy o f dosim etry 
ca lcu lations by d ire c tly  measuring the dose taken up and re ta ined by the 
gland, and the unce rta in ty  about the value and accuracy o f dosim etry has led 
some authors to  recommend the use of more em p irica l doses o f - ^ 1  which 
e lim ina te  the need fo r complex measurements (Wise et al. 1975).
1.3.19. Fo llow -up o f patients given ^-^1
In the early  months a fte r ^ ^ I  tre a tm e n t, patients are reviewed as 
o ften  as the c lin ica l course d ic ta tes. Therea fte r, when patien ts have become 
euthyro id , the main development to be antic ipa ted  is la te  onset 
hypothyroid ism . As has been discussed previously (1.3.9.), the annual 
incidence of th is  in a large number o f series is between 2 and 6% (Greig, 
1966; T o ft et a l., 1975; Segal e t a l., 1961). T o ft has dem onstrated tha t in 
subjects who have responded to  1-^1 only those w ith  e levation o f basal TSH 
run a risk  o f hypothyroid ism  in the short te rm  (T o ft e t al. 1974) and has 
suggested th a t such patients do not require to  be reviewed at more than 
yearly in te rva ls . O ther patients w ith  com plete ly norm al b iochem istry may be 
seen even less frequen tly . A dd itiona lly , patients who have become 
hypothyroid  and are tak ing  thyro id  hormone replacem ent may need some form  
o f in te rm itte n t rev iew  to  ensure th a t the dose o f thy ro id  hormone is
appropriate (B eckett, K e lle t, Gow, et a l., 1985).
The number o f patients given ^ ^ I>  and the long te rm  nature o f 
fo llow -up , means th a t the to ta l number o f patients requ iring  some fo rm  of 
regular rev iew  is la rge. In an a ttem p t to im prove e ffic ie n c y  and cost 
e ffectiveness o f such fo llow -up , com puter assisted pa tien t fo llow -up  schemes 
have been devised. In Scotland, the Scottish A utom ated Fo llow -up R egister 
(SAFUR) has been established fo r th is purpose. The system involves the 
patient's general p ra c tition e r, who is responsible fo r pa tien t contact and 
dispatch o f blood samples to  a centra l laboratory. C entra lised assessment o f 
labora to ry  results and patien t data is m aintained, w h ils t the loca l thyro id  
c lin ic  is responsible fo r pa tien t reca ll or other management change i f  results 
are unsa tis facto ry (Jones, Hedley and C urtis , 1982). A lthough proof tha t 
such a system is b e tte r in term s of qua lity  o f health care is lacking (T o ft, 
1983), there is some evidence tha t automated fo llow -up  registers are cost 
e ffe c tiv e  and more e ff ic ie n t than tra d ition a l ou tpatien t fo llow -up  based on a 
hospital c lin ic  (Hedley, Bewsher and Edwards, 1984).
SECTION FOUR
1.4. A N T ITH Y R O ID  DRUGS IN  THE TREATM ENT OF 
THYROTOXICOSIS
1.4.1. In troduction
Chem ical agents which reduce thy ro id  hormone fo rm a tion  include ion ic 
inh ib ito rs  o f the anion trap , agents which reduce thyro id  hormone release, 
and drugs which in h ib it iodide o rgan ifica tion . I t  is th is las t group which is 
o f p rinc ip le  c lin ica l value, and such agents w ill be considered in some de ta il. 
A rev iew  of the ion ic inh ib ito rs  and other chem ical agents which in h ib it 
thy ro id  hormone secretion has been published elsewhere (A lexander, Connell 
and M cCruden, 1981).
The f ir s t  agents shown to  in h ib it thyro id  hormone synthesis were 
sulphonamide drugs: in 1941, M cKenzie and co-workers reported thy ro id  
enlargem ent in ra ts given sulphaguanidine (M cKenzie, M cKenzie and 
M cC allum , 1941): fu r th e r investiga tion  indicated tha t th is was TSH dependent 
and associated w ith  hypothyroid ism . In subsequent studies, two m ajor groups 
o f compounds were shown to have a n tith y ro id  e ffec ts  - 1. aniline deriva tives, 
w hich include the sulphonamide drugs and 2. th iourylene agents which include 
a ll compounds in current m edical use (Astwood, Bissell and Hughes, 1945). 
The sulphonamide drugs have not been shown to  have m ajor an tith y ro id  
e ffe c t in man, possibly because o f lim ite d  dose and duration o f 
adm in is tra tion . A small fa l l in serum thyroxine levels a fte r adm in is tra tion  of 
sulphamethaxazole to  normal subjects has been dem onstrated, but 
hypothyroid ism  has not been reported  (Cohen, Beastall, R a tc lif fe , et al., 
1980). In animal studies, the potency of such drugs has been shown to be 
considerably le s s  than the th ioury lene agents such as m ethim azole or 
p ropy lth iou rac il (McKenzie and M cKenzie, 1943), and th is may be because 
the fo rm er group o f drugs is not concentrated w ith in  thy ro id  tissue (Personal 
observations). A lthough the mode of action of sulphonamide drugs has not 
been fu lly  investigated, i t  is lik e ly  tha t they in te rfe re  w ith  iodide 
o rgan ifica tion  through an in te rac tion  w ith  the thyro id  peroxidase.
1.4.2. A c tion  o f thiourylene agents
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STRUCTURE OF THIOURYLENE ANTITHYHOID DRUGS
THE CHEMICAL STRUCTURES OF THIOURACIL, PROPYLTHIOUR/OIL, 
METHIMAZOLE AND CARBIMAZOLE ARE SHOWN. NOTE THAT ALL 
SHARE A COMMON S = C - N GROUPING WHICH IS ESSENTIAL 
FOR ACTION. IN VIVO CARBIMAZOLE IS RAPIDLY CONVERTED TO 
METHIMAZOLE.
O f the th iourylene drugs, th iourea and th iou ra c il were in it ia lly  
investiga ted by Astwood et al. (1945). These were subsequently replaced by 
less to x ic  agents such as p ropy lth iou rac il and m ethim azole. In the U n ited  
Kingdom carbim azole has been used in place of m ethim azole: carb im azole is 
rap id ly  hydrolysed to  y ie ld  m ethim azole  in plasma or at a lka line pH 
(Nakashima and Taurog, 1979): in vivo th is  conversion may be enzym atic . 
There is no evidence tha t carb im azole has any a n tith y ro id  action  other than 
tha t m ediated by m ethim azole.
The chem ical s tructures o f representative  th iourylene drugs are shown 
in F igure 4. I t  w il l be noted th a t a ll drugs contain the grouping S=C-N 
which appears to  be essential fo r  the a n tith y ro id  e ffe c t. These drugs reduce 
thy ro id  hormone synthesis by inh ib ition  o f in tra th y ro id a l ox idation , and thus 
o rgan ifica tion  o f iodide, leading to  reduction  in fo rm a tion  o f iodotyrosine 
residues (Taurog, 1980). There is also evidence of inh ib ition  o f coupling o f 
these residues on the thyrog lobu lin  molecule by such drugs. This can be 
dem onstrated in v itro  using pu rified  thy ro id  peroxidase and m eth im azole, but 
is d if f ic u lt  to  demonstrate in vivo (lino , Yamada and Greer, 1961). Such 
studies suggest tha t the coupling reaction  is more sensitive to  the action  o f 
a n tith y ro id  drugs than iodide o rgan ifica tion  its e lf.
There is some debate about the mechanism by which these drugs 
a ffe c t iodide oxidation and o rgan ifica tion . This process is dependent on the 
enzyme thyro id  peroxidase and a supply o f hydrogen peroxide to  act as an 
e lectron  acceptor (Taurog, 1970). I t  is lik e ly  tha t the drugs in te ra c t w ith  
th is  enzyme. Taurog (1978) has suggested tha t norm ally  iodide and 
peroxidase fo rm  a complex, w ith  iodide being oxidised in the process by 
hydrogen peroxide. The chem ical nature o f oxidised iodide is unclear but 
may be e ithe r iodinium (I+) or iodine free  rad ic le . Tyrosine residues may
then react w ith  the enzym e/I complex to  give rise to iodotyrosine (Fig. 2).
A n tith y ro id  drugs such as m ethim azole may compete w ith  iodide fo r oxidation  
by thyro id  peroxidase/hydrogen peroxide, so tha t the drug is oxidised and 
iodide remains in inorganic fo rm . I t  has been suggested tha t oxidised drug 
may then in te ra c t w ith  peroxidase to  prevent irreve rs ib ly  fu rth e r enzyme 
action (Davidson, Soodak, Neary, e t a l., 1978). Davidson et al. (1978) 
dem onstrated tha t in circumstances where iodide a va ilab ility  was high, iodide 
w il l be oxidised in preference to  drug and tha t the enzyme iodide complex
may then react w ith  the drug to give rise to  oxidised drug which w ill be a
disulphide product which w ill not in a c tiva te  peroxidase. In th is process 
fa ilu re  o f o rg an ifica tion  of iodide w ill occur and free  iodide w ill be released. 
Thus, i t  is possible tha t drug competes w ith  e ithe r iodide or tyrosine residues 
as a substrate fo r oxidation by peroxidase/hydrogen peroxide or peroxidase/I
complexes, and the a va ila b ility  o f iodide may determ ine which oxidising 
species in te rac ts  w ith  drug. Much o f th is speculation is based on results 
from  in v itro  studies using the drug, peroxidase and iodide, in a ce ll free
system. The s itua tion  in the whole animal may d if fe r  s ig n ifican tly .
Thiourylene an tith y ro id  drugs are concentrated w ith in  the thy ro id  
glands o f experim enta l animals (Desbarats-Schonbaum, Endrenyl, Koves, et a l., 
1972; M archant, A lexander, Lazarus, et a l., 1972) and probably also o f man 
(Lazarus, M archant, A lexander, et a l., 1975). When rad iolabelled a n tith y ro id  
drugs are given (e.g. -^S -m eth im azo le) a thyro id /p lasm a gradient develops. 
Radiolabelled drug can be shown to  be present in the co llo id  and fo llic u la r  
cells o f the gland using autoradiography, w ith  a patte rn  o f d is tribu tion
s im ila r to  th a t o f tra ce r iodide (Ferguson, M archant and A lexander, 1971). 
Drug accum ulation and concentration appear to  be active  processes, being
inh ib ited  in v itro  by agents such as d in itropheno l, which uncouple ox idative
phosphorylation (Lang, 1982), and is enhanced in vivo by agents which 
s tim u la te  iodide trapp ing such as TSH or LATS (Lees and A lexander, 1978). 
However, p re lim ina ry  studies using thyro id  lobes in v itro  suggest tha t 
inh ib ition  o f iodide trapping w ith  the perchlorate  anion does not abolish drug 
accum ulation (Lang, 1982), and i t  appears from  such evidence tha t the
process of drug accum ulation is linked to , but not dependent upon, iodide 
m etabolism .
The re la tionsh ip  between drug concentra tion  and iodide uptake by the 
thyro id  gland has been explored in a series o f animal experim ents by
M archant (1971), Lees (1976) and Lang (1982). In summary, there is clear 
evidence th a t d ie ta ry  iodide depletion is associated w ith  a fa ll in drug 
accum ulation, and tha t d ie ta ry iodide excess enhances drug accum ulation by
the thyro id  gland. Acute adm in istra tion  o f iodide causes enhancement o f
drug accum ulation at a ll levels o f d ie ta ry  iodide in take. I t  is unclear how
the in te rac tio n  o f iodide a va ilab ility  and thyro ida l accum ulation o f a n tithy ro id  
drug a ffe c ts  c lin ica l e ffica cy  o f the agents. I t  is possible, however, tha t the
reported varia tions in response to  an tith y ro id  drug therapy re f le c t
geographical d iffe rences in d ie ta ry iodide (W artofsky, 1973; A z iz i, 1985).
Metabolism  of the th iourylene a n tith y ro id  drugs also occurs w ith in  the 
thy ro id  gland. O xidation  o f the drugs by in te rac tio n  w ith  thyro id  
peroxidase/hydrogen peroxide in itia te s  the m etabo lic  breakdown o f drug which 
gives rise to  free  sulphate and a number o f in te rm ed ia ry  m etabolites 
(M archant, 1971). These include m ethy lth iohydanto in  as a breakdown product 
o f m ethim azole and a number o f o ther un iden tified  m etabo lites (Skellern, 
K n igh t, Luman, et a l., 1977). Some of these m etabo lites, such as 
m ethylth iohydanto in , may also possess an tith y ro id  action , although animal 
studies suggest tha t these are much less potent than the parent compound 
(Skellern et a l. 1977). As w ith  accum ulation o f the drugs, in tra th y ro id a l 
metabolism  o f these compounds is in fluenced by iodide a va ila b ility . Thus, in 
animals m aintained on a low iodide in take, m etabolism  o f both m ethim azole 
and p ropy lth iourac il is enhanced by acute iodide adm in is tra tion  (Lang, Lees, 
A lexander, e t a l., 1983; M archant, Lees and A lexander, 1978). The possible 
reason fo r th is  in te rac tio n  between iodide a v a ila b ility  and drug oxidation has 
already been discussed. The studies o f Davidson et al. (1978) and Taurog 
(1970, 1978, 1980) suggest tha t, in conditions where a high drug/iodide ra tio  
is present, drug is oxidised d ire c tly  by thyro id  peroxidase, and tha t oxidised 
drug irreve rs ib ly  inactiva tes the enzyme: thus fu r th e r drug oxidation is 
inh ib ited . In conditions o f low drug/iodide ra tio , iodide form s an oxidised 
complex w ith  peroxidase, and th is complex then oxidises drug. I t  is 
suggested tha t drug oxidised in this way does not inac tiva te  thyro id  
peroxidase, and thus fu rth e r scope fo r fu rth e r drug metabolism  exists. 
A lthough th is hypothesis is a ttra c tiv e , there is no d ire c t in vivo con firm a to ry  
evidence, although the data c ited  above on drug oxidation  in vivo would be 
consistent w ith  i t  (Lang, 1982; Lees, 1976; M archant, 1971).
I t  has been suggested tha t in tra th y ro id a l accum ulation o f an tith y ro id  
drug is im portan t in the pharm acological sp e c ific ity  o f such agents. In man, 
Jansson and colleagues, using a sensitive gas chromatography/mass 
spectroscopy assay fo r m ethim azole have shown tha t thy ro id  levels o f the 
drug are higher than serum levels in subjects w ith  Graves' disease (Jansson, 
Dahlberg, Johansson, et a l., 1983). However, there was a wide va ria tion  in 
thyro id  drug concentra tion  between subjects, although w ith in  individuals, drug 
concentration throughout the gland appeared re la tiv e ly  homogeneous. 
In tra thyro ida l drug levels appear to  be s im ila r no m a tte r whether the last 
dose is taken shortly  before, or 20 hours before, rem oval o f thyro id  tissue,
and i t  appears th a t in tra th y ro id a l turnover o f drug is slow. This contrasts 
w ith  the re la tiv e ly  short h a lf- life  o f m ethim azole in plasma (3 hours) and i t  
seems lik e ly  tha t the plasma pharm acokinetic properties o f such drugs are o f 
l i t t le  re levance (Skellern, K n igh t, Low, et a l., 1980). The plasma h a lf- life  o f 
p ropy lth iou rac il is around 90 m inutes (S itar and Hunninghake, 1975). Both 
p ropy lth iou rac il and m ethim azole are cleared more rap id ly  from  the plasma 
o f th y ro to x ic  subjects than euthyro id  subjects (A lexander, Evans, M cAulay, et 
a l., 1975) and higher c ircu la tin g  drug levels are seen in patients w ith  renal 
im pa irm ent. P ro py lth io u rac il, but not m ethim azole im pairs peripheral 
conversion o f T4 to  T3, and th is may be o f add itional the rapeu tic  bene fit in 
thyro tox icos is  (Saberi, S terling  and U tige r, 1975).
1.4.3. E ffe c ts  o f a n tith y ro id  drugs on the course o f Graves' disease
A n tith y ro id  drugs such as m ethim azole and p ropy lth iou rac il are given 
to  patients w ith  Graves' disease to  reduce thyro id  hormone fo rm a tion . There 
has been considerable speculation as to  whether these agents m ight also 
a ffe c t the underlying im m unological course o f Graves' disease, and so induce 
remission o f the disorder. This guestion has proved excep tiona lly  d if f ic u lt  to  
answer: to dem onstrate an e ffe c t i t  would need to  be shown tha t the
remission ra te  a fte r tre a tm e n t w ith  an tith y ro id  drugs was higher than would 
be expected from  the natura l course o f the disorder. I t  does appear,
however, tha t the m a jo rity  o f series in which an tith y ro id  drugs have been 
given have reported  a higher remission ra te  than would be expected (around
25%) over a s im ila r period o f fo llow -up : the reported  rem ission rates a fte r a
single course o f tre a tm e n t w ith  an tithy ro id  drugs ranged from  33% to  77%
(Weetman, McGregor and H a ll, 1984). This v a ria b ility  may p a rtly  re f le c t 
d ifferences in b iochem ical and c lin ica l de fin itio n  o f rem ission and duration o f 
fo llow -up . In long term  surveillance of such patients trea ted  only w ith  a n ti- 
thyro id  drugs, i t  has been suggested tha t a considerable percentage o f those 
in it ia lly  in rem ission may eventua lly relapse (Sugrue, McEvoy, Feely, et al., 
1980). I f  th is  is so, i t  im plies tha t an tithy ro id  drugs may not influence the 
long te rm  course o f Graves' disease but may e ffe c t a re la tiv e ly  short lived  
change in some fa c to r o f pathogenic s ign ificance. There is in d irec t evidence 
tha t th is m ight be the case from  the studies o f A lexander and co-workers, 
who demonstrated tha t in subjects who entered rem ission during a n tithy ro id  
drug therapy a fa ll in iodide trapping by the gland was demonstrated
(A lexander, Harden and Shimmins, 1967; A lexander, M cL a rty , Robertson, et 
a l., 1970). A n tith y ro id  drug tre a tm e n t has been shown to  reduce the plasma 
concentra tion  o f thy ro id  s tim u la ting  imm unoglobulins, and th is  did no t occur 
in the same group of patients when trea ted  w ith  propranolol (McGregor e t al. 
1980). S im ila r findings have been reported from  a number o f o ther studies 
(M cGregor, Rees-Smith and H a ll, 1982), and i t  seems lik e ly  th a t th iourylene 
drugs act sp e c ifica lly  to  in h ib it synthesis o f thy ro id  d irected  antibodies 
(Fenzi, Hashizume, Roudebush, et al., 1979; M ich ie , Beck, M ahaffy , et al, 
1967). In v it ro , drugs can be shown to  im pa ir lym phocyte  response to  
m itogen ic and antigenic s tim u li (Weiss and Davies, 1981), and th is  e ffe c t may 
be a consequence o f action on monocytes (Ratanachaiyavong and McGregor, 
1985): monocytes are responsible fo r uptake and processing o f antigen which 
is then presented to  the lym phocyte . Weetman and colleagues have reported  
tha t an tith y ro id  drugs may act to  scavenge superoxide radicals in monocytes 
(Weetman, H o lt, Cam pbell, e t a l., 1983), a p roperty which is lik e ly  to  be o f 
im portance in the func tion  o f these cells. F ina lly , in patients w ith  Graves’ 
disease the ra tio  o f helper to  suppressor lym phocytes is abnorm ally high 
(Ludgate, e t al. 1984), and th is  is re turned to  normal during a n tith y ro id  drug 
therapy (Sridama, Pacini and De G root, 1982). There is, the re fo re , 
considerable in v itro  and in vivo evidence th a t a n tith y ro id  drugs may 
in fluence the sho rt-te rm  course o f Graves' disease by dim in ish ing the 
synthesis o f im m unological s tim u la to rs  d irected against the TSH recepto r: th is 
may be m ediated through a d ire c t e ffe c t on T-lym phocytes or, more like ly , 
o ther im m unocom petent cells such as antigen presenting monocytes. This 
concept is discussed more fu l ly  in Chapter 4.
1.4.4. C lin ica l use of an tith y ro id  drugs
Prolonged therapy w ith  an tith y ro id  drugs is usually given to  patients in 
the hope th a t the disease w il l enter remission during tre a tm e n t, and tha t 
ablative  therapy w ith  e ithe r surgery or 1 ^ 1  can |-,e avoided. This is most 
lik e ly  to  happen in patients w ith  small d iffuse goitres and a short h is to ry  o f 
thyrotoxicosis (A lexander et al. 1981; M cLa rty , 1973). Where these la tte r  
trea tm en ts  are ind icated, however, an tith y ro id  drugs may s t i l l  be o f value as 
preparatory trea tm en t. Where rapid and permanent con tro l o f thyro id  
hormone excess is im portan t (e.g. in the e lderly  or in patients w ith  
in te rcu rre n t illness), prolonged use o f an tith y ro id  drugs may not be
appropria te.
As a n tith y ro id  drugs are concentrated w ith in  the gland, there is no 
sim ple dose/response re la tionsh ip  in man. The effectiveness o f drug induced 
in h ib itio n  o f iodide o rgan ifica tion  can be measured using a su itab le  analysis 
o f iodide binding ra te , and from  such studies i t  is apparent tha t re la tiv e ly  
sm all doses of carb im azole/m eth im azole  are capable o f b locking iodide 
o rg an ifica tion  (McCruden, H ild itc h , Connell, e t a l., 1986): there appears to  be 
no reason in the m a jo rity  o f patien ts to  use doses in excess o f 30 mgs 
carb im azole da ily  (A lexander et al. 1981).
A fte r  contro l o f th y ro id  hormone excess has been achieved, continued 
use o f a dose o f drug s u ffic ie n t to  in h ib it fu l ly  iodide o rgan ifica tion  w il l lead 
to  ia trogen ic  hypothyroidism , and consequent go itre  enlargem ent. This may 
be avoided by using a low er dose o f drug or by m ain ta in ing  c ircu la tin g  
thy ro id  hormone levels w ith  exogenous thyro id  hormone. This la t te r  
combined trea tm en t w ill m a in ta in  suppression o f TSH, and so a llow  seria l 
measurements o f thyro id  radioisotope uptake to  be made, which may be of 
value in deciding whether patien ts have entered remission (A lexander e t al. 
1970; M cLa rty , 1973; W ilk in , Isles, Crooks, et a l., 1981). There is some 
evidence to  suggest tha t rem ission rates a fte r tre a tm e n t w ith  combined 
a n tith y ro id  d rug/thyro id  hormone therapy are higher than a fte r a n tith y ro id  
drug alone: th is may re fle c t the higher dose of drug used in the fo rm e r 
regim en (Ratanachaiyavong and M cGregor, 1985; Rom ald in i, Brom berg and 
Werner, 1983). A lthough both thyroxine  (100-200 ug/day) and t r i ­
iodothyronine (40-80 pg/day) have been used fo r th is purpose, thyrox ine  is 
the more e ffe c tive  agent in suppressing TSH secretion (Siwa et al. 1978; 
R idgway et al. 1980).
P ropy lth iou rac il is a less potent a n tith y ro id  agent than m ethim azole  in 
man, and doses of 300-600 mg/day are required to contro l thyro id  hormone 
excess.
I t  has been custom ary to  give an tith y ro id  drugs to  patients w ith  
Graves' disease fo r a fixed  course o f between 12 and 18 months. However, 
i t  would be o f value i f  the like lihood  o f a patien t rem ain ing in rem ission on 
w ithd raw a l o f drug therapy could be predicted during tre a tm e n t, so th a t a 
ra tiona l decision about the need fo r continued trea tm en t could be made. 
A lexander and colleagues (1970) suggested tha t i f  thyro id  iodide trapping, 
estim ated from  early radioiodine uptake measurements fe l l during a n tith y ro id
drug tre a tm e n t and remained low a fte r 6 months drug trea tm en t, rem ission 
was lik e ly  and drug trea tm en t could be stopped. However, W ilkins e t al. 
(1981) w ith  a s im ila r design o f study noted tha t a considerable number o f 
patients in th is  category relapsed shortly  a fte r stopping tre a tm e n t. In 
con trast, in a large study o f Japanese patien ts, Yam am oto reported  th a t 96% 
o f patients who showed suppression o f iodide uptake a fte r a course of 
an tith y ro id  drugs remained in rem ission on w ithd raw a l o f therapy (Yam am oto, 
Totsuka, K o jim a , et a l., 1983). M cGregor and colleagues (1980) suggested 
tha t a com bination o f a fa l l in TSH -receptor d irected  antibody t i t r e  and H LA  
group DR3 was strong ly p red ic tive  o f sustained remission on w ithd raw a l o f 
tre a tm e n t. This hypothesis remains to  be tested over a long period o f 
fo llow -up . In studies where short courses (less than 3 months) o f a n tith y ro id  
drugs have been given, i t  has been shown th a t the relapse ra te  on w ithd raw a l 
o f therapy is high (Burr, F itzge ra ld  and H offenberg , 1979; Greer, Kam m er 
and Bouma, 1977; M cFarlane, Davies, Longson, et a l., 1983). I t  the re fo re  
appears th a t to  achieve a reasonable rem ission ra te , drugs need to  be given 
fo r  a period greater than three months. Indeed i t  has been suggested tha t 
suppression o f iodide uptake during a n tith y ro id  drug trea tm en t can occur up 
to  three years a fte r the s ta rt o f therapy. During such long term  tre a tm e n t 
i t  has been reported tha t as many as 65% o f patients show suppression of 
in ta ke , and th a t 96% o f such patients rem ain in rem ission a fte r therapy is 
stopped (Yamamoto et al. 1983). There is l i t t le  doubt tha t where uptake 
measurements rem ain high during a n tith y ro id  trea tm en t, or where thy ro id  
s tim u la ting  antibody measurements do not fa l l,  remission is un like ly  and 
continued tre a tm e n t indicated.
1.4.5. Toxic e ffe c ts  o f an tith y ro id  drugs
Serious side e ffec ts  w ith  a n tith y ro id  drugs are rare. The development 
o f granulocytopaenia can occur at any tim e  during drug ingestion, and 
presents abrup tly  (T ro tte r, 1962). The reported  incidence of th is po te n tia lly  
serious adverse e ffe c t varies from  0.1 to  3% (Am rheinn, Kenney and Ross, 
1970). C h a rac te ris tic  m anifestations o f drug re la ted  granulocytopaenia 
include feve r and pharyngitis. Fo rtuna te ly , the neutrophil count usually rises 
on drug w ithd raw a l. A lthough the cause of the se lective leucopaenia is 
unclear, i t  has been suggested tha t drug spec ific  leucoagglutin ins are 
responsible fo r the e ffe c t, in a s im ila r manner to  the rare leukopaenia noted
w ith  p en ic illin  (B ilez ik ian , L a le li, Tsan, et a l., 1976). Even less common is 
the occurrence o f aplastic  anaemia, although th is  o ften  has a fa ta l outcome 
(Aksoy and Erdem, 1968). The incidence of these serious side e ffec ts  is 
probably s im ila r fo r  a ll drugs of th is group.
In a few  patients a "serum sickness" type reaction  has been reported 
w ith  a rthopathy, feve r and u rtica ria  (W iberg and N u tta l, 1972). Much more 
com m only patients may present w ith  an u rt ic a r ia l or maculopapular rash and 
p ru rit is . These e ffe c ts  disappear on drug w ithd raw a l, but may re tu rn  on 
rechallenge w ith  the drug (T ro tte r, 1962; Vasily and T y le r, 1980). O ther 
reactions are uncommon. H a ir loss has been reported  w ith  carbim azole 
(Papadopoulos and Harden, 1966), w hile , w ith  both m ethim azole and 
p ropy lth iou rac il, h epa to tox ic ity  has been documented w ith  pe ri-po rta l 
in fla m m a to ry  changes and b ile  duct stasis (Fedotin and L e fe r, 1975; Lunzer, 
Huang, Ginsberg, et a l., 1975). There are iso lated case reports o f the 
nephrotic syndrome and periphera l neuropathy occurring  in patients tak ing  
p ropy lth iou rac il (Reynolds and Bhathena, 1979; Roldan and N ig rin , 1972).
SECTION FIVE
AIMS OF THESIS
I t  w il l  be apparent fro m  the foregoing review  tha t, despite the 
widespx-ead use o f 1 ^ 1  tre a tm e n t, there  are s t i l l  areas o f unce rta in ty  
regarding its  use in the tre a tm e n t o f thyro tox icos is . In p a rticu la r, spec ific  
questions re la tin g  to  the early  e ffe c ts  o f ^ -^ I on thyro id  func tion  arise.
1. What is the incidence o f worsening o f b iochem ical thyro tox icos is  
im m ed ia te ly  a fte r ^ ^ - I,  and are such changes c lin ic a lly  im portant?
2. How do the e ffe c ts  o f 1 ^ 1  on thy ro id  physiological processes such 
as iodide trapp ing and o rgan ifica tion  re la te  to  biochem ical and c lin ica l
responses in the f ir s t  year a fte r therapy?
3. Can in fo rm a tion  about the e ffe c t o f -^^1 on thy ro id  iodide handling 
be used to  reduce the u np re d ic tab ility  o f c lin ica l response to  therapy over
the f ir s t  few  months?
4. How does the use of carb im azole p re trea tm ent a ffe c t the response
to 1311?
5. A re these po ten tia l e ffe c ts  o f carbim azole on response to  1-^1
re la ted  to  the phenomenon of drug accum ulation w ith in  the thy ro id  gland?
The present work sets out to  address these questions in a series o f 
studies in patients w ith  thyrotox icosis and in labora to ry  animals.
The f ir s t  part o f the rem ainder o f the thesis (Chapter 2) deals w ith
techniques used in the study o f th y ro to x ic  patients given the rapeu tic  ^ -^ I
including uptake of trace r doses of ^ 3 ^  The princip les and po ten tia l errors 
o f these measurements are considered and investigated experim enta lly .
The second part includes the results o f studies o f th y ro to x ic  patients 
trea ted  w ith  ^ -^ I.  The in it ia l chapter o f th is section deals w ith  the e ffe c t 
o f l - ^ l l  on thyro id  hormone concentrations im m edia te ly a fte r tre a tm e n t, and 
examines the e ffe c t o f p re trea tm ent w ith  carbim azole on the po ten tia l
exacerbation o f thyrotox icosis at th is  tim e . The use of early rad io iod ine
uptake measurements to p red ic t in it ia l c lin ica l and biochem ical response to  
1-^1 therapy is examined in the fo llow ing  chapter, as is the re la tionsh ip
between the e ffe c t o f on iodide handling and on biochem ical response.
In the next chapter the experience o f trans ien t hypothyroidism  in these 
studies is presented, and th is is fo llow ed  by data on the e ffe c t of 
therapy on the ra te  o f o rgan ifica tion  o f iodide in a small group of subjects 
in whom seria l measurements have been made. Studies on the e ffe c t o f 
carb im azole p re trea tm en t on outcome fo llow ing  trea tm en t in patients
w ith  thyro tox icos is  are then presented, and, in the last chapter o f this 
section a study on the e ffe c t o f a n tith y ro id  drug trea tm en t on the uptake 
and autoradiographic d is tribu tion  o f iodide in ra t thy ro id  is discussed.
The next part deals w ith  the phenomenon of a n tithy ro id  drug 
accum ulation by thy ro id  and other tissue, and the re la tionsh ip  o f th is  w ith  
tissue iodide trapp ing and o rgan ifica tion . The e ffe c ts  o f inh ib ition  o f iodide 
trapp ing on accum ulation o f labelled drug in mouse thyro id  is examined; data 
on accum ulation and autoradiographic d is trib u tio n  o f labelled drug and iodide 
by sa liva ry  gland are then presented, w h ile  in the next section the use of 
human polymorphonuclears as a model tissue in which to  study drug 
accum ulation is discussed.
F in a lly , an a ttem p t is made to  draw toge the r these various strands, 
and conclusions re levan t to  c lin ica l use o f rad ioiodine and an tith y ro id  drugs 
in thyro tox icos is  in re la tion  to  the question posed above are discussed.
CHAPTER TWO
METHODS USED IN  STUDY OF PATIENTS W ITH  
THYROTOXICOSIS
SECTION ONE 
C L IN IC A L  AND B IO CHEM ICAL METHODS
2.1.1. C lin ica l Assessment
A ll the patients included in th is study were assessed, trea ted  and 
fo llow ed-up by the author in the Radioisotope O u tpa tien t C lin ic  o f the 
Western In firm a ry . The patients were seen every 4 weeks in the year 
fo llow ing  1 ^ 1  therapy. A t each v is it, patients were c lin ic a lly  assessed, blood 
was drawn fo r measurement o f c ircu la tin g  thyro id  hormones, and, where part 
o f the study p ro toco l, uptake o f ^ ^ 1  was measured e ithe r using a simple in 
vivo s c in tilla tio n  counter or a gamma camera com puter system. (2.2.4.) 
Hypothyro id ism  was diagnosed in patients w ith  subnormal concentrations o f 
serum thyroxine  along w ith  elevated levels o f TSH. Thyrotoxicosis was 
diagnosed in patients w ith  elevated concentrations o f T3 and undetectable 
TSH. Graves' disease was diagnosed i f  patients had elevated concentrations 
o f T3 and T4, d iffuse uptake of tra ce r radioiodine (-^^1) over both lobes of 
the thy ro id  on scan and an elevated thyro id  uptake measurement 20 minutes 
a fte r intravenous in jec tion  o f tra ce r 123i ( 0f  dcise). Toxic nodular
go itre  was diagnosed in subjects in whom d is tribu tion  o f isotope (^ ^ 1 ) on 
thy ro id  scan was not uniform  over both lobes o f the thyro id : in a ll such 
patients T3 and T4 concentrations were elevated and in it ia l 20 m inute uptake 
o f 123i was y  0% o f in jected  dose. No patients included in studies had been 
trea ted  previously w ith  thyro id  surgery or ^ -^ I: patients w ith  known exposure 
to  rad io log ica l contrast media w ith in  the preceding three years were also 
excluded. Patients w ith  in te rcu rren t medical problems where rapid contro l o f 
thyrotoxicosis was desirable were not studied: fo r th is reason no patients in 
these studies had c lin ica l evidence o f cardiac disease. In view of the 
possible e ffe c t o f - ^ 1  on dysthyro id eye disease, patients w ith  WHO 
c lass ifica tion  grades IV -V I (Werner 1977) were not studied.
The purpose of the studies, which were approved by the local e th ica l 
com m ittee , was explained to  patients, a ll o f whom gave in form ed consent
before p a rtic ipa tion .
B iochem ical measurements
C ircu la tin g  levels o f thyrox ine , tri- iodo thyron ine  (both measurements o f 
to ta l serum content) and TSH, were measured by radioimmunoassay using 
com m erc ia lly  availab le systems. A ll o f these employed single antibody 
methods, w ith  antibody bound to  solid phase. F u rthe r deta ils o f these assays, 
including in te r-  and in tra-assay v a r ia b ility  are given in Table 2. A pa rt from  
the in te rna l qua lity  con tro l o f the com m ercia l assay, the re lia b il ity  o f the 
measurement o f T3 and T4 is regu la rly  assessed by p a rtic ipa tio n  in the 
U n ited  Kingdom externa l q ua lity  contro l scheme. Samples from  ind iv idual 
subjects were measured se ria lly  since these assays have m in im al interassay 
v a ria b ility .
Thyroglobulin  and thy ro troph in  receptor d irected  antibody were also 
measured using com m erc ia lly  availab le systems. D eta ils  o f these assays are 
given in Table 2. The thyro troph in  recepto r antibody (TRAb) is based on the 
p rinc ip le  o f inh ib ition  o f binding o f labelled TSH to  a standard preparation o f 
detergent solubilised TSH receptors (Southgate, Creagh, Teece, et a l., 1984). 
Assays based on this p rinc ip le  have been fu lly  va lidated in patients w ith  
Graves' disease (Rees-Smith e t a l., 1977; H ard is ty  e t a l., 1983). 
Measurement o f both thyrog lobu lin  and TRAb was perform ed on serum which 
had been stored frozen at -20°C ; samples were assayed from  each subject in 
a single batch. The presence o f endogenous an tithyrog lobu lin  antibodies in 
serum can compete fo r rad io labe lled  ligand in the assay o f thyrog lobu lin , 
leading to  innaccurate results (Izum i and Larsen, 1978): the presence o f a n ti­
thyrog lobu lin  antibodies was screened fo r before and a fte r therapy using
a coated red ce ll assay fo r the antibodies (thymune 'T ', Wellcome 
D iagnostics, Table 2) in a ll samples in which serum thyrog lobu lin  was 
measured.

SECTION TWO 
RADIOISOTOPE STUDIES
2.2.1. In troduc tion
Several radioisotopes o f iodine em it not only p a rticu la te  rad ia tion  but 
also gamma rays o f su itab ly high energy fo r  in vivo counting. C oncentra tion  
o f rad io iod ide by the thy ro id  gland allows externa l counting o f gamma
emmision over the neck to  be perform ed, and, a fte r appropriate ca lcu la tions 
are made, perm its quan tita tion  o f iodide trapp ing and o rgan ifica tion  by the 
thy ro id . Throughout the studies described in the fo llow ing  chapters, 123j_ 
iodide was used as tra ce r. This short lived  radioisotope (physical decay h a lf- 
l i fe  = 13 hours, gamma energy, 39 KeV) has favourable emmision
charac te ris tics  which allow  accurate gamma counting and imaging w ith  a
gamma camera. As the energy o f gamma emmision d iffe rs  from  th a t o f 
1-^1, (365 KeV) tra ce r studies using can made shortly  a fte r the use
o f the rapeu tic  ^ ^ 1  (physical h a lf- life  8.05 days). Since the rad ia tion  fro m  a
tra c e r dose o f - ^ 1  [s re la tiv e ly  low  (1.0 Rad, 80 pC i), i t  was possible to  
perfo rm  seria l radioisotope studies in patients trea ted  w ith  ^ ^ 1 .  On average 
each pa tien t had 8 tra ce r studies perform ed, de livering  a to ta l o f around 8 
Rad to  the gland: as the therapeutic  dose o f ^-^1 would expose the gland to  
between 3000 and 6000 Rad, th is  add itiona l rad ia tion  dose was not considered 
s ig n ifican t.
12^1 was obtained from  the A to m ic  Energy Research establishm ent 
(H arw ell), and from  Amersham In te rna tiona l, U .K .
2.2.2. In te rp re ta tio n  o f early iodide uptake studies
In a ll studies (80 qC i) was given by rapid intravenous in jec tion .
Fo llow ing in jec tion  the isotope is d is tribu ted  throughout the vascular 
com partm ent and equilibrates rap id ly  w ith  stable ( - ^ 1 )  iodide. Thyro ida l 
handling o f the radioisotope the re fo re  re fle c ts  the behaviour o f stable iodide. 
The tim e  course o f typ ica l thyro id  accum ulation o f 123j by norm al and 
th y ro to x ic  subjects is shown in F igure 5. I t  w il l be seen in both instances
th a t in it ia l uptake is rapid, but th a t in the thy ro to x ic  subjects a much
greater proportion o f the dose given is accum ulated in the early  phase.
Uptake w ith in  the f irs t  10-20 m inutes a fte r radioisotope adm in is tra tion  is
la rge ly  dependent upon trapping o f iodide by the thyro id  (IAEA repo rt, 1972):
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EARLY UPTAKE OF TRACER RADIOIODIDE ( I) BY THYROID GLAND
SCHEMATIC CURVES OF UPTAKE OF A TRACER DOSE (80uCi)OF 123I 
AFTER INTRAVENOUS INJECTION OF THE ISOTOPE AS MEASURED BY 
A GAMMA COUNTER. IN THE NORMAL SUBJECT UPTAKE INCREASES 
OVER THE HOUR OF MEASUREMENT, WITH THE GREATEST INCREASE 
BEING IN THE FIRST 20 MINUTES. THIS INITIAL PART OF THE 
UPTAKE CURVE (20 MINUTES) IS LARGELY A REFLECTION OF 
THYROID IODIDE TRAPPING, WHILE ORGANIFICATION OF TRAPPED 
IODIDE OCCURS AND ALSO CONTRIBUTES TO THE SECOND PERIOD 
(20 to 60 MINUTES). IN THE UNTREATED THYROTOXIC SUBJECT 
IODIDE TRAPPING IS MORE AVID, AND ORGANIFICATION CONTRIBUTES 
MORE TOTHE INITIAL (FIRST 20 MINUTES) OF UPTAKE THAN IN THE 
NORMAL. IN THE THYROTOXIC ON CARBIMAZOLE, TRAPPING IS 
UNAFFECTED BY THE DRUG, WHILE IODIDE ORGANIFICATION IS 
INHIBITED. WHILE THE INITIAL PORTION OF UPTAKE IS THEREFORE 
GREATER THAN USUAL, THERE IS LITTLE INCREASE IN UPTAKE 
BETWEEN 20 AND 60 MINUTES.
Thyroid <
Plasma
Bound iodine
---------------------i -----------------------------
. Iodide ,kb -Ktpt-------- f
Fig 6
COMPARTMENTAL DISTRIBUTION OF IODIDE
THEORETICAL REPRESENTATION OF THYROIDAL IODIDE HANDLING. 
CLEARANCE OF IODIDE FROM PLASMA BY THE GLAND CAN BE 
REPRESENTED BY A CONSTANT (C), WHICH IS PREDOMINANTLY 
DETERMINED BY IODIDE TRAPPING. ORGANIFICATION OF INTRA- 
THYROIDAL INORGANIC IODIDE CAN BE REPRESENTED BY ANOTHER 
RATE CONSTANT (KB). LEAK OF IODIDE FROM THYROID TO PLASMA 
IS EXPRESSED AS KTP: THIS WILL CONTRIBUTE TO THE OVERALL 
CLEARANCE FIGURE.
thus, i f  drugs which in h ib it iodide o rgan ifica tion  are given, uptake over this 
period should not be a ffe c ted  to  any great ex ten t. Subsequent uptake 
re fle c ts  both continued trapp ing o f iodide by the gland and incorpora tion  of 
iodide in to  organic fo rm . In subjects where iodide o rg an ifica tion  is inh ib ited , 
there  w ill the re fo re  be no m ajor increase in thy ro id  uptake a fte r the in it ia l 
trapp ing phase (Figure 5). As uptake o f 123j at 20 m inutes a fte r isotope 
in je c tion  has been shown to  be an acceptable measure o f thy ro id  iodide 
trapp ing (IAEA repo rt, 1976; M cL a rty  1973; W ilkins et a l., 1981) this has
been used as the princ ipa l radioisotope measurement in the present work. In 
some instances, the uptake o f radioisotope at 60 m inutes was also measured, 
and the change in uptake between 20 and 60 m inutes used to  provide an 
approxim ate index of capacity  fo r  iodide o rgan ifica tion  (2.3.3.).
2.2.3. Iodide k in e tic  studies
D is tribu tion  o f iodide in the thyro id  can be described using a sim ple 3 
com partm ent model (Figure 6) which consists o f a plasma and tw o thyro ida l 
iodine com partm ents (inorganic and organic). T ransfer o f iodide from  
com partm ent to  com partm ent can be described m a them atica lly , a llow ing ra te  
constants to be derived fo r these functions. In F igure 6, C (m l/m in )
represents clearance o f plasma iodide by the gland and is equivalent to 
thy ro id  iodide trapping. As discussed above, an early  iodine uptake 
measurement (between 10 and 20 m inutes a fte r intravenous in jec tion ) gives
an estim ate o f th is func tion . Kg (m in " l)  represents the incorpora tion  of 
inorganic iodide to  organic fo rm  (i.e. the function  accomplished by thyro id  
peroxidase and coupling o f iodotyrosines). Leakage o f free  inorganic iodide 
back to  plasma is described by a e x it ra te  constant (K yp ). The amount o f 
iodide rem aining w ith in  the gland a fte r fu rth e r uptake is blocked com plete ly 
by perchlorate and free  iodide discharged can be assumed to be in organic 
fo rm , and th is post-perch lorate  measurement is d ire c tly  re la ted  to the 
e ffic ie n cy  o f o rgan ifica tion  (Binding Rate Constant, K g). H ild itc h  has shown 
th a t analysis o f the uptake curve fo llow ing  intravenous in jec tion  o f tra ce r 
allows estim ation o f Kg to  be made (H ild itch , H orton  and A lexander,
1980), and has dem onstrated tha t this is closely corre la ted  w ith  the 
o rgan ifica tion  ra te  ca lcu lated from  residual uptake fo llow ing  adm in is tra tion  o f 
perchlorate . This has ve rifie d  independently the accuracy o f measurement of 
K g derived from  perchlorate discharge studies, and th is la t te r  technique has
the re fo re  been used in the rem ainder o f th is thesis to  measure the e ffe c t o f
l ^ l i  tre a tm e n t on thyro id  iodide o rgan ifica tion .
2.2.4. Measurement o f thy ro id  uptake
The a c tiv ity  o f tra ce r in the neck region viewed by a standard IAEA
co llim a ted  neck counter is d is tribu ted  in thyro ida l and ex tra thy ro ida l regions. 
Measurement o f thyro id  radioisotope uptake depends on accurate estim a tion  
o f e x tra th y ro id a l (i.e. vascular, lym pha tic ) ra d io a c tiv ity . C o rrec tion  fo r 
e x tra th y ro id a l ra d io a c tiv ity  is re la tiv e ly  easy when using a gamma camera 
(described below) (2.2.6.): however, when using a simple uptake counter, th is 
co rrec tion  is not possible. E x tra th y ro id a l neck ra d io a c tiv ity  is a po ten tia l 
source o f e rro r in measuring thy ro id  uptake in patients, especia lly when 
iodide trapp ing is low . In the fo rm u la  used fo r ca lcu la tion  o f thy ro id  uptake 
using a sim ple uptake counter average values fo r ex tra thy ro ida l a c t iv ity  as 
found by H ild itc h  (H ild itch , G illesp ie , Shimmins, et a l., 1967) and Shimmins 
(Shimmins, H ild itc h , Harden, et a l., 1969) have been used. Thus at tw o  
m inutes ex tra thy ro ida l a c tiv ity  w ith in  the fie ld  o f view o f the counter was 
taken to  be 7% o f the to ta l body ra d io a c tiv ity  ly ing  ou tw ith  the thy ro id  
gland. A t 20 minutes the corresponding figu re  is 6%. A t 60 m inutes, 
e x tra th y ro id a l a c tiv ity  is reduced to  84% o f the value at 20 m inutes.
Fo llow ing  rapid intravenous in jec tion  o f 80 pC i ^ ^ 1, neck uptake o f 
isotope was measured at 2 m inutes, 20 m inutes and, in some instances, 60 
m inutes using a standard co llim ated  uptake counter, placed 8.3 cms from  the 
patien t's  neck. An a liquot o f the in jected  solution was placed in an IAEA  
phantom and also counted under the same conditions. A llow ing  fo r 
rad ioac tive  decay the uptakes at 20 (and 60) minutes were ca lcu la ted using 
the sim ple equations shown below which co rrec t fo r  ex tra thy ro ida l 
ra d io a c tiv ity .
IF :-
T o ta l neck uptake (% dose in fie ld  o f in te res t)
= true  thyro id  uptake +
true  e x tra -th y ro id  counts (% dose)
A N D :-
when true  uptake tends towards zero,
measured neck a c tiv ity
= True E x tra th y ro id a l Counts (% dose) X 100 
(100 - True Thyro id  Uptake)
D ire c t measurement in p e rch lo ra te b lo cke d  glands shows 
mean neck a c t iv ity  7% at 2 mins
6% at 20 mins
THEREFORE:-
A t 2 m inutes: 7 = True E x tra th y ro id a l Counts X 100
(100-True Thyro id Uptake)
OR True E x tra th y ro id a l Counts = 700 -(7 X True T hyro id  Uptake)
100
THUS:-
To ta l Neck Uptake
= True Uptake + 700 - (7 X True Uptake)
100
= 7 + 0.93 x True Thyro id  Uptake
THEREFORE:-
True Uptake = (Neck Uptake - 7) X 0.93
An uptake measurement at 24 hours a fte r intravenous in jec tion  of
was used fo r ca lcu la tion  o f the dose of E x tra th y ro id a l a c tiv ity  was
considered to  be neglig ib le  at th is tim e and so to ta l neck counts were taken 
to  represent thy ro id  uptake. An a liquot of in jected  so lu tion was counted to 
allow  ca lcu la tion  o f percentage uptake.
2.2.3. S ta tis tica l varia tions in thyro id  uptake measurements
S ta tis tica l va ria tions in count ra te  resulted in uptakes o f greater than
10% having errors o f less than 1%; fo r uptake in the range 1-10% the e rro r
was less than 7%.
2.2.6. Thyro id  im aging and k in e tic  studies
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DISCHARGE OF IODIDE BY PERCHLORATE
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SCHEMATIC REPRESENTATION OF IODIDE UPTAKE (OF I) BY THYROID 
IN A SUBJECT WITH ORGANIFICATION FAILURE. AS IODIDE TRAPPING 
IS UNIMPAIRED INITIAL UPTAKE AFTER INTRAVENOUS INJECTION OF 
ISOTOPE IS NORMAL, BUT THERE IS NO IN0REASE IN UPTAKE BETWEEN 
20 and 60 MINUTES AS IODIDE TRAPPING IS BALANOED BY EXIT.
WHEN SODIUM PERCHLORATE IS GIVEN INTRAVENOUSLY TRAPPING IS 
BLOCKED, AND IODIDE EXIT FROM THE GLAND IS POSSIBLY INCREASED. 
THIS RESULTS IN A FALL IN THYROID RADIOISOTOPE CONTENT: THE 
IODIDE UPTAKE AFTER PERCHLORATE IS A MEASURE OF THE RESIDUAL 
CAPACITY FOR IODIDE ORGANIFICATION BY THE GLAND.
Scan size To estim ate thy ro id  size, the planar surface area o f a 
gamma camera image of the thy ro id  was measured. The gamma camera 
used was an Ohio Nuclear Series 100 camera linked to  a Varian V77 m in i 
com puter. The image was produced under zoom m agn ifica tion  using a 
standard para lle l hole co llim a to r, 30-60 m inutes a fte r intravenous 
adm in is tra tion  of ^ 3 i  (go pC i). The image was smoothed using the 
com puter, and an area fo r the image was derived by c ircum scrib ing  the 
image using a cursor. The estim ate  o f size was then made by c ircum scrib ing  
in the same manner a phantom o f known surface area. Mass (Grams) was 
taken to  be the area (cm ^)^/2  X 0.36. This estim ate of thyro id  mass has 
been shown previously to  co rre la te  reasonably w e ll w ith  thy ro id  size 
estim ated by ultrasound exam ination (Brown and Spencer, 1978).
2.2.7. K in e tic  studies
12^1 was given intravenously (150 pC i), and counts were acquired using 
the gamma cam era/com puter system. The patien t was supine fo r th is 
measurement, w ith  the standard co llim a to r placed 12 cms above the neck. 
E x tra th y ro id a l neck ra d io a c tiv ity  could be measured d ire c tly  by counting an 
area in the f ie ld  o f view ou tw ith  but adjacent to  the gland. A region to  the 
in fe r io r o f the gland displaced away from  the arm in which the bolus 
in je c tion  had been given was used in order to  e lim ina te  counts derived from  
the in it ia l in jec tion . A series o f 60 dynamic frames each of 60 seconds 
duration was acquired. For each fram e counts were determ ined fo r the 
thy ro id  area and subtraction of the ex tra thy ro ida l a c tiv ity  was made. An 
a liquo t o f in jected solution was also counted using an IAEA phantom, and 
thy ro id  uptake was then derived.
For investiga tion  of o rgan ifica tion  e ffic ien cy , 450 mgs o f sodium 
perch lora te  were given by intravenous in jec tion  30 minutes a fte r in jec tion  o f 
12^1: uptake of - ^ 1  was fo llow ed fo r  a fu rth e r 30 m inutes a fte r
adm in is tra tion  of sodium perchlorate. The e ffe c t o f sodium perchlorate  on 
the uptake curve in a patien t w ith  norm al o rgan ifica tion  and in a pa tien t 
w ith  an o rgan ifica tion  defect is shown in F igure 7. The value o f the 60 
m inute uptake measurement was taken as the post-perchlorate uptake and 
used fo r  deriva tion  of perchlorate discharge data.
2.2.8. D osim etry
The dose of 131j be given to  patients was ca lcu la ted using an 
estim a te  o f thyro id  gland mass, and 24 hour uptake o f in an a ttem p t to
standardise trea tm en t (100 p C i/g  o f thy ro id  tissue giving approxim ate ly 5000 
R ad /thyro id ). The form ula  fo r ca lcu la tion  o f dose was:
10 x mass in g divided by 24 hour uptake% (m Ci).
This dose o f ^ l j  was always given o ra lly  the day a fte r the tra ce r dose o f
USed fo r ca lcu la tion  o f 24 hour uptake.
In one group o f patients the e ffe c tiv e  h a lf- life  o f ^ l j  \n the thy ro id  
was measured, and th is is discussed more fu lly  la te r (3.6.1.). This involved 
counting neck ra d io a c tiv ity  at several tim es (in p ractice  4 tim es over 2 
weeks) a fte r ^ l j  therapy and ca lcu la ting  the ra te  o f decay o f neck counts. 
For th is  purpose patients were seen 24 hours a fte r adm in is tra tion  of ^ -^ I and 
a 24 hour uptake of the radioisotope ca lcu lated using the gamma 
cam era/com puter system w ith  a high energy para lle l hole co llim a to r. 
E x tra th y ro id a l a c tiv ity  was assumed to  be neglible at th is  tim e . As before, 
an a liquot (1 m Ci) o f isotope was counted in an IAEA  phantom fo r 
ca lib ra tion  purposes. Counts at th is  tim e  were used as a re ference point
(100%) and subsequent counts expressed as a percentage o f th is to  enable the
e ffe c tiv e  ha lf l i fe  o f in the gland to  be determ ined.
2.2.9. Analysis o f data
Standard s ta tis tica l methods were used throughout. Mean values are 
presented w ith  accompanying standard e rro r o f the mean; in ce rta in  
instances, where the data are c le a rly  not d is tribu ted  in a normal manner, the 
median point and in te rqu a rtile  ranges are given instead. Comparison o f data 
has been perform ed using s ta tis t ic a l tests where appropriate: where normal 
d is tribu tion  o f data cannot be assumed non param etric  tests have been used. 
Ind iv idua l analyses are detailed in the te x t.
SECTION THREE  
VA LID A TIO N  OF RADIOISOTOPE TECHNIQUES
2.3.1. In troduction
The human studies presented in th is thesis have re lied  heavily upon 
radioisotope uptake techniques and in a number o f instances data derived in 
a seria l manner from  a large number o f patients have been used. I t  was,
the re fo re , o f in te res t to  examine some of the problems associated w ith
thyro id  radioisotope uptake measurement and to  id e n tify  how these 
con tribu ted  to  the accuracy o f measurement.
2.3.2. E x tra th y ro id a l neck ra d io a c tiv ity  using thy ro id  uptake counter
In the previous chapter the use o f a standard co rrection  fo r 
ex tra thyro ida l neck ra d io a c tiv ity  in the measurement o f thy ro id  uptake using 
an uptake counter was described. This is based on the assumption tha t 
ex tra thyro ida l a c t iv ity  w ith in  the fie ld  o f view o f the counter is 7% o f to ta l 
body ex tra th y ro id a l a c tiv ity  at 2 m inutes a fte r the in jec tion  and 6% at 20 
m inutes a fte r in je c tion  (H ild itch  et a l., 1967; Shimmins et a l., 1969). These 
estim ates were derived in it ia lly  using - ^ 1  and to  ensure th a t they were 
appropriate fo r 123j counting, ex tra thyro ida l neck counts were measured in 
15 subjects who had no thyro id  uptake o f rad io iod ide. These were 15
patients who were studied a fte r radioiodine tre a tm e n t. Imaging w ith  the
gamma camera showed no ide n tifia b le  thyro id  uptake in a ll cases and neck 
counts in these subjects were the re fo re  assumed to  represent ex tra thyro ida l 
ra d io a c tiv ity : counts were expressed as percentage o f in jected  counts
measured in a standard thy ro id  phantom.
A t 2 m inutes a fte r in jec tion  neck counts ranged from  4.4 - 8.4%, 
w ith  a mean o f 6 + 1.2 (standard deviation); at 20 m inutes the range was 4.2 
- 8.3% w ith  a mean o f 5.6 + 1.3.
Comment
These data con firm  tha t there is decay in ex tra thy ro ida l a c tiv ity
between 2 and 20 m inutes using 12^I. The figures from  th is  sm all group of 
patients (6% at 2 m inutes and 5.6% at 20 m inutes) are not d issim ilar to
those found w ith  l ^ l l  (7 and 6%) and which are used in the rou tine
ca lcu la tion  of uptake by the thyro id . I t  was assumed tha t fo r p rac tica l
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purposes the derivation  o f thy ro id  uptake using the standard co rrec tion  fo r 
e x tra th y ro id a l a c tiv ity  was sa tis fac to ry .
2.3.3. E ffe c t o f anatom ical va ria tion  on accuracy o f uptake measurement
In a large series o f subjects i t  was fe l t  possible th a t in te r- in d iv id u a l 
va ria tion  in fac to rs  such as anatom ica l loca lisa tion  o f the thy ro id  m ight 
con tribu te  to d ifferences in uptake measurement. One possible source o f 
e rro r lies in the amount o f so ft tissue interposing between the neck counter 
and the thyro id  gland. For both uptake counter and gamma camera the 
co llim a to r is placed at a standard distance from  the an te rio r surface o f the 
neck and no account is taken o f so ft tissue thickness an te rio r to  the thy ro id .
In order to  estim ate  the degree o f possible e rro r due to  th is , a series o f
measurements was made, using the thy ro id  phantom containing an a liguo t o f 
e ithe r 123j or 131j^ Perspex blocks, which have a density and e lem ental
com position s im ila r to  human tissue were then interposed between the
phantom and co llim a to r and counts remeasured. The data derived fro m  both 
uptake counter and gamma camera in th is way are shown in Table 3. I t  w il l 
be noted tha t the th innest perspex block used (0.9 cms) caused a fa l l in 
counts fo r both ^ ^ 1  (14%) and ^-^1 (3%) using the uptake counter. Th icker 
blocks caused a progressive fa l l in count ra te , so tha t at the 2.2. cms 
thickness a 30% loss of counts was noted fo r using the gamma counter.
The loss o f counts was considerably less using the gamma camera 
system (20% loss at 2.2 cm thickness w ith  - ^ 1  and 13% fo r ^ -^ I)  re fle c tin g  
d iffe re n t co llim a to r geom etry. The low er loss o f counts w ith  1-^1 re fle c ts  
the higher energy of gamma emission from  th is isotope.
Q uan tita tive  radioisotope uptake does not norm ally  take account of 
in te r-in d iv id ua l v a ria b ility  in morphology. The data ind ica te  tha t 
in te rpos ition  o f tissue between the co llim a to r and the thy ro id  does cause loss 
o f counts. However, even in obese individuals i t  is un like ly  th a t there  w ill 
be greater than 0.9 cms of so ft tissue interposing between the thy ro id  and 
co llim a to r, and i t  is lik e ly  tha t the loss o f counts due to  th is fa c to r w il l be 
considerably less than 13%. This c lea rly  should have no im pact on seria l 
measurements w ith in  an ind iv idual subject, and i s  un like ly  to  be a m ajor 
source o f e rro r in in te r-ind iv idua l comparisons.
2.3.4. Loss o f counting e ffic ien cy  at high count rates
1200 -i
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CORRECTION FOR GAMMA CAMERA/COMPUTER DEAD TIME
101
AT VERY HLGH COUNT RATES (eg AFTER THERAPY) THE GAMMA
CAMERA/COMPUTER MAY NOT REGISTER ALL COUNTS (DEAD TIME).
COUNTS WERE ACQUIRED USING THE GAMMA CAMERA/COMPUTER FROM
A SERIES OF THYROID PHANTOMS CONTAINING A RANGE OF ALIQUOTS 
1 01OF I FROM 100 uCi to 10MCi. ACTUAL COUNTS OBSERVED 
WERE COMPARED WITH EXPECTED COUNTS FROM THE KNOWN ACTIVITY 
OF THE SAMPLE. AT LOW COUNT RATES THE ACTUAL AND EXPECTED 
COUNTS AGREED WELL, BUT THERE WAS LOSS OF COUNTING EFFICIENCY 
AT RATES OF > 400 KILOCOUNTS/ MINUTE. THIS CURVE WAS 
USED AS A CALIBRATION CURVE TO CORRECT HIGH COUNTS FOR LOSS 
OF EFFICIENCY.
Serial measurement o f neck counts were made a fte r adm in is tra tion  of 
the rapeu tic  using the gamma cam era/com puter system. The high doses
o f ra d io a c tiv ity  used (genera lly around 5 m Ci) give rise to  very high levels 
o f gamma emission. A t such high count rates, the a b ility  o f the gamma
camera and com puter to  reg is te r and re ta in  counts is c ruc ia l fo r  accuracy, 
and the phenomenon of dead tim e  at high count rates is known to  lead to  
loss o f counting e ffic ie n c y  (Adams, Jansen, Grames, et a l., 1974). In an 
e ffo r t  to quantita te  th is , and to perm it co rrection  o f measured counts a
ca lib ra tion  curve fo r loss o f counting e ffic ie n cy  at high count rates was
constructed.
A series o f measurements were made by placing doses o f l ^ l j  ranging 
from  0.1 - 10 mCi in the neck phantom. S ixty second counts were acquired 
fo r each dose, and are p lo tted  in F igure 8. I t  w il l be seen th a t although the
in it ia l increase in counts a t low doses is linear (up to  3 m Ci) deviation from
th is s tra igh t line becomes progressive as count ra te  rises above 400 000 
counts per m inute. This loss o f lin e a r ity  in counts p lo tted  against known
phantom content re fle c ts  loss o f counting e ffie n cy  o f the gamma 
cam era/com puter. The ca lib ra tion  curve constructed from  th is  allows 
co rrection  fo r th is loss o f e ffic ie n cy  to  be made. For example, a measured
count ra te  of 800 000 counts per m inute re fle c ts  a true  count o f 923 000
counts per m inute. This co rrec tion  was rou tine ly  applied in ca lcu la tion  o f
counts fo llow ing  ^ - 4  therapy in derivation  o f e ffe c tive  h a lf- life  o f ^ -^ I.
2.3.3. Estim ation  o f o rgan ifica tion  e ffic ie n cy  using spot uptake measurements
Accurate  detection o f o rgan ifica tion  defects fo r iodide has, in the
past, involved the use o f perchlorate discharge studies (1.3.5.). An
a lte rna tive  method was described by H ild itch  et al. (1980) using sophisticated 
com puter assisted analysis o f the uptake curve fo llow ing  intravenous in jection  
o f tra ce r radioiodine. Both o f these techniques involve the adm in istra tion  of 
perchlorate , and norm ally involve the use of a gamma cam era/com puter 
system. Exam ination o f the uptake curve (Figures 5 and 7) indicates tha t in 
normal subjects uptake increases between 20 and 60 m inutes. I t  has been 
noted previously tha t uptake at 20 minutes is la rge ly  a function  o f iodide 
trapping (IAEA, 1972) and tha t subsequent uptake re fle c ts  both trapping and 
o rgan ifica tion . Where o rgan ifica tion  is inh ib ited , the in it ia l portion o f the 
uptake curve is normal, but l i t t le  increase is seen between 20 and 60
m inutes. The re la tionsh ip  between the 20 and 60 m inute uptake is the re fo re  
c ru c ia lly  dependent upon thyro id  iodide o rgan ifica tion , and in an e ffo r t  to  
find  a sim ple tes t fo r  o rgan ifica tion  e ffic ie n c y  th is  re la tionsh ip  was examined 
fu r th e r in a sm all group o f patients.
Seventeen subjects were studied: 10 were tak ing  Carbim azole as
a n tith y ro id  therapy fo r thyrotox icosis, and 7 were known to  be euthyro id  on 
no drug therapy. None o f the th y ro to x ic  subjects had a 20 m inute uptake
greater than 20%. The thy ro to x ic  subjects had ingested between 20 and 40 
mg o f carb im azole 4-6 hours before the study was perform ed. In a ll subjects 
130 pC i o f 123i  was in jected in travenously and the counts acquired as
described in the previous section (2.2.6.) using a gamma cam era/com puter 
system over the next 60 m inutes. C orrections fo r background ra d io a c tiv ity  
was made as described, and uptake value at 20 m inutes and 60 m inutes
ca lcu la ted. A f te r  60 minutes sodium perchlora te  was in jected  in travenously 
(300 mg) and uptake fo llow ed fo r the next 30 m inutes. The perchlora te
discharge was expressed as percentage of 60 m inute uptake discharged by
perch lora te .
A ll subjects taking carbim azole had a positive discharge w ith  
perchlora te  w ith  a range of discharge of 10-63%. No discharge was seen in
any normal subject. The change in uptake between 20 and 60 minutes
expressed as a percentage of 20 m inute uptake is shown in Figure 9. I t  w il l 
be noted th a t the percentage increase was less than 75% in a ll subjects who 
had a positive discharge, and greater than 60% in a ll subjects who had 
normal o rgan ifica tion . In only one normal subject was the percentage
increase less than 75%. The re la tionsh ip  between percentage increase uptake 
and measured perchlorate  discharge is shown in F igure 10. I t  w il l be noted 
tha t there was a highly s ign ifican t inverse co rre la tion  between the two 
variables (r = -0.87, p < 0.001).
These data ind icate  tha t the increase in uptake between 20 and 60 
m inutes gives a crude but fa ir ly  re liab le  measure o f o rgan ifica tion  
im pa irm ent. In a ll subjects where the ra tio  between 60 and 20 m inute 
uptake was less than 1.6 (i.e. a percentage increase from  the 20 m inute 
uptake of less than 60%) an o rgan ifica tion  defect was present, and th is was 
inversely co rre la ted  w ith  the more accurate ly  defined perchlorate discharge. 
A ra tio  o f g reater than 1.75 between 60 and 20 m inute uptake measurements 
was invariab ly  associated w ith  normal o rgan ifica tion . No subject in th is
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1 PI
CHANCE IN THYROID UPTAKE OF I FROM 20 TO 60 MINUTES 
1PPUPTAKE OF I BY THE THYROID AFTER INTRAVENOUS INJECTION 
OF ISOTOPE AT 20 AND 60 MINUTES IN N3RM/-YL SUBJECTS AND 
THYROTOXIC PATIENTS TAKINO A BLOCKING DOSE OF CARBIMAZOLE. 
THE % INCREASE IN UPTAKE BETWEEN 20 AND 60 MINUTES WAS 
SIGNIFICANTLY LOWER (p< 0.01) IN THE SUBJECTS WITH 
IATROGENIC ORGANIFICATION BLOCK.
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1??RELATIONSHIP BETWEEN CHANGE IN UPTAKE OF I FROM 20
123TO 60 MINUTES AND DISCHARGE OF I BY PERCHLORATE
1 22
THYROIDAL UPTAKE OF I WAS MEASURED FOR 60 MINUTES AFTER 
INTRAVENOUS INJECTION OF ISOTOPE (8GuCi) IN 10 THYROTOXIC
SUBJECTS 4-6 HOURS AFTER INOESTION OF 40 mg CARBIMAZOLE.
122AT 60 MINUTES AFTER I IJ'UECTION SODIUM PERCHLORATE 300ug 
WAS GIVEN INTRAVENOUSLY, AND UPTAKE FOLLOWED FOR A 
FURTHER 30 MINUTES. THERE WAS A CLOSE INVERSE RELATIONSHIP 
BETWEEN THE INCREASE IN UPTAKE FROM 20 TO 60 MINUTES AFTER 
ISOTOPE INJECTION AND THE POST PERCHLORATE DISCHARGE (r = -0.87).
study had a 20 m inute uptake o f greater than 20%: in thyro tox icos is  uptake 
may o ften  be very rapid w ith  o rgan ifica tion  making a m ajor con tribu tion  to 
the 20 m inute uptake (IAEA, 1972), and in th is circum stance the ra tio  
between 20 and 60 m inute uptake w ill be fa lse ly  low . This index of 
o rg an ifica tion  is the re fo re  not appropriate where in it ia l (i.e. 20 m inute) 
uptake is high. I t  is the re fo re  suggested th a t in subjects w ith  normal in it ia l 
(i.e. 20 m inute) uptake measurements, the ra tio  o f 60 to  20 m inute uptakes 
(less than 1.6) may provide a crude index o f the presence of an 
o rgan ifica tion  defect. This can be perform ed easily using a thy ro id  uptake 
counter w ith o u t the need to  adm inister perch lora te . This simple 
measurement is used la te r in the thesis (3.2.6.) to  give an estim ate o f 
o rg an ifica tion  e ffic ie n cy  fo llow ing  1 ^ 1  therapy in th y ro to x ic  subjects.
CHAPTER THREE
STUDIES W ITH RA DIO ACTIVE IO D IN E (131I) IN  THE  
TREATM ENT OF THYRO TO XICO SIS.
SECTION ONE
IM M ED IA TE EFFECTS OF 0 N TH Y R O ID  HORMONE  
CO NCENTRATIONS IN  TH Y R O TO X IC  SUBJECTS.
3.1.1. In troduction
Several authors have reported worsening o f c lin ica l features of 
thyrotoxicosis a fte r ^ -^ I  therapy, and in a number o f instances thyro id  
hormone levels have been reported to rise in such patients (C reu tz ig  e t al. 
1976; Shafer and N u tta l, 1973; Tamagna et a l. 1979; V iherkoski, 1970). 
Indeed, Parker and Lawson (1973), in review ing Scottish m o rta lity  s ta tis tics , 
reported tha t a number o f deaths appeared to fo llo w  1 ^ 1  therapy in e lderly  
patien ts. The po ten tia l rise in c ircu la ting  thyro id  hormone concentrations 
and associated exacerbation o f thyrotoxicosis may re f le c t irrad ia tio n  
th y ro id itis , w ith  release o f preform ed T3 and T4 in to  the c ircu la tio n  (Einhorn 
et al. 1967). In tha t instance i t  m ight be expected tha t the rise in 
c ircu la tin g  hormone levels m ight be accompanied by changes in c ircu la tin g  
concentrations o f thyrog lobulin  and, at some stage, by im m unological changes. 
A ccord ing ly , the e ffe c t o f l - ^ I  therapy on concentrations o f T3 and T4 have 
been examined in a group of thy ro tox ic  subjects, and the re la tionsh ip  
between these changes and c ircu la ting  concentrations o f thyrog lobulin  and 
TSH recepto r d irected  antibodies (TRAb) has been assessed. In addition, the 
e ffe c t o f carbim azole tre a tm e n t before 1 ^1  adm in istra tion  on these variables 
has been examined in a seria l manner fo llow ing  ^ -^ I trea tm en t.
3.1.2. Patients and methods
T w en ty-fou r patients w ith  thyrotoxicosis were studied. A ll had d iffuse 
enlargem ent o f the thyro id , and at the tim e o f in it ia l diagnosis had elevation 
o f both T4 and T3. In a ll subjects the uptake o f 123j 20  m inutes a fte r 
intravenous in jec tion  o f the trace r was elevated.
Patients were assigned randomly to  two groups: e ithe r im m ediate
86.
tre a tm e n t w ith  131j or in it ia l therapy w ith  carb im azole fo llow ed by 131js In 
th is la t te r  group carbim azole (10-15 mgs tw ice  da ily  w ith  Thyroxine 0.1 mg 
per day) was given fo r a m inim um  o f 3 months. A t the tim e  o f 131j 
therapy a ll patien ts in this group were c lin ic a lly  and b iochem ica lly  euthyro id , 
and none had e levation o f TSH. A ll drugs were discontinued 48 hours before 
a pre 131] therapy tra ce r uptake study (using 123j) ancj there fo re  72 hours 
before 131j adm in is tra tion .
Blood samples were drawn fo r measurement o f T3, T4, thyrog lobulin  
concentra tion  and TRAb. Serum from  each subject was frozen and stored at 
-20°C  u n til subsequent analysis o f thyrog lobu lin  and TRAb in a single assay. 
D eriva tion  and perform ance of these assays has already been considered. 
Blood samples were taken im m edia te ly before 131j adm in is tra tion  and at 2, 
6, 9, 16, 23, 42 and 70 days a fte r therapy. T3 and T4 were measured at a ll 
o f the above tim e  points, whereas thyrog lobu lin  and TRAb were measured 
only in basal samples, a t 2 days and 42 days a fte r ^31i tre a tm e n t. The dose 
o f 1 3 ^ was ca lcu lated using data derived from  the 123j tra ce r study as 
described (2.2.8.) Comparison o f group means was made using the Mann 
W hitney U Test. L inear corre la tions were ca lcu la ted using the sum o f least 
squares method.
3.1.3. Results
F u rthe r deta ils o f the patients studied are shown in Table 4. The
groups were s im ila r w ith  regard to age, go itre  size, and dose o f 131j given. 
By d e fin itio n , in the group given 131l alone a ll patients were c lin ic a lly  and
b iochem ica lly  thy ro to x ic  whereas those in the group pretreated w ith
1 ^1carbim azole were euthyro id  at the tim e  o f -LOXj  adm in is tra tion .
Serum thyroxine
Ind iv idua l and mean values fo r serum thyroxine in both groups of 
subjects are shown in Table 5 and Figure 11. I t  w il l be noted, in the group 
o f subjects given 3.31 j ai one tha t serum thyroxine rose in 5 out o f 12 
subjects two days a fte r therapy, but the mean change in serum T4 was
ins ign ifican t. Therea fte r, mean serum T4 fe l l  gradually so tha t by 10 weeks 
a fte r trea tm en t was w ith in  the normal range. In a ll subjects in whom serum
T4 rose a fte r trea tm en t, the maximum change and peak leve l occurred w ith in
the f ir s t  two days.
1
D
ET
AI
LS
 
OF
 
PA
TI
EN
TS
 
S
TU
D
IE
D
: 
IM
M
ED
IA
TE
 
EF
FE
CT
S 
OF
 
I 
ON
 
TH
YR
OI
D 
HO
RM
ON
E 
C
O
N
C
EN
TR
AT
IO
N
S
87,
U-to
w cn M  -H
CO
Q O
Xw
cn
o
tH
+ i
r-'-
[>•
CO
T—i
+ l
o'Cj-
CO 
CD 
+ l
^r
C\J
^r
CD 
+ l
In
CD^r
CM
rH
o
wM M H tH 
<  CO 
CU tH
lD
co 
+ 1
CD
CM
CM
+ 1
CM
tH
If )
CD
tH
+ 1
ID
00
CM
LD 
+ 1
tH
ID
fe
rH
(AJ
a
CU M
CD 
CM 
+ 1 
CD 
ID
CM 
+ I
lD
lD
CO
tH 
+ 1
CO
CD
CM
C"
LD
+ 1
O
ID
CO
til
tH
CM
CM
1
CH
AN
GE
S 
IN 
SE
RU
M 
TH
YR
O
XI
NE
 
AN
D 
TR
IIO
D
O
TH
YR
O
N
IN
E 
IM
M
ED
IA
TE
LY
 
AF
TE
R 
I 
TR
EA
TM
EN
T
88.
co
Ho
w
I—I 
§
cn CD cn ID CM CD rH OJ
ID CD 00 o O CD CM CM x—1 o o
ID • • • • • • • • • • • •
H CM CO rH i n m CO CO CM CM
H
rH
co CO co co 00 00 D lD D 00
rH CD CO CD o in o O CM rH ch ID
CD CM ID CM in CD i n m ID cn CM CM
CD ID CM i n CM CM ID CM
>3 CD O CD in CD rH CD CM CO CO
<
Q  CD CM CM uo IN CD i n CO "cr CO CM
LO ID in i n ID D
O CM ID o 00 cn O 00 o D 00 CD
CM CO CM CD cn co in m 'CT IN CO CO
a
P  n cn rH ID CD O i n£  <h in CD CO D 00 o IN i n rH 00
CO • • • • • • • • • • • •
m CO IN CO IN rH CD CD CD CO
rH
CO IN rH O O cn 00 X—1 O o CD
CD CD cn O CD O CM CD CD CO CM CM CO
t—i rH rH X—1 rH CM CM rH rH rH rH rH rH
M
T—I
co
T—(
ID CM o 00 o o rH o CD tD
cl; IN CO CM CM rH <3- 00 rH IN ID CO D
<* 01
rH x—1 rH CM CM CM rH CM rH rH rH rH
CD
>i co ID cn 00 O CO CO IN CM *—1 oocn C" C\J CO CO rH IN CM IN CD ID CD
Q  CD rH rH rH CM CM CvJ rH CM x—1 rH rH rH
in Q CM CD 00 cn IN CD 55 Q CMo oo ¥ rH rH CD cn i n O s r O 00
CM CM CM rH CM co CM rH CM CM CM CM rH
W
§ H
2  rH o CD oo o CM O CD CD 00 55 CD CDu  co X—1 CD IN cn 00 CM rH CD rH 003 rH rH CO rH CM CM CM CM CM rH CM (\j rH
wMEh •
< Q o rH CMCL, 2 rH CM co ID CD IN oo CD rH rH X—1
89.
in
a
3
CO
ID
00
rH
K  CD
CD
Q tD
CM
H
rH
00
tH
M
00
ID
T—I
CD
(D
CM
00
03
tH CD CM 00 CD tH 00 N LO
CD CM CM o CD CM 00 m m CO CD
• . • • • • • . • 9 4
rH tH rH CM CM CM rH tH rH rH rH
tH CM in cn in
03 tH CD rH cn CD 00 rH co cn
• . • • • • • . • • •
rH tH rH rH 00 CM rH tH CM rH rH
CD ■^ r CD oo ^ r CM co
tH CD CD CD CD rH in o CO rH
• . • • • • • . • • •
rH t—( rH CM CM CO rH CM CM rH CM
oo in 00 tH in CO CD CD O
00 CD in 00 CD CM cn O - cn CO tH
CM tH tH CM CM CM O CO CM tH CM
00 00 CO 00 in m CM LD
rH 00 in oo IN CM co tH co in N
• . • • • • • • 9 . •
CM tH rH CM vH co rH CM CM tH tH
00 O 00 00 CM rH in in tH CO
CD CM O NJ CD rH cn CO "sT CM
rH tH rH rH tH tH tH
t> IN CD IN CO O o N - o o tH
CD CD 00 00 O CO rH CM CO 00
rH rH rH tH tH tH tH
e'­ CM CM rH CM tH o CD tHen IN rH o o CM oo 00 CO tH CM
rH rH rH tH tH tH tH
Q? O o CD CM 2> o CM CD CM CM
o CM CM in rH O cn CO CO tH CM
rH tH rH rH t—1 tH tH tH tH
in cD rH CD o 00 in 92 o in
CD CM c\j in rH tH O CM CM tH
tH rH rH tH rH tH tH tH tH
oo lD CD 00 cn o rH CM CO
tH tH rH tH rH tH tH CM CM CM CM
000-
''T
CM
13
6 
153
 
13
7 
87 
92 
3 
4.
05
 
2.8
4 
2.
27
Tmean + SEM
200-
1311 alone160-
120 -
Carbimazole pretreatment
80-
i
131 j Days
Therapy
Fig 11
1 01EFFECT OF I ON SERUM THYROXINE CONCENTRATIONS 
101THE EFFECT OF I THERAPY ON SERUM THYROXINE CONCENTRATIONS
101
IS SHOWN. 12 SUBJECTS WERE GIVEN I AS SOLE TREATMENT,
1 01
AND 12 WERE MADE EUTHYROID BEFORE I WITH CARBIMAZDLE.
131I HAD NO NET EFFECT ON HORMONE LEVELS IMMEDIATELY AFTER 
ADMINISTRATION, ALTHOUGH IN APPROXIMATELY 50% OF SUBJECTS 
AN ACUTE INCREASE WAS OBSERVED (SEE TABLE 5).
In the group p re trea ted  w ith  carb im azole, there was again no net 
change in serum T4 im m ed ia te ly a fte r therapy, although in a small number 
o f patients (4) concentrations rose. T herea fte r, mean serum thyroxine levels 
rose gradually so tha t by 10 weeks a fte r tre a tm e n t mean levels were higher 
than in the group given 1 ^ 1  alone. This re fle c te d  a progressive increase in 
serum thyroxine  concentrations to fra nk ly  elevated values in 6 o f the 12 
subjects studied in th is  group.
T ri-iodo thyron ine
In the group given l ^ l j  ai one serum T3 rose in 7 out o f 12 subjects 
and fe l l in the rem ain ing 3 by 2 days a fte r therapy: mean T3 was higher 
although th is  did not reach s ta tis tic a l s ign ificance fo r the group (Table 3, 
F igure 12). Serum T3 concentrations fe l l g radually in a ll subjects the re a fte r.
Serum T3 concentrations rose w ith in  tw o days o f l ^ l j  therapy in 6 out 
o f 12 subjects p re trea ted  w ith  carb im azole. As w ith  serum thyroxine  
concentrations, mean serum T3 concentrations th e re a fte r rose so tha t by 10 
weeks a fte r therapy mean value in this group was s ig n ifica n tly  higher (p < 
0.05) than in subjects given 1-^1 alone.
Fo llow ing the im m ediate changes in serum T4 and T3 a fte r 1-^1 
therapy, patients in the group given alone showed a slow decline in
mean thyro id  hormone concentrations. In th is group 5 subjects remained 
thy ro to x ic  by 10 weeks a fte r trea tm en t. Despite th is, in a ll subjects 
concentrations o f both T4 and T3 were low er at th is tim e  than before 
therapy and 4 subjects were hypothyroid (having been euthyro id  9, 16, 23 and 
42 days a fte r 1 ^1 ). Three subjects were euthyro id  10 weeks a fte r therapy 
and remained so during subsequent fo llow -up .
In the group p re treated w ith  carbim azole 6 subjects had elevated 
serum thyroxine  levels 10 weeks a fte r trea tm en t, although in only 2 was 
there c lin ica l evidence o f thyrotoxicosis. One subject was hypothyroid and 
the rem ainder o f th is group was euthyro id a t th is tim e .
Serum thyrog lobulin
Serum thyrog lobu lin  levels were elevated before trea tm en t in only 5 o f 
the subjects given - ^ 1  alone and in 3 o f the subjects pre trea ted w ith  
C arbim azole. Thyroglobulin  levels fo llow ing  therapy are shown in F igure
13. As endogenous antibodies to thyrog lobulin  can compete fo r ligand in the
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101EFFECT OF I ON SERUM TRIIODOTHYRONINE 
101THE EFFECT OF I THERAPY ON SERUM TRIIODOTHYRONINE
1CONCENTRATIONS IS SHOWN. 12 SUBJECTS WERE GIVEN I AS
SOLE TREATMENT, AND 12 WERE MADE EUTHYROID BEFORE 131I
101WITH CARBIMAZOLE. IMMEDIATELY AFTER I ADMINISTRATION 
THERE WAS A RISE IN HORMONE CONCENTRATIONS IN APPROXIMATELY 
50% OF SUBJECTS, ALTHOUGH NO CHANGE IN MEAN HORMONE LEVELS 
OCCURRED.
1
I alone Carbimazole pretreatment
6/52Basal 2 days
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8 0 -
6 0 -
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Fig 13
SERUM THYROGLOBULIN CONCENTRATIONS BEFORE AND AFTER 
101
I TREATMENT___________________________________
SERUM THYROGLOBULIN CONCENTRATIONS BEFORE, 2 AND 42 DAYS
1S1 101
AFTER I TREATMENT. 12 SUBJECTS WERE GTVEN I AS
SOLE THERAPY (LEFT HAND PANEL) AND 12 WERE MADE EUTHYROID
1 01WITH CARBIMAZOLE BEFORE oxI . ANTI-THYROGLOBULIN ANTIBODIES 
WERE DETECTED IN THOSE SUBJECTS MARKED *.
131 I alone Carbimazole pretreatment
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Fig 14
CHANGE IN TSH-RECEPTOR DIRECTED ANTIBODY FOLLOWING 
1 01
I THERAPY__________________________________
SERUM LEVELS OF TSH DISPLACING ANTIBODY (TRAb) BEFORE. 2 AND 
42 DAYS AFTER 13II THERAPY. 12 SUBJECTS WERE GIVEN l3lI 
AS SOLE THERAPY (LEFT HAND PANEL) AND 12 WERE GIVEN CARBIMAZOLE 
BEFORE 131I. THE SHADED AREA REPRESENTS THE RANGE OF VALUES 
FOUND IN NORMAL SUBJECTS. VALUES IN THE CARBIMAZOLE PRE­
TREATED SUBJECTS BEFORE 131I WERE SIGNIFICANTLY LOWER 
(p <0.01, MANN WHITNEY U TEST) THAN THOSE UN THE 131I-AL0NE 
GROUP.
radioimmunoassay used, an tithyrog lobu lin  antibodies were measured in serum 
before and six weeks a fte r l ^ I  (Izum i and Larsen, 1978): patients who had 
positive  results are id e n tified  in F igure 13. In only 3 subjects in the group 
given l - ^ I  alone did serum thyrog lobulin  rise 48 hours a fte r 131i therapy, and 
in one o f these subjects a fu rth e r rise was seen during the next 6 weeks. 
Thyrog lobu lin  levels were higher 6 weeks a fte r 131i therapy than before 
tre a tm e n t in 6 subjects.
In the subjects pre trea ted  w ith  carb im azole serum thyrog lobulin  rose 
48 hours a fte r  l ^ l j  therapy in 6 subjects, and in only one o f these subjects 
did a fu r th e r rise occur at 6 weeks. L it t le  change was seen in thyrog lobu lin  
in the rem ain ing subjects. In 6 out o f 12 subjects serum thyrog lobulin  was 
higher 6 weeks a fte r therapy than before tre a tm e n t w ith  131i# j^ e  change
in thyrog lobu lin  was not d iffe re n t in th is group compared to those patients
given 131j alone, and rise which occurred in most subjects in e ithe r group 
was sm all.
TRAb
Changes in TRAb fo llow ing  131j therapy are shown in F igure 14.
TRAb t itre s  were elevated in 9 out o f 12 subjects given ^ ^ 1  alone and in 6
out o f 12 o f those pre trea ted w ith  carb im azole (taken im m ed ia te ly  before 
131-1 adm in is tra tion): mean concentration was higher (p < 0.01) in the fo rm e r 
group. A f te r  l ^ I  therapy a m ajor change in TRAb occurred in only one 
subject in the group pre treated w ith  Carbim azole and no change was noted in 
the group given l - ^ I  alone.
3.1.4. R elationship between changes in thy ro id  hormone levels, thyrog lobulin  
and TRAb a fte r 1 ^1  therapy.
131j alone
Changes in T3 and T4 im m ed ia te ly  (w ith in  48 hours) a fte r 131j were 
pos itive ly  re la ted  (r = 0.44, p < 0.05). There was no re la tionship  between 
change in serum thyrog lobulin  and T3 or T4, or between TRAb and T3 or T4 
(summarised in Table 6). S im ila rly , ne ither size o f dose nor p re trea tm ent 
go itre  size was re la ted  to  subsequent changes in any o f the above variables. 
Subsequent (a t 6 weeks) changes in T3 and T4 were highly corre la ted  (r =
0.88, p < 0.01).
92.
Carbim azole p re trea tm ent
No re la tionsh ip  was seen between change in T3 and T4 e ithe r 
im m ed ia te ly  or 6 weeks a fte r therapy (Table 6); fu rth e r, changes in
serum thyrog lobu lin , TRAb, dose o f given, and p re trea tm en t thyro id  size
were not re la ted  to  changes in T3 or T4 a fte r therapy.
3.1.3. Discussion
Im m ediate  changes in T4 and T3
Early  a fte r therapy both T3 and T4 concentrations rose in
approxim ate ly 50% o f patients studied: the percentage change from  basal in 
both hormones was s im ila r in the two groups of patients ( l ^ l j  ai one and 
carbim azole p re trea tm ent). In no subject was the rise in thyro id  hormone 
concentra tion  associated w ith  adverse c lin ica l consequences. In a ll subjects 
in whom T3 or T4 rose as a consequence o f ^ ^ I  tre a tm e n t this was greatest 
w ith in  48 hours o f therapy. There have been a few  reports o f worsening of 
b iochem ical features o f thyrotoxicosis fo llow ing  ^-^1 therapy (C reutz ig  et al. 
1976; Lamberg, 1959; Shafer and N u tta l, 1975; Tamagna et al. 1979; 
V iherkoski e t al. 1970). In one study o f 44 patien ts, seria l measurements o f 
T3 and T4 were made during the f irs t  week a fte r ^ -^ I:  only m inor changes 
in T3 were noted, and these were not re la ted  to  a lte ra tio n  in c lin ica l state  
(C reu tz ig  et al. 1976). In a study o f 13 patients given 1-^1 therapy, Shaffer 
and N u tta l (1975) reported  tha t T3 rose in a number o f patients 5 days a fte r 
tre a tm e n t, although measurement o f thyro id  hormone concentrations was not 
made at ea rlie r tim es. In contrast Tamagna and colleagues (1979) reported 
th a t in 14 patients given ^ -^ I neither mean T3 nor T4 levels changed, 
although hormone concentrations in 3 subjects showed a small rise at 10 days
a fte r therapy. The curren t study examined the course o f thyro id  hormone
1 *31levels a fte r -LO-Li  more fu lly  than these previous series and showed a 
tem porary worsening o f biochemical thyrotoxicosis in approxim ate ly 50% o f 
patients studied. This was shown to be m axim al w ith in  48 hours a fte r 
trea tm en t. The change in T4 was re la ted to  tha t o f T3 only in the group of 
patients given ^-^1 alone. This may re fle c t the a lte red  re lationship between 
T4 and T3 in the carbim azole pretreated group before 1 ^ 1  therapy. A fte r  
l ^ l i  therapy there was a tendency fo r T4 to rise and fo r T3 to fa ll in this
la t te r  group accounting fo r the lack o f re la tionsh ip  between the two 
variables.
The cause of the early  rise in thyro id  hormone concentra tion  a fte r 
1-^1 therapy may re f le c t irrad ia tio n  th y ro id it is  w ith  release o f preform ed 
thy ro id  hormone from  the co llo id  o f the gland in to  the c ircu la tio n . This 
would be supported by the ra p id ity  o f the rise fo llow ing  adm in is tra tion .
However, no consistent change in serum thyrog lobulin  levels fo llow ing  1 ^1  
therapy was observed although in 50% of subjects levels were higher a fte r 
than before 1-^1: i t  m ight be expected tha t irrad ia tio n  th y ro id it is  would lead 
to  release of thyrog lobulin  from  the co llo id  o f the gland. Indeed, in studies 
o f the e ffe c t o f 1-^1 therapy on serum thyrog lobulin  levels, o ther authors 
(Izum i and Larsen, 1978) have reported tha t thyrog lobulin  rose as early as 
tw o days a fte r trea tm en t.
The measurement o f thyrog lobulin  in serum using conventional double 
antibody radioimmunoassay techniques is com plicated by the presence of 
endogenous an tithyrog lobu lin  antibodies which compete w ith  the assay 
antibody fo r ligand, g iving inaccurate results (Izum i and Larsen, 1978). In
view o f th is, most reports o f change on serum tlrp/rcgldtxilln a fte r 1 ^ 1  have
included only patients who were negative fo r an tithyrog lobu lin  antibody 
(Feldt-Rasmussen et al. 1982; Gardner et al. 1979; U lle re  and Van H erle, 
1978). In the present study patients were screened fo r an tithyrog lobu lin  
antibodies before and six weeks a fte r 1-^1 therapy: only seven positive 
results were found (iden tified  in Figure 16). In the m a jo rity  o f patients, 
the re fo re , i t  seems un like ly  tha t the presence of an tithyrog lobu lin  antibody in 
serum in te rfe red  w ith  assay perform ance.
I t  is possible tha t the assay used to detect c ircu la tin g  thyrog lobulin  in 
the current study was not capable o f detecting re la tiv e ly  sm all changes in
concentration. However, the reported sens itiv ity  o f the assay in the study o f 
Gardner et al. (1979) was s im ila r to tha t in the current report, and the
cause of the fa ilu re  to observe a more s ign ifican t rise in thyrog lobulin  is 
the re fo re  uncerta in. One possible explanation is tha t the dose o f - ^ 1  used 
in the current study was ra the r lower than tha t in the series reported by 
Gardner: despite th is, however, T3 or T4 levels rose in more than 50% of 
the subjects studied in the current series and a s ign ifican t proportion of 
patients subsequently became hypothyroid. A dd itiona lly , serum thyrog lobulin  
was measured on only two occasions, and i t  is possible tha t a rise in levels
was missed. However, i f  the rise in T4 and T3 re fle c ts  irrad ia tio n  
th y ro id it is , serum thyrog lobulin  concentrations m ight be expected to rise at 
the same tim e  as T4 and T3.
Carbim azole p re trea tm ent did not a ffe c t the percentage change in
e ithe r T3 or T4 in subjects in whom levels rose a fte r ^ 4  therapy, although
absolute changes in both hormones were less than the group given 1 ^ 4  alone. 
This sm alle r absolute rise in T3 and T4 may re f le c t the depleted 
in tra th y ro id a l pool o f T3 and T4 in subjects p re treated w ith  carb im azole. 
Thus, in only 4 subjects from  th is  group did T3 concentrations rise o u tw ith  
the norm al re ference range im m ed ia te ly  a fte r ^ 4  therapy.
In none o f the subjects studied e ithe r w ith  this pro toco l, or, indeed, in
any o f the subjects included in th is  thesis, did abrupt worsening o f c lin ica l
cond ition  fo llo w  ^ 4  therapy. This contrasts w ith  experience reported  from  
Scandinavia where Lamberg (1959) and V iherkoski (1970) reported  two series 
o f patients given ^ 4  therapy in whom there was an appreciable incidence of 
th y ro id  storm  im m ed ia te ly  a fte r tre a tm e n t. In a ll o f the a ffec ted  patients 
there  were, however, other com plica ting  m edical conditions such as
congestive cardiac fa ilu re , and the patients were a ll e lderly . In contrast, the 
m a jo rity  o f patients included in th is  study were aged less than 60 years and 
none had s ign ifican t in te rcu rren t illness. I f  thyro id  storm  is consequence o f 
an im m ediate  rise in T3 and T4 levels fo llow ing  ^ 4  adm in is tra tion ,
p re trea tm en t w ith  carbim azole lim ite d  tha t po tentia l increase by reducing
basal hormone levels and provides a ra tiona l basis fo r use o f a n tith y ro id  
drugs as preparatory trea tm en t before - ^ 4  adm in istra tion  in subjects a t risk 
o f c lin ica l de te rio ra tion  in the event o f a rise in T3 or T4; such patients
would include the e lderly, subjects w ith  thyrocard iac disease or subjects w ith  
o ther m ajor in te rcu rren t illness. This would be consistent w ith  the 
observation o f Viherkoski et al. (1970) tha t worsening o f c lin ica l features o f 
thyro tox icos is  a fte r 1 ^4  was not seen in patients p re trea ted  w ith  
carb im azole.
3.1.6. Changes in TRAb status
Basal TRAb measurement was elevated in a ll but three o f the subjects 
given ^ 4  alone, and in seven o f the subjects given carbim azole before ^ 4  
tre a tm e n t. Thus, mean TRAb levels were lower in the group given 
carb im azole, suggesting tha t the drug had reduced the level o f im m unological
stim u la tion  o f the gland. This e ffe c t o f carbim azole was reported in it ia lly  
by M cG regor and colleagues (M cGregor, Peterson, C a p iffe r i, et al. 1979) and 
has since been confirm ed by other workers (Fenzi e t al. 1979; Bech and 
Madsen, 1980). In the group of subjects reported  in the curren t study ^ 4  
tre a tm e n t had no major e ffe c t on TRAb levels. A tkinson and colleagues 
(A tkinson, McGregor, K endall-Taylo r, e t al. 1982) reported tha t both
bioassayable and im m unologically detectab le  thyro troph in  receptor s tim u la ting  
antibody rose a fte r ^ 4  trea tm en t. The ir study showed tha t the percentage 
o f positive values using both assays increased fo llow ing  therapy, and th a t at 
three months a fte r trea tm en t the mean value using both assay systems was 
higher. S im ila rly , Bech and Madsen (1980) using a bioassay method to 
measure thy ro id  s tim u la ting  im m unoglobulin showed tha t there was an in it ia l 
fa l l  in t i t r e  w ith in  the f ir s t  2 weeks a fte r l ^ l j  therapy, but th is was 
fo llow ed  by a h ighly s ign ifican t and sustained rise.
The negative find ing  in the curren t study contrasts w ith  these results. 
The method used to measure TRAb is based on tha t reported by A tkinson et 
al. (1982), and was c learly  able to  detect increased a c tiv ity  in the basal
s ta te . The cause of the rise in antibody t i t r e  reported by other workers 
fo llo w in g  - ^ 4  trea tm en t may re f le c t release o f thyro id  antigen leading to 
s tim u la tion  o f helper T-lym phocytes and consequent increase in antibody
production, and i t  may be tha t th is would not become evident w ith in  2-42
days o f ^ 4  adm in istra tion . An a lte rna tive  explanation fo r the rise in 
antibody fo llow ing  1 ^4  is tha t suppressor T-lym phocytes w ith in  the thyro id
gland are more susceptible than other im m unocom petent cells to irrad ia tio n  
damage (M cGregor et al. 1979), and tha t 1 ^ 4  therapy the re fo re  causes
fu r th e r abnorm a lity  o f the helper-suppressor T -ce ll ra tio  leading to a rise in
antibody production. However, in only 2 subjects in the current study were 
TRAb values at six weeks a fte r tre a tm e n t s ig n ifican tly  higher than before 
- ^ 4  adm in is tra tion . For reasons which are not clear this contrasts w ith  
experience reported by other workers, but may be a consequence o f tim in g
o f measurements.
3.1.7. Summary
In summary, serial measurements have shown tha t in around 50% o f 
patients given ^ 4  trea tm ent there is a tem porary rise in both T3 and T4, 
and tha t th is  reaches a maximum w ith in  48 hours o f l ^ l j  adm in is tra tion .
C arbim azole p re trea tm en t lowered basal levels o f both hormones but 
appeared not to  a ffe c t s ig n ifican tly  the p roportiona l increase fo llow ing  
irra d ia tio n . No evidence o f c lin ica l de te rio ra tion  in any subject was seen 
a fte r ^ 4  therapy. There was no re la tionsh ip  between change in thyro id  
hormone levels and e ithe r c ircu la tin g  thyrog lobu lin  or TRAb fo llow ing  1 ^4  
adm in is tra tion .
SECTION TWO
RELATIONSHIP BETWEEN TH YR O ID  ISOTOPE UPTAKE
MEASUREMENTS AND BIO CHEM ICAL AND C L IN IC A L OUTCOME  
FOLLOW ING 131I TH ER A PY.
3.2.1. In troduction
The c lin ica l and biochem ical outcome a fte r tre a tm e n t o f patients w ith  
thyrotoxicosis using subablative dose o f - ^ 4  is uncerta in . Thus, patients may 
e ithe r become euthyro id  a fte r a variable period o f tim e  or rem ain thy ro to x ic ; 
o f the fo rm er group o f patients, some progress to hypothyro id ism , some have 
a relapse o f thyro tox icos is  and the rem ainder rem ain euthyro id . In addition, 
im m ed ia te ly  a fte r ^ 4  therapy there may be delay o f up to  several months 
before the residual capacity  fo r thyro id  hormonogenesis is evident. Because 
o f th is d if f ic u lty  in determ in ing the im m ediate e ffe c t o f 1 ^ 4  trea tm en t on 
thy ro id  function , some e ffo rts  have been d irected  to  exam ining other 
measures o f thy ro id  status in an a ttem p t to p red ic t outcome early  a fte r - ^ 4  
adm in is tra tion . M yant (1953 a + b) examined the prognostic value of 
measurement o f thyro id  uptake o f trace r ^ 4  fo llow ing  doses o f the same 
isotope. He reported tha t at 3 weeks a fte r therapy, thy ro id  uptake 24 hours 
a fte r oral tra ce r adm in is tra tion  had fa llen  in a high proportion of patients, 
and th a t subsequent measurements showed p a rtia l recovery o f th is function  in 
the m a jo rity  o f these. He noted tha t remission from  thyro tox icos is  was less 
lik e ly  to  develop in those patients who showed no fa ll in uptake 3 weeks 
a fte r therapy. Since then, a small number o f authors have made s im ila r 
measurements fo llow ing  ^ 4  therapy (Einhorn and Hastad, 1961; Franco et al. 
1970; Larsson, 1955; Sagel et al. 1973). These studies, using a va rie ty  o f 
tra ce r isotopes and techniques o f uptake measurement have, in the m a jo rity  
o f instances, lacked precise biochem ical d e fin ition  o f thyro id  hormone levels. 
In the current study, repeated measurements o f early  (20 m in) thyro id  uptake 
o f 1 ^4  a fte r intravenous adm in istra tion  o f trace r have been made fo llow ing  
■ ^4  therapy in a group o f patients w ith  thyrotox icosis. These have been 
compared w ith  changes in biochem ical function  over the f ir s t  year a fte r 
trea tm en t.
3.2.2. Patients and methods
F if ty - f iv e  patients w ith  thyro tox icos is  were trea ted  w ith  ^ -^ I.  F o rty - 
two had Graves' disease and the rem ainder had m u lti-nodu la r go itre . 
T w e n ty -fo u r patients were made euthyro id  w ith  carbim azole (30 mg per day) 
before adm in istra tion . To prevent ia trogen ic hypothyroid ism  T3
supplements (60 pg)/day were also given to  th is group o f patients. A ll drugs 
were discontinued 5 days before ^-^1 therapy. The rem ain ing 31 patients 
rece ived trea tm en t alone. F u rthe r details o f the patients studied is
given in Table 7.
Patients were seen on the day im m ed ia te ly  before - ^ 1  tre a tm e n t, and 
assessed c lin ic a lly . Blood was drawn fo r measurement o f thyro id  hormone 
levels, and thyro id  uptake o f -^ 3 j Was measured 20 m inutes a fte r intravenous 
adm in is tra tion  of the trace r: a fu r th e r uptake measurement was made at 24 
hours. The thyro id  was imaged using the gamma camera, and the planar 
surface area of the scan used to  determ ine thyro id  mass. The dose of
rad io iod ine adm inistered was ca lcu la ted using the method described previously
131(2.2.8.) D e ta ils  o f thyro id  size, uptake and doses o f I given are shown in 
Table 8.
Fo llow ing 1-^1 therapy patients were seen every 4 weeks fo r  a period 
o f one year. On each occasion (unless permanent hypothyroid ism  had 
supervened) patien ts were assessed c lin ic a lly  and blood was drawn fo r 
measurement o f thyro id  hormone levels. Thyro id uptake o f -^ 3 j was 
measured 20 and 60 m inutes a fte r intravenous adm in is tra tion  o f the isotope. 
P atien ts w ith  permanent hypothyroidism  were started  on an appropriate dose 
o f thyrox ine : permanent hypothyroidism  was distinguished from  p o te n tia lly  
trans ien t hypothyroidism  by in it ia lly  s ta rting  a ll hypothyroid patients on t r i ­
iodothyronine. This was w ithdraw n a fte r a m inim um  o f 8 weeks, and basal 
thy ro id  function  reassessed one week la te r. Subjects w ith  pers is ten tly  low 
levels o f thyroxine, e levation o f TSH and low uptake values were presumed 
at th is stage to  have permanent hypothyroidism  and started  on Thyroxine.
Patients w ith  persistent symptoms and signs o f thyro tox icos is  4 months 
a fte r  - ^ 1  trea tm en t were s tarted  on Carbim azole w ith  T3 supplements, th is 
was continued fo r 6 months. A t  th is stage trea tm en t was w ithdraw n and 
basal thy ro id  function  reassessed. In a ll o f such instances thyro tox icos is  
recurred  w ith in  6 weeks.
3.2.3. Results
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One year a fte r trea tm en t 12 patients were s t i l l  thy ro to x ic , 20
had developed permanent hypothyroidism  and the rem ainder were euthyro id. 
The d is tribu tion  o f patients in to  these a rb ita ry  biochem ical c lass ifica tions 
over the f ir s t  year of fo llow -up  is shown in Table 9 ( it  is assumed fo r this 
purpose tha t 4 patients given carbim azole because o f persistent thyrotoxicosis 
between 4 and 10 months a fte r trea tm en t were th y ro to x ic  during th is tim e).
I t  w il l be seen tha t by 4 months a fte r therapy most patients who 
became euthyro id  in the f ir s t  year o f fo llow -up  had already done so, and this 
is also the case fo r patients who develop permanent hypothyroid ism . The 
mean tim e  to  development o f permanent hypothyroidism  was 9.6 + 1.2 weeks.
The influence o f p re trea tm en t w ith  carbim azole on overa ll c lin ica l and 
biochem ical outcome fo llow ing  1-^1 is discussed la te r.
3.2.4. Radioisotope studies and biochem ical outcome
Tw enty m inute uptake measurements before adm in is tra tion  are
shown in F igure 13: the patients have been subdivided fo r th is purpose 
according to  biochem ical outcome one year a fte r trea tm en t. I t  w il l be noted 
th a t those patients who fa ile d  to  enter remission had a higher 20 m inute 
uptake o f ^ 3 j  before - ^ 1  therapy was given (p < 0.03), suggesting tha t the 
underlying disease process in these subjects was more severe. P re trea tm ent 
go itre  size, and dose o f ^ -^ I given are shown in Table 7. I t  w il l be noted 
th a t fo r neither o f these variables was there s ign ifican t d iffe rence  between 
the groups classified according to outcome, although there was a tendency 
fo r  the subjects w ith  the highest uptakes to receive s lig h tly  low er doses of 
1-^1 (the dose ca lcu la tion  involves the recip rocal o f the 24 hour uptake). 
There was, however, no evidence to  suggest tha t the dose given to these 
subjects who fa iled  to enter remission was s ig n ifican tly  lower than tha t given 
to  the other 2 groups.
Serial measurements o f 20 m inute uptake fo r the 12 months a fte r 
therapy are shown in Figure 16. In all patients 20 m inute uptake o f 1 ^1  
had fa llen  by 4 weeks a fte r 1 ^ 1  therapy. A t th is  tim e , uptake in those 
subjects who were euthyro id one year a fte r trea tm en t was higher than in 
those who developed permanent hypothyroidism and low er than in those who 
remained thy ro to x ic  (p < 0.05). Despite this there was considerable overlap 
between the groups. No recovery o f uptake function  was seen in those 
patients beccming hypothyroid, while  a rise in uptake between 4-12 weeks
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120  101 20 MINUTE UPTAKE OF I BEFORE I TREATMENT
120UPTAKE OF I 20 MINUTES AFTER INTRAVENOUS INJECTION OF 
ISOTOPE IN 55 THYROTOXIC SUBJECTS: MEASUREMENT WAS MADE ON 
THE DAY BEFORE 131I ADMINISTRATION. THE THREE COLUMNS 
IDENTIFY SUBJECTS ACCORDINO TO BIOCHEMICAL STATE 1 YEAR AFTER 
TREATMENT: MEDIAN UPTAKE WAS HIGHER (p <  0.05, MANN WHITNEY 
U TEST) IN THOSE SUBJECTS WHO REMAINED THYROTOXIC THAN IN 
THOSE WHO RESPONDED TO 131I. THE OPEN CIRCLES REPRESENT 
THOSE SUBJECTS WHO WERE MADE EUTHYROID BEFORE 131I TREATMENT 
WITH CARBIMAZOLE: THE CLOSED CIRCLES THOSE WHO RECEIVED 131I 
AS SOLE THERAPY.
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120 101SERIAL CHANGES IN 20 MINUTE UPTAKE OF °I AFTER TREATMENT
120UPTAKE OF I WAS MEASURED 20 MINUTES AFTER INTRAVENOUS INJECTION 
OF ISOTOPE BEFORE AND AT 4-WEEKLY INTERVALS AFTER 1311 TREATMENT 
IN 55 SUBJECTS. SUBJECTS ARE CLASSIFIED ACCORDING TO BIOCHEMICAL 
OUTCOME ONE YEAR AFIER131I ADMINISTRATION. VALUES SHOWN 
ARE MEDIAN AND INTERQUARTILE RANGE. POUR WEEKS AFTER 131i THERAPY 
UPTAKE WAS HIGHER IN THOSE SUBJECTS WHO FAILED TO FULLY RESPOND 
(p <0.05, MANN WHITNEY U TEST) AND LOWER (p<0.01) IN THOSE 
WHO DEVELOPED PERMANENT HYPOTHYROIDISM THAN IN THOSE WHO WERE 
EUTHYROID AT ONE YEAR.
occurred in those who were' euthyro id  one year a fte r ^^ 1. A t one year a fte r 
1 -^1  therapy, uptake in this group remained lower than in those who were 
s t i l l  th y ro to x ic  ( p < 0 .0 1 ).
3.2.5. Changes in radioisotope uptake w ith  tim e
(a)Patients who became perm anently hypothyroid
(Table 10) A fte r  the in it ia l fa l l in 20 m inute uptake 4 weeks a fte r 
trea tm en t, no recovery o f isotope trapping was seen in the m a jo rity  (13 
out o f 2 0 ) o f patients who developed permanent hypothyroid ism , so tha t mean 
uptake values o f less than 2% o f in jected  dose were found. These subjects 
a ll developed biochem ical hypothyroidism  w ith  12  weeks o f 1 ^ 1  trea tm en t: 
a ll subsequent measurements (up to  16 and 24 weeks), when TSH levels were 
high, were low . In the rem ain ing 7 subjects measurable uptake o f 123j was 
present 8-12 weeks a fte r ^ ^ 1  therapy. This was less than 6 % o f in jected  
dose in a ll instances, and by 24 weeks a fte r 1 ^ 1  therapy was less than 4% 
in a ll patients. A ll o f these subjects developed biochem ical hypothyroid ism  
w ith in  24 weeks o f adm in is tra tion . The patte rn  o f uptake changes in
those patients p re trea ted w ith  carbim azole who developed hypothyroid ism  
compared w ith  those given 1-^1 alone was very s im ila r (Figure 17), and the 
tim e  taken to  develop biochem ical hypothyroidism  was not d iffe re n t in those 
patients pre trea ted w ith  Carbim azole compared to  those given l ^ l j  ai one# j n
the group given alone changes in T4 and T3 were para lle l (F igure 17);
131
w hile  hormone levels had fa llen  by four weeks a fte r I , there  was a lag 
period between the m ajor fa l l in uptake and its  fu l l b iochem ical expression.
(b)Patients euthyro id one year a fte r trea tm en t
In a ll but one patien t, 20 m inute uptake showed some recovery a fte r 
the in it ia l fa l l noted at 4 weeks a fte r l - ^ I  adm in istra tion , so tha t mean 20 
m inute uptake at 12 weeks a fte r 131I trea tm en t was 8.5% (range 1.4-17.1, 
Table 11). No d iffe rence in the patte rn  o f response (degree o f fa l l a fte r 
therapy or in subsequent measurements) was seen in the group o f patients
given carbim azole p re trea tm ent compared to  those given 1 ^ 1  alone (Figure
18). A ll but one o f the patients given 131I alone had responded to
radioiodine w ith  e ithe r normal or low thyro id  hormone levels (4 patients had 
an episode of transient hypothyroidism ) by 12 weeks a fte r ^ 1
adm in is tra tion . The single patien t who did not respond in th is  tim e  had m ild
105.
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F ig  17
RELATIONSHIP BETWEEN EARLY IODIDE UPTAKE AND THYROID 
HORMONES IN SUBJECTS HYPOTHYROID AFTER 131I TREATMENT
1 PS
SERIAL CHANCES IN 20 MINUTE UPTAKE OF °I (SOLID DOTS),
SERUM THYROXINE (BROKEN LINE) AND TRIIODOTHYRONINE (SOLID
1 SI
LINE) BEFORE AND AFTER I THERAPY IN PATIENTS WHO WERE
1 SI
HYPOTHYROID 1 YEAR AFTER I TREATMENT. PATIENTS GIVEN 
1STI AS SOLE TREATMENT ARE SHOWN IN THE LEFT HAND PANEL, 
AND THOSE MADE EUTHYROID WITH CARBIMAZOLE IN THE RIGHT. 
VALUES SHOWN ARE MEAN AND STANDARD ERROR OF THE MEAN.
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T3 tox icos is  u n til 6 months a fte r  tre a tm e n t. In the group given carb im azo le  
p re tre a tm e n t, 3 subjects rem ained eu thyro id  a t a ll tim es a fte r  1 ^ 1  
a d m in is tra tio n , 2 had an episode o f tra ns ien t hypothyro id ism  w ith in  the f ir s t  
12 weeks a fte r  1 ^ 1, and the rem ainder (6 ) had a m ild  episode of biochemical 
th y ro to x ico s is  between 4 to  36 weeks a fte r  therapy. In none of these 
pa tien ts  was the illness severe, and did not w a rran t o ther tre a tm e n t. U ptake 
values in th is  sm all subgroup o f pa tien ts  did not appear to  d if fe r  fro m  those 
who rem ained euthyro id  throughout, a lthough numbers are sm all (Table 12). 
By one year a fte r therapy a ll but 2 o f th is  group o f patien ts had uptake 
m easurem ents w ith in  the norm al range (Table 11). Again, in the group given 
-^-^1 alone changes in T4 and T3 leve ls were very s im ila r a fte r  ^ -^ I  (F igure 
18), w ith  a progressive fa l l to  eu thyro id  values over the f ir s t  12 weeks. As 
w ith  the previous group m ajor e ffe c ts  o f 1 -^ 1  on isotope uptake were not 
im m e d ia te ly  expressed in c irc u la tin g  hormone levels, presum ably due to  
p re fo rm ed  stores o f hormone w ith in  the gland. The p a rtia l recovery  o f 
trapp ing  fu n c tio n  from  4-12 weeks is then responsible fo r  m a in ta in ing  
subseguent hormonogenesis. In the group p re trea ted  w ith  carb im azoleT3 and 
T4 leve ls again changed in pa ra lle l. H ow ever, in th is  instance the re  was no 
o ve ra ll fa l l  in hormone levels im m ed ia te ly  a fte r  - ^ 1, and instead a sm all 
rise occurred  between 0 -8  weeks.
(c) P a tien ts  who fa ile d  to  respond
Tw elve  subjects had pers is tent b iochem ica l and c lin ica l thy ro to x ico s is  
one year a fte r  therapy. In a ll instances, uptake measurements fe l l a fte r  ^-^1 
a d m in is tra tio n , w ith  the la rgest decline being w ith in  the f ir s t  4 weeks (Table 
13, F igu re  19). F u rthe r fa l l in uptake over the next few  months was seen in 
4 ind iv idua ls : in the rem ainder a rise in uptake then occurred. In no p a tie n t, 
how ever, was the uptake measurement one year a fte r therapy higher than 
th a t be fo re  ^ -^ 1  adm in is tra tion , and in 3 pa tien ts  was just above the norm al 
range. T hyro tox icos is  in a ll but 4 subjects (3 given p re trea tm e n t w ith  
ca rb im azo le ) was m ild , w ith  T3 values between 2.46 and 3.0 nmol/1, and T4 
between 150 and 190 nmol/1. In the 4 o ther subjects there  were m arked 
c lin ic a l sym ptom s and signs, and carb im azo le  was the re fo re  used to  con tro l 
c lin ic a l and b iochem ica l thyro tox icos is  between 4 and 10 months a fte r 
a d m in is tra tio n . On stopping carb im azole, a ll patien ts relapsed w ith in  6 weeks 
and uptake values rem ained high. In 2 o f these 4 there  was very l i t t le
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F ig  18
RELATIONSHIP BETWEEN EARLY IODIDE UPTAKE AND THYROID 
HORMONES IN SUBJECTS EUTHYROID AFTER 1311 TREATMENT
SERIAL CHANCES IN 20 MINUTE UPTAKE OF I (SOLID DOTS), 
SERUM THYROXINE (BROKEN LINE) AND TRIIODOTHYRONINE (SOLID
  131
LINE) BEFORE AND AFTER I THERAPY IN PATIENTS WHO WERE
131
EUTHYROID 1 YEAR AFTER I TREATMENT. PATIENTS GIVEN 
131I AS SOLE TREATMENT ARE SHOWN IN THE LEFT HAND PANEL, 
AND THOSE MADE EUTHYROID WITH CARBIMAZOLE IN THE RIGHT. 
VALUES SHOWN ARE MEAN AND STANDARD ERROR OF THE MEAN.
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Fig 19
RELATIONSHIP BETWEEN EARLY IODIDE UPTAKE AND THYROID HORMONES
IN SUBJECTS THYROTOXIC AFTER 131I TREATMENT_ _  _ _
SERIAL CHANGES IN 20 MINUTE UPTAKE OF I (SOLID DOTS), SERUM
THYROXINE (BROKEN LINE) AND TRIIODOTHYRONINE (SOLID LINE)
1 S1BEFORE AND AFTER I THERAPY IN PATIENTS WHO WERE STILL
101 101 
THYROTOXIC 1 YEAR AFTER I TREATMENT. PATIENTS GIVEN I
AS SOLE TREATMENT ARE SHOWN IN THE LEFT HAND PANEL, AND
THOSE MADE EUTHYROID WITH CARBIMAZOLE IN THE RIGHT. VALUES
SHOWN ARE MEAN AND STANDARD ERROR OF THE MEAN.
112.
%
 OF
 
DO
SE
.
TA
BL
E 
14 
(P
A
R
T
I)
113.
TA
BL
E 
14 
(P
AR
T 
II
)
114.
CM
CM
CM
CM
CM
CM CD
CM
CM
CM CMCM
CD
CM
CM
CM
H
H
CM
D O
CM
CD
CMI
CD I
CM
CO
CM
O
O
K KW W O
O  CD CD CM
li II II II
s  'cr c o o
U  E-I Eh  CM
change in uptake a fte r therapy, while in the other 2 uptake
measurement 4 weeks a fte r ^ -^ I adm in istra tion  were considerably reduced 
(Table 14).
P atien ts  given carbim azole before l ^ l j  adm in is tra tion  had a ll relapsed 
w ith in  8 weeks o f stopping the drug (in a ll but one pa tien t w ith in  the f ir s t  4 
weeks). A lthough mean p r e - l^ l j  therpy uptake was higher in th is group, th is 
d iffe rence  between the groups was not s ign ifican t using appropriate tests fo r 
non p a ram e trica lly  d is tribu ted  data.
The re la tionsh ip  between changes in 123j Uptake and T4 and T3 is 
shown in F igure 19. I t  w il l be noted tha t in the group given ^ -^ I alone, T3 
and T4 levels changed to  a s im ila r extent fo llow ing  therapy. The
maximum fa l l in uptake values again occurred w ith in  the f ir s t  four weeks 
a fte r tre a tm e n t; the re fo re  mean (and median) values changed l i t t le .  There 
was again a delay between maximum change in uptake and maximum 
biochem ical response.
In those patients pre treated w ith  carbim azole uptake values were very 
high, and, owing to  sm all numbers, the changes displayed in F igure 19 are 
less un ifo rm . However, there was a gradual fa l l in uptake over the f ir s t  12 
weeks a fte r -^-4  therapy. This was not re fle c ted  in thyro id  hormone levels 
which progressively rose over this period, presumably due to  w ithdraw al o f 
the ia trogen ic  o rgan ifica tion  blockade. As 3 o f th is group were then 
res ta rted  on carb im azole therapy, subsequent thyro id  homrone changes cannot 
be analysed.
3.2.6. Assessment o f o rgan ifica tion  im pairm ent using 60 and 20 m inute uptake
meassurements o f ^ ^ 1
S ixty m inute uptake measurements were made in a ll subjects fo llow ing  
l ^ l i  therapy. In a p re lim inary study (2.3.5.) a ra tio  o f 1.6 or less between 
60 and 20  m inute uptake was shown to  be associated w ith  a defect o f iodide 
o rgan ifica tion . This may only be applicable where uptake measurement a t 20 
m inutes a fte r intravenous in jection  o f trace r is measurable, pre ferab ly 
g reater than 4%. In addition, where uptake is greater than 20% w ith in  the 
f ir s t  20 minutes the s ignificance of a ra tio  o f 1.6 or less is uncertain. In 17 
patients o f the curren t series a low ra tio  between 60 and 20 m inute uptakes 
was found w ith in  the f irs t  4 months a fte r l ^ I  adm in istra tion . Fu rthe r 
deta ils o f these patients are shown in Table 15. No abnormal ra tios were
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found la te r than 4 months a fte r l ^ l j  adm in istra tion . I t  w il l noted tha t the 
m a jo rity  o f patients had an abnormal ra tio  w ith in  the f irs t  12 weeks a fte r
adm in is tra tion , and tha t 5 o f these patients developed permanent 
hypothyro id ism  in the fo llow ing  4 weeks. F ive o f the 17 patients had been 
p re trea ted  w ith  carbim azole, the remainder having been given 1 -^1  alone. 
This p roportion  o f carbimazole pretreated patients (20%) developing an 
abnormal ra t io  was lower than in patients given alone (40%) (X = 4.6, p 
< 0.05).
3.2.7. Dose o f 1-^1: Patients divided by outcome at one year
The doses o f adm inistered are summarized in Table 16. Those
patien ts  who fa ile d  to  enter remission were given a s lig h tly  higher mean dose 
of 1 -^1  than those who responded, although this did not reach s ta tis tic a l 
s ign ificance . No d iffe rence  in the dose o f given was seen between
those p re trea ted  w ith  carbimazole and those given -^-4  therapy alone.
3.2.8. G o tire  size: Patients divided by outcome at one year
G o tire  size, estim ated from  the planar surface area on thyro id  isotope 
scan im m ed ia te ly  before - ^ 1  therapy is shown in Table 16. I t  w il l again be 
seen th a t the estim ated size was greatest in those patients who subsequently 
rem ained th y ro to x ic , although this did not reach s ta tis tic a l s ign ificance.
3.2.9. Discussion
In th is  series o f 55 patients, 12 remained thy ro to x ic  one year a fte r 
rad io iod ine therapy. Twenty three became euthyro id, o f whom 6 had a short 
episode o f trans ien t hypothyroidism , and the rem aining 20 developed 
permanent hypothyroid ism  w ith in  the f irs t  year. The incidence o f permanent 
hypothyro id ism  a fte r 1^ 1I is partly  a function  o f dose o f radioiodine
adm inistered (Glennon et al. 1972; Hagen et al. 1967; H ard isty et al. 1981):
i t  has been suggested from  a re trospective analysis o f patients trea ted  at the 
Mayo c lin ic  th a t the incidence of hypothyroidism is greater cu rren tly  than in 
previously years, w ith  as many as 90% o f patients becoming hypothyroid one
year a fte r tre a tm e n t (Cunnien et al. 1982): th is, however, may re f le c t a
tendency to  give higher in it ia l doses o f ^--^1 therapy. In the current series, 
however, those patients who became hypothyroid did not appear to  rece ive 
higher doses o f •^^ ^■1 compared w ith  those who became euthyro id or remained
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th y ro to x ic , suggesting the con tribu tion  o f o ther fac to rs  to eventual outcome.
O f those patients developing permanent hypothyroidism , the m a jo rity  
did so w ith in  12  weeks of 1 ^ 1  adm in is tra tion , many w ith in  8 weeks: no 
pa tien t became hypothyro id  la te r than 4 months a fte r 1 ^1  therapy. This 
was accompanied in a ll subjects by a rapid fa l l in early  iodine uptake. The 
early  phase o f the uptake curve (w ith in  20  minutes o f intravenous 
adm is tra tion  o f isotope) is an index o f iodide trapping (IAEA Report, 1972), 
w h ile  uptake at la te r tim es is dependent upon both trapping and 
o rg an ifica tion . Iodide trapp ing is norm a lly  the ra te  lim it in g  step in thyro id  
hormonogenesis, and studies o f early  iodide uptake there fore  examine an 
im p o rta n t physiological variable in con tro l o f thy ro id  function . In a ll 
pa tien ts , iodide trapp ing fe ll to  v ir tu a lly  undetectable levels 4 weeks a fte r 
1 ^ 1  adm in is tra tion , and showed only m in im al recovery in a small number o f 
patien ts th e re a fte r. This re fle c ts , the re fo re , severe im pairm ent o f the 
dom inant thy ro id  physiological process, and inev itab le  progression to 
hypothyroid ism  is the re fo re  to be expected. In a ll such patients th is severe 
loss o f iodide trapp ing was present despite very high leve l o f TSH. Larsson 
(1955), who made la te  (24 hours) and ind ire c t measurements o f trace r ^ ^ I  
uptake a fte r ^ -^ 1  therapy, showed tha t in the m a jo rity  o f patients who were 
hypothyro id  a fte r trea tm en t, very low tra ce r uptake values were recorded.
The response o f the thyro id  to  1-^1 therapy was rapid (w ith in  4 weeks) 
in a ll patients who became hypothyroid. A lthough i t  is like ly  tha t iodide 
trapp ing declines much earlie r than th is fo llow ing  1 ^ 1  adm in istra tion , ea rlie r 
measurements are not possible because of the very high background levels o f 
rad ia tion  in the gland. In a ll subjects there was a lag between th is fa l l in 
iodide trapp ing and the biochemical response (Figure 17): this presumably 
re fle c ts  the long disappearance h a lf- life  o f thyrox ine  (7 days) and the store 
o f preform ed thy ro id  hormone w ith in  the gland. Thus, although the c lin ica l 
and biochem ical response to  l ^ l j  adm in istra tion  may be delayed, th is does 
not re f le c t the rapid e ffe c t o f rad ia tion  on im po rtan t thyro id  physiological 
processes. This gap between uptake response and biochem ical response has 
been noted by Myant (1953 a + b) and Franco et al. (1970).
Twenty three patients were euthyro id  one year a fte r 1 ^1  
adm in is tra tion . O f those given ^-^1 alone, a ll but one patien t had become 
euthyro id  w ith in  12 weeks of trea tm en t. In contrast, although a ll patients 
pre trea ted w ith  Carbimazole were euthyro id before l ^ I  was given, in 6
subjects an episode o f thyro tox icos is  occurred a fte r 131j adm in istra tion , and 
these subjects were not euthyro id  u n til 6 months a fte r trea tm en t. Uptake 
values fe l l in a ll patients in th is  group fo llow ing  131j therapy, and the 
median value 4 weeks a fte r tre a tm e n t was s ig n ifican tly  higher than tha t in 
those patien ts who became perm anently hypothyroid (Figure 16, Table 11). 
This suggests tha t the degree o f damage sustained by the thyro id  fo llow ing  
1-^1 was less in th is  euthyro id  group o f patients. In 10 patients from  this 
group, uptake at th is  tim e  (4 weeks) was less than 2%, ind icating  almost 
com plete  loss o f iodide trapp ing func tion . Thereafter, iodide uptake rose in 
a ll patien ts w ith  values rem ain ing w ith in  the normal range in the m a jo rity  o f 
instances. Thus, in th is  group o f patients tem porary loss o f thyro id  function  
was fo llow ed  by p a rtia l recovery so tha t normal thyro id  hormone levels were 
m ain ta ined. As w ith  permanent hypothyroidism , there was a lag period 
between the response o f iodide trapp ing to  131j adm in istra tion  (rapid) and the 
re fle c tio n  o f th is  in thyro id  b iochem ical change (Figure 18). The patte rn  o f 
thy ro id  uptake fo llow ed b yp a rtia l recovery is s im ila r to  tha t noted by M yant 
(1953 a + b) who noted th a t uptake measurements fe l l 3 weeks a fte r 131j 
adm in is tra tion , and tha t in a number o f patients measurements rose 
th e re a fte r. He observed tha t where no fu rth e r uptake occurred, patients did 
not become euthyro id . S im ila rly , Einhorn and Hastad (1961) measured uptake 
o f 132 'low ing  l - ^ I  therapy and showed tha t the greatest fa l l in uptake 
occurred in those patients who subsequently entered remission. Carbim azole 
p re trea tm en t had no e ffe c t on th is  pa tte rn  o f uptake behaviour (F igure 18). 
In th is subgroup mean thyro id  hormone levels did not fa l l a fte r 131^ anc] 
indeed, rose s ligh tly . This again demonstrates the delay between e ffe c ts  o f 
131i on iodide trapping and biochem ical response. I t  is lik e ly  tha t 
w ithd raw a l o f carbimazole fo r fiv e  days before 131j therapy allows an 
increase in thyro id  hormonogenesis, so tha t fo llow ing  131j trea tm en t, when 
iodide trapping tem pora rily  fa lls , hormone content o f the gland is su ffic ie n t 
to  m ainta in  c ircu la ting  T4 and T3 u n til trapping recovers.
Twelve patients remained thy ro to x ic  one year a fte r trea tm en t w ith  
131j. 0f  these, 4 remained severely thy ro tox ic  and required carbim azole 
therapy to  contro l symptoms between 4 and 10 months a fte r 3.31j 
adm in is tra tion . In the rem ainder, some evidence of biochem ical response to  
tre a tm e n t was noted and in these patients the c lin ica l signs and symptoms of 
thyrotoxicosis were m ild. A ll patients showed evidence of some response to
rad io iod ine in term s o f a fa l l o f 20 m inute uptake a fte r 131j adm inistration, 
although th is  was sm all in several instances. As w ith  the other categories o f 
pa tien t, the m axim um  fa ll in iodide trapp ing occurred w ith in  4 weeks o f 
131if and b iochem ica l response some weeks la te r (F igure 19).
3.2.10. Im p lica tions o f a lte red  radioisotope uptake fo llow ing  131j therapy
The general pa tte rn  of 20 m inute uptake measurements fo llow ing  131f 
therapy was s im ila r in th is study to  tha t reported elsewhere (discussed 
above): in a ll patien ts a fa l l in uptake early  a fte r trea tm en t was fo llow ed by 
a variable  degree o f recovery in the subsequent 4-8 weeks. Uptake
measurements th e re a fte r remained fa ir ly  stable. Thyro id  functiona l reserve 
(i.e. the capac ity  to  synthesise thyro id  hormone) is determ ined, a fte r 131j 
adm in is tra tion , by the rem aining a b ility  to trap  iodide and the im portan t 
e ffe c ts  o f 131j tre a tm e n t on th is aspect o f thyro id  func tion  occur early a fte r 
tre a tm e n t. As other workers have noted, however, there is a lag between
th is  response and its  b iochem ical expression, presumably because of the store 
o f p reform ed thy ro id  hormone w ith in  the gland.
The reason fo r  the biphasic response to  ^-31j adm in istra tion , w ith  an 
in it ia l fa l l  in uptake fo llow ed by pa rtia l recovery is unclear. I t  is possible 
th a t there is, at ce llu la r leve l, tem porary d isruption o f ce ll function  w ith  
loss o f iodide trapping, and tha t this gradually recovers over the subsequent 
few  weeks. I t  seems unlike ly  tha t the recovery o f iodide trapp ing function
represents replacem ent o f thyro id  cells: the dose o f rad ia tion  adm inistered is 
one which would prevent fu rth e r ce ll rep lica tion . In general, thyro id  ce ll 
func tion  is considered rad io-resis tan t, in contrast to  the re la tive  rad io-
se n s itiv ity  o f ce ll rep lica tion  (A l-H indaw i and Wilson, 1965). This is 
re fle c te d  in studies showing cum m ulative increases in la te  hypothyroidism  in 
the years a fte r therapy (Greig, 1973; D w orkin, 1971; T o ft et al. 1975).
I t  is possible tha t part of the explanation fo r the change in uptake 
behaviour lies in the heterogenetity o f isotope d is tribu tion  throughout the 
gland (Studer, Peter and Gerber, 1985). I t  is possible tha t fo llow ing  
adm in is tra tion  some fo llic le s , which are more active  in iodide trapping, 
receive a higher exposure to rad iation  than others and i t  may be tha t cells 
from  such fo llic le s  are permanently damaged: the a c tiv ity  o f these fo llic le s  
w il l la rge ly determ ine the p re irrad ia tion  trace r uptake, and loss o f th is tissue 
w il l account fo r the in it ia l fa ll in uptake a fte r -131j adm in istra tion . F o llic les
which are re la tiv e ly  inactive  before m i w m trap  less isotope and may 
rece ive  a re la tiv e ly  lower dose o f rad ia tion  and thus be capable o f continued 
iodide trapp ing  fo llow ing  131j therapy. However, the steady increase in 
incidence o f hypothyroidism  in the years fo llow ing  ^-31j therapy indicates th a t 
ce llu la r damage (at least to  the nucleus) is a very generalised phenomenon 
w ith in  the gland.
A spectrum  o f thyro id  damage fo llow ing  ^31j therapy ranging from  
com plete  loss o f function  to m in im al change in uptake was noted. The 
reason fo r  th is  is unclear. Smith and Wilson (1967) showed tha t the dose of 
131l had a m ajor bearing on the incidence of early hypothyroidism , and th is 
has been confirm ed in a large number o f patients trea ted  w ith  a range of 
doses o f (Cevallos et al. 1974; Glennon et al. 1972; Hagen et al. 1967). 
How ever, in the current study an a ttem p t to give the same dose of 131j t0  
a ll pa tien ts  was made. The dose o f rad ia tion  delivered to the thy ro id  is a 
fun c tio n  o f the adm inistered dose o f isotope, gland mass and the e ffe c tiv e  
h a lf- l ife  o f 131j# A lthough some inaccuracy in estim ation o f gland mass 
using sc in tig raphy is inevitab le , and although there may be some v a r ia b ility  
in e ffe c t iv e  h a lf- life  o f - ^ 1  in patients w ith  thyrotoxicosis, i t  seems un like ly  
th a t these variables would be su ffic ie n t to  account fo r the d iffe rences in 
response noted. Thus, the mean estim ate of goitre size in the group o f 
pa tien ts  who fa ile d  to  become euthyro id a fte r ^31j was grea te r than tha t in 
those who responded more fu lly : this fo rm er group there fo re  received a 
higher dose o f *31^ an(j  the antic ipated rad iation  per unit mass of gland
should have been s im ila r. The va ria b ility  and sens itiv ity  o f response cannot
be explained by the use of an tithyro id  drugs, as the patte rn  o f isotope
uptake and biochem ical response were s im ilia r in those patients given no 
p re trea tm e n t.
Exam ination of the isotope uptake data suggests tha t the spectrum  o f 
thy ro id  damage fo llow ing  3-31j therapy is continuous. There was, the re fo re , a 
range o f d isruption of function  from  permanent loss o f trapping o f iodide to  
trans ien t loss o f trapping w ith  a variable degree of recovery to  m inim um
change in isotope uptake w ith  l i t t le  change in thyro id  hormone production. 
I t  is evident from  the foregoing data and discussion tha t the e ffec ts  o f I 
on th y ro id  ce ll function  occur early a fte r adm inistration o f the isotope.
3.2.11. E ffe c ts  on iodide organ ifica tion
I t  was demonstrated in a p ilo t investiga tion  tha t the increase in 
uptake of tra ce r iodide between 20  and 60 m inutes a fte r intravenous 
in jec tion  o f tra ce r was a crude measure o f iodide o rgan ifica tion  (2.3.5.). O f 
the 55 patien ts in this study, 30% had an abnorm ally low ra tio  of uptake 
between 20 and 60 minutes w ith in  the f ir s t  4 months a fte r 131j trea tm en t. 
This may represent a true  defect o f iodide o rgan ifica tion  in such subjects: 
the figu re  is rem arkably s im ila r to tha t reported by Gray (1975) who studied 
a group of patien ts fo llow ing  ^ -^ I therapy using a perchlorate discharge test. 
O f the patien ts in the curren t study shown to  have an abnormal ra tio , 4 had 
persistent thyro tox icos is , 5 developed permanent hypothyroidism  and the other 
9 became euthyro id  over the subsequent few  weeks (3 o f th is group had an 
episode o f trans ien t hypothyroidism ). Tw enty percent o f the patients 
p re trea ted  w ith  carbim azole had an abnormal ra tio  w ith in  the f ir s t  the few  
months a f t e r  131} adm in is tra tion , whereas 40% of those not pretreated had 
an abnormal ra tio , th is d iffe rence  was s ign ifican t using a tes t. This may 
be evidence o f a rad io -p ro tec tive  e ffe c t o f carbim azole. I t  must be stressed 
th a t the 60:20 m inute uptake ra tio  is a very ind ire c t means o f assessing 
iodide o rgan ifica tion . This is especially so when uptake measurements are 
low , at a tim e  when s ta tis tic a l errors in counting can s ig n ifica n tly  a ffe c t the 
resu lt. The data need, the re fo re , to be in terpre ted  w ith  caution. A more 
deta iled study o f iodide o rgan ifica tion  defects fo llow ing  131j therapy is 
presented in chapter 4. From this p re lim inary data, however, i t  does appear 
th a t such defects are not uncommon a fte r ^ l j  tre a tm e n t and are most 
evident in the early months.
3.2.12. Use o f radioisotope uptake studies to  p red ict b iochem ical outcome 
fo llow ing  ~ ^ I  therapy
From the above discussion i t  is clear tha t the p rinc ipa l determ inant of 
residual thyro id  reserve a fte r 131I therapy is the a b ility  to  trap  iodide. 
Thus, subjects in whom iodide trapping, as assessed by the 20 m inute uptake 
o f 123i, remained elevated a fte r ^ ^ l j  trea tm en t did not enter remission while 
those subjects in whom iodide trapping became neglig ib le developed 
permanent hypothyroidism . From Figure 16 i t  w il l be noted tha t, as early as 
4  weeks a fte r 131j- adm in is tra tion , s ign ifican t d ifferences between those 
patients who became euthyroid and those who were e ithe r hypothyroid or 
thy ro to x ic  one year a fte r trea tm en t can be seen, and th a t, from  12 weeks
onwards, l i t t le  change in uptake behaviour occurred in those patients who 
were not a lready hypothyroid. Despite th is s ta tis tic a l separation, there was 
some overlap between the groups. However, a ll patients whose uptake 4 
weeks a fte r  therapy, was 4% or less responded to  ( i.e. became e ither
eu thyro id  or hypothyroid), w hile  no patien ts whose uptakes were higher than 
8 % at 4 weeks a fte r trea tm en t responded. An uptake o f less than 2% 
between 8 and 12 weeks a fte r tre a tm e n t was, in a ll but one instance, 
associated w ith  the development o f permanent hypothyroidism .
3.2.13. Im p lica tions  fo r pa tien t management
The main problem im m ed ia te ly  a fte r ^-31i adm in istra tion  is the
u nce rta in ty  surrounding the response o f an individual patien t, and the lag
period between trea tm en t and the tim e  fo r  th is response to be expressed in 
c lin ic a l or b iochem ical change. For example, the period between trea tm en t 
and norm a lisa tion  o f thyro id  b iochem istry in those patients who did respond 
(131j group alone) was 12.7 + 2.4 weeks. This uncerta in ty  in response may 
s t i l l  occur in patients who are given de libe ra te ly  "ab la tive ”  doses o f ^31j 
(K enda ll-T ay lo r, K e ir and Ross, 1984; Safa and Skillern, 1975) in tha t 
hypothyro id ism  is not inevitab le . In e lderly  subjects, or in patients w ith
thyroca rd iac  disease this may be unsatis factory, exposing those patients, who 
do not respond adequately, to delay before fu rth e r necessary trea tm en t is
arranged. Because o f th is, an tithy ro id  drugs may sometimes be given before 
131i tre a tm e n t and continued fo r a variable tim e  the rea fte r. When the
e ffe c ts  o f 131i are assumed to have occurred, an tithyro id  therapy is 
discontinued. W ith this policy, residual thy ro id  function  on cessation of drug 
tre a tm e n t is unknown and patients may be exposed to  risk o f relapse of 
thyro tox icos is  (Viherkoski et al. 1970).
Use o f early iodine uptake measurements may be of value in
pred ic ting  outcome over this period. Where the uptake 4 weeks a fte r - ^ I  
therapy is high (i.e. greater than 8%) response to  trea tm en t is most un like ly  
and a second dose of ^ -^ I can be given. Where the uptake has fa llen  to  less
than 4 %, 4 weeks a fte r trea tm en t, fu r th e r trea tm en t is lik e ly  to  be
unnecessary. Uptake measurements o f less than 2% at 8 weeks a fte r 
tre a tm e n t are ind icative  o f like ly  permanent hypothyroidism and such patients 
should be managed accordingly. While the e ffec ts  o f an tithyro id  drugs given 
a fte r 131j therapy on uptake measurements were not examined in th is study,
and although a n tith y ro id  drug trea tm en t is thought to influence uptake 
behaviour (A lexander et al. 1967; M cLa rty , 1973; W ilk in  et al. 1981) i t  is 
lik e ly  tha t s im ila r assumptions can be made regarding the high or low (i.e. 
g reate r than 8 % or less than 2%) uptake measurements a fte r ^-31j therapy in 
drug trea ted  patien ts. The use o f carbim azole p re trea tm ent alone does not 
seem to  change s ig n ifica n tly  the patte rn  o f response o f uptake, nor its  
b iochem ical expression a fte r ^ 3 1 \ The po ten tia l rad iop ro tec tive  e ffe c t of 
such therapy is discussed more fu lly  in sections 5-7 o f th is  chapter.
SECTION THREE
TR ANSIENT HYPO THYRO ID ISM  FOLLOW ING RADIOIO DINE  
THERAPY FOR THYROTOXICOSIS
3.3.1. In trod u c tion
R ecovery o f thy ro id  func tion  fo llow ing  hypothyroidism  induced by l ^ l j  
the rapy has been reported  in a number o f series since the in troduction  o f 
th is  fo rm  o f tre a tm e n t (Dorfm ann et al. 1977; M cG irr et al. 1964; Segal et 
al. 1961). This phenomenon, described as transient hypothyroidism , occurs 
w ith in  12  months o f therapy and adequate thyro id  hormone production
recovers over the course o f a few  months. Despite considerable experience 
gained w ith  l ^ l j  therapy over 30 years ne ither the mechanism underlying the 
phenomenon nor e ffe c tiv e  means of p red ic ting  recovery o f "ea rly  
hypo thyro id ism " are c lear. The experience o f transien t hypothyroidism  in
patien ts given in the curren t studies w ill be presented in th is section.
3.3.2. P atien ts and methods
F if ty  f iv e  patients w ith  c lin ica l and biochem ical evidence of 
thyro tox icos is  trea ted  w ith  were fo llow ed fo r a m inim um o f 12 months.
D uring th is  f ir s t  year a fte r - ^ 1  therapy patients were seen every 4 weeks. 
The deta ils o f these patients have already been given in the preceding
section (Tables 7 + 8 ). S im ila rly , p re trea tm ent assessment and dosim etry 
have already been described.
A t each v is it patients were assessed c lin ic a lly  and blood was taken fo r 
measurement o f T3, T4 and TSH. Before therapy, and at each v is it (unless 
on thy ro id  hormone replacem ent) thyro id  uptake o f ^^3j 20 and 60 minutes 
a fte r intravenous adm inistration of the isotope was measured. K in e tic  
analysis o f 123j uptake was perform ed in 2 subjects who developed transien t 
hypothyroidism  using the gamma cam era/com puter system.
Hypothyro id ism  was diagnosed on the basis o f a low serum 
concentra tion  o f T4 and elevated serum TSH. Thyro id hormone replacem ent 
therapy was given i f  c lin ica lly  indicated using tri- iodo thyron ine  20  pg t. i.d . 
This was w ithdraw n a fte r m inimum of 8 weeks fo r at least 7 days, and basal 
b iochem istry and uptake measurements repeated. Permanent hypothyroidism  
was diagnosed i f  w ithdraw al o f replacement therapy resulted in a rise o f
serum TSH w ith  a pers is ten tly  subnormal serum T4.
3.3.3. Results
Six patients developed hypothyroid ism  which was transien t during the 
f ir s t  12 months o f fo llow -up , a ll w ith in  12 weeks o f 1-^1 therapy. Fu rthe r 
deta ils  o f these patients are shown in Table 17. I t  w il l be noted tha t 2 
pa tien ts had received carbim azole before 1 ^ 1  trea tm en t whereas 4 had not. 
The mean delay before onset o f hypothyroidism  a fte r l ^ l j  was 9 weeks, and 
the mean duration of hypothyroidism  was 8 weeks. Subsequent fo llow -up  of 
these patients fo r as long as 3 years has shown tha t 2 have developed 
permanent hypothyroidism  (both 4 years a fte r ^ - 4  therapy, subjects 2 and 6 ) 
and 4 have remained euthyro id . Serial uptake data fo r these 6 patients are 
also shown in Table 18. In patients 1 and 2 k ine tic  analysis o f radioisotope 
(123i) uptake showed a m ajor de fect o f iodide o rgan ifica tion  w ith  a low 
derived binding ra te  fo r iodide (Kb) at the tim e  o f diagnosis o f 
hypothyroidism . The normal thy ro id  gland incorporates over 15% o f the 
the o re tica l in tra th y ro id a l inorganic iodide pool in to  organic form  per m inute. 
In both o f these patients the value derived fo r binding ra te  was less than 
0.05 (5%) per m inute. W ith tim e , seria l k ine tic  studies show a re tu rn  to 
norm al o rgan ifica tion , the im provem ent coinciding w ith  a rise in serum T4. 
I t  is o f in terest tha t the ra tio  between 20 and 60 m inute uptakes in these 
patien ts at the tim e  o f the o rgan ifica tion  defect was less than 1 .6 .
In pa tien t 3 an elevated 20 m inute uptake at the tim e  of diagnosis o f 
hypothyroidism  was noted, w ith  a ra tio  o f 60:20 m inute uptake o f 1.39. 
R eturn  o f normal thyro id  hormone levels was associated w ith  a fa l l in 20 
m inute uptake but an increase in the ra tio  between 60 and 20  m inutes (1 .8 ). 
In patients 4 and 5, 20 m inute uptake was not elevated when TSH was high, 
and in patient 4 the ra tio  between 60 and 20 m inute uptake was low. In 
pa tien t 6 , there was again an abnorm ally low ra tio  between 60 and 20 
m inute  uptake at the tim e  of diagnosis o f hypothyroidism , w ith  an increase 
in the ra tio  associated w ith  re tu rn  o f normal thyro id  function .
In contrast, in most subjects in whom hypothyroidism proved to  be 
permanent, early radioiodine uptake measurements were low when TSH was 
high and did not re tu rn  to  normal w ith in  the period o f observation.
3.3.4. Discussion
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The data con firm  tha t transien t hypothyroidism  occurs in a proportion 
o f th y ro to x ic  patients trea ted  w ith  ^ -^ I.  The percentage in this series (11%) 
is s im ila r to  tha t reported by M cG irr e t al. (1964) and Dorfm an (1977). 
U n til re ce n tly , however, precise biochem ical d e fin ition  o f thyro id  status has 
not been possible and many e a rlie r reports are, there fo re , less w e ll 
documented. In the most com plete series to  date, Sawers (Sawers, T o ft, 
Irv in e , e t a l. 1980) suggested th a t trans ien t hypothyroidism  m ight be due to  
e ithe r a recovery o f fo llic u la r  ce ll func tion  fo llow ing  irrad ia tion  damage or 
to  com pensatory hypertrophy/hyperp lasia  o f undamaged cells: no evidence in 
support o f e ithe r hypothesis was produced. In 3 patients (1,2 and 3) w ith  
trans ien t hypothyroid ism  in the curren t series, early  123j Up take was elevated 
beyond the norm al established range. In th is  s itua tion , i t  seems lik e ly  tha t 
hypothyro id ism  is due to  fa ilu re  o f o rgan ifica tion  o f iodide: the elevated 20 
m inute  uptake indicates tha t the trapping mechanism fo r iodide was capable 
o f responding in a re la tiv e ly  norm al manner to  elevated serum concentrations 
o f TSH. Increased iodide trapp ing at a tim e  o f inadequate thyro id  hormone 
production is very suggestive o f a defect in iodide
o rg an ifica tion . We have confirm ed tha t a binding defect fo r  iodide was 
present a t the tim e  o f hypothyroidism  in 2 patients from  this group in whom 
seria l k in e tic  studies were perform ed, w ith  recovery o f this defect occurring 
over the fo llow ing  weeks. A s im ila r s itua tion  appears to be present in 
pa tien t 3 in whom the ra tio  o f 60:20 m inute uptakes was low at the tim e  o f 
hypothyro id ism . In pa tien t 6 , 20 m inute uptake o f 123j was at the upper end 
o f the norm al d is tribu tion , but again the ra tio  between 60 and 20  m inute 
uptake was abnorm ally low, suggesting tha t o rgan ifica tion  was severely 
im paired. A rise in this ra tio  was associated w ith  recovery o f thyro id  
hormonogenesis.
In patien t 4, the 20 m inute uptake o f 123j was not elevated at the 
tim e  o f diagnosis of hypothyroidism  despite an elevated serum concentration 
o f TSH, suggesting rad ia tion  damage to  the iodide trapping process. Thyro id 
hormone production increased over the next few  weeks w ithou t any m ajor 
change in 20  m inute uptake o f 1^3j. there  was, however, an increase in the 
60 m inute uptake over this period. This may again be consistent w ith  in it ia l 
im pa irm en t o f o rgan ifica tion  im proving a llow ing increased thyro id  hormone 
production.
In pa tien t 5 20 m inute uptake o f 123j was j ow at  the tim e  of
diagnosis o f hypothyro id ism , again ind ica ting  dysfunction o f iodide trapping. 
The increm ent between 20 and 60 m inutes was not abnormal, however, 
suggesting th a t o rg an ifica tion  o f iodide was re la tiv e ly  unimpaired. Over the 
subsequent few  weeks thyro id  hormone production recovered and associated 
w ith  th is  was a sm all rise in early  iodine uptake measurements. This patien t 
rece ived carb im azole tre a tm e n t p rio r to  1 ^ 4  therapy and i t  is possible tha t 
th is  may induce in tra th y ro id a l iodide depletion (Barandes, H urley and Becker, 
1973; Harden, A lexander and Koutras, 1966). W ith reduction  in the amount 
o f iodide trapped by the gland fo llow ing  131] therapy, insu ffic ien t 
in tra th y ro id a l iodide may have been available to  m ain ta in  sa tis fac to ry  thyro id  
hormone production. Over a period o f tim e , w ith  some recovery o f iodide 
trapp ing , in tra th y ro id a l stores may have been replenished s u ff ic ie n tly  to a llow 
sa tis fa c to ry  thy ro id  hormone production.
I t  seems, the re fo re , tha t the mechanisms underlying transien t 
hypothyroid ism  may not be homogeneous. There is evidence, however, in th is 
group o f patien ts th a t revers ib le  im pa irm ent o f o rgan ifica tion  w ith  or w ithou t 
changes in trapp ing o f iodide can lead to  trans ien t hypothyroidism . 
Reversib le o rg an ifica tion  defects fo llow ing  - ^ 4  therapy have been noted by 
Gray (1975), who showed tha t in some patients trea ted  w ith  - ^ 4 ,  iodide 
could be discharged from  the gland by sodium perchlorate  in the early stages 
a fte r tre a tm e n t. In a ll the patients studied by Gray, th is  defect improved 
over a period o f some weeks. O ther authors have cla im ed tha t m inor 
degrees o f im pa irm en t o f o rgan ifica tion  are common fo llow ing  1 ^4  therapy 
(K irk land , 1954; Suzuki and Mashimo, 1972), although these abnorm alities 
reported  were not associated w ith  any consistent c lin ica l or b iochem ical 
changes. In chapter 2 o f this section evidence o f im pa irm ent o f
o rg an ifica tion  was seen in around 30% o f patients studied w ith in  the f ir s t  4 
months a fte r ^ 4  adm in istra tion . I t  is o f in te rest tha t a ll cases of transien t 
hypothyroid ism  in th is series also occurred w ith in  the f ir s t  4 months a fte r 
therapy, and i t  seems lik e ly  tha t this reversib le im pa irm ent o f thyro id  iodide 
processing is responsible fo r the m a jo rity  o f cases of reversib le
hypothyroidism . In contrast, m ajor damage to the iodide trapp ing mechanism
does not appear to  recover and results in permanent hypothyroid ism .
Fa ilu re  to  recognise hypothyroidism  tha t is trans ien t fo llow ing  ^ 4  
therapy involves placing a s ign ifican t percentage o f patients on unnecessary 
replacem ent trea tm en t. I f  the aim of 134  trea tm en t is to  a tta in
euthyro id ism  w ithou t the need fo r replacem ent therapy, i t  is c lea rly  
im p o rta n t th a t those patients whose hypothyroidism  may be transient are 
recognised and dealt w ith  according ly. I t  has been suggested tha t is 
reasonable to  w ithho ld  replacem ent therapy fo r a short period in a ll patients 
developing hypothyroid ism  early a fte r l ^ I ,  to  a llow possible recovery to  
occur (Sawers et al. 1980). Symptoms o f hypothyroidism  in patients who 
have been re ce n tly  th y ro to x ic  may, however, be uncom fortable and th is 
po licy  may involve placing an unacceptably high number o f patients at risk 
o f such symptom s. An a lte rna tive  po licy  m ight be to  use T ri-iodo thyron ine  
as rep lacem ent therapy in early  hypothyroid ism  i f  c lin ic a lly  ind icated and to 
w ithd raw  tre a tm e n t a fte r a period o f tim e  to  reassess thyro id  function . This 
system would be ra the r im p ra c tica l fo r general application and would also 
re su lt in abrupt changes in thy ro id  hormone status in th is group o f patients. 
As an a lte rn a tive , measurement o f early  uptake at the tim e  o f diagnosis
o f hypothyro id ism  may be o f some p red ic tive  value. Where uptake is low 
(less than 2%) at the tim e  o f TSH e levation , hypothyroidism  is due to  fa ilu re  
o f iodide trapp ing  and is un like ly  to  recover: placement o f the pa tien t on 
perm anent replacem ent therapy would be reasonable. Where early  iodine 
uptake is g reate r than 2 % hypothyroidism  may be due, in part, to  im pa irm ent 
o f in tra th y ro id a l o rgan ifica tion  o f iodide, p a rticu la rly  when uptake is elevated 
beyond the norm al range, and recovery o f thyro id  function  in th is  s itua tion  
may be antic ipa ted . In th is s itua tion  i t  would be reasonable e ithe r to  
w ithho ld  therapy i f  symptoms are m in im al or to  use a lim ite d  course o f 
rep lacem ent therapy before reassessment o f thy ro id  b iosynthetic capacity.
SECTION FOUR
IM P A IR M E N T OF IO DIDE O R G A N IFIC A TIO N  FOLLOWING
131I THERAPY
3.4.1. In trod u c tion
O f the 2 m ajor physiological processes involved in synthesis o f thyro id  
hormones (iodide trapp ing and subsequent incorpora tion  in to  organic fo rm ) 
iodide trapp ing is ra te  lim it in g  (Ingbar, 1978) in tha t the m a jo rity  o f trapped 
iodide is rap id ly  bound. In certa in  circumstances, however, im pairm ent o f 
o rg an ifica tion  o f iodide may l im it  thyro id  hormone fo rm a tion . Thus, in 
patien ts trea ted  w ith  the a n tith y ro id  drug carb im azole, iodide trapping is not 
d ire c tly  a ffe c ted  and thyro id  function  is reduced by inh ib ition  of 
o rgan ifica tion . H ild itc h , using a sensitive perchlorate discharge test validated 
by k in e tic  analysis o f the uptake curve (H ild itch  et al. 1980) studied patients 
trea ted  w ith  carb im azole and showed tha t there was dose re la ted  inh ib ition  
o f o rg an ifica tion  o f iodide using the drug, and tha t c lin ica l and biochem ical 
response m irro r the e ffe c ts  o f drug on this function  (H ild itch , 1978). E arlie r 
in th is  chapter evidence was presented tha t o rgan ifica tion  im pairm ent as 
assessed by the crude ra tio  o f 60:20 m inute uptake o f ^ 3 j  was present in 
around one th ird  o f patients early a fte r tre a tm e n t, and i t  was suggested 
th a t th is m ight account fo r  transien t hypothyroidism .
The e ffe c ts  o f on thyro id  iodide trapp ing have been considered
e a rlie r in this chapter; in the current section deta iled  studies of iodide 
o rgan ifica tion  capacity  fo llow ing  131I therapy are considered.
3.4.2. Patients and methods
Twenty fou r patients w ith  thyrotoxicosis were studied: a ll were
c lin ic a lly  thy ro to x ic  at the tim e of entry to  the study w ith  elevated 
concentrations o f both T3 and T4, elevated uptake measurements o f 123j 20 
minutes a fte r intravenous in jec tion  of trace r and d iffuse uptake of isotope on 
scanning. Twelve o f the subjects were given carbim azole w ith  thyro id  
hormone supplements (20-30 mg carbimazole and 0.1 mg T4 daily) so tha t 
subjects in th is group was a ll euthyroid at the tim e  o f adm in istra tion  of 
13 4 .  The other 12 patients were given alone. F u rthe r details o f these
patients have already been given (3.1.2.). Carbim azole and thyro id  hormone
supplements were w ithdraw n 72 hours before 131I adm in istra tion . Pre 131I 
assessment and ca lcu la tion  of dose o f were perform ed as described in
chapter 2 .
P atien ts  were reviewed every 4 weeks a fte r adm in istra tion .
M easurem ent o f iodide o rgan ifica tion  was perform ed at 6 , 16, 32 and 48 
weeks a fte r adm in is tra tion  unless patients were being trea ted  fo r
hypothyro id ism  (transient hypothyroid ism  was excluded as described in section 
3) or fo r  relapse o f thyro tox icos is . A trace r dose o f 123j (250  p c i)  was 
given in travenously and uptake o f the isotope measured over the next 30 
m inutes using a gamma cam era/com puter system as described earlie r. 
Sodium perchlora te  (450 mg) was then given by intravenous in jec tion  and the 
e ffe c t on fu r th e r accum ulation and re ten tion  o f trace r fo llow ed fo r the next 
30 m inutes. A fa l l in the uptake measurement a fte r adm in is tra tion  of 
perch lo ra te  was regarded as a positive  tes t, w ith  the d iffe rence  between the 
uptake measurement im m ed ia te ly  before and 30 minutes a fte r perchlorate  
being expressed as the post-perch lorate  discharge. H ild itch  (1978) has shown 
th a t there  is a close co rre la tion  between this measurement and binding ra te  
fo r  iodide (Kg) using k in e tic  analysis o f radioisotope uptake curves. A 
ty p ic a l uptake curve in a patien t w ith  no evidence of o rgan ifica tion  
im pa irm en t, and in one w ith  a positive perchlorate discharge tes t has been 
shown in F igure 7.
3.4.3. Results
P a tien t characteris tics and the biochemical outcome fo llow ing  
therapy over the subsequent 12 months are summarised in Table 19. The 
experience o f o rgan ifica tion  defects fo llow ing  adm in is tra tion  in this
group o f patients is summarised in Table 20. I t  w ill be seen tha t o f those 
subjects given 131I therapy alone, 3 (25%) (No. 5,11,12) had an o rgan ifica tion  
de fec t 6 weeks a fte r adm in is tra tion . Ten weeks la te r, the defect was
s t i l l  present in those subjects, but a fu rth e r 3 (in whom uptake measurement 
was very low at 6 weeks) (No. 2,3,6) had developed positive tests. In a ll 
subjects in whom the study could be repeated at 32 weeks (those who had 
not become hypothyroid) the percentage of 123I discharged by perchlorate  
fe l l w ith  tim e  or disappeared. By 48 weeks a fte r trea tm en t a positive test 
was s t i l l  present in 2 subjects, although the size of the discharge was very 
sm all in both instances. In one subject (number 5) the tes t had also been
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TABLE 20 (PART I)
SERIAL ORGANIFICATION STUDIES AFTER 131 I  TREATMENT
A . PATIENTS GP  
131
NO. BEFORE I  
2 0 *
JEN 1311 ALONE
6 WEEKS 
20 ;
CL04 DISCHARGE %
16 WEEKS 
20 ;
CL04 DISCHARGE %
32 WEEKS 
20 ;
CL04 DISCHARGE %
48 WEEKS 
20 ;
CL04 DISCHARGE %
1 1 9 .9 9 ; - 7 .2  ; - 5 .2  ; - 5 .6  ; -
2 2 9 .1 0  ; - 7 .8  ; 1 7 .1 9 .4  ; 7 .1
3 1 0 .0 0 .5  ; - 1 0 .7  ; 4 0 .9 1 8 .5  ; -
4 2 9 .9 1 2 .8  ; - 2 9 .9  ; - 2 9 .5  ; - 1 8 .2  ; 5 .3
5 3 8 .8 1 1 .3  ; 3 1 .7 9 .5  ; 16 1 5 .5  ; - 5 .7  ; 1 1 .3
6 1 3 .7 o ; - 2 .8  ; 2 4 .7 HYPOTHYROID
7 3 3 .4 1 2 .5  ; - 1 6 .4  ; - 1 3 .7  ; - 1 1 .5  ; -
8 2 9 .2 1 .3  ; - 1 1 .6  ; - 1 1 .4  ; - 6 .3  ; -
9 1 9 .4 1 .6  ; - 1 .4  ; - HYPOTHYROID
10 8 .6 0 .5  ; - HYPOTHYROID
11 2 9 .2 1 .6  ; 6 3 .4 1 .9  ; 9 2 .4 HYPOTHYROID
12 2 7 .6 1 3 .0  ; 1 2 .4 1 5 .4  ; 4 .2 1 6 .6  ; 1 .8 1'7.0  ; -
B . PATIENTS PRE 
131NO. BEFORE XI  
2 0 *
TREATED WITH CARBIMAZD
6 WEEKS 
20 ;
CL04 DISCHARGE %
LE
16 WEEKS 
20  ;
CL04 DISCHARGE: %
32 WEEKS 
20 ;
CL04 DISCHARGE %
4 8  WEEKS 
20  ;
CL04 DISCHARGE %
13 1 8 .9 2 .5  ; 4 8 .9 2 .1  ; 4 2 . ] HYPOTHYROID
14 3 9 .2 1 7 .2  ; 2 6 .0 2 1 .2  ; 7 .1 2 3 .5  ; - 2 2 .7  ; -
16  3 1 .1 1 6 .8  ; - 1 0 .6  ; - 4 7 .5  ; - RETREATED
16 2 3 .3 4 .3  ; - ON CARBIMAZOLE ON CARBIMAZOLE 1 4 .9  ; -
17 6 2 .9 0  ; - 2 3 .7  ; - RETREATED
18 6 .1 4 .4  ; - 5 .2  ; -
19 6 .4 8 .4  ; 5 .9 6 .5  ; - 4 .7  ; -
20  2 2 .5 6 .5  ; - 4 .6  ; -
21 4 7 .3 2 3 .2  ; - 1 4 .3  ; -  j-------------------------j_
22 2 9 .1 2 6 .0  ; - 1 7 .9  ; -  J
23 2 7 .6 1 0 .4  ; - 9 . 0  ; - 1 5 .1  ; -  | 8 .7  ; -
24 2 8 .1 3 0 .0  ; - 3 1 .2  ; - RETREATED !1
*  20  = UPTAKE OF TRACER 123I  AT 20 MINUTES
**C L 0 4  % = % OF UPTAKE DISCHARGED 30  MINUTES AFTER I . V .  PERCHLORATE
positive  a t 6 and 16 weeks a fte r 1 5 1 I, w h ile  in the o ther (No. 4) the tes t had 
previously been negative. Thus, 50% of subjects in th is group had evidence
o f iodide o rg a n ifica tio n  defects w ith in  the f ir s t  4 months a fte r l ^ l j
adm in is tra tio n .
O f the subjects given carb im azole  before l ^ l j  therapy, 2 (No. 13,14) 
had a pos itive  tes t 6 weeks a fte r  and in one fu r th e r subject (No. 19) in
whom the measurem ent at 6 weeks could not be made, a positive tes t was
noted a t 16 weeks. One o f these subjects (number 13) was hypothyro id  at 16 
weeks and was not studied fu r th e r. O f the o the r 2, the defects were not 
present a t subsequent tim es. Thus, o f th is  group only 25% had a positive
perch lo ra te  discharge tests fo llo w in g  1 -^ 1  therapy.
I t  w il l  be noted th a t the patients who developed positive  perch lo ra te  
tests were not id e n tif ie d  by any typ ica l p re trea tm e n t ch a rac te ris tic  or post 
tre a tm e n t uptake m easurement. P ositive  tests were present in subjects who 
had a w ide range o f p re -perch lo ra te  uptake measurements (1-21%). However, 
in those subjects in whom the tes t was positive  there was an inverse 
co rre la tio n  (F igure 20) between the size o f the perch lora te  discharge and the 
p re -pe rch lo ra te  uptake measurement.
The e ffe c t o f o rg an ifica tion  im pa irm en t on biochem ical fun c tio n  is 
exam ined in Table 21. In the subjects w ith  very large defects, uptake of 
1 ^ 1  a t 30 m inutes a fte r  in je c tio n  o f the tra c e r was also very low  and those 
subjects e ith e r were or became hypothyro id  sho rtly  a fte r the tes t. In 
con tras t, 2 subjects w ith  persistent thy ro tox icos is  had positive  tests. In both 
o f these, the perch lo ra te  discharge was sm all and the ra te  lim it in g  step in 
th y ro id  hormonogensis was s t i l l  c lea rly  iod ide trapp ing. O f those subjects 
who were euthyro id  at the tim e  o f tes ting , p re -perch lo ra te  uptake was not
low er in those who had no discharge (mean = 10.4%) than in those who had a
positive  tes t (8 .6 %).
3.4.4. Discussion
Inco rpo ra tion  o f plasma inorganic iodide in to  thy ro id  hormone 
comprises 2 p rinc ip le  b iochem ica l processes (discussed in 1. 1 . 2 .): the trapp ing  
o f iodide across the thy ro id  ce ll membrane against a concentra tion  gradient 
and the subsequent o rg an ifica tion  o f th is  in tra th y ro id a l inorganic iodide to  
fo rm  iodotyrosine residues. The e ffe c t o f ^ -^ I  on iodide trapp ing has been 
discussed in section 2 o f th is  chapter.
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RELATIONSHIP BETWEEN EARLY IODIDE ( I) UPTAKE AND 
PERCHLORATE DISCHARGE IN SUBJECTS WITH ORGANIFICATION DEFECTS 
FOLLOWING 131I TREATMENT.
THE UPTAKE OF °I 20 MINUTES AFTER INTRAVENOUS INJECTION
OF ISOTOPE IS PLOTTED AGAINST THE PERCENTAGE OF UPTAKE DISCHARGED
BY PERCHLORATE IN THOSE SUBJECTS WHO HAD POSITIVE TESTS FOLLOWING 
1 SI I, THERE IS AN INVERSE RELATIONSHIP BETWEEN THE TWO MEASUREMENTS 
(r =-0.61) SUGGESTING THAT WHEN ORGANIFICATION IS IMPAIRED,
THE SEVERITY OF DAMAGE TO IODIDE TRAPPING IS REFLECTED IN 
THE SIZE OF THE ORGANIFICATION DEFECT.
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E ffic ie n c y  o f o rg an ifica tion  o f iodide in the cu rren t study was assessed 
by measuring the amount o f tra ce r 12;5I discharged from  the thyro id  a fte r 
intravenous adm in is tra tion  o f sodium perch lora te . This technique has been 
va lida ted  previously by H ild itc h  (1978): in a study o f patients w ith
thy ro to x ico s is  i t  was dem onstrated tha t the tes t accura te ly  measured the 
e ffe c t o f the a n tith y ro id  drug carb im azole on iodide o rg an ifica tion  (H ild itch  
e t al. 1980). N orm a l subjects and patients w ith  un treated thyro tox icos is  had 
no iodide discharged by perch lo ra te  ind ica ting  norm al o rgan ifica tion .
In the  cu rren t study, 3 o f the subjects given l ^ l j  ai one had clear 
evidence o f o rg a n ifica tio n  im pa irm ent 6 weeks a fte r tre a tm e n t, and 30% of 
the subjects in th is  group had a positive tes t at 16 weeks. O f these, 2 
subjects had very low iodine uptake measurements and were b iochem ica lly  
hypo thyro id , 2 were euthyro id  and 2 had persistent thyro tox icos is . O f these 
las t 4 subjects, the o rg an ifica tion  defects tended to  im prove w ith  tim e . In 
con tras t, in the group given carb im azole p re trea tm en t before 1 ^ 1  therapy 
only 25% o f subjects had evidence o f o rg an ifica tion  im pa irm en t at any tim e  
a fte r  1-^1 therapy. A lthough sm all numbers preclude s ta t is t ic a l analysis o f 
such data, i t  seems possible th a t p re trea tm en t w ith  carb im azole was 
associated w ith  a lesser degree of rad ia tion  damage to  the o rgan ifica tion  
process, and may be fu r th e r evidence o f a rad iop ro te c tive  e ffe c t o f 
ca rb im azo le . The inverse co rre la tion  between the degree o f o rgan ifica tion  
im pa irm en t (percentage discharged) and the early  iodine uptake (Figure 20) 
may re f le c t the spectrum  o f seve rity  o f irra d ia tio n  damage in such patients.
The incidence of o rgan ifica tion  im pa irm en t fo llo w in g  ^ -^ I  has been 
d if f ic u l t  to  assess from  previous studies. K irk land  (1954) using a th iocyanate 
discharge tes t, reported  th a t almost a ll patients given ^ ^ 1  showed discharge 
o f tra c e r iod ide and in te rp re te d  th is  as being consistent w ith  o rgan ifica tion  
im pa irm en t. I t  is now recognised, however, tha t th iocyanate  its e lf  im pairs
iodide o rg an fica tion  and is thus unsuitable fo r studying the phenomenon. 
S tew art and M urray (1967) described an a lte rna tive  means o f assessing
o rg a n ifica tio n  using adm in is tra tion  o f oral perchlorate  along w ith  a range o f 
doses o f c a rr ie r iodide (1 0 0 -2 0 0 0  ug), and measured the discharge o f tra ce r 
1 3 1 I. They showed th a t a dose o f 750 pg o f iodide cause the tes t to
become positive  in norm al subjects, while a sm aller dose o f iodide induced 
the tes t to  become positive in subjects w ith  untreated thyro tox icos is . 
S im ila r ly , in 7 o f 11 patients trea ted  w ith  ^-^I» adm in is tra tion  o f g reater
than 20 0  pg o f iodide led to  a pos itive  tes t, w hile  perchlora te  tests in the 
absence of iodide were norm al. O ther workers have used a s im ila r 
iod ide /p e rch lo ra te  discharge tes t in pa tien ts trea ted  w ith  l ^ I .  K ie ffe r  and 
colleagues (K ie ffe r , M edeiros-N eto, Rueta, et a l., 1965) showed th a t a ll 
pa tien ts  who responded to  therapy had a positive tes t w ith in  4 months
o f 1 ^ 1 , w h ile  Suzuki and Mashimo (1972) also found a high incidence of 
pos itive  tests at a s im ila r tim e . There is no evidence, however, tha t 
combined iod ide /perch lo ra te  tests provide an accurate measure o f iodide 
o rg a n ific a tio n  ra te . While the te s t may be a sensitive ind ica to r o f thy ro id  
dys function , i t  is lik e ly  th a t i t  basica lly  dem onstrates increased se n s itiv ity  to 
the  acute e ffe c ts  o f iodide a dm in is tra tion  on iodide o rg an ifica tion  (W o lff- 
C h a ik o ff e ffe c t)  (W o lff and C h a iko ff, 1948). Thus, Koutras and colleagues in 
1964 dem onstrated th a t add ition  o f a sm all amount o f iodide to  the d ie t o f 
norm al subjects led to an increase in absolute thyro id  iodide uptake w ith o u t 
changing c irc u la tin g  levels o f p ro te in  bound iodide (Koutras, A lexander, 
Harden, e t al. 1964). I t  was deduced fro m  th is  tha t the increased d ie ta ry  
in take  o f iodide caused a fa l l  in iodide o rgan ifica tion  ra te . A lthough th is 
evidence is in d ire c t, the studies o f o the r workers support th is hypothesis. 
B raverm an reported  th a t when patien ts were given potassium iodide 
supplem ents a fte r  ^ ^ 1  therapy or sub to ta l thyro idectom y, more than 50% 
became hypothyro id  (Braverman, Woeber and Ingbar, 1969) (i.e. did not escape 
as is usual fro m  the W o lff-C h a ik o ff e ffe c t) . Before potassium iodide was 
given only one subject had a positive  perch lora te  discharge tes t, w h ile  a ll 
subjects had a positive  test a fte rw ards. The authors suggested th a t the 
th y ro id  gland in Graves' disease is uniquely susceptible to  the blocking e ffe c t 
o f iod ide on o rg an ifica tion . Whether th is is so is uncerta in , but ' i t  does 
suggest th a t the use o f iodide w ith  perch lora te  may induce o rg an ifica tion  
im pa irm en t ra th e r than dem onstrating its  presence in the basal sta te .
M ore re ce n tly  G ray (1975) used an intravenous perchlora te  tes t s im ila r 
to  th a t in the cu rren t study. He found tha t around one th ird  o f patien ts 
fro m  a group given ^ -^ I therapy had a positive test w ith in  3 months o f 
tre a tm e n t: in con tras t, a much higher ra te  o f o rgan ifica tion  im pa irm en t a fte r 
tre a tm e n t w ith  12-*I was seen. In an e a rlie r section (3.2.6.) in d irec t evidence 
o f im pa irm en t o f iodide o rgan ifica tion  was found in 30% o f a la rger group o f 
pa tien ts  given -^^1. I t  is o f in te res t th a t the peak incidence o f positive  
perch lo ra te  discharge tests in the group o f patients described in the cu rren t
chapter (16 weeks) is s im ila r to  the tim in g  o f the abnormal ra tio  in early  
uptake measurements (3.2.6.) lending credence to the use o f the 60 to  20 
m inu te  uptake ra t io  as a measure o f o rg an ifica tion  im pa irm en t. Using the 
more sensitive  te s t in the cu rren t study around 38% of patients had an 
episode o f o rg a n ifica tio n  im pa irm en t fo llo w in g  l ^ l j  tre a tm e n t, and th is  was 
more common i f  patien ts who were given carb im azole before therapy
are excluded.
Iodide o rg a n ifica tio n  seems to  be less sensitive to  the e ffe c ts  o f 
ion ising ra d ia tio n  than iodide trapping. Thus, although a marked fa l l in 20 
m inu te  iodide uptake occurred in a ll subjects in the cu rren t study, less than 
50% had evidence o f im pa irm en t o f o rg an ifica tion  at the same tim e . The 
reason fo r  th is  is unclear. Iodide trapp ing  is localised to  the basal thy ro id  
ce ll membrane, whereas o rg an ifica tion  occurs at the apex o f the ce ll at the 
c e ll/c o llo id  in te rfa c e , near the s ite  o f deposition o f labelled iodide w ith in  the 
fo l l ic le  (Ekholm  and W ollm an, 1975). I t  m igh t be supposed, the re fo re , th a t 
the b iochem ica l mechanisms involved in o rg an ifica tion  would be exposed to  at 
least as great an amount o f rad ia tion  as those involved in iodide trapp ing. 
This p ro x im ity  o f the s ite  o f o rg an ifica tion  to  the source o f rad ia tion  was 
thought to  be a possible explanation fo r the higher incidence o f 
o rg a n ifica tio n  de fec t fo llo w in g  ^ ^ 1, which em its e lectrons w ith  a very short 
range o f tra v e l w ith in  tissue (Gray, 1975; E r t l et al. 1970).
I t  may be o f re levance tha t the process o f iodide o rgan ifica tion  
involves generation o f free  radicals derived from  iodide; there is norm a lly  a 
means o f p ro te c tin g  the ce ll from  free  rad ica l damage: fo r example free  
iodide derived rad ica ls w il l react w ith  tyros ine residues on the thyrog lobulin  
m olecule to  fo rm  iodotyrosines. The damaging e ffe c ts  o f rad ia tion  in tissues 
may also be due to production o f free  rad icals (possibly superoxide or 
hydroxyl) (Phil and Edjarn, 1958): i t  may be tha t the specialised nature o f 
thy ro id  peroxidase/H 2 0 2 /iod ide /ty ros ine  in te rac tio n  can lead to  neu tra lisa tion  
o f the fre e  rad ic les produced by rad ia tion  and so reduce the exten t o f 
ra d ia tion  damage to  the portion of the ce ll involved in iodide o rgan ifica tion . 
I t  is known th a t in o ther tissues enzymes of the peroxidase class can act, 
along w ith  superoxide dismutase, to  neutra lise hydroxyl free  radicals.
The im pact o f o rgan ifica tion  defects on thy ro id  hormone production in 
the cu rren t study appears to be sm all. Thus, persistent b iochem ical 
thy ro tox icos is  was present in 3 subjects by 16 weeks a fte r l - ^ I  therapy at a
t im e  when o rg a n ifica tio n  im pa irm en t was present. I t  is c lear tha t there  is 
considerable reserve of thy ro id  o rg an ifica tion  capacity  w ith in  which thy ro id  
hormonogenesis can be regula ted by iodide trapp ing. H ypothyro id ism  may 
develop as a consequence of o rg an ifica tion  im pa irm ent only in exceptional 
c ircum stances where iodide trapp ing  is c r it ic a lly  reduced. Given the 
tendency fo r  th is  o rg a n ifica tio n  im pa irm en t to im prove w ith  tim e  in the 
cu rre n t study, such hypothyro id ism  would be expected to  be tem pora ry. This 
phenomenon has been discussed in 3.3.4.
In sum m ary, using a sensitive intravenous perch lora te  discharge tes t 
less than 50% of patien ts studied had evidence of o rg an ifica tion  im pa irm en t 
fo llo w in g  1 ^ 1  therapy: th is  data is consistent w ith  previous studies; the 
defects  in o rg a n ifica tio n  tended to  im prove w ith  tim e . No evidence o f a 
m a jo r e ffe c t o f o rg a n ifica tio n  im pa irm en t on thy ro id  hormone production was 
seen. Im pa irm en t o f o rg a n ifica tio n  may be less common in subjects 
p re trea ted  w ith  C arb im azo le , possibly re fle c tin g  a ra d io -p ro te c tive  action  o f 
the  drug.
SECTION FIVE  
EFFEC T OF PRETREATM ENT W ITH CARBIM AZO LE ON  
OUTCOM E AFTER 131I TH ER A PY
3.5.1. In tro d u c tio n
The response w ith in  one year o f tre a tm e n t to  subablative doses of l ^ l j  
is variab le  and is in fluenced by a number o f fac to rs  which include go itre  
size, e ffe c t iv e  h a lf - l i fe  o f adm inistered dose o f l ^ l j  and u n ifo rm ity  o f 
rad io isotope uptake w ith in  the gland (Wilson, 1976). The use o f th ioury lene 
a n tith y ro id  drugs before  l ^ l j  therapy may also a lte r the response to  ^ -^ I  by 
a " ra d io -p ro te c tiv e " e ffe c t. Crooks et al. (1960) showed tha t p re trea tm en t 
w ith  m e th y lth io u ra c il low ered the single dose cure ra te  fo llo w in g  1 ^ 4 , w h ile  
a subsequent study showed th a t potassium perch lora te , which is chem ica lly  
and pharm acodynam ica lly  d is tin c t, did not produce th is  e ffe c t (Buchanan et 
al. 1965). In a com parison o f the e ffe c ts  o f p re trea tm en t w ith  carb im azole 
on the response to  l - ^ I  therapy w ith  1 ^ 1  alone Goolden and Fraser (1969) 
were unable to  dem onstra te  any change in outcom e in the combined therapy 
group. M ore recen t studies, however, have suggested tha t th is  drug does 
low er the  incidence o f early  hypothyroid ism  fo llo w in g  - ^ 1  tre a tm e n t (Aro et 
a l. 1981; B lidda l e t a l. 1982; Reynolds and Kotchen, 1979; Steinbach et al. 
1979). In these la t te r  studies an tith y ro id  drugs were given both before and 
a fte r  ^ -^ I  therapy, and in te rp re ta tio n  o f rem ission rates in th is  se tting  may 
be com plica ted  by the e ffe c ts  of carbim azole on the course o f auto-im m une 
th y ro id  disease (W eetman et al. 1984). The e ffe c t o f carbim azole 
p re trea tm en t alone on early  outcome fo llow ing  -^-4  therapy in a group o f 
pa tien ts  w ith  thy ro to x ico s is  is examined in the cu rren t chapter.
3.5.2. Subjects and methods
Seventy nine patien ts  w ith  c lin ica l and b iochem ical thyrotox icosis were 
studied. T h ir ty  six subjects were trea ted  w ith  carb im azole, 20 to  30 mg per 
day before ^-^1 therapy. Carbim azole was used fo r  a m in im um  o f 3 months 
and thy ro id  hormone supplements (tr i- iodo thy ron ine  60 tig  per day or 
thy rox ine  0.1 mg per day) given to  prevent ia trogen ic  hypothyroid ism . A t 
the tim e  of 131I adm in is tra tion  a ll patients in th is group were c lin ic a lly  
eu thyro id , none having e levation  o f serum TSH. C arbim azole and thy ro id  
hormone tre a tm e n t was w ithdraw n 5 days before 1-^1 therapy in 24 patien ts
and 72 hours b e fo re  tre a tm e n t in the o th e r 12. The o th e r 43 pa tie n ts  w ere 
given th e ra p y  w ith o u t ca rb im azo le  p re tre a tm e n t. The age and sex
d is tr ib u tio n  and inc id en ce  o f th y ro id  n o d u la r ity  w ere  s im ila r  in  the  2 groups. 
F u rth e r d e ta ils  o f the  tre a tm e n t groups are given in Table  22. P re tre a tm e n t 
assessment b e fo re  a d m in is tra tio n  and ca lc u la tio n  o f dose o f 1 ^ 1  was
perfo rm ed  as described  in  chap te r 2. The pa tien ts  w ere  assessed c lin ic a lly  a t 
m on th ly  in te rv a ls  fo r  one year a fte r  l ^ l j  the rapy , and a t each v is it  b lood 
was taken  fo r  m easurem ent o f T4, T3 and TSH. H yp o th y ro id ism  was 
diagnosed b io c h e m ic a lly  on the  basis o f a low  serum  T4 and an e leva ted  
serum co n c e n tra tio n  o f TSH. T rans ien t hypo thyro id ism  was id e n tif ie d  in a 
sm all num ber o f p a tie n ts  (6 ) as described p rev ious ly : a ll pa tie n ts  who had an 
episode o f tra n s ie n t h ypo thy ro id ism  were b io ch e m ica lly  e u th y ro id  one year 
a fte r  tre a tm e n t. A sm a ll num ber o f pa tien ts  had c lin ic a lly  m arked 
th y ro to x ico s is  fo llo w in g  and ca rb im azo le  was given to  such subjects
betw een 4 and 10 m onths a f te r  tre a tm e n t. On w ith d ra w a l o f tre a tm e n t w ith  
C a rb im azo le  a ll o f these subjects (n = 5) had a re lapse o f th y ro to x ico s is . 
F o r the  purpose o f th is  s tudy  the y  are regarded as th y ro to x ic  fo r  the  whole 
o f the  f i r s t  yea r. S im ila r ly ,  i f  a second dose o f - ^ 1  given 4 m onths a fte r  
the in it ia l dose such p a tie n ts  ( 1 ) w ere regarded as being th y ro to x ic  fo r  the  
whole o f the  f i r s t  year.
3.5.3. R esu lts
O utcom e fo llo w in g  ^ ^ I  the rapy in  the 2 groups o f pa tien ts  is shown in 
Table  23. The inc idence  o f perm anent hypo thyro id ism  3 m onths a fte r  
the rapy  was h ighe r in  the  pa tien ts  given 1-^1 alone (40% v 19%). In 
co n tra s t, p a tie n ts  p re tre a te d  w ith  carb im azo le  had a h igher inc idence o f 
th y ro to x ico s is  a t th is  t im e  (X 2 = 4.5, p < 0.05). One year a fte r  the rapy the 
inc idence  o f p e rs is te n t th y ro to x ico s is  in the 2 groups was s im ila r (25%). 
H ow ever, m ore  p a tie n ts  in  the  group given 1-^1 alone w ere  hypo thyro id  and 
less were e u th y ro id  than in  the com bined tre a tm e n t group (p < 0.05). Six 
pa tie n ts  had an episode o f tra n s ie n t hypo thyro id ism , 2 o f these in  the group 
g iven ca rb im azo le . There  was l i t t le  o ve ra ll change in th y ro id  fu n c tio n  
betw een 3 m onths and one year a fte r  1 -^ 1  a d m in is tra tio n .
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3.5.4. Discussion
Pretreatment with carbimazole appeared to result in a lower incidence of
131hypothyroidism 12 months after I.Data were analysed by Chi-squared test
using a 2*2 layout(hypothyroid v.non-hypothyroid) without application of
Yates' correction.This layout appears to assume that these two alternative
1 31outcomes are discrete events.Clearly, thyroid function after forms a
continuous spectrum, and the diagnostic classifications adopted are a
convenience based on biochemically defined groupings.As these definitions
employ more than one hormonal component(e.g .T^+TSH),it is clearly simpler
in this type of'analysis to rely on definitions of thyroid status as used
herein than to examine other non-independent hormonal variables.This
approach also reflects the subdivision of patients used in clinical
management of thyroid disease.However,more serious objections are the
relatively small sample size and borderline nature of the statistical
significance which necessitate caution in interpretion of the apparent
radioprotective effect of carbimazole.Although other studies of 
131antithyroid drug/ I treatment have also suggested that drug use is
radioprotective(see below),clarification of the significance of such an
action of carbimazole requires a larger prospective study.
A further point to be considered concerns study design.It is assumed
that the two groups studied were similar in all respects apart from the
use of carbimazole(see table 22),and that any difference in outcome
131reflects a specific interaction of drug with I.However, carbimazole
131made patients in the pretreatment group euthyroid before I
administration, and it is possible that this difference in thyroid status
131altered the response to I, rather than any specific interaction with
drug.The studies of Crooks(1960) and Buchanan(1965) suggest that a
radioprotective action of drug pretreatment is specific to thiourylene
agents such as methylthiouracil and carbimazole, and is not seen with
other drugs which also impair thyroid function(discussed below),and it
seems unlikely that a radioprotective effect is a non-specific phenomenon
of altered thyroid function.However, the inevitable and major effects of
carbimazole on thyroid hormone levels do make assessment of potential
interaction of drug and 131I difficult:ideally, the two groups should have
131similar levels of thyroid hormones at the time of administration of I, 
and not at some earlier period.The nature of the action of carbimazole 
given for therapeutic reasons excludes this possibility, and this 
criticism applies to all such studies.Although the current design is 
appropriate insofar as it reflects clinical practice, a more rigorous
1 5 0
approach, giving carbimazole for a brief time insufficient to alter 
thyroid hormone levels would be preferred to study radioprotection free of 
other influences.
Despite these qualifications the results of this study may support the
hypothesis that pretreatment alone with carbimazole is
131radioprotective.Twelve months after I this group had a lower incidence
of hypothyroidism and contained a higher proportion of euthyroid
131patients.The mean dose of I given to the carbimazole pretreatment group
131was slightly but not significantly lower than that given to the group
123and this was accounted for by the higher mean 24 hour uptake in the
131combined treatment group.As the amount of given was calculated to
deliver the same radiation dose to each patient, those with higher 24 hour
uptakes received slightly lower doses.It Is unlikely that this difference
in dose would result in the changes in early outcome observed.
These results are consistent with data reported by Aro and
colleagues(1981) and Bliddal et.al.(1982) who independently reported that
131patients given carbimazole both before and after had a higher relapse
rate and a lower incidence of early hypothyroidism compared to those given 
131 I alone.In a smaller study Steinbach et.al.(1979) examined the effects
131of methimazole and propylthiouracil on response to I.Drugs were not 
131stopped before I, and were given for variable times after.While the
incidence of hypothyroidism was lower In the combined treatment group,the
small numbers(24) and lack of information on treatment regimens detract
from the significance of the findings.In the only previous study where
131carbimazole has been given solely before I(drug stopped 48 hours
before) there was no major effect on outcome 1 year after
treatment(Goolden and Fraser,1969).This study was performed before
sensitive assays for T^ and TSH were available and it is possible that
diagnostic classification was less accurate than currently possible.In a
major review of ^ ^ i  therapy Nofal(1966) also noted that antithyroid drug
use was associated with a lower incidence of early hypothyroidism.
There are a number of possible mechanisms by which antithyroid drugs
131might reduce radiation damage following I therapy.As tissue damage
following may be secondary to generation of superoxide
radicals,possibly from H202 , oxidative reduction of peroxidase enzyme in 
the thyroid cell by carbimazole or related drugs might alter H202 
availability and limit superoxide formation:in view of the rapidity of 
regeneration of thyroid peroxidase to an oxidised state after antithyroid 
drug withdrawal in vitro(Taurog,1976) it seems unlikely that this
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mechanism would be effective 5 days after stopping carbimazole.Drugs of
the thiourylene group all contain a -SH moeity, and during intrathyroidal
drug metabolism it is possible that disulphide bonds are formed with
follicular cell protein(Marchant et.al.1978).Such bonds have been shown to
confer radioprotection, possibly by interacting with radiation produced
free radicals(Phil and Edjarn,1958).However, antithyroid drugs were
withdrawn in the majority of subjects in the current study and in that of
i qi
Crooks (1960) 5 days before I . It is known that the -SH residue of
thiourylene drugs is normally oxidised to sulphate and excreted in the
urine(Marchant et.al.1978), and it is unclear whether sufficient numbers
of sulphydryl groupings in stable covalent bonds with thyroid cell protein
would remain to provide radioprotection 5 days after drug withdrawal.
Alteration in thyroid iodide kinetics by antithyroid drugs might
131influence the response to I. In studies where drugs were restarted
131shortly after I therapy, or were continued during treatment, it is
likely that drug induced iodide organification block will reduce retention 
131of within the gland. In most studies, however, the dose given to each
patient was calculated using tracer iodide uptake data and this should 
allow for the possibility that drug therapy has altered iodide kinetics, 
so that the total radiation dose received by each patient is the same.This
has generally resulted in patients given combined therapy receiving
131 131slightly higher therapeutic doses of I than those receiving I
alone(Bliddal et.al.1982;Crooks et.al.1960;Reynolds and Kotchen, 1979).
131However, the kinetics of tracer doses of I may differ from those of 
therapeutic doses, especially In patients given medical antithyroid 
therapy(De Groot and Stanbury,1975) and it is possible that this 
difference in the handling of therapeutic and tracer quantities of the 
isotope account for some of the radioprotective effect.
Alternatively, antithyroid drugs might alter the biological and
1 O 1
therefore effective half-life of I therapy by induction of
intrathyroidal Iodide depletion.Harden and colleagues(1966) suggested that
carbimazole therapy resulted in a contracted intrathyroidal iodide
pool:this would lead to a shortened biological and therefore effective
half-life of 131I, reducing the radiation dose to the gland.Crooks
et.al.(1960), however, found no significant difference in the mean
biological half-life of 131i given to patients pretreated with
131methylthiouracil compared with those given I alone.However, carbimazole 
is a considerably more potent inhibitor of iodide organification than 
methylthiouracil, and it is possible that more complete blockade of this
process would cause a greater upset in thyroid iodide homeostasis.Data on
the effect of carbimazole pretreatment on thyroid iodide turnover are
reported in the following section.
A further possibility is that antithyroid drugs might alter the
131immunological response to I.There may be a rise in thyroid
131autoantibodies after I therapy Gravesr disease(Atkinson et.al.1982;Bech
and Madsen 1980;0'Gorman et.al.1964), and it has been suggested previously
131that hypothyroidism following I is related in part to radiation induced
immune thyroiditis, although this mechanism has been thought to be of
little importance(Lundell and Holm,1980;0'Gorman et.al.1964).Carbimazole
is known to lower autoantibody levels In autoimmune thyroid
disease(Weetman et.al .1984):it is possible that pretreatment with
1 31carbimazole diminishes the autoantibody rise following therapy and so
reduces the incidence of hypothyroidism.In the current study, however, the
reduction in early hypothyroidism in patients pretreated with carbimazole
was associated a higher incidence of post treatment thyrotoxicosis.If
1 31carbimazole was modifying the effect of XJ-Li by inhibiting thyroid
autoimmune processes, it might be expected that the incidence of
thyrotoxicosis after treatment would also be lower.Further, in section 1
1 31of this chapter no evidence of a rise in TRAb following was noted
131either in the group given I alone or in the group given carbimazole
pretreatment, and it seems unlikely that the apparent radioprotective
effect of carbimazole Is immunologically related.
In summary pretreatment with carbimazole, stopping therapy 2-5 days 
131before I, may lead to a reduced incidence of early hypothyroidism.The
borderline nature of the significance of the finding by conventional
statistical testing demands a degree of caution in interpretation of these
data, although they are in keeping with the majority of previous studies
131of this interaction.As x''xi therapy is often given to older patients who
are more likely to have intercurrent disease this may lead to a
disadvantageous delay in cure.However, data presented in section 1 of this
chapter suggested that carbimazole pretreatment prevented major increase
131in thyroid hormone levels immediately after I, so reducing the
possibility of clinical deterioration in susceptible patients.This
advantage must be set against any reduction in initial response rate;as
123the early response can be predicted from measurements of I uptake 
shortly after therapy, this may be of no great consequence.The cause
of the possible radioprotective action of carbimazole is unclear, and is 
the subject of further examination in this thesis.
SECTION SIX
IN FLU E N C E  OF C A R B IM A ZO LE PR ETR EA TM ENT ON TH Y R O ID  
IO D ID E  K IN E TIC S  BEFORE AND AFTER TH ER A PY
3.6.1. In trod u c tion
Evidence th a t p re tre a tm e n t w ith  a n tith y ro id  drugs reduces the e ffe c t 
o f has been presented in the previous chapter. I t  is possible th a t th is
re f le c ts  an action  o f such drugs on thy ro ida l k ine tics  o f ^ 4 , leading to
a lte red  uptake or re ten tio n  o f the  isotope w ith in  the gland. As the rad ia tion  
dose to  tissue is a consequence o f not only the physical p roperties o f the 
isotope used but also the dura tion  of exposure, such considerations may 
in fluence  the ra d ia tio n  de livered  to  the thy ro id  in subjects given - ^ I .  For 
exam ple, the amount o f ra d ia tio n  de livered is dependent both on the physical 
decay o f the isotope (physical h a lf- life ) ,  and the duration  o f re ten tio n  o f the 
isotope by the gland (b io log ica l h a lf- life ) .  Physical and b io log ica l h a lf- l ife  
can be combined to  give rise  to  expression o f e ffe c tiv e  h a lf- l ife ,  and th is  is 
an im p o rta n t de te rm inan t o f ra d ia tio n  delivered to  the thy ro id  by ^ ^ 1  
the rapy.
THUS: E ffe c t iv e  T l / 2  = Physical T l /2  X B io log ica l T l/2
Physical T l /2  + B io log ica l T l /2
I f  a n tith y ro id  drugs e ffe c t thy ro id  iodide tu rnover then th is  m igh t 
exp la in  the e ffe c t o f these drugs on response to  ^ -^ I.  Harden et al. (1966) 
suggested th a t carb im azole  therapy, by b locking incorpora tion  o f iodide in to  
organ ic fo rm , reduced the th y ro id  iodide content and th is  is also suggested 
using more d ire c t measures o f th y ro id  iodide content (Lee, Siegal, Harpen, et 
a l., 1982; Barandes et a l., 1973; H o ffe r, Bernstein, G ottschalk et a l., 1971). 
This con trac ted  in tra th y ro id a l iodide pool could the re fo re  reduce the 
b io log ica l h a lf- l ife  o f 1 ^ 1  w ith in  the gland and consequently reduce the 
e ffe c t iv e  h a lf- l ife .  Thus, the e ffe c t o f carb im azole p re trea tm en t may be to  
low er the ra d ia tion  delivered to  the thy ro id  from  a given dose o f isotope. 
D e ta iled  studies o f dos im etry  have the re fo re  been made in a sm all group o f 
pa tien ts  given l ^ I .  jh e  e ffe c t o f p re trea tm en t w ith  carb im azole  on the 
re la tionsh ip  between tra c e r and therapy isotope handling has also been 
exam ined.
3.6.2. P a tien ts  and methods
T w enty  fo u r subjects w ith  thy ro tox icos is  (Graves' disease) were studied: 
these have been described in section one o f th is  chapter. A ll were c lin ic a lly  
and b iochem ica lly  th y ro to x ic  at the tim e  o f e n try  to  the study. Patien ts 
were random ly assigned to  rece ive e ithe r d ire c tly  (Group A) or to  have
the rapy w ith  a n tith y ro id  drugs (carb im azole  10-15 mg tw ice  da ily  w ith  
thy rox ine  0.1 mg per day) fo r a m in im um  o f 3 months and un til a ll were
c lin ic a lly  and b iochem ica lly  eu thyro id . A t th a t t im e  subjects in th is  group
(B) also rece ived  1 ^ 1  therapy. Drugs were stopped 48 hours before a tra ce r
study, w hich was perfo rm ed 24 hours before 1 ^ 1  therapy was given.
3.6.3. Study design
Subjects were studied im m ed ia te ly  a fte r lunch on the day o f the 
tra c e r study. Was given (80 pC i) by rap id  intravenous bolus in je c tion
and uptake o f isotope at 20 m inutes and 24 hours was measured as described 
in chapter 2. T hyro id  size and the dose of ^ ^ 1  to  be adm inistered were 
also ca lcu la ted  as described. The dose of 1 ^ 1  was given by mouth at 
between 2 and 3 p.m. on the day a fte r the 1^3j study. Tw enty fou r hours 
a fte r  the the ra p eu tic  dose, uptake o f l ^ l j  j sotope by the thy ro id  was 
measured by the gamma cam era/com puter system using the a liquot o f ^ ^ 1  
(1-2 m C i) as standard. C o rrec tion  fo r camera and com puter dead tim e  was 
made as described e a rlie r (2.3.4.). Thyro id  counts were then measured at 5, 
15 and 22  days a fte r  th is in it ia l study and again corrected  fo r loss o f 
e ff ic ie n c y  at high count ra tes. The decay in thy ro id  counts was then p lo tted  
using s e m i-lo g a rith m ic  paper to  derive an e ffe c tiv e  h a lf- life  fo r  1 -^1  w ith in  
the thy ro id  (F igure 21). In a ll cases a single exponentia l function  was an 
adequate f i t  to  the data. From these data and from  the known physical 
h a lf- l ife  o f the isotope the b io log ica l h a lf- l ife  can be derived easily i.e .:
RADS = 740 X 24 hour uptake X m Ci X E ffe c tiv e  T l/2  X Mev
Mass (grams)
3.6.4. Results
F u rthe r deta ils  o f the patients studied are shown in Table 24. I t  w il l 
be seen th a t the groups had s im ila r d is trib u tio n  o f age and sex: estim ated
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Days following ^ 1  therapy
Fig 21
1 S1
DERIVATION OF EFFECTIVE HALF LIFE OF I
1
THYROID COUNTS FOLLOWING I THERAPY WERE ACQUIRED WITH
THE GAMMA CAMERA/COMPUTER AT 1, 5, 15 AND 22 DAYS AFTER
-1 0-1 __
I, WITH APPROPRIATE CORRECTION FOR COMPUTER/CAMERA DEAD
TJME. TYPICAL EXPONENTIAL DELAY IN COUNTS IS SHOWN IN THE
MAIN GRAPH. THE INSET SHOWS A SEMI-LOGARITHMIC PLOT OF
THE DATA, ALLOWING A HALF LIFE FOR THYROID COUNTS (EFFECTIVE
HALF LIFE) TO BE PLOTTED.
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1 22  1 21 
24 HOUR THYROID UPTAKE OF TRACER ( I) AND THERAPY ( I)
RADIOIODINE___________________________________________
1 22  1 21 
THYROID UPTAKE OF I (80uCi) AND I (THERAPY DOSE) IN
122  121 
THYROTOXIC SUBJECTS. I WAS GIVEN INTRAVENOUSLY AND I
ORALLY. SUBJECTS MADE EUTHYROID WITH CARBIMAZOLE BEFORE
1 21 121I THERAPY SHOWN AS OPEN CIRCLES; THOSE GIVEN I AS SOLE
TREATMENT AS CLOSED. MEAN (AND SEM) FOR TRACER AND THERAPY
UPTAKES SHOWN: TRACER UPTAKE WAS SIGNIFICANTLY HIGHER THAN
THERAPY (p<0.01, MANN, WHITNEY U-TEST).
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1 pp
RELATIONSHIP BETWEEN THYROID UPTAKE OF TRACER ( I) AND 
THERAPY (131I) DOSES OF RADIOIODINE
THE RELATIONSHIP BETWEEN THE 24 HOUR THYROID UPTAKE OF TRACER
1 p q  -I q i
I (80uCi) AND THERAPY ° I IN EACH SUBJECT IS SHOWN.
1B1THOSE SUBJECTS GIVEN I AS SOLE THERAPY ARE SHOWN IN
THE LEFT HAND PANEL, AND THOSE MADE EUTHYROID WITH CARBIMAZOLE 
1B1
BEFORE I TREATMENT IN THE RIGHT. THERE WAS A SIGNIFICANT 
POSITIVE RELATIONSHIP (p <  O.Ol) BETWEEN TRACER AND THERAPY 
UPTAKE IN BOTH GROUPS OF SUBJECTS, BUT THIS DIFFERED FROM 
THE LINE OF IDENTITY (SHOWN AS SOLID LINE).
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EFFECTIVE HALF LIFE OF RADIOIODINE ( I) FOLLOWING I
THERAPY IN THYROTOXIC SUBJECTS_______________
1P1THE EFFECTIVE HALF LIFE OF I IN THE THYROID IN PATIENTS
WITH THYROTOXICOSIS IS SHOWN FOR INDIVIDUAL SUBJECTS.
1 P1
PATIENTS GIVEN I AS SOLE THERAPY FOR THYROTOXICOSIS ARE 
SHOWN IN THE LEFT HAND COLUMN, WHILE THOSE MADE EUTHYROID 
WITH CARBIMAZOLE BEFORE 131I ARE SHOWN IN THE RIGHT. MEAN 
AND STANDARD ERROR OF THE MEAN FOR BOTH GROUPS ARE SHOWN.
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1
BIOLOGICAL HALF LIFE OF RADIOIODINE ( I) FOLLOWING 
1R1
I THERAPY IN THYROTOXIC SUBJECTS_______________
1 R1THE BIOLOGICAL HALF LIFE OF I IN THE THYROID IN
PATIENTS WITH THYROTOXICOSIS IS SHOWN FOR INDIVIDUAL
1 S1SUBJECTS. PATIENTS GIVEN I AS SOLE THERAPY FOR
THYROTOXICOSIS ARE SHOWN IN THE LEFT HAND COLUMN WHILE
1 STTHOSE MADE EUTHYROID WITH CARBIMAZOLE BEFORE ° I ARE 
SHOWN IN THE RIGHT. MEAN AND STANDARD ERROR OF THE MEAN 
FOR BOTH GROUPS ARE SHOWN.
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RADIATION DOSE TO THE THYROID IN THYROTOXIC SUBJECTS 
GIVEN 131I TREATMENT
RADIATION DOSE (EXPRESSED IN RADS) TO THE THYROID IN
THYROTOXIC PATIENTS GIVEN 131I.
1 31
PATIENTS GIVEN I AS
SOLE THERAPY ARE SHOWN ON THE LEFT, AND THOSE MADE
131
EUTHYROID WITH CARBIMAZOLE BEFORE I TREATMENT ON THE 
RIGHT. MEAN AND STANDARD ERROR OF THE MEAN FOR BOTH 
GROUPS ARE SHOWN.
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th y ro id  mass, 20 m inute  uptake, 24 hour uptake o f 123I and dose of 
given to  the 2 groups were also not s ig n ific a n tly  d iffe re n t.
The 24 hour uptake measurements o f 123j (tra ce r) and (therapy)
are displayed in F igure  22. I t  w il l be noted tha t measurement of uptake o f 
the  la t te r  isotope was cons is ten tly  low er than th a t o f 123j (p < o.QOl; Mann- 
W hitney U tes t), a lthough a good co rre la tion  between the 2 measurements 
was seen (F igure 23). Thus, the regression line  re la tin g  the 2 measurements 
d iffe re d  s ig n if ic a n tly  fro m  the line  o f id e n tity  (p < 0.05). This find ing  o f 
h igher uptake o f tra c e r 123I than therapy 131I was seen both in those 
subjects p re trea ted  w ith  carb im azole and those given alone and there
was no evidence th a t carb im azole  a lte red  th is  re la tionsh ip . E ffe c tiv e  h a lf-  
l i fe  and derived b io log ica l h a lf- l ife  fo r  the 2 groups o f patients are shown in 
F igures 24 and 25; i t  w il l be noted th a t mean e ffe c tiv e  h a lf- l ife  and 
b io log ica l h a lf- l i fe  were not d iffe re n t when the groups were compared. The 
ra d ia tio n  dose de livered  to  the thy ro id  in each pa tien t could be ca lcu la ted  
using th is  data and th is  derived rad ia tion  dose is shown in F igure 26. I t  w il l  
be noted th a t carb im azole  p re trea tm en t had no apparent e ffe c t on ra d ia tion  
de livered  to  the  th y ro id .
3.6.5. Discussion
E ffe c t o f C arb im azo le  p re trea tm en t on e ffe c tiv e  h a lf- l ife  o f l - ^ I
The measured e ffe c tiv e  h a lf- l ife  o f - ^ 1  in th is  study is s im ila r to  
th a t reported  by o the r workers in th y ro to x ic  subjects (Cullen, W illiam s and 
M alone, 1976). There was no d iffe rence  in e ffe c tiv e  h a lf- life  between the 
tre a tm e n t groups: ne ithe r the derived value fo r  b io log ica l h a lf- life  nor the 
ca lcu la ted  dose o f rad ia tion  delivered to  the gland were a ffe c ted  by 
carb im azole  p re trea tm e n t.
I t  was proposed tha t carb im azole m ight affect b io log ica l tu rnover o f 
iod ide w ith in  the gland by reducing in tra th y ro id a l iodide content. However, 
carb im azole  was used in the curren t study fo r  between 3 and 5 months, and 
th is  rr^  be an in s u ff ic ie n tly  long tim e  fo r  iodide depletion to develop to  a 
degree th a t would a ffe c t e ffe c tiv e  h a lf- life  o f 1-^1. F u rthe r, the patien ts in 
th is  study were given thyrox ine  supplements along w ith  carb im azole: th is  
represents a s ig n ifica n t source o f increased d ie ta ry  iodide a v a ila b ility  and 
may, by increasing plasma inorganic iodide concentra tion , help m a in ta in  
thy ro ida l iodide stores. Both sets o f subjects were s im ila r in term s o f basal
uptake data and go itre  size, and i t  seems un like ly  th a t there  was any reason 
fo r  the carb im azole  p re trea ted  group to have an e ffe c tiv e  h a lf- l ife  which 
would otherw ise d if fe r  from  the group o f subjects given l ^ l j  alone. In an 
e a r lie r study o f the e ffe c t o f m e th y lth io u ra c il on b io log ica l h a lf- l ife  o f 1 51 I, 
Crooks et al. (1960) reported  th a t the mean b io log ica l h a lf- l ife  was 11.7 
days. This is ra th e r shorte r than the mean b io log ica l h a lf- l ife  reported  in 
the cu rren t series. How ever, the measurement o f Crooks was made using a 
s im ple neck c o llim a to r and counter, w ith o u t com puter analysis o f data and i t  
is un like ly  th a t the very high count ra te  fo llo w in g  a therapy dose o f 131j 
would be accura te ly  measured w ith  such equipm ent. In the cu rren t study 
high count ra tes were co rrec ted  fo r  loss o f e ffic ie n c y  at high count rates 
and i t  is believed th a t th is approach has e lim ina ted  a possible source o f 
techn ica l e rro r in counting. F u rthe r, changes in d ie ta ry  iodide a v a ila b ility  
since the 1950s and 60s may have led to  pro longation of b io log ica l h a lf- life  
o f iodide in the general popu la tion . For these reasons these data and those 
o f Crooks may not be d ire c t ly  com parable.
In section 5 an e ffe c t o f carb im azole p re trea tm en t on outcome 
fo llo w in g  ^ - 4  was described: fu rthe rm o re , in the m ajor series described t y  Arp 
e t a l. (1981) and B lidda l e t al. (1982), in which a rad io  p ro te c tive  ac tion  o f 
carb im azole  was noted, doses o f carb im azole  s im ila r to  th a t used in the 
cu rren t study were given fo r  an equiva lent period o f tim e  before l ^ l  
therapy. I t  the re fo re  seems un like ly  th a t the e ffe c t o f carb im azole on early  
response to  l ^ I  is a consequence o f a lte red  thy ro ida l k ine tics  o f 1 ^ 1.
5.6.6. D iscrepancy between therapy and tra ce r uptake measurements
I t  was noted in th is  series o f patien ts tha t 24 hour uptake of ^2^I 
a fte r  i.v . in je c tion  measured using the gamma counter was low er than the 24 
hour uptake o f ^ -^ I  a fte r oral adm in is tra tion  in most (23 out o f 24) subjects 
(p < 0.001) (F igure 23). The o vera ll co rre la tion  between the 2 measurements 
was good (r = 0 .8 8 ) and th is  was s im ila r when patients pre trea ted  w ith  
carb im azole  were exam ined separa te ly  from  those given ^ -^ 1  alone.
I t  is possible th a t th is  discrepancy is a rte fa c tua l: the counts over the 
neck 24 hours a fte r 1 -^1  adm in is tra tion  were very high when counting 
e ff ic ie n c y  o f the gamma camera system may be less accurate . However, 
co rre c tio n  fo r loss o f e ff ic ie n c y  and com puter and camera dead tim e  was 
made in th is  study (2.3.4.). I t  is also un like ly  tha t a non-system atic e rro r
would re su lt in counts using ^ 4  being u n ifo rm ly  low er than those w ith  ^ 3 ^
O’Connor and colleagues (1979) and Malone and Cullen (1975) reported  
th a t the measurements o f ora l therapy and tra ce r uptake by the thy ro id  
gland were very s im ila r, and showed th a t the regression line  re la ting  the 
data was id e n tic a l to  the line  o f id e n tity . However, o ther workers have 
reported  th a t in some patients the k ine tics  o f therapy doses o f ^ 4  may 
d if fe r  fro m  tra c e r doses (De G root and S tanbury, 1975; Freedberg et a l., 
1952). One unexplored poss ib ility  is th a t ra d ia tio n  fro m  the therapy dose has 
a very ea rly  e ffe c t on iodide trapp ing  and o rg an ifica tion , so tha t uptake 
w ith in  the  f ir s t  24 hours is lim ite d  by th is  means.
A lthough  the re  was a sm all sys tem atic  d iffe rence  of uptake when 
therapy and tra c e r doses of rad io iod ine  were compared in the cu rren t study, 
the good co rre la tio n  between the measurements im p lies th a t tra ce r uptake 
studies may s t i l l  be o f value in p red ic ting  the general behaviour o f therapy 
doses o f -^ -4 , and may s t i l l  be o f use in dosim etry. I t  has been proposed 
th a t a n tith y ro id  drug therapy m igh t d is to rt the re la tionsh ip  between tra c e r 
and the rapy isotope uptake and so make dos im etry  less accurate  (De G root 
and S tanbury, 1975). In the cu rren t study no evidence o f such an e ffe c t was 
seen: the  re la tionsh ip  between tra c e r and the rapy uptake was s im ila r in  the 
group o f pa tien ts  p re trea ted  w ith  carb im azole  compared w ith  those given 
1^-4 alone.
SECTION SEVEN
EFFEC T OF PR ETR EA TM E N T W ITH CARB IM AZO LE ON  
IO D ID E  (125I)  U P TA K E , O R G A N IF IC A TIO N  AND  
D IS TR IB U TIO N  IN  RAT TH Y R O ID
3.7.1. In tro d u c tio n
Studies in pa tien ts w ith  thy ro tox icos is  presented e a rlie r in th is  section 
in d ica te  th a t p re trea tm e n t w ith  carb im azole, stopping the drug several days 
befo re  1 ^ 4  tre a tm e n t has a ra d io p ro te c tive  e ffe c t. The mechanism o f th is  
is not fu l ly  understood, and the poss ib ility  th a t a n tith y ro id  drugs m igh t a ffe c t 
the k ine tics  o f 1 ^ 4  w ith in  the  th y ro id  has been investiga ted  in  the previous 
chapter. D rug tre a tm e n t is also known to  a lte r the h is to log ica l appearance 
o f the th y ro id  gland (H a lm i, 1978), and i t  is possible th a t th is  m igh t a ffec t 
the  in tra th y ro id a l d is tr ib u tio n  o f the rapeu tic  ^ 4 .  In the cu rren t chapter the 
e ffe c ts  o f a n tith y ro id  drug tre a tm e n t on th y ro id  h is to log ica l appearance and
the d is tr ib u tio n  o f iodide w ith in  the glands o f experim enta l animals are
exam ined.
3.7.2. Methods
A d u lt m ale Sprague-Daw ley ra ts  were used, o f average w e ight 265 g (+
17, SEM). Anim als were housed 2 per cage, and fed  d ie t 41B (Oxoid,
Basingstoke) w ith  norm al iod ine content (iodine content 2.4 pg/g) and 
rece ived  drink ing  w a te r ad lib . They were divided in to  3 groups (6  per 
group):
(a) no tre a tm e n t given.
(b) M eth im azo le  0.5 mg per day, stopping drug 48 hours before end of
experim ent (M eth im azole given fo r 19 days).
(c) M e th im azo le  0.5 mg per day, drug continued u n til end o f experim ent
(21  days).
M eth im azo le  (Sigma) was given by addition to  d rink ing  w a te r. 
M easurem ent o f loss o f w a te r fro m  the drinking bottles  a llowed the average
in take  o f drug to  be estim ated: th is  corresponded w e ll to  the intended
in take .
A f te r  21 days animals were given an in tra pe rito n ea l in je c tion  o f 20
pC i o f 125I in 0.1 m l volume (NaC l 0.9%). N ine ty  m inutes la te r animals
were s a c rif ice d  by card iac puncture under e ther anaesthesia and a blood 
sample was taken fo r measurement o f plasma a c tiv ity : thy ro id  glands
were ra p id ly  d isected and rem oved. One lobe from  each anim al was placed 
im m e d ia te ly  in fo rm a l saline fo r  h is to log ica l exam ination: the other was 
weighed using a tors ion balance and placed in 2 m l ice c o ld /1 0% 
tr ic h lo ra c e t ic  acid (TC A) conta in ing  10"^ m o la r m eth im azole  and 10"^ m olar 
potassium iodide to  prevent fu r th e r o rg a n ifica tio n  o f free  iodide. The tissue 
was im m e d ia te ly  dispersed using a ground glass homogeniser.
3.7.5. C a lcu la tio n  o f iodide trapp ing  a b ility
The a b il ity  o f the thy ro id  to  tra p  iodide was ca lcu la ted  from  the ra t io  
o f counts between plasma and tissue (co rrec ted  fo r  w e ight and volume). For 
th is  purpose 0 .1  m l plasma was added to  an appropria te  volume (2  m l saline) 
and counted using an autogamma counter w ith  appropria te  background 
su b tra c tio n . Homogenised thy ro id  in equ iva lent volume TC A was counted at 
the same tim e . R a tio  o f counts in tissue d iv ided by counts in plasma was 
then ca lcu la ted  fo r  each anim al.
3.7.4. C a lcu la tion  o f o rg an ifica tion  e ff ic ie n c y
In anim als on a n tith y ro id  drugs the thy ro id  can tra p  iodide but is 
unable to  o rg an ify  the anion. The o rgan ified  iodine w ith in  the gland w il l  be 
p ro te in  bound whereas inorganic iodide is not. As pro te in  is insoluble in 
t r ic h lo ra c e t ic  acid, the pro te in  bound iodide w il l p re c ip ita te  out in so lu tion  
and iod ide rem ain ing  in so lution w il l re f le c t the inorganic iodide w ith in  the 
gland (A lexander and W o lff, 1966). Thus, the greater the in h ib ition  o f 
o rg a n ifica tio n , the low er w ill be counts in the p re c ip ita te  fra c tio n .
A f te r  ca lcu la tion  o f iodide trapp ing  the TCA suspension was 
cen trifuged  at 3000 rpm fo r 10 m inutes: the p re c ip ita te  at the bottom  o f the 
tube was re ta ined  and the supernatant discarded. Fresh TCA was then 
added, hom ogenisation repeated and the so lu tion  again centrifuged . This 
procedure was repeated on one fu r th e r occasion: counts in the supernatant at 
th a t po in t were neg lig ib ly  raised above backgroud and the rem ain ing  
p re c ip ita te  counts were assumed to  represent prote in-bound (i.e . o rgan ified ) 
iod ide. A f te r  counting and appropria te  co rrec tion  fo r w e ight, in h ib itio n  o f 
o rg a n ifica tio n  was then expressed as to ta l thy ro id  counts minus p ro te in  bound 
th y ro id  counts divided by to ta l th y ro id  counts.
3.7.5. H is to lo g ica l studies and autoradiography
F orm a lin  fixe d  glands were embedded in wax and sections cu t. 
A lte rn a te  sections were mounted on glass slides and stained using 
haem atoxylin  and eosin fo r  conventional h is to log ica l exam ination. The other 
sections were m ounted on glass slides and prepared fo r  autoradiography. 
B r ie f ly , clean glass slides were coated in I lfo rd  G5 nuclear emulsion (50:50 
w ith  d is tille d  w a te r) and a llow ed to  dry. E ight m icron  th ic k  sections o f 
tissue were cu t and a ttached to  the emulsion coated slides by pressure: slides 
were then s tored  in a lig h t fre e  conta iner. A f te r  exposure the slides were 
counter sta ined w ith  haem atoxylin  and eosin. C on tro l slides wer exposed at
w eekly in te rva ls  u n til optim um  images were produced (best resu lts were 
achieved at 4 weeks).
3.7.6. Results
The mean w e ight o f ra ts  in each group at the end o f the study is 
shown in Table 25. I t  w il l  be seen tha t animals in groups B and C gained 
s ig n if ic a n tly  less w e ight than those in group A . Mean th y ro id  weights (2 
lobes) are also shown: despite the lower body w e ights, animals given 
M eth im azo le  had subs tan tia lly  la rge r thy ro id  glands. T hyro id  iodide trapp ing  
and o rg a n ifica tio n  is also deta iled  in Table 25. I t  w il l  be noted tha t thy ro id  
trapp ing  o f iodide as assessed by the tissue/p lasm a ra tio  occurred in a ll 
groups, but th a t th is was s ig n ific a n tly  g reate r in animals in groups B and C 
than in co n tro l animals. M in im a l (less than 15%) in h ib ition  o f o rgan ifica tion  
as assessed by the proportion  o f iodide which was TCA insoluble was sem in  
groups A and B, whereas in animals on m ethim azole  at the tim e  o f
s a c rifice  greate r than 80% o f iodide was in inorganic fo rm  (i.e. soluble in 
TCA).
3.7.7. H is to logy
T yp ica l thy ro id  h is to log ica l specimens and corresponding 
autoradiographs are displayed in F igure 27 (plates 1-6). N orm al ra t thy ro id  
h is to logy is represented in p la te  1 : fo llic le s  o f normal size w ith  enclosed 
co llo id  are seen. The accompanying autoradiograph (p la te  2) shows th a t 
rad io labe lled  iodide localises over co llo id  and at the c o llo id /c e ll in te rfa ce . 
U ptake by each fo l l ic le  is not iden tica l h igh ligh ting  the heterogenous nature
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EFFECTS OF ANTITHYROID DRUG TREATMENT ON THYROID HISTOLOGY
1 PE
AND DISTRIBUTION OF TRACER ( I) RADIOIODINE IN THE RAT 
PLATE 1 (x30Q)
NORMAL RAT THYROID HISTOLOGY SHOWING FOLLICLES COMPRISING 
A BASAL LAYER OF CELLS ENCLOSING COLLOID. (HAEMATOXYLIN AND 
EOSIN).
PLATE 2 (x3QO)
1 PEAUTORADIOGRAPH SHOWING DISTRIBUTION OF I (ISOTOPE INJECTED 
90 MINUTES BEFORE SACRIFICE). NOTE DISTRIBUTION OF IODIDE 
(SILVER GRAINS) OVER COLLOID AND AT COLLOID/CELL INTERFACE. 
IODIDE DISTRIBUTION BETWEEN FOLLICLES IS NOT HOMOGENOUS 
(H + E COUNTERSTAIN).
Fig 27
PLATE 3 (x30Q)
HISTOLOGY OF THYROID: METHIMAZOLE 0.5mg/DAY GIVEN FOR 19 DAYS: 
DRUG STOPPED 48 HOURS BEFORE SACRIFICE. NOTE NORMAL FOLLICULAR 
ARCHITECTURE.
PLATE 4
125AUTOGRADIOGRAPH SHOWING DISTRIBUTION OF I: METHIMAZOLE 
0.5mg/DAY FOR 19 DAYS, STOPPED 48 HOURS BEFORE SACRIFICE. 
NOTE DISTRIBUTION OF IODIDE SIMILAR TO NORMAL GLAND.
Fig 27 
PLATE 5
HISTOLOGY OF THYROID: METHIMAZOLE 0.5mg/DAY GIVEN FOR 21 DAYS: 
DRUG CONTINUED UNTIL SACRIFICE. NOTE LOSS OF FOLLICULAR 
ARCHITECTURE, WITH HYPERTROPHY OF CELLS.
PLATE 6
125AUTORADIOGRAPH SHOWING DISTRIBUTION OF I: METHIMAZOLE 
O.&ng/DAY FOR 21 DAYS, CONTINUED UNTIL SACRIFICE. DISTRIBUTION 
OF IODIDE IS VERY PATCHY, WITH NO OBVIOUS RELATIONSHIP TO 
CELLS OR POTENTIAL COLLOID SPACE.
o f iodide uptake by fo llic le s  (Studer et al. 1985).
Tissue from  group B (m eth im azole stopped 48 hours before sa c rifice ) is 
shown in p lates 3 and 4. I t  w il l be seen tha t average fo llic u la r  size is less 
than in p la te  1 , but th a t the overa ll h is to log ica l appearance is s im ila r. 
There appears to  be some enlargem ent o f fo llic u la r  ce ll size, suggested by 
increased nuc lea r/cy top lasm ic  ra tio . Autoradiography again shows loca lisa tion  
o f iodide over co llo id , and at the c e ll/c o llo id  in te rfa ce . The hete rogene ity  in 
uptake is more evident in these sections than in group A.
T yp ica l slides prepared fro m  group C animals (m eth im azole continued 
u n til sa c rif ice ) are shown in plates 5 and 6 . * The thy ro id  h is to log ica l 
appearance in  these sections is abnormal w ith  marked loss o f co llo id  from  
fo llic le s : apparent hypertrophy o f fo l l ic le  cells is again seen.
A uto rad iography shows less accum ulation o f iodide over the in te rna l aspects 
o f fo llic le s  w ith  ra th e r patchy d is trib u tio n  o f iodide throughout the section.
3.7.8. Discussion
A n tith y ro id  drug therapy fo r  3 weeks im pa ired norm al thy ro id  func tion  
re su lting  in reduced w e ight gain in the animals in groups B and C. Increased 
th y ro id  gland w e ight in these animals confirm ed th a t hypothyro id ism  had 
developed, resu lting  in TSH s tim u la tion  o f thy ro id  grow th. In ra ts from  
group B (m eth im azole  stopped 48 hours before sa c rifice ) increased TSH 
s tim u la tio n  in the gland was also re fle c te d  in increased thy ro id  iodide
trapp ing . However, iodide o rg an ifica tion  was norm al and did not d if fe r  from
untrea ted  ra ts . The data fo r  thy ro id  trapp ing and o rg an ifica tion  o f iodide in 
untrea ted  animals is very s im ila r to  tha t described by M archant (1971) using 
the  same technique. I t  seems, the re fo re , th a t 48 hours a fte r stopping
m eth im azo le  there  is no detectab le  e ffe c t on thy ro id  iodide o rgan ifica tion . 
In con trast, in ra ts in whom the drug was continued u n til the tim e  of 
sa c rif ice , thy ro id  iodide o rgan ifica tion  was severely inh ib ited  (greater than 
80%): trapp ing  of iodide and thyro id  w e ight in th is group o f animals was very 
s im ila r to  animals in group B.
The e ffe c t o f a n tith y ro id  drugs on thy ro id  h is to log ica l appearance has 
been reported  previously (H a lm i, 1978). In ra ts s t i l l  rece iv ing  m eth im azole  in 
the cu rren t study there was almost com plete absence o f co llo id  w ith
hypertrophied fo llic u la r  ce lls. In contrast, where drug had been stopped fo r  
as l i t t le  as 48 hours previously, h isto log ica l appearance was l i t t le  d iffe re n t
fro m  untrea ted  animals w ith  reappearance o f co llo id  m a te ria l. Average 
fo ll ic u la r  d iam ete r did, however, appear a l i t t le  less than in untreated ra ts , 
and the re  was apparent hypertrophy o f fo llic u la r  cells. The e ffe c ts  o f 
a n tith y ro id  drug tre a tm e n t on the d is trib u tio n  o f labelled iodide appeared to  
be tra ns ien t. Thus, in the animals s t i l l  rece iv ing  drug, iodide d is tr ib u tio n  
was patchy and much less c le a rly  id e n tif ie d  w ith  the lumen of the fo l l ic le  
than in anim als in groups A and B, re fle c tin g  the in a b ility  o f animals in 
group C to  o rgan ify  iodide. In both group A and B animals, fo l lic u la r  
d is tr ib u tio n  o f iodide did not appear homogeneous. This seems un like ly  to  be 
due to  a r te fa c t re la ted  to  section of tissues, as fo llic le s  of very s im ila r size 
had considerable d iffe rences in apparent density o f s ilve r granules. This 
v a r ia b ility  in fo llic u la r  accum ulation o f iodide has been noted in o ther 
au to rad iograph ic  studies and may re f le c t gene tica lly  determ ined d iffe rences in 
iod ide trapp ing  by ’parent' fo l lic le  cells (Studer et al. 1985). However, the re  
was no evidence th a t d is trib u tio n  o f iodide w ith in  the gland was abnormal in 
anim als where m ethim azole  had been given u n til 48 hours before sa c rifice .
In sum m ary, norm al thy ro id  av id ly  trapped iodide and o rgan ified  
g rea te r than 90% o f the anion taken up. Stopping m ethim azole  (which is the 
a c tive  compound in plasma derived from  carb im azole) 48 hours before the 
study allowed norm al o rgan ifica tion  to  occur and had no m ajor e ffe c t on 
th y ro id  h is to log ica l appearance or on in tra th y ro id a l iodide d is trib u tio n . In 
con tras t, where drug was continued u n til the tim e  o f study, profound e ffe c ts  
on iodide o rg an ifica tion , h is to log ica l appearance and thyro ida l iodide
d is tr ib u tio n  were noted.
When a n tith y ro id  drugs had been given before 1 ^ 1  therapy in 
th y ro to x ic  patien ts they have generally been discontinued at least 48 hours 
beforehand (see previous section). Drug m etabolism  in man appears s im ila r 
to  th a t in ra t (M archant, 19719; M archant et al. 1978), and i t  would
th e re fo re  be expected tha t in man no e ffe c t on o rgan ifica tion  o f iodide 
would be present at this tim e : indeed, studies o f the duration of ac tion  o f 
m eth im azo le  in  man suggest tha t inh ib ition  o f o rgan ifica tion  persists fo r  less 
than 24 hours (McCruden, H ild itc h , Connell, et al. 1985). S im ila r ly , the 
e ffe c ts  o f m eth im azole  on h isto log ica l appearances and on in tra th y ro id a l
iodide d is tr ib u tio n  were much less evident when the drug had been stopped 
fo r  48 hours, so th a t labelled iodide appeared in a norm al re la tionsh ip  w ith  
co llo id  and fo llic u la r  ce ll borders. I t  the re fo re  seems un like ly  th a t the
e ffe c t o f a n tith y ro id  drugs fo llo w in g  ^ ^ I  tre a tm e n t on early  outcom e is a 
fu n c tio n  o f a lte red  o rg a n ifica tio n  (and thus re ten tion ) or d is trib u tio n  o f ^ - ^ 1. 
H ow ever, where a n tith y ro id  drugs continue to  be given when ls
adm in istered profound e ffe c ts  on the re ten tion  and d is trib u tio n  o f iodide 
w ith in  the gland w il l  occur and th is  is lik e ly  to  a ffe c t the response o f the 
th y ro id  to  tre a tm e n t. In con tras t, the p rac tice  o f d iscontinu ing drugs fo r  a t 
least 48 hours before l - ^ I  adm in is tra tion  appears to  restore  th y ro id  h is to logy 
and fu n c tio n  to  re la tiv e  n o rm a lity .
CHAPTER FOUR  
TISSUE A C C U M U LA TIO N  OF A N T IT H Y R O ID  DRUGS: 
IN TER A C TIO N S W ITH IO D ID E
SECTION ONE  
EFFEC T OF IN H IB IT IO N  OF IO D ID E  TRAPPING  ON 
U PTAK E OF R A DIO LABELLED P R O P YLTH IO U R A C IL  AND  
M ETH IM A ZO LE BY MOUSE T H Y R O ID  GLAND
4.1.1. In trod u c tion
In the preceding section i t  was shown th a t carb im azole influences the 
reponse o f pa tien ts  w ith  thyro tox icos is  to -*--^1 therapy: evidence has been 
presented th a t th is  e ffe c t is not associated w ith  a lte ra tio n  in the re ten tio n  
or d is tr ib u tio n  o f iodide w ith in  the gland, and i t  seems lik e ly  to  be 
associated w ith  some chem ical p roperty  o f the drug. A n tith y ro id  drugs o f 
the  th iou ry lene  group are unusual in th a t they are concentrated w ith in  th e ir  
ta rg e t tissue in both man and experim enta l anim al (M archant et al. 1978), 
and fa c to rs  which m od ify  the accum ulation o f drug by the thy ro id  gland may, 
th e re fo re , s ig n if ic a n tly  in fluence a n tith y ro id  drug action , which may include 
ra d iop ro te c tion .
M archant investiga ted  the phenomenon o f a n tith y ro id  drug accum ulation 
in the ra t, and showed tha t accum ulation was pos itive ly  co rre la ted  w ith  
d ie ta ry  iodide in take  and increased by fac to rs  w hich acu te ly  s tim u la ted  iodide 
uptake by the th y ro id  (M archant et al. 1978). This suggested tha t drug 
accum ula tion  m igh t be in some way associated w ith  the anion trap , although 
the mechanism rem ained obscure. The e ffe c t o f the opposite manoeuvre, 
nam ely acute in h ib ition  o f thyro id  iodide trapp ing on a n tith y ro id  drug 
accum ula tion  by the gland is examined here.
4.1.2. Anim als and drugs
A d u lt male m ice o f TO stra in  (An im al Suppliers, Welwyn Garden C ity )  
were used. They were m aintained on com m ercia l d ie t 41B (oxoid, iodine 
con ten t 2.4 pg/g ) fo r at least 7 days before the experim ent. Tap w a te r was 
ava ilab le  ad lib .
35 S-M ethim azole (28 pC i/m m o l) and ^ 5S -P ropy lth iou rac il (20
p C i/m m o l) were obtained from  Amersham In te rn a tion a l L td ., Bucks. Both
drugs had been shown to  be more than 98% pure by th in  layer 
chrom atography (Lang, 1983 a + b). C a rrie r free  sodium 125j was obtained 
fro m  Am ersham  In te rn a tion a l.
4.1.3. Methods
R adio labe lled  drugs were dissolved im m ed ia te ly  before use in a lka line  
so lu tion  (pH 8 ) to  give a range o f concentrations from  0.1 pg - 1 mg in 0.1 
m l volum e. Sodium perch lo ra te  (10 mg) dissolved in 0.9% sodium ch loride 
so lu tion  (0.1 m l volume) was in jected  in tra p e rito n e a lly  30 m inutes before 
in tra p e rito n e a l in je c tion  o f ^ - la b e l le d  drug. C on tro l animals rece ived 
norm al saline instead o f perch lo ra te . S ixty m inutes a fte r the adm in is tra tion  
o f -^S -labe lled  drug, animals were k illed  by exsanguination, blood being 
w ithd raw n in to  a heparin ized syringe by card iac puncture under e ther 
anaesthesia. Thyro id  glands were dissected out, weighed on a tors ion balance 
and digested in soluene (Packard). Samples o f 0.1 m l plasma were digested 
in hyam ine hydroxide (10% volume in 50% m ethanol). Plasma samples were 
counted in NE250 s c in t il la to r  (Nuclear Enterprises, Edinburgh) and tissue in 
to luene s c in t il la to r  using a liqu id  s c in tilla t io n  counter w ith  an in te rna l 
s tandard /channe ls-ra tio  method o f quench co rrec tion . For ca lcuation  o f 1 ^ 1  
uptake, separate animals were in jec ted  in tra p e rito n e a lly  w ith  0.5 pC i sodium 
1 2 ^ in 0.1 m l volume 30 m intues a fte r adm in is tra tion  o f sodium perch lora te  
or saline. Tissue was removed as before and a ll samples counted in an 
au tom a tic  gamma counter.
In a ll experim ents 6 animals were used in each group.
4.1.4. Results
E ffe c t o f sodium perch lora te  on accum ulation o f iodide
In the con tro l animals avid trapping o f iodide (c a rrie r free  125j)  was 
seen w ith  a mean tissue/plasm a ra tio  o f 307 + 92 (SD). In animals 
p re trea ted  w ith  perch lora te , trapping was inh ib ited  w ith  a mean tissue/plasm a 
ra t io  o f 1.37 + 0.4 (p < 0.001).
4.1.5. E ffe c t o f sodium perchlora te  on accum ulation o f ^ S - M e t h i m a z o l e  
These results are shown in Table 26. A t doses o f 0.1 and 10
pg /an im a l in tra th y ro id a l accum ulation o f m eth im azole  was seen w ith  
thyro id /p lasm a ra tios  in excess o f 2. H igher doses (100 and 1000 pg)
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resu lted  in thyro id /p lasm a  ra tios  near un ity .
For the 0.1 and 10 pg doses, p re trea tm en t w ith  sodium perch lo ra te  
was associated w ith  a s ig n ifican t fa l l  in the absolute amount o f labe lled  drug 
accum ula ted w ith in  the gland and also a s ig n ifica n t fa l l  in tissue/plasm a ra tio  
fo r  the drug. No s ig n ifican t d iffe rence  was seen in plasma concentra tions o f 
^^5 -M eth im azo le  in the animals tre a te d  w ith  sodium perch lora te . A t the 
h igher dose studied, perch lo ra te  had no s ig n ifican t e ffe c t on drug 
accum ula tion .
4.1.7. E ffe c t o f sodium perch lo ra te  on accum ula tion  o f - ^ S - P r o p y l t h i o u r a c i l
These resu lts are shown in Table 27. A t both doses studied (0.1 and
10 tig ) intrathyroidal accumulation of -^S-Propylthiouracil was noted,
although a fa ll in tissue/plasma ratio for the drug was noted at the higher 
dose studied. In both instances pretreatm ent with sodium perchlorate 
significantly diminished the tissue/plasma ratio for -^S-labelled drug. A 
significant fa ll in the absolute amount of drug accumulated within the 
thyroid was also noted at the 10 pg dose. No effect on plasma 
concentration of ^S-Propylth iouracil Was noted in the animals given sodium 
perchlorate compared with control.
4.1.8. Discussion
A ccum ula tion  o f ^S -M e th im a zo le  and -^^5-Propylth iouracil w ith in
mouse th y ro id  gland has been dem onstrated: m axim al tissue/plasm a ra tios  
occurred at the lowest drug concentrations studied. While i t  is accepted 
th a t some m etabo lic  degradation of -^S labelled  drug would occur during the 
tim e  course o f the experim ent, -^S uptake is taken to  represent a ll -^S 
labe lled  compound and re fe rred  to  as parent compound. Acute adm in is tra tion  
o f sodium perch lora te  caused a s ig n ifican t fa l l  in the absolute amount o f 
5 5 S-M eth im azole  accum ulated at the two low er (0.1 and 10 pg) dose levels 
and conseguently a fa ll in the tissue/plasm a ra tios. A s im ila r e ffe c t was
seen fo r  -^S -P ro p y lth iou ra c il. Perch lora te  could not be shown to  a lte r the 
am ount o f drug accum ulated at higher dose levels o f 5 5S-M ethim azole  
stud ied, and did not s ig n ifica n tly  in fluence plasma concentrations o f e ithe r 
-^S -M eth im azo le  or -^ ^ -P ro p y lth io u ra c il.
These data suggest tha t i t  is possible tha t tw o separate processes 
in fluence  in tra th y ro id a l drug content. A saturable mechanism which is
in fluenced by acute in h ib ition  o f the anion trap  may operate at low plasma 
concentra tions o f drug. A t higher drug dosage, passage o f drug to w ith in  the 
th y ro id  ce lls may be w ho lly  dependent on the plasma concentra tion , and not 
a ffe c te d  by acute in h ib itio n  o f the anion trap .
The cause o f th is p a rtia l in h ib ition  by perch lo ra te  o f a n tith y ro id  drug 
accum ula tion  is not im m ed ia te ly  c lear. A lthough there  is considerable 
in fo rm a tio n  ava ilab le  on fac to rs  which m od ify  a n tith y ro id  drug accum ulation 
w ith in  the gland, the mechanism of th is is not known (M archant, 1971; Lang, 
1982; Lees, 1976). Factors such as TSH and LATS which s tim u la te  iodide 
trapp ing  have been shown to  increase drug uptake and m etabolism  by ra t 
th y ro id  (Lees and A lexander, 1978). I t  seems u n like ly , however, tha t th is 
energy-dependent, membrane associated anion trap  is d ire c tly  responsible fo r 
drug accum ula tion . A lthough i t  has been dem onstrated in the cu rren t study 
th a t perch lo ra te  adm in is tra tion  was associated w ith  a fa l l in drug 
accum ula tion  w ith in  the gland, drug accum ula tion  s t i l l  persisted at a tim e  
when iodide trapp ing  was alm ost com p le te ly  inh ib ited . Using an in v itro  
system , Lang (1982) showed tha t ouabain and d in itropheno l, both inh ib ito rs  o f 
ac tive  transpo rt, did not abolish thy ro id  drug accum ula tion. There is, 
the re fo re , evidence from  both in vivo and in v itro  studies tha t a n tith y ro id  
drug accum ula tion  w ith in  the gland does not depend so le ly on a func tion ing  
iodide trap .
P erch lo ra te  co m p e titive ly  blocks iodide trapp ing  by the gland. As 
iodide e x it fro m  the fo llic u la r ce ll is also increased by perch lo ra te  
adm in is trtion  (H ild itc h , 1978) th is  w ill have the e ffe c t o f causing an acute 
fa l l  in in tra th y ro id a l inorganic iodide. Previous studies have shown th a t 
a n tith y ro id  drug accum ulation is enhanced by increasing iodide a va ila b ility : 
less drug is accum ulated by animals on a low  iodine in take than by animals 
on a norm al d ie t (Lang et al. 1983 a + b). S im ila rly , acute adm in is tra tion  o f 
potassium iodide in experim enta l animals causes increased drug accum ulation 
although at very high doses of iodide adm in is tra tion  an unexplained 
paradoxical decrease in drug accum ulation may be seen (Lang et al. 1983 a 
+ b). The resu lts  o f the current study are consistent w ith  these previous 
reports  and suggest th a t acute in tra th y ro id a l iodide deple tion is associated 
w ith  a decrease in drug accum ulation. O ther fac to rs  which have been shown 
to  increase drug accum ulation, such as thy ro id  s tim u la tin g  hormone may do 
so in d ire c tly  by increasing in tra thyro ida l iodide content (Lees and A lexander,
172.
1978).
The reason why drug accum ulation is re la ted  in th is  way to thy ro id  
iodide con ten t is not known. Previous studies in ra t have shown th a t 
rad io labe lled  a n tith y ro id  drug is accum ulated w ith in  the thy ro id  gland and
th a t the auto rad iograph ic  loca lisa tion  o f drug w ith in  the gland is id e n tica l to 
th a t o f iod ide, being w ith in  the co llo id  and at the c o llo id /c e ll in te rfa ce  
(Ferguson et a l. 1971). A f te r  trapp ing o f iodide by the fo llic u la r  ce ll, the 
anion is ra p id ly  o rgan ified  by the thy ro id  peroxidase enzyme system, and th is 
is probably also responsible fo r ox idation  o f drugs such as m ethim azole  and 
p ro p y lth io u ra c il. I t  the re fo re  appears tha t iodide and a n tith y ro id  drugs 
com pete fo r  a common ox ida tive  enzyme a fte r in it ia l uptake by the gland,
and subsequent lo ca lisa tion  w ith in  the gland may re f le c t th is .
A n tith y ro id  drug ox ida tion  is also increased in animals on a high iodine 
in take , and reduced in animals on a low in take  (M archant et al. 1978):
enhanced drug m etabolism  in the presence o f a com peting substrate appears 
paradoxical. Taurog (1976), who has reported  a s im ila r phenomenon in v it ro , 
has suggested th a t w ith  a high in tra th y ro id a l d rug/iod ide ra tio , drug:enzyme 
in te ra c tio n  causes irreve rs ib le  in a c tiva tio n  o f thy ro id  peroxidase and 
subsequent drug ox ida tion  is the re fo re  prevented. W ith  a low er drug/iod ide 
ra t io , an enzym e:iodide com plex may be responsible fo r oxid ising the drug 
and reducing iodine to  iodide. This accounts fo r drug in h ib ition  o f iodide 
o rg a n ifica tio n  and i t  is suggested th a t such a process may spare the enzyme 
fro m  irreve rs ib le  in a c tiva tio n  and allow  continued drug oxida tion  to  occur 
(Davidson e t a l. 1978). I f ,  the re fo re , drug accum ulation is dependent on 
subsequent m etabo lic  stops, a fa l l in in tra th y ro id a l iodide could in h ib it 
accum ula tion  by p r im a rily  re ta rd ing  drug ox ida tion . This concept is fu r th e r 
considered at the end o f th is  section.
SECTION TWO
A C C U M U LA TIO N  OF TH IO U R YLE N E A N T IT H Y R O ID  DRUGS 
IN  MOUSE SALIVARY G LAND
4.2.1. In trod u c tion
In the preceding section  i t  was suggested th a t a n tith y ro id  drug 
accum ula tion  was re la ted  to  the a b ility  o f thy ro id  tissue to  o rgan ify  iodide, 
and not sp e c ific a lly  re la ted  to  iod ide trapping. I f  th is were so, i t  m igh t be 
expected th a t a n tith y ro id  drug accum ula tion  m ight not occur in tissues where 
d issocia tion  o f iodide trapp ing  and o rg an ifica tion  exists. Salivary gland tissue 
has an anion tra p  which is very s im ila r to  tha t on the thy ro id , but lacks the 
a b il ity  to  o rgan ify  iodide (F le tche r et al. 1956; Lazarus, 1972): the po ten tia l 
uptake o f a n tith y ro id  drugs by mouse sa liva ry  (submandibular) gland has 
th e re fo re  been examined. As in it ia l findings ind icated th a t the gland did, in 
fa c t ,  accum ulate  a n tith y ro id  drug th is  was fu r th e r investiga ted  using 
h is tochem ica l methods and autoradiography in an a tte m p t to  loca lise  the s ite  
o f drug and iodide deposition w ith in  sa liva ry  gland. In view o f the close 
re la tionsh ip  in thy ro id  gland between the s ite  o f a n tith y ro id  drug and iodide 
deposition and o f thy ro id  peroxidase, th is  was investiga ted  in sa liva ry  gland 
by enzyme h istochem ica l techniques which localise peroxidase a c t iv ity  and 
was fu r th e r assessed by id e n tify in g  the s ite  o f g lucose-6 -phosphate 
dehydrogenase a c tiv ity ,  which is essential fo r  generation o f hydrogen peroxide 
in  tissues (B ancro ft, 1977).
4.2.2. Methods
A d u lt male m ice o f the TO stra in  (Anim al Suppliers) were used. They 
were m ain ta ined on com m ercia l d ie t 41B (Oxoid) fo r at least 7 days before 
the experim ent; tap w a te r was availab le ad lib .
3 5 S-labelIed M ethim azole  (28 qC i/m m o l) and 3 5S -P ropy lth iou rac il (20 
q C i/m m o l) were obtained from  Amersham In te rna tiona l L td . 125j sodium 
iodide (c a rrie r free ) was also obta ined from  Amersham In te rn a tion a l.
Drugs labelled w ith  33S were dissolved im m ed ia te ly  before use in 
a lka line  so lu tion  (pH 8 ) to  give a series o f concentrations ranging fro m  0.1 
pg to  1 mg drug in 0.1 m l volume. Drug was in jec ted  in tra p e rito n e a lly  at 
va ry ing  tim es from  2.5 to  320 m inutes before death. Anim als were k ille d  by 
exsanguination under ether anaesthesia. Submandibular and th y ro id  glands
were dissected out and digested in soluene (Packard). Samples o f 0 .1  m l 
plasma were digested in hyam ine hydroxide (1 0 % by volume in 50% 
m ethanol). The samples were counted in appropria te s c in tilla to rs  (plasma in 
a d iox in  based s c in t il la to r ,  NE 250, N uclear Enterprises; tissue in a to luene 
based s c in t il la to r , 5g PPO and O .lg P O P O P /litre  toluene) in a Packard 
T ric a rb  liqu id  s c in tilla t io n  counter using an in te rna l standard, channels ra tio  
m ethod o f quench co rrec tion . For ca lcu la tion  o f 125j uptake, separate 
anim als were in jec ted  in tra p e rito n e a lly  w ith  1 pC i ^25j sodium iodide in 0.1 
m l volum e: tissues were rem oved as before and a ll samples counted in an 
a u to m a tic  gamma counter.
To assess the e ffe c t o f co m p e titive  in h ib ition  o f the anion tra p  on 
uptake o f iodide and drugs, a separate group o f animals was in jec ted  
in tra p e rito n e a lly  w ith  10  mgs sodium perch lora te  dissolved in 0 .1  m l saline 
so lu tion  30 m inute before adm in is tra tio n  o f drug or iodide.
Six animals were used in each group.
4.2.3. Autoradiography
A liquo ts  (0.1 m l) o f so lu tion  conta in ing  100 pC i 3 3 S-M ethim azole, 3 3S- 
P ro p y lth io u ra c il, or sodium iodide were in jec ted  in tra p e rito n e a lly .
A n im a ls  were k ille d  a fte r  30 m inutes, submandibular glands were dissected 
ou t, and a portion  was im m ed ia te ly  frozen  in isopentane cooled w ith  liqu id  
n itrogen . Clean glass slides subbed in ge la tin  were dipped in I lfo rd  G5 
N uc lear emulsion which had been d ilu ted  w ith  an equal volume o f d is tille d  
w a te r. These were a llowed to  dry and then stored at -20°C . The frozen  
sa liva ry  glands were mounted on a chuck and 8 pM sections cu t in a 
c ryo s ta t m aintained at -20°C . Tissue sections were a ttached to  the 
em ulsion-coated slides by pressure and were then le f t  in a lig h t- fre e  box fo r 
6 weeks. C on tro l (i.e. non rad ioac tive  tissue) sections were included fo r 
chem ography and la te n t image fad ing. A t exposure the slides were thawed 
and the  tissues fixed  in phosphate buffe red  10% fo rm a lin  before developing. 
C ounte r s ta in ing  was w ith  haem atoxylin  and eosin.
4.2.4. Loca lisa tion  o f peroxidase a c tiv ity
Mouse submandibular glands were frozen and 10 pM sections cu t in a 
c ryo s ta t. These were incubated in T ris -H C l b u ffe r (pH 7.2) w ith  3,3- 
d iam inobenzadine (2 x 10“ 3 mol/1) and hydrogen peroxide (1%). A f te r
12-i
10-
2 -
Unlty
20020 40 60 80 100 300
Minutes a fte r in jection
Fig 28
1 28
ACCUMULATION OF IODIDE ( I) BY MOUSE SUBMANDIBULAR GLAND 
THE ACCUMULATION OF 125I BY MOUSE SUBMANDIBULAR GLAND IS 
EXPRESSED AS TISSUE/PLASMA RATIO OF THE ISOTOPE. l.OuCi OF 
125I WAS INJECTED INTRAPERITONEALLY, AND SUBMANDIBULAR GLANDS 
REMOVED AT VARYING TIMES UP TO 320 MINUTES AFTER INJECTION.
IT WILL BE SEEN THAT UPTAKE OF IODIDE BY SUBMANDIBULAR GLAND 
RAPIDLY INCREASED OVER THE FIRST HOUR AFTER INJECTION, AND 
MORE SLOWLY THEREAFTER. EACH POINT REPRESENTS THE MEAN 
OF 3 ANIMALS.
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Fig 29 
PLATE 1
3SAUTORADIOGRAPH OF S-METHIMAZOLE ACTIVITY IN MOUSE SUBMANDIBULAR 
GLAND. DARK GRANULES (SILVER GRAINS) ARE SEEN IN THE LUMEN 
OR THE CONVOLUTED GRANULAR TUBULE (CGT) AND SURROUNDING 
LINING CELLS (x300).
Fig 29 
PLATE 2
PEAUTORADIOGRAPH OF S-PROPYLTHIOURACIL ACTIVITY IN MOUSE 
SUBMANDIBULAR GLAND. DARK GRANULES (SILVER GRAINS) SEEN 
WITHIN LUMEN (L) INTRALOBULAR DUCT. (x250).
Fig 29 
PLATE 3
AUTORADIOGRAPH OF 125I IN MOUSE SUBMANDIBULAR GLAND. DARK 
GRANULES (SILVER GRAINS) SEEM IN DUCTAL EPITHELIUM. (x200). 
(DE).
Fig 30
LOCALISATION OF PEROXIDASE ACTIVITY IN SALIVARY GLAND 
OF MOUSE_________________________________________
DARK STAINING (OXIDISED DIAMINO BENZADINE) SEEN IN CELLS
LINING INTRALOBULAR DUCT LUMEN (L) (INTRALOBULAR DUCTAL
EPITHELIUM, (DE) (x350).
Fig 31
LOCALISATION OF GLUC0SE-6-FH0SFHATE DEHYDROGENASE 
ACTIVITY IN SALIVARY GLAND OF MOUSE
Dark staining (precipitated nitroblue tetrazolium) in 
intralobular ductal epithelium (DE) (x350).
incubation  at 25°C fo r  15 m inutes, section were dehydrated through graded 
alcohols and m ounted. Peroxidase a c tiv ity  was m arked by a brown deposit 
(due to  oxidised diam inobenzadine) (B ancro ft, 1977).
4.2.5. Loca lisa tion  o f q lucose-6 -phosphate dehydrogenase a c t iv ity
Frozen sections (8  pM th ick ) o f mouse subm andibular gland were
incubated at 37°C in phosphate-buffered medium (pH 7.4) conta in ing
disodium -glucose-6 -phosphate (10~2 mol/1), NADP (10” 2 mol/1) and n itrob lue  
te tra z o liu m  (10“ ^ mol/1). A t the end o f 30 m inute  incubation the sections 
were mounted in g lyce ro l je lly . G lucose-6 -phosphate dehydrogenase a c t iv ity  
was ind ica ted  by purple p re c ip ita te  (B ancro ft, 1977).
4.2.6. Results
(a) A ccum ula tion  o f iodide and -^S -M eth im azo le  by subm andibular gland 
D ata  fo r  iodide are shown graph ica lly in F igure 28. A ccum ula tion  o f
iodide by sa liva ry  gland was confirm ed w ith  increasing tissue/p lasm a ra tios  
o ccurring  over a 5 hour period. Table 28 shows the resu lts obtained fo r  
accum ula tion  o f -^S -M eth im azo le . I t  w il l be noted th a t the highest 
tissue/p lasm a ra t io  was achieved w ith  the lowest dose o f m eth im azole , and 
w ith  higher doses o f drug, tissue/plasm a ra tios fe l l.  A ccum ula tion  was seen 
to  be a ra p id ly  occurring  process w ith  a m axim al tissue/p lasm a ra tio  being
observed very sh o rtly  a fte r  in trape ritonea l in je c tion  o f drug.
(b) E ffe c t o f sodium perch lora te  on accum ulation o f -^^5-P ropylth iouracil, 
-^S -M eth im azo le  and Sodium iodide by submandibular gland
These resu lts are summarised in Table 29. Anim als were given e ithe r 
saline or 10 mgs sodium perchlorate  30 m inute before drug or iodide 
adm in is tra tion , and were k ille d  one hour a fte r th is . Sodium perch lora te  
com p le te ly  inh ib ited  accum ulation o f iodide by the subm andibular gland. 
A n tith y ro id  drug accum ulation, however, continued although tissue/p lasm a 
ra tios  and absolute amount o f drug accum ulated w ith in  the gland appeared 
low er in animals given perch lora te  (not s ign ifican t).
(c) Loca lisa tion  o f 3 5 S-M ethim azole, 3 5S -P ropy lth iou rac il and 125I Sodium 
iodide in  mouse sa liva ry  gland
T yp ica l autoradiographs of ^ 5S-M ethim azole (P la te  1) and 5 5S-
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P ro p y lth io u ra c il (P la te  2) are shown in F igure 29. For both drugs the s ite  o f 
lo ca lisa tion  was the same as rad io labe lled  iodide being w ith in  the lumen of 
the convo lu ted granular tubule and in tra lob u la r ducta l ep ithe lium  o f the 
gland. No accum ula tion  o f s ilve r granules, which would ind ica te  accum ula tion  
o f rad io labe l was seen elsewhere in the tissue. F igure 29 also shows an 
autoradiograph o f sodium iodide showing d is trib u tio n  o f rad io labe l in
in tra lo b u la r ducta l ep ithe lium .
(d) L oca lisa tion  o f peroxidase
A ty p ic a l h is tochem ica lly  stained section is shown in F igure 30. I t  
was apparent th a t peroxidase a c tiv ity  (dark sta in ing) was localised to  
in tra lo b u la r ducta l ep ithe lium .
(e) Loca lisa tion  o f g lucose-6 -phosphate dehydrogenase a c tiv ity  
G lucose-6 -phosphate dehydrogenase a c tiv ity  (dark sta in ing) was again
loca lised  to  the in tra lob u la r ducta l ep ithe lium  (Figure 31). These find ings 
in d ica te  th a t peroxidase a c tiv ity  and the energy pathways required  fo r  
peroxide generation were localised to  the same area o f the gland as iodide 
and rcdLolabelled an tith y ro id  drug accum ulation.
4.2.7. Discussion
A ccum u la tion  o f -^S -P ropy lth iou rac il ancj ^^5 _|V^ e t}~tj ma2 0 j e j-,as been
shown in mouse submandibular gland. Autoradiography ind icated th a t th is  
occurred in  the  in tra lobu la r ducta l ep ithe lium : rad iolabel was also seen w ith in  
the  lumen o f the convoluted granular tubu le . (The anatom y o f the 
subm andibular gland o f mouse is shown schem atica lly  in F igure 32). This was 
id e n tica l to  the loca lisa tion  of iodide w ith in  the gland. Peroxidase a c tiv ity ,  
w hich was dem onstrated using the technique of h is tochem istry  w ith  
diam inobenzadine as substrate, was s im ila r ly  seen in these areas, and 
g lucose-6 -phosphate dehydrogenase, which is responsible fo r generation o f 
hydrogen peroxide through the hexose-rnonqdno^pbate shunt, was found in the 
ce lls  lin in g  the in tra lobu la r duct, adding support to  the concept tha t th is  is 
the  locus o f peroxidase enzyme complex a c tiv ity .  I t  is o f in te res t th a t 
auto rad iograph ic studies of the loca lisa tion  o f 3 5 S -P ropylth iou rac il in ra t 
thy ro id  gland ind ica te  tha t the h is to log ica l loca lisa tion  o f the drug again 
resembles th a t o f iodide, in tha t both are concentrated w ith in  the co llo id
Acinus
Intercalated duct
Convoluted granular 
tubule
Intralobular duct
Fig 32
ANATOMY OF MOUSE SALIVARY GLAM)
A SCHEMATIC REPRESENTATION OF SALIVARY GLAND ANATOMY IS 
SHOWN: THIS ILLUSTRATES THE RELATIONSHIP BETWEEN
CONVOLUTED GRANULAR TUBULE AND INTRALOBULAR DUCT.
(Ferguson e t a l. 1971).
A ccum u la tion  o f drug by the subm andibular gland appeared to  be a 
saturab le  process, w ith  m axim al tissue/plasm a ra tios  being achieved w ith  the 
low est concen tra tion  o f drug used. This would suggest th a t the accum ula tion  
o f the drug is not m ere ly a product o f passive transm em brane passage. 
F u rthe rm ore , the highest tissue/plasma ra tio  fo r  drug was found very sh o rtly  
a fte r  in je c tio n , again suggesting tha t in it ia l accum ula tion  was spec ific  and 
a c tive . This evidence, and the s im ila r ity  in anatom ica l loca lisa tion  between 
rad io labe lled  drug and iodide, raises the p o s s ib ility  th a t the drug shares w ith  
iodide a s im ila r mechanism of accum ulation. However, when iodide trapp ing  
by sa liva ry  gland was com plete ly inh ib ited  by the perch lora te  anion, 
accum ula tion  o f both -^S -P ropy lth iou rac il anc] 35s_|^et.|^mazC)i e g ianc]
was not abolished: th is  is s im ila r to data presented in the previous chapter 
on the e ffe c t o f perch lo ra te  on thy ro ida l drug accum ula tion. This suggests 
th a t fo r  both drugs some other mechanism is responsible fo r  drug 
accum ula tion.
Both th y ro id  and sa liva ry  gland tissue possess a peroxidase enzyme 
system  (A lexander, 1959), although these may not be chem ica lly  id e n tica l. 
Using h is tochem ica l techniques, peroxidase a c t iv ity  was localised to  areas in 
w hich accum ula tion  o f both iodide and ^ S - la b e lle d  drug occurred. The 
fu n c tio n  o f a sa liva ry  peroxidase/iodide system is unclear. I f  the anion tra p , 
as these resu lts suggest, is not d ire c tly  im p lica ted  in a n tith y ro id  drug 
accum ula tion  by the submandibular gland, i t  is possible tha t the peroxidase 
enzyme system w hich is responsible fo r a n tith y ro id  drug oxidation m ight also 
be invo lved in drug accum ulation by both thy ro id  and sa liva ry  gland tissue. 
I t  is o f in te res t tha t accum ulation of p ropy lth iou rac il and m ethim azole has 
been reported  in  polym orphonuclear leucocytes (Lam and Lindsay, 1979): these 
cells also conta in  a peroxidase (myeloperoxidase) system and also accum ulate 
iod ide, but lack an anion trapping mechanism. I t  may be tha t i t  is the 
possession o f a peroxidase enzyme system which determ ines the a b ility  o f 
tissues to  oxidise and accum ulate th ioury lene a n tith y ro id  drugs, and not 
p r im a rily  the a b ility  to  accum ulate iodide. In contrast, lym phocytes have 
been shown not to  concentrate  35S-labelled m ethim azole  (Shewring and 
Lazarus, 1983) and these cells lack peroxidase a c tiv ity  (Weetman, 1984 c)
In conclusion, the re fo re , ^ S - P r o p y l t h i o u r a c i l  ancj ^ s .f^ g th im a z o le
accum ulated in the mouse submandibular gland. A lthough both the thy ro id
and sa liva ry  gland in the mouse conta in  an ac tive  anion trap , and although 
the s ite  o f lo ca lisa tion  fo r iodide and drug in both tissues is the same, i t  
seems ve ry  lik e ly  tha t the method o f accum ula tion  fo r  iodide and drug 
d if fe r .  The presence of peroxidase a c t iv ity  in a ll tissues which have been 
shown to  accum ulate th ioury lene  a n tith y ro id  drugs raises the poss ib ility  th a t 
th is  may be im p o rta n t in the mechanism o f accum ula tion, and i t  is suggested 
(see previous section) th a t th is  is re la ted  to  subsequent drug m etabolism .
SECTION THREE  
A N T IT H Y R O ID  DRUG A C C U M U LA TIO N  IN  H U M A N  
PO LYM O RPHO NUCLEAR CELLS
4.3.1. In trod u c tion
In the preceding sections the accum ulation o f a n tith y ro id  drugs in 
tissues which possess an energy dependent, membrane associated anion tra p  
has been investiga ted , and evidence presented tha t drug accum ula tion  is a 
fu n c tio n  not o f th is , but o f peroxidase enzyme capable o f oxid is ing 
a n tith y ro id  drug. There have been reports th a t human w h ite  blood cells 
(polymorphs) accum ulate a n tith y ro id  drugs (Lam and Lindsay, 1979): these 
ce lls do not, as fa r as is known, have a spec ific  anion tra p  and the re fo re  
present a useful model in which to  examine th is phenomenon fu r th e r. 
Polym orphonuclears are m e tab o lica lly  very much more ac tive  when 
phagocytosing than when res ting , and fo r th is  reason ce ll uptake o f drug was 
stud ied during phagocytosis s tim u la ted  by zymosan partic les  opsonised w ith  
plasma components (includ ing gam maglobulin and fib ro ne c tin ).
4.3.2. Methods 
Isotopes and chem icals
•^S -P rop y lth io u rac il (46 u C i/m m o l) and ca rrie r fre e  ^ 5 j  sodium iodide 
and ^^^T c -P e rte c h n e ta te  (50 p C i/m m o l) were obta ined fro m  the 
Rad iochem ica l C entre , Amersham . Sodium iodide, potassium perch lo ra te , 
m eth im azo le , zymosan and ouabain were obtained from  the Sigma 
C orpora tion .
C e ll p reparation
Venous blood (50 m l) was drawn from  healthy volunteers and m ixed 
im m ed ia te ly  w ith  preservative fre e  heparin. No subject was tak ing  any drug 
tre a tm e n t at the tim e  o f the study. The to ta l leucocytes were obtained by 
se le c tive ly  sedim enting the erythrocytes w ith  plasmagel (Labo ra to ire  Roger 
Bellon) and the mononuclear cells were then separated from  the polymorphs 
by density ce n trifuga tion  on F ico ll-Paque (Pharmacia). The residual 
e ry th rocy tes  were lysed in hypertonic saline and the polymorphs f in a lly  
resuspended in Gey's solution (Gibco, B iocu lt) w ith  the pH adjusted to  7.4. 
The average y ie ld  from  50 m l blood was 4 x 10^ cells. These were shown
to  be at least 95% viable by exclusion o f trypan blue at the s ta r t o f 
incubations. A ll isotopes and drugs were dissolved in Gey’s so lu tion : drugs 
were in  a range o f concentrations fro m  1 0 “ 3-10“ ^ m olar.
Phagocytosis
Zymosan partic les were opsonised by incubation at 37°C fo r  30 
m inutes w ith  fresh autologous plasma, and then suspended in Gey's so lu tion . 
A f in a l zymosan concentra tion  o f 1 m g/m l was used to  s tim u la te  
phagocytosis by polymorphs: phagocytosis was in it ia te d  10  m inutes a fte r  tes t 
drugs and radioisotopes were placed in the ce ll suspension.
Radio isotope uptake by cells
In order to  measure ce ll/superna tan t ra tios, 30 x 10^ cells in  1 m l 
w ere incubated at 3 7 °C  fo r one hour a fte r adding opsonised zymosan. The 
a c tiv it ie s  o f the radioisotopes in the ce ll suspension and in the supernatant 
w ere then counted. Cells were separated by cen trifu g a tio n  at 400 g fo r  10 
m inutes. The polymorph volume o f the suspension was ca lcu la ted  based on
ce ll count and assumption of a un ifo rm  ce ll volume (1 x 10^ cells = 0.7 p i).
In h ib it io n  o f ce ll peroxidase a c t iv ity
E ffe c t o f drugs on ce ll peroxidase a c tiv ity  was exam ined by m easuring 
chem ilum inescence of phagocytosing polymorphs. This is assayed using photon 
emission fro m  in te rac tio n  between a tes t chem ical (lum ino l) and peroxidase. 
A lig h t sensitive instrum ent (lum inom eter) is used fo r th is purpose. 
Fo llow ing  dark adaptation o f the cells fo r 30 m inutes, chem ilum inescence was
measured by incubating 5 x 106 cells in 175 p i phosphate bu ffe red  saline at
37°C toge the r w ith  25 pi lum ino l (10“ ^). Test chem icals were added (25 p i) 
to  give a fin a l concentra tion  o f 1 0 " 4 m olar, and phagocytosis in it ia te d  by 
add ition  o f 25 p i of a 10  pg /m l so lution o f opsonised zymosan. 
Chem ilum inescence was measured fo r  100 seconds using a Packard P ic o lite  
lum inom ete r (Stock, Coderre and Levine, 1982). The resu lts are expressed as 
a percentage o f the contro l in which saline was substitu ted  fo r  tes t drug.
A ll incubations were perform ed in duplicates o f six.
4.3.3. Results
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UPTAKE OF IODIDE ( I) AND S-PROPYLTHIOURACIL BY 
POLYTORPHONUCLEAR CELLS
1 PS ^ s
THE UPTAKE OF IODIDE ( I) (OPEN COLUMNS) AND S-
PROPYLTHIOURACIL (HATCHED COLUMiE) BY RESTING (EXTREME
LEFT) AND FHAGOCYTOSING POLYMORPHONUCLEAR CELLS (STIMULATED
BY ZYMDSAN). OCflBAIN (ImM) AND PERCHLORATE (2mM) HAD NO
EFFECT ON UPTAKE OF 125I OR 35S-PROPYLIHIOURACIL;
METHIMAZOLE (ImM), PROPYLTHIOURACIL (ImM) AND IODIDE (IrriM)
IPS PS
ALL INHIBITED UPTAKE OF BOTH I AND S-PROPYLTHIOURACIL 
(ALL p<£LO.Ol). ALL INCUBATIOPE WERE PERFORMED IN GROUPS 
OF 6. MEAN AND STANDARD ERROR OF MEAN ARE SHOWN.
183.
N e ith e r res ting  nor phagocytosing ce lls accum ulated 99m j c_ 
P ertechne ta te  a fte r  60 m inutes incubation w h ile  c lear uptake o f both iodide 
ancj 35s_pr 0 p y ith i0u rac il occurred w ith  ce ll/supe rna tan t ra tios  o f 16.8 
and 7.4 re sp ec tive ly  (F igure 33). The e ffe c ts  o f various drugs on polym orph 
accum ula tion  o f iod ide and p ro py lth io u rac il by phagocytosing polymorphs are 
shown in F igure  33. These agents were added to  the ce ll suspension 10 
m inutes before  zymosan. N e ith e r ouabain nor pe rch lo ra te  a ffe c te d  uptake o f 
125i or - ^ S - P r o p y l t h io u r a c i l .  U nlabelled m eth im azo le , however, inh ib ite d  
uptake o f both agents. Both unlabelled p ro p y lth io u ra c il and unlabelled iodide 
at high concen tra tion  also inh ib ited  uptake o f labe lled  m a te ria l, a lthough th is  
is d i f f ic u l t  to  eva luate  as these unlabelled drugs would g re a tly  d im in ish the 
sp ec ific  a c t iv ity  o f the corresponding rad io iso top ic  chem ica l. I t  was evident, 
however, th a t iod ide inh ib ited  p ro py lth io u rac il accum ula tion  and vice versa.
The e ffe c t o f these chem icals on m yeloperoxidase a c tiv ity  is shown in 
Table 30: th is  was measured by chem ilum inescence, and values are expressed 
as a percentage o f con tro l. M eth im azole  and p ro py lth io u rac il (0.1 m m ol) 
both decreased m yeloperoxidase a c t iv ity  whereas iodide, ouabain and 
perch lo ra te  had no d iscern ib le  e ffe c t.
4.3.4. D iscussion
The ce ll model used in th is  study was the human polym orph in w hich 
m yeloperoxidase a c t iv ity  had been s tim u la ted  by phagocytosis o f opsonized 
zymosan p a rtic les . Polym orphonuclear m yeloperoxidase is necessary fo r  the 
generation o f oxygen s ing le t free  rad icals (Belch, J. Personal C om m unica tion), 
possibly using ch lo ride  ion as an enzyme c o -fa c to r. These very re a c tive
pa rtic les  are responsible fo r the bac te ric id a l p roperties o f the cells. N e ith e r
m eth im azo le  or p ro py lth io u rac il a ffe c t ingestion o f zymosan by polymorphs
and th is has been confirm ed using a labe lled  zymosan system (Ferguson, 
A lexander, C onne ll, e t al. 1983; Lam and Lindsay, 1979).
U ptake o f iodide by tissue such as thy ro id , is dependent upon an
energy dependent anion trap , which can be c o m p e tit iv e ly  inh ib ited  by o the r
anions such as perch lo ra te , and is abolished by ouabain which inh ib its
sodium /potassium  ATPase a c tiv ity . In the  polym orph, ne ithe r ouabain nor 
perch lo ra te  a ffe c te d  iodide accum ulation during phagocytosis, and th is
suggests th a t uptake o f the anion is the re fo re  independent o f the membrane 
associated anion tra p . I t  is un like ly  th a t iodide accum ulation is a non
sp ec ific  e ffe c t o f phagocytosis as uptake o f iodide was inh ib ited  by 
m eth im azo le  and p ro py lth io u rac il wh ich do not a ffe c t accum ula tion  of 
opsonized zymosan pa rtic les  (Ferguson et a l. 1983). I t  seems, the re fo re , th a t 
the uptake o f iodide is a consequence o f m yeloperoxidase a c t iv ity ;  th is
enzyme has a s im ila r ox ida tion  po te n tia l to  th y ro id  peroxidase, and may be 
capable o f ox id is ing  iodide. This would account fo r the in h ib itio n  o f iodide 
uptake by the th iou ry lene  drugs, which were shown in the  cu rren t study to  
in h ib it also m yeloperoxidase a c t iv ity  as measured by chem ilum inesce.
This system , the re fo re , a llowed ce ll accum ula tion  o f p ro py lth io u rac il to  
be studied independently from  an anion trapp ing  mechanism associated w ith  
ce ll membranes. The drug was accum ulated by polym orphs, co n firm ing  an
in it ia l re p o rt by Lam and Lindsay (1979).
I t  is o f in te res t th a t a n tith y ro id  drugs appear not to  be concentra ted  
in lym phocytes (Shewring and Lazarus, 1983), cells w hich lack the high 
concentra tions o f m yeloperoxidase present in polym orphs. A lthough in it ia l 
w ork on the immunosuppressive actions o f a n tith y ro id  drugs in Graves' disease 
suggested th a t th is  m igh t be due to  an e ffe c t on lym phocyte  fun c tio n  
(M cGregor e t al. 1980), i t  now appears m ore lik e ly  th a t th is  e ffe c t is a 
consequence o f im pa irm en t o f m onocyte processing and presentation o f
antigen (Ratanachaiyavong and M cG regor, 1985). P o te n tia l accum ula tion  o f 
a n tith y ro id  drug by monocytes has not been studied, but i t  is known th a t 
such cells conta in  an ac tive  H 2 0 2 /peroxidase system : i t  may be th a t
concen tra tion  o f a n tith y ro id  drugs by monocytes as a consequence o f th is  
enzyme com plex is a p re requ is ite  fo r any e ffe c t on immune functions 
(discussed in chapter 5).
P erch lo ra te , which is a spec ific  co m p e titive  b locker o f the anion tra p  
in the thy ro id  and sa liva ry  gland, did not a ffe c t drug uptake, and ouabain, an 
in h ib ito r o f membrane associated sodium /potassium  ATPase a c tiv ity  also had 
no e ffe c t: these data the re fo re  supplement findings presented in the previous 
tw o chapters derived from  tissues which have an ac tive  anion trapp ing
mechanism. A dd itio n  o f unlabelled p ro py lth io u rac il and m eth im azole  to  
polymorphs blocked labe lled  p ro py lth io u rac il accum ula tion , and s im ila r 
concentra tions o f both drugs also inh ib ited  m yeloperoxidase a c tiv ity .  Iodide 
also blocked accum ula tion  o f drug, although did not s ig n if ic a n tly  in h ib it 
m yeloperoxidase. This may re f le c t d iffe rences in the in te ra c tio n  between 
th y ro id  peroxidase,iodide and drugs discussed by Taurog (1978) and Davidson
et a l. (1978). I t  is possible th a t the accum ula tion  o f iodide and 
p ro p y lth io u ra c il by human polym orphonuclear ce lls is a fu n c tio n  o f in te ra c tio n  
w ith  m yeloperoxidase, a c tiva ted  during phagocytosis. Resting cells did not 
accum ula te  e ith e r iodide or drug and th is  may re f le c t in a c tiv ity  o f 
m yeloperoxidase in  such cells.
The im p lic a tio n  o f the above data to  the mechanism o f thy ro ida l 
accum ula tion  o f a n tith y ro id  drugs is discussed in the concluding portion  o f 
th is  chapter.
A n tith y ro id  drugs are not reported  to  a ffe c t m ature w h ite  ce ll 
fu n c tio n  in man during c lin ica l use, although are occasionally a cause o f 
leucopenia (T ro tte r , 1962). A ccum ula tion  o f drug on ly occurred when cells 
were a c tiv e ly  phagocytosing: most polymorphs in the periphera l c ircu la tio n  
are not a c tiva te d  and i t  seems un like ly  th a t drug accum ula tion  would occur 
to  a great e x te n t in v ivo ; although absence o f peroxidase in polymorphs in 
man is a cause o f chronic granulom atous disease, the e ffe c t on 
m yeloperoxidase o f m eth im azole  and p ro p y lth io u ra c il a t high concen tra tion  in 
vivo was one o f p a rtia l in h ib itio n  only. I t  seems un like ly  th a t a n tith y ro id  
drug therapy would have an im p o rta n t e ffe c t on the  e ff ic ie n c y  o f polym orph 
fu n c tio n  in  man.
SECTION FOUR  
SUM M ARY OF STUDIES ON A C C U M U LA TIO N  OF 
A N T IT H Y R O ID  DRUGS
4.4.1.
The data presented in th is  section , derived fro m  anim al th y ro id  and
sa liva ry  tissue and fro m  human w h ite  blood cells show th a t tissue
concen tra tion  o f th iou ry lene  a n tith y ro id  drugs is a m ore generalised
phenomenon than h ith e rto  suspected. I t  seemed in it ia l ly  th a t drug 
accum ula tion  m igh t be re la ted  to  iodide trapp ing  (M archant et al. 1978): 
acute blockade o f the iodide tra p , however, reduced, but did not abolish, 
drug accum ula tion  in mouse th y ro id  gland and had l i t t le  e ffe c t on 
accum ula tion  in mouse subm andibular gland. F u rthe r, drug accum ula tion  was 
found in human polymorphs w h ich  lack a spec ific  membrane associated iodide 
tra p : iodide uptake by these ce lls was not inh ib ited  by a co m p e titive  anion 
(pe rch lo ra te ) or by ouabain. I t  is c lear, the re fo re , th a t the presence o f an 
a c tive  iodide tra p  is not a p re requ is ite  fo r  a n tith y ro id  drug accum ula tion .
Subsequent evidence suggested th a t the presence o f a peroxidase 
enzym e system is a fea tu re  o f tissues which accum ulate  a n tith y ro id  drugs. 
Indeed, in mouse sa liva ry  gland the loca lisa tion  o f labe lled  a n tith y ro id  drug 
was very s im ila r to  tha t o f the s ite  o f peroxidase generation and a c t iv ity .  
Previous studies have suggested th a t th is  is also the case fo r  ra t th y ro id  
tissue (Ferguson et al. 1971). A d d itio n a lly , in human polymorphs, a n tith y ro id  
drugs were shown to  in h ib it peroxidase a c t iv ity  at doses w hich also reduced 
uptake o f labelled  p ro p y lth io u ra c il. Conversely, lym phocytes, w hich lack a 
peroxidase enzyme com plex, do not concentra te  these drugs (Shewring and 
Lazarus, 1983).
I t  is possible th a t drug accum ula tion  w ith in  the thy ro id  is dependent 
on subsequent drug ox ida tion : th is  m igh t explain the re la tionsh ip  between
iodide in take  and drug concen tra tion  by the gland. The process of
accum ula tion  may, in part, be one o f passive transm em brane d iffu s ion  w h ich  
reaches an equ ilib rium  between e x tra c e llu la r and in tra c e llu la r drug (F igure 
34). In the suggested scheme, ou tlined  in F igure  34, the in tra c e llu la r 
concen tra tion  o f fre e , non oxid ised drug is governed by the ra te  o f ox ida tion  
o f drug by peroxidase. Where drug ox ida tion  is inh ib ited , as during re s tr ic te d  
iodine in take  or by o the r agents w hich in h ib it peroxidase (such as o ther
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HYPOTHETICAL SCHEME FOR UPTAKE OF ANTITHYROID DRUGS (AID) BY 
THYROID TISSUE
SUGGESTED INTERACTION BETWEEN INTRATHYROIDAL IODIDE AND 
ANTIIHYROID DRUG TO REGULATE INTRACELLULAR ACCUMULATION 
OF LATTER.
(a) (LEFT) NORMAL IODIDE AVAILABILITY: LOW INTRACELLULAR 
ANTI THYROID DRUG/IODIDE RATIO. THYROID PEROXIDASE (TPO)
AND IODIDE (I) FORM All OXIDISED COMPLEX WITH HYDROGEN 
PEROXIDE (H^02) ACTING AS AN ELECTRON ACCEPTOR. THIS WOULD 
NORMALLY BE AVAILABLE FOR IODINATIOM OF TYROSINE RESIDUES 
ON THYROGLOBULIN, BUT ATD ACTS AS AN ALTERNATIVE ELECTRON 
DONOR RESULTING IN DRUG OXIDATION (ATDOXID). TPO AND l“
ARE THEN AVAILABLE TO FORM AN OXIDISED COMPLEX WHICH CAN IN 
TURN OXIDISE MORE ATD.
(b) (RIGHT) IODIDE DEPLETION: HIGH INTRACELLULAR ANTI­
THYROID DRUG/IODIDE RATIO. TPO IS OXIDISED NORMALLY BY 
H^02, BUT AS I IS NOT AVAILABLE IT DIRECTLY OXIDISES ATD.
IT IS SUGGESTED (DAVIDSON ET AL 1978) THAT ATDOXID INACTIVATES 
TPO SO THAT IT CANNOT BE REOXIDISED BY H202: THUS FURTHER 
ATD OXIDATION CANNOT PROCEED. IF ENTRY OF ATD TO FOLLICULAR 
CELLS IS GOVERNED BY SUBSEQUENT ATD METABOLISM, MORE ATD 
SHOULD BE ACCUMULATED IN SITUATION (a) ABOVE THAN (b).
OTHER PROCESSES WHICH ALTER ATD OXIDATION (INCREASE: TSH, 
DECREASE: OTHER INHIBITORS OF TPO) WILL SIMILARLY AFFECT 
INTRACELLULAR DRUG ACCUMULATION.
a n tith y ro id  drugs) in tra c e llu la r levels o f fre e , non oxidised drug may rise  and 
so in h ib it fu r th e r accum ula tion; the opposite w il l occur when drug ox ida tion  
is enhanced (e.g. by high iodide in take  or by TSH). Such a scheme m igh t 
exp la in  the close re la tionsh ip  in anim al studies between events which enhance 
a n tith y ro id  drug ox ida tion  and those w hich increase accum ula tion  such as 
iodide a v a ila b ility , TSH and LATS s tim u la tio n  o f the thy ro id . I t  is known 
th a t o x ida tive  m etabolism  o f m e th im azo le  and p ro py lth io u rac il is d ire c t ly  
re la te d  to  in tra -th y ro id a l iodide con ten t (M archant et al, 1978; Lang et al. 
1983 a + b). Tissue/plasma ra tios  in excess o f 40 have been reported  fo r  
th y ro id  accum ula tion  o f -^S -m eth im azo le  (M archant, 1971; Lees, 1978), and 
the hypothesis ou tlined  above is u n like ly  to  account alone fo r  such high 
gradients. How ever, o ther physio-chem ica l fa c to rs , such as pK of drugs, are 
also lik e ly  to  in fluence  d is tr ib u tio n  o f non-m etabolised drug across a sem i- 
perm eable membrane (e.g. plasma mem brane).
I t  is possible th a t th is  has im p lica tio n s  fo r  c lin ic a l use o f a n tith y ro id  
drugs. I t  may be th a t in te ra c tio n  between thy ro id  peroxidase and drugs and 
iodide regula tes in tra th y ro id a l accum ula tion  o f drug: th is in te ra c tio n  may act 
to  m a in ta in  re la tiv e ly  constant in tra th y ro id a l drug levels over a range o f 
plasma concentra tions o f drug. This may p a rtly  explain the much longer 
in tra th y ro id a l ac tion  o f such agents when compared w ith  the re la t iv e ly  short 
plasma h a lf - l i fe  o f the drugs (M cCruden e t al. 1985). I t  m igh t also suggest 
th a t high doses o f a n tith y ro id  drugs o ffe r  l i t t le  advantage over low er doses, 
as both m igh t be expected to  generate s im ila r in tra th y ro id a l drug leve ls. 
This concept is p a rtly  borne out by c lin ic a l experience, w ith  s im ila r ex te n t 
and dura tion  o f in h ib ition  o f iodide o rg a n ifica tio n  occurring  w ith  a range o f 
doses o f carb im azole  (McCruden et al. 1985; M cCruden, Low , C onne ll, e t al. 
1981; Low , H ild itc h  and A lexander 1979).
CH APTER FIVE
F IN A L  CONCLUSIONS
5.1.1. In trod u c tion
In considering the aims o f th is  thesis a num ber o f questions re la tin g  
to  the ea rly  e ffe c ts  o f ^ -^ I  tre a tm e n t on th y ro id  fu n c tio n , and the 
in te rac tio n s  between ^ -^ I ,  a n tith y ro id  drugs and iodide were considered. In 
the subsequent chapters conta in ing  experim enta l data (3 and 4) studies 
re laven t to  these questions have been presented. The p rinc ipa l conclusions 
fro m  these studies are summarised below, w ith  re ite ra tio n  o f the o rig ina l 
questions.
5.1.2. What is the incidence o f worsening o f b iochem ica l th y ro to x ico is  a fte r  
l ^ l i , and are such changes c lin ic a lly  im portan t?
D a ta  on the im m ed ia te  e ffe c ts  o f ^ ^ 1  therapy on c ircu la tin g  th y ro id  
hormone leve ls was presented in chapter 3, section 1. These showed th a t in 
around 50% o f pa tien ts a rise in both T3 and T4 occurred, and th a t 
p re tre a tm e n t w ith  the  a n tith y ro id  drug carb im azole  did not prevent an 
increase in hormone leve ls. As most patien ts on carb im azole  had low er 
in it ia l concentra tions o f T3 and T4, however, the peak levels achieved were 
much reduced and such therapy should, in theo ry , e lim ina te  the risk  o f 
exacerbation  o f thy ro tox icos is  a fte r ^ ^ I .  In no p a tie n t in e ithe r group was 
the rise in thy ro id  hormone levels associated w ith  c lin ic a l de te rio ra tio n . The 
m axim um  rise in hormone levels occurred w ith in  48 hours o f 1-^1 therapy, 
and was shortlived  (less than 1 week). This seems lik e ly  to be a 
consequence o f ra d ia tion  th y ro id it is  leading to  d isruption  o f thy ro id  fo llic u la r  
in te g r ity , w ith  leakage o f p re form ed T4 and T3 from  the gland. This was, 
su rp ris ing ly , not associated w ith  a consistent change in c ircu la tin g  
concentra tions of thyrog lobu lin , and the cause o f th is  is not c lear. I t  is 
possible th a t the frequency and tim in g  o f sam pling fo r  thy rog lobu lin  was not 
appropria te . H owever, assays fo r serum thyrog lobu lin  concentra tions are 
prone to  in te rfe re n ce  fro m  endogenous autoantibody, and th is  may also have 
obfuscated sm all changes in serum thyrog lobu lin  leve ls. A lthough the 
m a jo r ity  o f patients in th is series were negative fo r  a n tith y rog lobu lin  
antibody using a red ce ll agg lu tina tion  technique, the re  is some evidence tha t
th is  may be a re la t iv e ly  insensitive  means o f m easuring antibody levels (Isumi 
and Larsen, 1978). A d d itio n a lly , no change in levels o f TSH recep to r 
d irec ted  im m unoglobulin  (th y ro trop h in  recep to r binding d isp lacing antibody) 
was detected fo llo w in g  l ^ l j .  th is  contrasts w ith  some previous studies which 
have shown a rise  in th y ro id  s tim u la tin g  im m unoglobu lin  and TRAb fo llo w in g  
131l therapy (A tk inson  et al. 1982; Bech and Madsen, 1980). A lthough in th is  
instance sample tim in g  was s im ila r to th a t o f o the r studies, i t  is possible 
th a t the re la t iv e ly  sm all number o f subjects (24) in whom the measurement 
was made in th is  thesis may account fo r  the negative fin d ing . Previous 
studies have, however, fa ile d  to  show any re la tionsh ip  between im m unolog ica l 
changes fo llo w in g  131j anc| c lin ic a l or b iochem ica l events.
5.1.3. How do the e ffe c ts  o f 131j on thy ro id  physio log ica l processes such as 
iodide trapp ing  and o rg a n ifica tio n  re la te  to  b iochem ica l and c lin ic a l responses 
in the f ir s t  year a fte r  therapy, and can such in fo rm a tio n  reduce the  
u nce rta in ty  about the ea rly  response to  l - ^ I?
The e ffe c ts  o f 1-^1 on thy ro id  iodide handling and the b iochem ica l 
consequences o f these changes were presented in sections 2 to  6 o f chapter 
3. In a ll patien ts 1 ^ 1  caused a fa l l in 20 m inute  uptake o f ^ ^ 1 ,  which 
re fle c ts  iodide trapp ing . This fa l l  was m axim al in most pa tien ts  by 4 weeks 
a fte r  l ^ I  a dm in is tra tion . Where m ajor in h ib itio n  o f iod ide trapp ing  at th is 
t im e  was not fo llow ed  by at least p a rtia l recovery, perm anent hypothyro id ism  
ensued w ith in  2 months. In con tras t, those patien ts whose trapp ing  fun c tio n  
was not severely im pa ired  at th is  tim e  (in p ra c tice  a 20  m inu te  uptake o f 
g rea te r than 8%) tended to  rem ain th y ro to x ic . A lthough the re  was a degree 
o f overlap between p a tie n t groups, i t  was dem onstrated th a t the outcom e 
w ith in  the f ir s t  year a fte r  therapy was p red icted by th is measure o f
iodide trapp ing 4 weeks a fte r  131j adm in is tra tion . For the m a jo rity  o f 
pa tien ts the im p o rta n t consideration fo llow ing  therapy is w hether cure
o f thyro tox icos is  resu lts : i f  not fu r th e r tre a tm e n t is required . When the 20 
m inute  uptake o f 1^3j at 4 weeks a fte r tre a tm e n t was 4% or less, patien ts 
in va riab ly  became e ithe r eu thyro id  or hypothyro id  w ith in  the next few  
m onths. As m entioned above, an uptake o f g reate r than 8 % ind ica ted  fa ilu re  
o f tre a tm e n t. This may have some value in the planning o f fu tu re  therapy 
fo r  patien ts, as at th is  tim e  most patients have not shown a consistent 
b iochem ical response. Uptake measurements longer than 4 weeks from  133-1
adm in is tra tio n  tended to  m ir ro r the b iochem ica l and c lin ic a l status o f the
pa tien ts  at th a t t im e . These measurements may be o f especial use in
pa tien ts  whose true  thy ro id  fu n c tio n a l reserve fo llo w in g  131j tre a tm e n t is 
obscured by continued a n tith y ro id  drug tre a tm e n t; w ithd raw a l o f drugs in 
such instances may be associated w ith  relapse o f thy ro to x ico s is . U ptake 
measurements may id e n tify  pa tien ts  who have fa ile d  to  respond to  an in it ia l 
dose o f a llow ing  more ra tio n a l planning o f fu tu re  m anagem ent.
These data ind ica te  th a t the p rinc ipa l e ffe c ts  o f ^31j on th y ro id  ce ll 
fu n c tio n  occur early  a fte r  tre a tm e n t, and tha t these dete rm ine  c lin ic a l 
outcom e. In those patien ts who do respond to  l ^ I ,  the e ffe c ts  o f tre a tm e n t 
are m axim al ea rly  a fte r  131* a dm in is tra tion , and apparent delay in response 
is due to  the lag between changes in thy ro id  iodide handling and
corresponding b iochem ica l change. A lthough patien ts  w ith  m ore severe 
thy ro tox icos is  (as measured by the 24 hour uptake o f 123j) tended to  respond 
less w e ll to  therapy w ith  a g rea te r incidence o f pers is tant thy ro to x ico s is , th is  
was a poor p red ic to r o f outcom e. S im ila r ly , there  was l i t t le  d iffe re n ce  in 
pre therapy go itre  size in those patien ts  who responded and those who did
not.
The e ffe c ts  o f 131j the rapy on iodide o rg a n ifica tio n  were also 
considered using both in d ire c t measurem ent (the ra tio  o f 60:20 m inu te  uptake 
o f ancj a q u a n tita tive  d ire c t perch lo ra te  discharge te s t. These studies
suggested th a t im pa irm en t o f o rg an ifica tion  occurred in up to  50% o f 
pa tien ts  fo llo w in g  131j tre a tm e n t: th is  was most fre q u e n tly  seen between 2 
and 4 months a fte r therapy and tended to  recover spontaneously. These 
find ings are in general agreem ent w ith  previous studies o f o rg a n ifica tio n  
im pa irm en t fo llo w in g  ^-31j therapy (G ray, 1975).
Evidence o f o rg a n ifica tio n  im pa irm en t was seen in 5 out o f 6 pa tien ts  
who developed trans ien t hypothyro id ism , and recovery o f hypothyro id ism  
appeared to  coincide w ith  im provem ent in o rg an ifica tion  e ff ic ie n c y . These 
studies suggest th a t trans ien t hypothyro id ism  fo llo w in g  ^.31i therapy is a 
consequence o f o rg a n ifica tio n  fa ilu re  in a gland w ith  a c r it ic a l fa l l  in  th y ro id  
iod ide trapp ing . As perm anent hypothyro id ism  was inva riab ly  associated w ith  
severe loss o f trapp ing  fun c tio n  i t  is suggested th a t hypothyro id ism  occurring  
in  the early  months a fte r ^.31j adm in is tra tion  in pa tien ts w ith  measurable 
iod ide trapp ing  fun c tio n  (20 m inu te  uptake o f 123j g rea te r than 4%) is 
p o te n tia lly  tem porary  in nature.
In sum m ary, the re fo re , ^-31 j therapy causes an early  fa l l  o f va riab le  
e x te n t in trapp ing  func tion  fo r  iod ide in a ll pa tien ts . This seems to  be 
im p o rta n t in de te rm in ing  subsequent b iochem ica l and c lin ic a l course over the 
next 12 months. Im pa irm ent o f o rg a n ifica tio n  o f iodide seems to  be a less 
frequen t occurrence, and has a lesser im pact on overa ll th y ro id  horm ogenetic  
capac ity . U n like  im pa irm en t o f iod ide trapp ing , o rg a n ifica tio n  defects appear 
fu l ly  reve rs ib le  over a period o f several weeks.
I f  the theory tha t the early  ( f ir s t  year) e ffe c ts  o f 131j 0n th y ro id  
fu n c tio n  re f le c t irra d ia tio n  damage to  ce ll m etabo lic  processes, and th a t la te  
e ffe c ts  (i.e. a fte r the f ir s t  year) re f le c t ce ll s te r ilisa tio n  is co rre c t (D w ork in , 
1971) then the early  response to  ^31j js determ ined w ith in  fou r weeks o f 
a dm in is tra tio n  o f tre a tm e n t. This is borne out by the p red ic tion  o f f ir s t  
year outcom e fro m  uptake data at. fou r weeks (discussed above). I t  is said 
th a t the in it ia l response to ^31i tre a tm e n t can be slow and unpred ic tab le : by 
m easuring early  iodide uptake fo u r weeks a fte r  131j adm in is tra tio n , p a tie n t 
response can be easily assessed and fu tu re  management thereby fa c il ita te d . 
This may be especia lly so where patien ts are tak ing  a n tith y ro id  drug 
tre a tm e n t a fte r adm in is tra tion , thus obscuring b iochem ica l response to
irra d ia tio n . Indeed, as the response to  ^31j (as measured by iodide uptake) 
occurs w ith in  fou r weeks o f the rapy, and as patien ts who do not respond 
adequately a t th is  tim e  w il l have pers is tan t thyro tox icos is , and thus requ ire  a 
second dose o f ^ - ^ 1, there appears to  be no great ju s t if ic a tio n  fo r  using 
a n tith y ro id  drugs a fte r 131j therapy.
5.1.4. How does the use o f ca rb im azole  p re trea tm en t a ffe c t the response to  
131t7
A m ajor portion  o f the studies in th is  thesis have exam ined the e ffe c t 
o f carb im azole  p re trea tm en t on response to 3-3Tj therapy. O f 79 patien ts  
stud ied, 36 had been p re trea ted  w ith  carb im azole before 3.31j ancj the 
rem ainder were given 3-31j as in it ia l therapy. C arb im azole p re trea tm e n t was 
associated w ith  a reduced incidence o f hypothyro id ism  during the f i r s t  year 
a fte r  - ^ 1, and a correspondingly h igher p roportion  o f pe rs is ten tly  th y ro to x ic  
pa tien ts . This find ing  is in agreem ent w ith  the m a jo r ity  o f studies which 
have p rospective ly examined th is  e ffe c t o f carb im azole  (A ro  et a l, 1979; 
B lidda l e t al, 1982; Steinbach et a l, 1979). C arb im azole also appeared to 
reduce the occurrence o f o rg an ifica tion  defects fo llo w in g  ^31i adm in is tra tio n ,
but had no m ajor e ffe c t on the p a tte rn  o f change in trapp ing  fu n c tio n  
fo llo w in g  - ^ 1  therapy. C arb im azo le  p re tre a tm e n t did not prevent a rise  in 
T4 and T3 concentra tions fo llo w in g  3-31j adm in is tra tio n , although th is  rise was 
not associated w ith  thy ro id  hormone levels above the upper end o f the 
norm al range. C arb im azo le  p re tre a tm e n t be fo re  131j m ay, the re fo re , reduce 
the poss ib ility  o f c lin ic a l d e te rio ra tio n  due to  a rise in T3 and T4 fo llo w in g  
ir ra d ia tio n .
The possible mechanism o f the apparent ra d iop ro te c tive  e ffe c t o f 
ca rb im azo le  in reducing response to  ^-31j }s 0f  in te re s t: th a t th is  m igh t be 
due to  a change in the k ine tics , or d is tr ib u tio n , o f 131j was exam ined in  the 
fin a l 2 sections o f chapter 3. C arb im azo le  p re trea tm e n t did not a lte r  the 
e ffe c t iv e  or b io log ica l h a lf- l ife  o f ^-31j w ith in  the th y ro id  and, th e re fo re , had 
no m a jo r e ffe c t on the ra d ia tion  dose de livered  to  the gland. In add ition , 
carb im azo le  stopped 48 hours before iod ide adm in is tra tion  had no m a jo r 
e ffe c t on the o rg a n ifica tio n  or d is tr ib u tio n  o f 3.31j j n ra t  th y ro id . I t  is 
u n like ly , th e re fo re , th a t the ra d io p ro te c tive  e ffe c t o f carb im azole  is due to  
the above e ffe c ts . The other possible e ffe c ts  o f carb im azole  in reducing the  
ra d ia tio n  damage fro m  3.31j are considered in section  5 o f chapter 3. The 
m ost l ik e ly  explanation  may be th a t ca rb im azo le , or a breakdown product o f 
the  drug (perhaps sulphate coupled to  th y ro id  ce ll p ro te in ) reacts  w ith  fre e  
rad ica ls  produced fro m  irra d ia tio n  o f th y ro id  tissue. The e ffe c t o f su lphydry l 
groups in reducing free  rad ica l damage has been known fo r  many years (Phil 
and Edjarn, 1958), and i t  is also known th a t a n tith y ro id  drugs are m etabolised 
w ith in  th y ro id  ce lls to  give rise  to  sulphate (M archant, 1971). I t  is perhaps 
o f re levance th a t i t  has re ce n tly  been suggested th a t a n tith y ro id  drugs may 
a ffe c t m ononuclear ce ll fun c tio n  by scavenging fre e  rad ica ls in monocytes 
(Tay lo r et al, 1984; Weetman et al, 1984), thus in h ib itin g  antigen processing 
and presentation  to  lym phocytes. I t  is suggested th a t th is  may account fo r 
the apparent immunosuppressive e ffe c t o f carb im azole  in Graves' disease 
(R atanchaiyavong and M cG regor 1985). The po ten tia l in te ra c tio n  between 
a n tith y ro id  drugs o f th is class and fre e  rad ica ls  appears to  be a w idespread 
p ro pe rty  in  tissues and may, indeed, underlie  the basis o f a n tith y ro id  ac tion : 
the o rg a n ifica tio n  o f iodide may invo lve the generation o f iod ine fre e  
rad ica ls  w hich can then in te ra c t w ith  a n tith y ro id  drug or tyrosine residues on 
thy rog lo b u lin . As free  rad ica l generation may be the mechanism by w hich 
tissue damage in a number o f disease states may occur, such as ischaem ic
damage to  m yocard ia l ce lls, jo in t in fla m m a tion  in rheum ato id  a r th r it is  and 
alcohol induced hep a titis  (Anon, 1985b; H a lliw e ll and G u tte ridge , 1984; 
R ow ley, G u tte ridge  and B lake, 1984; R yle , 1984) the  po te n tia l p ro te c tio n  o f 
tissue by drugs such as m eth im azole  is in te res tin g  and o f p o te n tia l 
the ra p eu tic  im portance .
5.1.5. A re  the e ffe c ts  o f carb im azole  on response to  131j re la ted  to  the 
phenomenon of drug accum ulation w ith in  the thyro id?
In the f in a l section of th is thesis the phenomenon o f accum ula tion  o f 
a n tith y ro id  drugs by both human (polymorphs) and anim al (thy ro id  and
subm andibular gland) tissue was investiga ted . A ccum u la tion  o f drug was seen 
to  be independent o f the presence o f a fun c tio na l anion trapp ing  mechanism, 
but to  be reduced by blockade o f the tra p  by perch lo ra te . D rug
accum ula tion  was enhanced in polymorphs by s tim u la tio n  o f m yeloperoxidase 
a c t iv ity  by phagocytosis, and reduced by in h ib ito rs  o f peroxidase. In mouse 
subm andibular gland drug loca lisa tion  was shown to  be the same as th a t o f 
the peroxidase enzyme com plex and also o f the energy pathway necessary fo r  
generation o f H 2O 2 (g lucose-6 -phosphate dehydrogenase), which can act as 
substra te  fo r  peroxidase. I t  the re fo re  seems possible th a t the phenomenon o f 
drug accum ula tion  is c r it ic a lly  re la ted  to  drug in te ra c tio n  w ith  tissue 
peroxidase, and a suggested scheme based on th is  in te ra c tio n  is proposed in 
section  4 o f chap ter 4. I f  th is is co rre c t, then concen tra tion  o f th iou ry lene  
a n tith y ro id  drugs may occur in any ce ll type where ox ida tion  o f a n tith y ro id  
drugs by a su itab le  peroxidase/oxidase/cata lase enzyme occurs. This appears 
to  be the case fo r  the tissues studied in th is thesis, and also appears to  so 
fo r  m acrophage/m onocyte cells (Weetman et al, 1984c). In monocytes one 
consequence o f in tra c e llu la r drug concen tra tion  is th a t a n tith y ro id  drug can
act as a scavenger o f free  oxygen derived rad ica ls (Taylor et al. 1984), and 
th is  may account fo r the immunosuppressive e ffe c t o f the drugs. ^31j 
induced damage to  thy ro id  cells is probably a consequence o f free  rad ica l 
generation; i t  seems reasonable to  suppose th a t the fre e  rad ica l scavenging 
p rope rty  o f a n tith y ro id  drug, or o f drug m etabo lites  inc lud ing  su lpha te /ce ll 
p ro te in  com plex, can account fo r  the ra d io p ro te c tive  e ffe c t o f the drug.
Thus, the process o f drug accum ula tion  and o f 
rad iopro tection /im m unosuppression  appear to  be linked  through drug/peroxidase 
in te ra c tio n . The in te ra c tio n  between drug and peroxidase appears to  be a
consequence o f the a b ility  o f the enzyme to  use drug as an a lte rn a tive  
substra te , and re fle c ts  the appropriateness o f the redox po te n tia l o f drug. 
Peroxidase can also act as a scavenger o f fre e  rad ica ls w ith in  tissue, and the 
p roperties o f a n tith y ro id  drugs in th is ro le  probably re f le c t the s im ila r ity  o f 
redox po ten tia ls  fo r  drug and enzyme.
In sum m ary, th e re fo re , the apparently  unique p roperties o f th iou ry lene  
a n tith y ro id  drugs discussed above appear to  share a common lin k  through 
drug in te ra c tio n  w ith  ce llu la r peroxidase enzymes. Thus, drug concen tra tion  
w ith in  the ce ll, acute in h ib itio n  o f iodide o rg a n ifica tio n , im pa irm en t o f 
antigen presentation  and consequent immunosuppression and ra d iop ro te c tion  
are a ll face ts  o f drug a c t iv ity  which may be d ire c t consequences o f the 
chem ica l p roperties o f the compounds which a llow  ox ida tive  in te ra c tio n  w ith  
tissue peroxidase and oxygen fre e  rad ica ls.
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